UNITED STATES ENVIRONMENTAL PROTECTION AGENCY 

WASHINGTON, D.C. 20460 

MEMORANDUM 

Date: 6/29/2015 

OFFICE OF CHEMICAL SAFETY AND 

POLLUTION PREVENTION 

SUBJECT: Pentachloronitrobenzene (PCNB): Data Evaluation Records (DERs) for EDSP 

Tier 1 Assays 

PC Code: 056502 

Decision No.: 469792, 472270, 475227 

Petition No.: NA 

DP Barcode: D405372, D407069, D409239 

Registration No.: NA 

Risk Assessment Type: NA 

TXR No.: 0056474 

MRID No.: See Table 

Regulatory Action: NA 

Case No.: NA 

CAS No.: 

40 CFR: NA 

FROM: Greg Akerman, Ph.D. ~ Immediate Office 

Health Effects Division (7509P) 

THROUGH: Jess Rowland ~ ..,...n_ 

Deputy Director 

Health Effects Division 

TO: Jolene Trujillo 

Biologist/Chemical Review Manager 

Risk Management and Implementation Branch V 

Pesticide Re-evaluation Division (7505P) 

I. ACTION REQUESTED 

Ver.Apr. 2010 

The Pesticide Re-evaluation Division (PRD) of OPP has requested that the Health Effects 

Division (HED) review the Endocrine Disruptor Screening Program (EDSP) Tier 1 assays 

submitted in response to the agency's Test Order for PCNB: Test Order# EDSP-056502-105. 

Page I of2 

Page 1 of 207
Page 2 of 2 

II. RESPONSE

Attached are the EDSP Tier 1 assay DERs for PCNB.

III. MRID Table

Chemical: Pentachloronitrobenzene (PCNB) PC Code: 056502

Guideline Assay MRID 

890.1100 Amphibian Metamorphosis Assay (Frog) 49042101

890.1150 Androgen Receptor Binding (Rat Prostate) 48946801

890.1200 Aromatase Assay (Human Recombinant) 48916701

890.1250 Estrogen Receptor Binding NA

890.1300 Estrogen Receptor Transcriptional Activation 

(Human Cell Line HeLa-9903) NA

890.1350 Fish Short-Term Reproduction 49042102

890.1400 Hershberger (Rat) 48916702

890.1450 Female Pubertal (Rat) 49042103

890.1500 Male Pubertal (Rat) 49042103

890.1550 Steroidogenesis (Human Cell Line – H295R) 48916704

890.1600 Uterotrophic (Rat) NA

NA= Not Applicable (requirement satisfied by other scientifically relevant information (OSRI))

Page 2 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁ

ԡԹՌԹԯԽՉՍՁՊԽՅԽՆՌ    ԢԭԞ

ԬԢ

ԢԭԞ

ԢԭԞ

ԱԽՋՌԪԹՌԽՊՁԹՄ  ԭԠԫԟԱԽԻՀՆՁԻԹ

ԠՇՅՅՇՆԫԹՅԽ ԭԽՆՌԹԻՀՄՇՊՇՆՁՌՊՇ

ԠՀԽՅՁԻԹՄԫԹՅԽ  ԦԲԭԞԠ  

 ԠԞ԰ԫԹՅԽ 

ԠԞ԰ԫՇ 

԰ՑՆՇՆՑՅՋ 

ԢԭԞԭԠԠՇԼԽ

ԭՊՁՅԹՊՑԯԽՎՁԽՏԽՊ ԢՄՁՒԹԺԽՌՀԨՊՍՈՃԹ

ԢՆՎՁՊՇՆՅԽՆՌԹՄ԰ԻՁԽՆՌՁՋՌԠԡԪ԰ՅՁՌՀ

԰ԽԻՇՆԼԹՊՑԯԽՎՁԽՏԽՊ
ՋԱԽՊՁ԰ԪՑԽՊՋԭ

ԢՆՎՁՊՇՆՅԽՆՌԹՄ԰ԻՁԽՆՌՁՋՌԠԡԪ԰ՅՁՌՀ

ԭՊՁՅԹՊՑԯԽՎՁԽՏԽՊ ԢԼՏԹՊԼ԰ԻՇՄՄՇՆ

ԱՇՐՁԻՇՄՇԿՁՋՌԲ԰ԢԭԞԬԭԭԢԣԢԡԢԯ

԰ԽԻՇՆԼԹՊՑԯԽՎՁԽՏԽՊ ԠԹՌՀԽՊՁՆԽԞՍԺԽԽ

԰ԽՆՁՇՊ԰ԻՁԽՆՌՁՋՌԲ԰ԢԭԞԬԭԭԢԣԢԡ

ԡԹՌԽԢՎԹՄՍԹՌՁՇՆԠՇՅՈՄԽՌԽԼ#ԼԼՅՅ

ԠԦԱԞԱԦԬԫ԰ԻՀՆԽՁԼԽՊ԰ԷԱԷԨԽՆ

ԞՋՋԹՑԾՇՊՌՀԽԡԽՌԽԻՌՁՇՆՇԾԱՀՑՊՇՁԼ

ԩՌԼԢԹՋՌՇՆԪԹՊՑՄԹՆԼԩ

ԠՇՊՈՇՊԹՌՁՇՆ԰ՌՍԼՑԻՇՅՈՄԽՌԽԼԧԹ

ՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡ

ԭԹԿԽՇԾ

ԞԡԭԟԹՊԻՇԼԽ  

ԢԠԡԡԹՌԹԭՇՁՆՌ  

ԞԪԯԦԡ   

ԞԤՍՁԼԽՄՁՆԽ   

 ԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹ

 

Մ     ԭՍՊՁՌՑ
    

ՇԺԽՆՒԽՆԽ

ԫՇՌՊԽՈՇՊՌԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ



ԮՍՁՆՌՇՒԽՆԽ



Թ ԡԹՌԽ

ԭՀԡ   ԡԹՌԽ 

ԭՀԡ   ԡԹՌԽ  
ՆՇՄՇՆԿԽՊՏՁՌՀ

ԯԟ

 ԡԹՌԽ  

ԡԢԯԟ

ՑՑՑՑ%

ՆԼԹՄՄԹՆԼԥԬԨՊՍԽԿԽՊԭԠԫԟԱԽԻՀՆՁԻԹՄԞՅՈՀՁԺ

ԼԞԻՌՁՎԽ԰ՍԺՋՌԹՆԻԽՋԲՆՈՍԺՄՁՋՀԽԼՋՌՍԼՑՈԽՊԾՇՊՅԽԼԺՑԴ

ԩԹԺՇՊԹՌՇՊՑ ՈՊՇՂԽԻՌ ՆՍՅԺԽՊԞ԰ՌՍԼՑՋՈՇՆՋՇՊԽ

ՆՍԹՊՑ

ԫՍՅԺԽՊ

ԹՑ
ԣՊՇԿ

ՀԢԭԞ

ԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋ

ԴՁՄԼՄՁԾԽԦՆՌԽՊՆԹՌՁՇՆԹՄ

ԽԼԞՅՎԹԻԠՀԽՅՁԻԹՄ

Page 3 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԫՇՌԽԱՀԽԲ԰ԢԭԞԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅ
Ԣԡ԰ԭԱՁԽՊՋԻՊԽԽՆՁՆԿԺԹՌՌԽՊՑՁՋԻՇՅՈՊՁՋԽԼՇԾԽՄԽՎԽՆ

ՋԻՊԽԽՆՁՆԿԹՋՋԹՑՋՁՆՌԽՆԼԽԼՌՇՁԼԽՆՌՁԾՑԹԻՀԽՅՁԻԹՄ0ՋՄՁՃԽՄՑԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՁԽՁՌՋՈՇՌԽՆՌՁԹՄՌՇՁՆՌԽՊԹԻՌՏՁՌՀ

ՌՀԽԽՋՌՊՇԿԽՆԹՆԼՊՇԿԽՆՇՊՌՀՑՊՇՁԼ
ԢԞՇՊԱՈԹՌՀՏԹՑՋԱՀԽՊՇԺՍՋՌՆԽՋՋՇԾՌՀԽԱՁԽՊԺԹՌՌԽՊՑՁՋԺԹՋԽԼՇՆ

ՌՀԽՋՌՊԽՆԿՌՀՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄԹՋՋԹՑՌՇՁԼԽՆՌՁԾՑՈՇՌԽՆՌՁԹՄԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՏՁՌՀԻՇՅՈՄԽՅԽՆՌԹՊՑԽՆԼՈՇՁՆՌՋ

ՏՁՌՀՁՆՌՀԽԹՋՋԹՑՏՀԽՊԽԹՎԹՁՄԹԺՄԽԹՆԼՊԽԼՍՆԼԹՆԻՑԹԻՊՇՋՋՌՀԽԺԹՌՌԽՊՑԱՀՍՋՌՀԽՊԽՋՍՄՌՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄ

ԹՋՋԹՑՋՀՇՍՄԼՆՇՌԺԽԻՇՆՋՁԼԽՊԽԼՁՆՁՋՇՄԹՌՁՇՆԺՍՌՊԹՌՀԽՊՋՀՇՍՄԼԺԽԻՇՆՋՁԼԽՊԽԼՁՆՌՀԽԻՇՆՌԽՐՌՇԾՇՌՀԽՊԹՋՋԹՑՋ

ՁՆՌՀԽԺԹՌՌԽՊՑԹՋՏԽՄՄԹՋԬՌՀԽՊ԰ԻՁԽՆՌՁԾՁԻԹՄՄՑԯԽՄԽՎԹՆՌԦՆԾՇՊՅԹՌՁՇՆ
Ԭ԰ԯԦԦՆՇՊԼԽՊՌՇԼԽՌԽՊՅՁՆԽՁԾԹԻՀԽՅՁԻԹՄ

ՀԹՋՌՀԽՈՇՌԽՆՌՁԹՄՌՇՁՆՌԽՊԹԻՌՏՁՌՀՌՀԽԢԞՇՊԱՈԹՌՀՏԹՑՋԹԴԽՁԿՀՌՇԾԢՎՁԼԽՆԻԽ
ԴՇԢԽՎԹՄՍԹՌՁՇՆՇԾԱՁԽՊ

ԹՋՋԹՑՊԽՋՍՄՌՋՁՆԻՇՅԺՁՆԹՌՁՇՆՏՁՌՀՌՀԽԾՁՆԼՁՆԿՋՁՆՌՀԽԬ԰ԯԦՋՀՇՍՄԼԺԽՍՆԼԽՊՌԹՃԽՆ
ՊԽԾԽՊՌՇՌՀԽԴՇԢ

ԡՇԻՍՅԽՆՌ

ԢԵԢԠԲԱԦԳԢ԰ԲԪԪԞԯԶ

ԱՀԽԼԹՑԹՋՋԹՑՇԾԭԠԫԟՌԽԻՀՆՁԻԹՄ
ՈՍՊՁՌՑՇՆԹՅՈՀՁԺՁԹՆՅԽՌԹՅՇՊՈՀՇՋՁՋՇԾԞԾՊՁԻԹՆԻՄԹՏԽԼԾՊՇԿ
ԵԽՆՇՈՍՋ

ՄԹԽՎՁՋՏԹՋԻՇՆԼՍԻՌԽԼՍՆԼԽՊԾՄՇՏՌՀՊՇՍԿՀԻՇՆԼՁՌՁՇՆՋԞՅՈՀՁԺՁԹՆՄԹՊՎԹԽԹՌԫՁԽՍՏՃՇՇՈԣԹԺԽՊ
ԫԣՋՌԹԿԽ


ՌԹԼՈՇՄԽՋԿՊՇՍՈ  ՌԹԼՈՇՄԽՋՊԽՈՄՁԻԹՌԽՏԽՊԽ ԽՐՈՇՋԽԼ ՌՇ Թ ՆԽԿԹՌՁՎԽ ԻՇՆՌՊՇՄ ԹՆԼ ՆՇՅՁՆԹՄ ԻՇՆԻԽՆՌՊԹՌՁՇՆՋ ՇԾ

ԹՆԼՅԿԹՁԩՌՀԽԠԳՇԾՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋԽՐԻԽԽԼԽԼՇՎԽՊՌՀԽԻՇՍՊՋԽ

ՇԾՌՀԽՋՌՍԼՑ
ՁԽՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼԱՀԽՌՁՅԽՏԽՁԿՀՌԽԼԹՎԽՊԹԿԽ
ԱԴԞԻՇՆԻԽՆՌՊԹՌՁՇՆՋ
ԻԹՄԻՍՄԹՌԽԼ

ԺՑՌՀԽՊԽՎՁԽՏԽՊՏԽՊԽ
ԩԬԮԻՇՆՌՊՇՄԹՆԼՅԿԹՁԩԱՀԽՌԽՋՌՋՑՋՌԽՅՏԹՋ

ՅԹՁՆՌԹՁՆԽԼԹՌՌՇՇ

ԠԹՆԼԹՈԥՇԾՌՇ

ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԹՄՄԽԾԾԽԻՌՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄ

ԟՑՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆՅԽԹՆՋՍՊՎՁՎԹՄՏԹՋՁՆԺՇՌՀՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՌՀԽՅՁԼՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆ

ՌՀԽՄՇՏՌՊԽԹՌՅԽՆՌԿՊՇՍՈԹՆԼՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈԠՄՁՆՁԻԹՄՋՁԿՆՋ
ՁԽԺԽՀԹՎՁՇՊԹՄԹՆԼՇՌՀԽՊՋՍԺՄԽՌՀԹՄ

ԽԾԾԽԻՌՋՁՆԻՄՍԼՁՆԿՌԹՁՄԻՍՊՎԹՌՍՊԽԹՆԼՋՅԹՄՄՋՁՒԽՏԽՊԽՇԺՋԽՊՎԽԼՁՆԹՄՄՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՏՁՌՀՆՇԹՈՈԹՊԽՆՌՈԹՌՌԽՊՆ

ԱԹՁՄԻՍՊՎԹՌՍՊԽՏԹՋՋԽԽՆՁՆ
ՇԾՌԹԼՈՇՄԽՋՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՁՆ



ԹՆԼ
ՌԹԼՈՇՄԽՋՌՀԽՄՇՏՅՁԼԹՆԼՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՋՈԽԻՌՁՎԽՄՑ԰ՅԹՄՄՋՁՒԽՏԹՋՋԽԽՆՁՆՇՆԽ

ՌԹԼՈՇՄԽԽԹԻՀՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՅՁԼՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ

ԡԹՑՅԽԼՁԹՆԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՏԹՋՊԽԼՍԻԽԼԹՌԹՄՄՌՊԽԹՌԽԼՄԽՎԽՄՋ
ԫԣՈԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ

ՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ԫԣԣՍՊՌՀԽՊՅՇՊԽԭԠԫԟՋՁԿՆՁԾՁԻԹՆՌՄՑԼԽԻՊԽԹՋԽԼԡԹՑՋՆՇՍՌՌՇՎԽՆՌ
԰Գԩ

ĻԹՆԼՏԽՌՏԽՁԿՀՌ
ĻԹՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
ՈԡՍՆՆԽՌՌ0Ջ

Page 4 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԫՇԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌՏԹՋՇԺՋԽՊՎԽԼԱՀԽՊԽՏԽՊԽՆՇՋՁԿՆՁԾՁԻԹՆՌԽԾԾԽԻՌՋՇՆՆՇՊՅԹՄՁՒԽԼ
ԾՇՊ԰ԳԩՀՁՆԼՄՁՅԺ

ՄԽՆԿՌՀ
ԥԩԩՇՆԡԹՑՇՊԹՌԹՆՑՌՊԽԹՌՅԽՆՌՄԽՎԽՄԱՀԽՇՆԽՄԹՌԽՋՌԹԿԽ
ԫԣ ՌԹԼՈՇՄԽՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ՏԹՋԽՐԻՄՍԼԽԼԾՊՇՅԹՆԹՄՑՋՁՋԾՇՊԻՇՆՌՁՆՍՇՍՋԽՆԼՈՇՁՆՌՋ
԰ԳԩՏԽՁԿՀՌԹՆԼՆՇՊՅԹՄՁՒԽԼԥԩԩ

ԱՀԽՁՆԻՁԼԽՆԻԽԹՆԼՋԽՎԽՊՁՌՑՇԾՌՀՑՊՇՁԼԿՊՇՋՋՈԹՌՀՇՄՇԿՑԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑ
ԾՇՄՄՁԻՄԽՋՁՒԽԾՁՆԼՁՆԿՋՏԹՋՎՁՋՍԹՄՄՑ

ՇԺՋԽՊՎԽԼՌՇԺԽԿՊԽԹՌԽՊՏՁՌՀՁՆԻՊԽԹՋՁՆԿՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋԱՀԽՋՌՍԼՑԹՍՌՀՇՊԹՆԹՄՑՒԽԼՌՀԽՁՆԻՁԼԽՆԻԽԹՆԼՋԽՎԽՊՁՌՑ

ԻՇՍՆՌՋՍՋՁՆԿՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՋՌԽՈԼՇՏՆՌԽՋՌԹՆԼԼԽՌԽՊՅՁՆԽԼՌՀԹՌՌՀԽԼՁԾԾԽՊԽՆԻԽՋՏԽՊԽՆՇՌՋՌԹՌՁՋՌՁԻԹՄՄՑ

ՋՁԿՆՁԾՁԻԹՆՌ
Ո 

ԱՀԽՌԽՋՌՈԽՊԾՇՊՅԹՆԻԽԹՆԼՎԹՄՁԼՁՌՑԻՊՁՌԽՊՁԹՏԽՊԽԿԽՆԽՊԹՄՄՑՅԽՌԽՐԻԽՈՌՌՀԽԠԳՇԾՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ԽՐԻԽԽԼԽԼԾՇՊԹՄՄՌԽՋՌՅԹՌԽՊՁԹՄՄԽՎԽՄՋՇՎԽՊՌՀԽՋՌՍԼՑԼՍՊԹՌՁՇՆ
ՊԹՆԿԽՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼՏՀՁԻՀ

ՏԹՋԹՌՌՊՁԺՍՌԽԼՌՇՌՀԽԹԾԾՁՆՁՌՑՇԾՌՀԽՌԽՋՌՅԹՌԽՊՁԹՄՌՇԺՁՆԼՌՇԿՄԹՋՋՌԹՆՃՋԾՇՇԼՌԹԼՈՇՄԽՋԹՆԼԽՐԻՊԽՌԽԼՇՊԿԹՆՁԻՅԹՌՌԽՊ

ԱՀՁՋՁՆՌՊՇԼՍԻԽՋՍՆԻԽՊՌԹՁՆՌՑՁՆՌՇՌՀԽՁՆՌԽՊՈՊԽՌԹՌՁՇՆՇԾԽՐՈՇՋՍՊԽԹՋՋՇԻՁԹՌԽԼՏՁՌՀԽԾԾԽԻՌՋՁՆՌՀՁՋԹՋՋԹՑԫՇՆԽՌՀԽՄԽՋՋ

ՌՀԽՋՌՍԼՑՁՋՇՌՀԽՊՏՁՋԽԿԽՆԽՊԹՄՄՑՋՇՍՆԼ

ԱՀՁՋԹՋՋԹՑՋԹՌՁՋԾՁԽՋՌՀԽԢԡ԰ԭԱՁԽՊԱԽՋՌԬՊԼԽՊՊԽՉՍՁՊԽՅԽՆՌԾՇՊԹՆԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ
ԬԠ԰ԭԭ

ԤՍՁԼԽՄՁՆԽ

ԯԽՋՍՄՌՋ԰ՑՆՇՈՋՁՋ

ԱԽՋՌՇՊԿԹՆՁՋՅԫԣՋՌԹԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

ԱԽՋՌՇՊԿԹՆՁՋՅՌՇՌԹՄՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՇՈՌՁՇՆԹՄԫՇՌՊԽՈՇՊՌԽԼ

ԱԽՋՌՌՑՈԽԣՄՇՏՌՀՊՇՍԿՀ

Page 5 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽ  ԰ՍՅՅԹՊՑ ՇԾ ԡԽՎԽՄՇՈՅԽՆՌԹՄ ԹՆԼ ԱՀՑՊՇՁԼ ԭԹՌՀՇՄՇԿՑԥՁՋՌՇՈԹՌՀՇՄՇԿՑ ԢԾԾԽԻՌՋ ՁՆ ՌՀԽ ԞՅՈՀՁԺՁԹՆ

ԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ
ԞԪԞՏՁՌՀԭԠԫԟ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԫԣԡԽՎԽՄՇՈՅԽՆՌԹՄ

԰ՌԹԿԽ

ԥՁՆԼԩՁՅԺ

ԩԽՆԿՌՀ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԡԽՎԽՄՇՈՅԽՆՌ

ԱՀՑՊՇՁԼԤՊՇՋՋԹՆԼ

ԥՁՋՌՇՈԹՌՀՇՄՇԿՑ

ԡԹՑ ԡԹՑ ԡԹՑ

ԡԹՑ



ԡԹՑ ԡԹՑ ԡԹՑ

 ԫՇ ԶԽՋ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ

 ԫՇ ԶԽՋ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ

 ԫՇ ԶԽՋ ԫՇ ԫՇ ԫՇ ԫՇ ԶԽՋ



 Ԟ՟ՑԽՋՠՁՆԼՁԻԹՌԽՋԹՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄՍՆՄԽՋՋ

ՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼ



 ԱՀԽԻՊՁՌԽՊՁԹԾՇՊՋՁԿՆՁԾՁԻԹՆԻԽԹՊԽԼԽՋԻՊՁԺԽԼՁՆՌՀԽԯԽՎՁԽՏԽՊ0ՋԞՆԹՄՑՋՁՋԹՆԼ԰ՌԹՌՁՋՌՁԻԹՄԳԽՊՁԾՁԻԹՌՁՇՆՋԽԻՌՁՇՆՋՇԾ

ՌՀԽ ԡԢԯ  ԠՇՆԻՄՍՋՁՇՆՋ ՊԽԿԹՊԼՁՆԿ ՀՁՋՌՇՈԹՌՀՇՄՇԿՑ ՅԹՑ ԺԽ ՀԽԹՎՁՄՑ ՏԽՁԿՀՌԽԼ ԺՑ ՌՀԽ ԽՐՈԽՊՌ ՇՈՁՆՁՇՆ ՇԾ Թ

ԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ



 ԥՁՆԼՄՁՅԺՄԽՆԿՌՀՁՋՆՇՊՅԹՄՁՒԽԼՌՇՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰Գԩ



 ԟԹՋԽԼՇՆՎՁՋՍԹՄԹՋՋԽՋՋՅԽՆՌՇԾՁՆԻՁԼԽՆԻԽԹՆԼՋԽՎԽՊՁՌՑԼԹՌԹՀՇՏԽՎԽՊՌՀԽՋՌՍԼՑԹՍՌՀՇՊՊԽՈՇՊՌԽԼՌՀԹՌՌՀԽ

ԼՁԾԾԽՊԽՆԻԽՋՏԽՊԽՆՇՌՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌ

 

Page 6 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

Ԧ ԪԞԱԢԯԦԞԩ԰ԞԫԡԪԢԱԥԬԡ԰ 

 ԤՍՁԼԽՄՁՆԽԣՇՄՄՇՏԽԼԱՀՁՋՋՌՍԼՑՏԹՋԻՇՆԼՍԻՌԽԼԾՇՄՄՇՏՁՆԿԿՍՁԼԽՄՁՆԽՋՇՍՌՄՁՆԽԼՁՆԲ԰ԢԭԞԢՆԼՇԻՊՁՆԽ

ԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅԱԽՋՌԤՍՁԼԽՄՁՆԽՋԬԠ԰ԭԭԞՅՈՀՁԺՁԹՆ

ԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ
ԣՊՇԿ
ԬԻՌՇԺԽՊԱՀԽԾՇՄՄՇՏՁՆԿԼԽՎՁԹՌՁՇՆ
ՋՏԽՊԽ

ՆՇՌԽԼ

 ԱՀԽՈՀՇՌՇՈԽՊՁՇԼ
ՀՊՋՄՁԿՀՌՀՊՋԼԹՊՃՏԹՋՆՇՌԻՇՆՋՁՋՌԽՆՌՏՁՌՀՌՀԽՊԽԻՇՅՅԽՆԼԽԼՈՀՇՌՇՈԽՊՁՇԼ


ՀՊՋՄՁԿՀՌՀՇՍՊՋԼԹՊՃ

 ԱՀԽՏԹՌԽՊՀԹՊԼՆԽՋՋԼՍՊՁՆԿՌՀԽԼԽԾՁՆՁՌՁՎԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼ
ՅԿԩԹՋԠԹԠԬԽՐԻԽԽԼԽԼՌՀԽ

ՊԽԻՇՅՅԽՆԼԽԼՊԹՆԿԽ
ՅԿԩԹՋԠԹԠԬ

 ԱՀԽԾՄՇՏՌՀՊՇՍԿՀՊԹՌԽ
ԻԹՅԩՅՁՆԽՐԻԽԽԼԽԼՌՀԽՊԽԻՇՅՅԽՆԼԽԼՊԹՌԽ
ՅԩՅՁՆ

 ԱՀԽԾԽԽԼՁՆԿՊԹՌԽՋԾՇՊՌԹԼՈՇՄԽՋԼՍՊՁՆԿՌՀԽԼԽԾՁՆՁՌՁՎԽՋՌՍԼՑՁՆԻՊԽԹՋԽԼԾՊՇՅՅԿՄԹՊՎԹԽԼԹՑԹՌՌԽՋՌ

ՁՆՁՌՁԹՌՁՇՆՌՇՅԿՄԹՊՎԹԽԼԹՑԺՑՌՀԽՄԹՋՌՏԽԽՃՇԾՌՀԽՌԽՋՌՏՀՁԻՀՏԹՋՆՇՌԻՇՆՋՁՋՌԽՆՌՏՁՌՀՌՀԽ

ՊԽԻՇՅՅԽՆԼԽԼԾԽԽԼՁՆԿՊԹՌԽՇԾՅԿՄԹՊՎԹԼԹՑԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆՌՇՅԿՄԹՊՎԹԼԹՑՁՆՌՀԽՄԹՋՌՏԽԽՃ

ՇԾՌՀԽՌԽՋՌ

 ԱՀԽԹՅՅՇՆՁԹԾՄՍՇՊՁԼԽԻՀՄՇՊԹՌԽԹՆԼՈԽՊԻՀՄՇՊԹՌԽԻՇՆԻԽՆՌՊԹՌՁՇՆՋՁՆՌՀԽԼՁՄՍՌՁՇՆՏԹՌԽՊՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼ

 ԱՀԽԠԳՇԾՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋԽՐԻԽԽԼԽԼԾՇՊԹՄՄՌԽՋՌՅԹՌԽՊՁԹՄՄԽՎԽՄՋՇՎԽՊՌՀԽՋՌՍԼՑԼՍՊԹՌՁՇՆ

 ԱԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋԼԽԻՊԽԹՋԽԼԹԾՌԽՊՌՀԽԹԼԼՁՌՁՇՆՇԾՇՊԿԹՆՁՋՅՋՇՆԡԹՑՏՀՁԻՀՏԹՋԹՌՌՊՁԺՍՌԽԼՌՇՌՀԽԹԾԾՁՆՁՌՑ

ՇԾՌՀԽՌԽՋՌՅԹՌԽՊՁԹՄՌՇԺՁՆԼՌՇԿՄԹՋՋՌԹՆՃՋԾՇՇԼՌԹԼՈՇՄԽՋԹՆԼԽՐԻՊԽՌԽԼՇՊԿԹՆՁԻՅԹՌՌԽՊ

ԱՀԽՎԹՊՁԹԺՁՄՁՌՑՁՆՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՊԽԾՄԽԻՌԽԼՁՆՀՁԿՀԽՊՌՀԹՆՊԽԻՇՅՅԽՆԼԽԼԠԳՋՁՆՌՊՇԼՍԻԽՋՍՆԻԽՊՌԹՁՆՌՑ

ՁՆՌՇՌՀԽՁՆՌԽՊՈՊԽՌԹՌՁՇՆՇԾԽՐՈՇՋՍՊԽԹՋՋՇԻՁԹՌԽԼՏՁՌՀԽԾԾԽԻՌՋՁՆՌՀՁՋՋՌՍԼՑԥՇՏԽՎԽՊՌՀԽՋՌՍԼՑՁՋՇՌՀԽՊՏՁՋԽ

ԿԽՆԽՊԹՄՄՑՋՇՍՆԼ

Page 7 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 ԠՇՅՈՄՁԹՆԻԽ   ԰ՁԿՆԽԼԹՆԼԼԹՌԽԼԫՇԡԹՌԹԠՇՆԾՁԼԽՆՌՁԹՄՁՌՑԤՇՇԼԩԹԺՇՊԹՌՇՊՑԭՊԹԻՌՁԻԽ
Ԥԩԭ

ԹՆԼԮՍԹՄՁՌՑԞՋՋՍՊԹՆԻԽՋՌԹՌԽՅԽՆՌՋՏԽՊԽՈՊՇՎՁԼԽԼԱՀՁՋՋՌՍԼՑՏԹՋԻՇՆԼՍԻՌԽԼ

ՁՆԻՇՅՈՄՁԹՆԻԽՏՁՌՀԹՄՄՈԽՊՌՁՆԽՆՌԬԢԠԡ
ԬԢԠԡԹՆԼԲ԰ԢԭԞ
Ԡԣԯ

ԭԹՊՌԤԩԭՊԽԿՍՄԹՌՁՇՆՋՏՁՌՀՌՀԽԾՇՄՄՇՏՁՆԿԽՐԻԽՈՌՁՇՆՋՈԽՊՁՇԼՁԻԹՆԹՄՑՋԽՋՇԾ

ՏԹՌԽՊԾՇՊՈՇՌԽՆՌՁԹՄԻՇՆՌԹՅՁՆԹՆՌՋՏԽՊԽՈԽՊԾՇՊՅԽԼՍՋՁՆԿԹԻԽՊՌՁԾՁԽԼՄԹԺՇՊԹՌՇՊՑԹՆԼ

ՋՌԹՆԼԹՊԼԲ԰ԢԭԞԹՆԹՄՑՌՁԻԹՄՅԽՌՀՇԼՋՈՊԽՄՁՅՁՆԹՊՑԹՆԹՄՑՋԽՋՇԾՏԹՌԽՊՁՇԼՁԼԽ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽՆՇՌՈԽՊԾՇՊՅԽԼԹԻԻՇՊԼՁՆԿՌՇԤԩԭՋՌԹՆԼԹՊԼՋԹՆԼՌՀԽ

ԻՀԹՊԹԻՌԽՊՁՒԹՌՁՇՆԹՆԼՋՌԹԺՁՄՁՌՑՇԾՌՀԽՌԽՋՌՋՍԺՋՌԹՆԻԽՍՆԼԽՊՌՀԽՋՌՇՊԹԿԽԻՇՆԼՁՌՁՇՆՋ

ՇԾՌՀԽՌԽՋՌՋՁՌԽՏԹՋՆՇՌԼԽՌԽՊՅՁՆԽԼՁՆԹԻԻՇՊԼԹՆԻԽՏՁՌՀԤՇՇԼԩԹԺՇՊԹՌՇՊՑԭՊԹԻՌՁԻԽ

԰ՌԹՆԼԹՊԼՋ

ԞԱԽՋՌԪԹՌԽՊՁԹՄ    ԭԠԫԟԱԽԻՀՆՁԻԹՄ

ԡԽՋԻՊՁՈՌՁՇՆ    ԭՇՏԼԽՊ

ԩՇՌԫՇԟԹՌԻՀԫՇ ԩ

 

ԭՍՊՁՌՑ     

ԦՅՈՍՊՁՌՁԽՋ    ԫՇՆԽՄՁՋՌԽԼ

԰ՌԹԺՁՄՁՌՑՇԾԠՇՅՈՇՍՆԼԪԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՑՁԽՄԼԽԼՊԽԻՇՎԽՊՁԽՋՇԾՌՇՇԾՆՇՅՁՆԹՄՏՁՌՀ

ԻՇԽԾԾՁԻՁԽՆՌՋՇԾՎԹՊՁԹՌՁՇՆՇԾՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼԱԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽՋՍԺՋՌԹՆՌՁԹՄՄՑՄՇՏԽՊԹՌԡԹՑՌՀԹՆԡԹՑՏՀՁԻՀ

ԹԻԻՇՍՆՌԽԼԾՇՊՌՀԽՄԹՊԿԽՊՊԹՆԿԽՁՆՊԽԻՇՎԽՊՁԽՋԯԹՆԿԽՁՆՅԽԹՆՅԽԹՋՍՊԽԼ

ՊԽԻՇՎԽՊՁԽՋԾՊՇՅԡԹՑՌՇՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆՏԹՋ


ՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼԱՀԽՊԹՆԿԽՁՆՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽ

ԹՌՌՊՁԺՍՌԽԼՌՇՌՀԽԹԾԾՁՆՁՌՑՇԾՌՀԽՌԽՋՌՅԹՌԽՊՁԹՄՌՇԺՁՆԼՌՇԿՄԹՋՋՌԹՆՃՋԾՇՇԼ

ՌԹԼՈՇՄԽՋԹՆԼԽՐԻՊԽՌԽԼՇՊԿԹՆՁԻՅԹՌՌԽՊ

԰ՌՇՊԹԿԽԠՇՆԼՁՌՁՇՆՋՇԾ  ԰ՌՇՊԽԼՍՆԼԽՊԹՅԺՁԽՆՌԻՇՆԼՁՌՁՇՆՋ

ԱԽՋՌԠՀԽՅՁԻԹՄՋ  

Page 8 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԟԱԽՋՌԬՊԿԹՆՁՋՅ

ԱԹԺՄԽԤԽՆԽՊԹՄԦՆԾՇՊՅԹՌՁՇՆԞԺՇՍՌՌՀԽԱԽՋՌ԰ՈԽԻՁԽՋԹՆԼԭԹՊԽՆՌԹՄԠԹՊԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

԰ՈԽԻՁԽՋԻՇՅՅՇՆՆԹՅԽ ԞԾՊՁԻԹՆԻՄԹՏԽԼԾՊՇԿ ԢԭԞՊԽԻՇՅՅԽՆԼՋԞԾՊՁԻԹՆԻՄԹՏԽԼԾՊՇԿ


ԵԽՆՇՈՍՋՄԹԽՎՁՋԴԽՋՌԽՊՆ#ԞԾՊՁԻԹ%ԻՄԹՏԽԼ

ԾՊՇԿ԰ՁՄՍՊԹՆԹ
ԵԽՆՇՈՍՋՌՊՇՈՁԻԹՄՁՋՅԹՑԺԽ

ՍՋԽԼԹՋԹՆԹՄՌԽՊՆԹՌԽՋՈԽԻՁԽՋՀՇՏԽՎԽՊԹՄՁՋՌ

ՇԾԹՄՄՇԾՌՀԽՆԽԻԽՋՋԹՊՑՈՊՇՌՇԻՇՄԼԽՎՁԹՌՁՇՆՋՌՇ

ԹԻԻՇՅՅՇԼԹՌԽՌՀՁՋՋՈԽԻՁԽՋՁՋՊԽԻՇՅՅԽՆԼԽԼ

ԾՇՊՁՆԻՄՍՋՁՇՆՁՆՌՀԽՋՌՍԼՑՊԽՈՇՊՌԱՀԽԿՍՁԼԽՄՁՆԽ

ՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹ

ՍՋԽԼՌՇՋՍՈՈՇՊՌՌՀԽՊԽՄՁԹԺՁՄՁՌՑՇԾՌՀԽՌԽՋՌԺԽ

ՁԼԽՆՌՁԾՁԽԼ

԰ՈԽԻՁԽՋՋԻՁԽՆՌՁԾՁԻՆԹՅԽ ԵԽՆՇՈՍՋՄԹԽՎՁՋ԰ՈԽԻՁԽՋՋՌՊԹՁՆ
ՁԾՋՌԹՌԽԼ ԫՇՌՊԽՈՇՊՌԽԼ

 Բ԰ԢՆՎՁՊՇՆՅԽՆՌԹՄԭՊՇՌԽԻՌՁՇՆԞԿԽՆԻՑ
ԢԭԞ
ԠՇՊՊԽԻՌՁՇՆՋԹՆԼԠՄԹՊՁԾՁԻԹՌՁՇՆՋՇՆԱԽԻՀՆՁԻԹՄԞՋՈԽԻՌՋՇԾՌՀԽԱԽՋՌԤՍՁԼԽՄՁՆԽՋԾՇՊՌՀԽԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ

԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅԱՁԽՊԞՋՋԹՑՋ
ԬԠ԰ԭԭԱԽՋՌԤՍՁԼԽՄՁՆԽ԰ԽՊՁԽՋԪԹՊԻՀԬԾԾՁԻԽՇԾԠՀԽՅՁԻԹՄ԰ԹԾԽՌՑԹՆԼԭՇՄՄՍՌՁՇՆԭՊԽՎԽՆՌՁՇՆ
ԬԠ԰ԭԭԴԹՋՀՁՆԿՌՇՆԡԠ
ՀՌՌՈՏՏՏԽՈԹԿՇՎԽՆԼՇՈՍԺՋԹՋՋԹՑՎԹՄՁԼԹՌՁՇՆԻՄԹՊՁԾՁԻԹՌՁՇՆԼՇԻՈԼԾ

Page 9 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԽՊԽՈԹՊԽՆՌՋՅԹՁՆՌԹՁՆԽԼԹՋՁՆՀՇՍՋԽՋՌՇԻՃ!

ԶԽՋ ԠՍՄՌՍՊԽՋՏԽՊԽՅԹՁՆՌԹՁՆԽԼԾՇՊՇՆԽՅՇՆՌՀ

ՈՊՁՇՊՌՇՌԽՋՌՁՆՁՌՁԹՌՁՇՆԺՑԴՁՄԼՄՁԾԽԦՆՌԽՊՆԹՌՁՇՆԹՄԩՌԼԹԾՌԽՊԺԽՁՆԿՇԺՌԹՁՆԽԼԾՊՇՅԵԽՆՇՈՍՋԦՇԾԡԽՐՌԽՊԪՁԻՀՁԿԹՆ

ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՄԹՊՎԹԽ ՍՋԽԼ ՁՆ ՌՀԽ

ԹՋՋԹՑԺԽԼԽՊՁՎԽԼԾՊՇՅՁՆՀՇՍՋԽԹԼՍՄՌՋ

ԴԽՊԽՈԹՊԽՆՌԹՄԹԻԻՄՁՅԹՌՁՇՆԻՇՆԼՁՌՁՇՆՋՋԹՅԽԹՋԼԽԾՁՆՁՌՁՎԽՌԽՋՌ!

ԶԽՋ

ԞԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼԾՇՊՈԹՊԽՆՌԹՄԾՊՇԿՋ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԻԹԼԹՑՋ

ԡԽՌԹՁՄՋՇՆՈԹՊԽՆՌԹՄԾԽԽԼՁՆԿ ԞԼՍՄՌԾՊՇԿՋՏԽՊԽԾԽԼԹՌԹ

ՊԹՌԽՋՍԾԾՁԻՁԽՆՌՌՇՅԹՁՆՌԹՁՆՌՀԽՀԽԹՄՌՀՇԾՌՀԽԻՍՄՌՍՊԽ

ԣՇՇԼՋՇՍՊԻԽՁՋԷԽՁԿՄԽՊԟՊՇՋԦՆԻՇԾԤԹՊԼՆԽՊՋԭԽՆՆՋՑՄՎԹՆՁԹ

ԡԽՌԹՁՄՋՇՆՈԹՊԽՆՌԹՄՀԽԹՄՌՀ ԭԹՊԽՆՌԹՄԾՊՇԿՋՏԽՊԽՁՆ

ԿՇՇԼՀԽԹՄՌՀՋՀՇՏՁՆԿՆՇՋՁԿՆՋՇԾԼՁՋԽԹՋԽՇՊՋՌՊԽՋՋ

Page 10 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԩԹՊՎԹՄ԰ԽՄԽԻՌՁՇՆԹՆԼԠԹՊԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԟԽՋՌՋՁՆԿՄԽՋՈԹՏՆ! ԶԽՋ ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌՌՀԽԺԽՋՌ-

ՁՆԼՁՎՁԼՍԹՄՋՈԹՏՆՋՏՁՌՀԹՅՁՆՁՅՍՅՇԾ

ՄԹՊՎԹԽՋՈԹՏՆԺԽԽՎԹՄՍԹՌԽԼՌՇՁԼԽՆՌՁԾՑՌՀԽ

ԺԽՋՌՋՁՆԿՄԽՋՈԹՏՆԹՆԼՌՀԹՌՌՀԽՄԹՊՎԹԽՋԽՄԽԻՌԽԼ

ԾՇՊՌԽՋՌՁՆԿՇՊՁԿՁՆԹՌԽԾՊՇՅՌՀԽԺԽՋՌՋՁՆԿՄԽՋՈԹՏՆ


ՁԽՌՀԽՋՈԹՏՆՋԹՊԽՆՇՌԻՇՅՁՐԽԼ

ԫՍՅԺԽՊՇԾՋՈԹՏՆՋԽՎԹՄՍԹՌԽԼ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԱՀՊԽԽ

ԫՍՅԺԽՊՇԾԽԿԿՋՋԹՅՈՄԽԼՈԽՊՋՈԹՏՆ

ԽԿԿՋԾՊՇՅԹՋՁՆԿՄԽՋՈԹՏՆՏԽՊԽԽՎԹՄՍԹՌԽԼԾՇՊՎՁԹԺՁՄՁՌՑ

ԢՅԺՊՑՇՆՁԻՎՁԹԺՁՄՁՌՑՏԹՋԻՀԽԻՃԽԼԼԹՁՄՑ

ԫԣՋՌԹԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽԼԽԾՁՆՁՌՁՎԽՋՌՍԼՑԺԽ

ՁՆՁՌՁԹՌԽԼՏՁՌՀՄԹՊՎԹԽԹՌԫՁԽՍՏՃՇՇՈ-ԣԹԺԽՊ


ԫԣԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽ
ԼԹՑՋ

ՈՇՋՌԾԽՊՌՁՄՁՒԹՌՁՇՆ

ԞԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ ԼԹՑՋՈՇՋՌԾԽՊՌՁՄՁՒԹՌՁՇՆ


ԼՈԾ

ԪԽԹՆՌՇՌԹՄՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾՊԽՈՇՊՌԽԼ

ԫՇՌԹՈՈՄՁԻԹԺՄԽ

ԯԹՆԿԽՇԾՌՇՌԹՄՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾՊԽՈՇՊՌԽԼ

ԫՇՌԹՈՈՄՁԻԹԺՄԽ

ԴԹՋՌՀԽՇՈՌՁՇՆԹՄՋՁՒԽՋԽՄԽԻՌՁՇՆՅԽՌՀՇԼՍՋԽԼ!

ԫՇ 

Page 11 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՄԹՊՎԹՄՋԽՄԽԻՌՁՇՆ ԞՋՄԹՊՎԹԽՊԽԹԻՀԽԼԫԣ

ՋՌԹԿԽՌԹԼՈՇՄԽՋՌՀԹՌՅԽՌՌՀԽԻՊՁՌԽՊՁԹԾՇՊՀՁՆԼՄՁՅԺՅՇՊՈՀՇՄՇԿՑՏԽՊԽՈՄԹԻԽԼՇՆԽՇՊՌՏՇԹՌԹՌՁՅԽՁՆՌՇՌՊԹՆՋԾԽՊՎԽՋՋԽՄՋՍՆՌՁՄԽԹԻՀՎԽՋՋԽՄԻՇՆՌԹՁՆԽԼՌԹԼՈՇՄԽՋ

ԩՇԹԼՁՆԿՊԹՌԽ
ՊԽԹՊՁՆԿԼԽՆՋՁՌՑ ՄԹՊՎԹԽԩ ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՊԽԹՊՁՆԿ ԼԽՆՋՁՌՑ


ՄՇԹԼՁՆԿ ՊԹՌԽ ՆՇՌ ԽՐԻԽԽԼ ԹՈՈՊՇՐՁՅԹՌԽՄՑ 

ՄԹՊՎԹԽԩ ԻՍՄՌՍՊՁՆԿ ՋՑՋՌԽՅ ԾՇՊ ԾՄՇՏՌՀՊՇՍԿՀ

ՋՑՋՌԽՅՋ ՇՊ  ՌԹԼՈՇՄԽՋԩ ՁՆ ՋՌԹՌՁԻՊԽՆԽՏԹՄ

ԽՐՈՇՋՍՊԽՋՑՋՌԽՅՋ

ԱՑՈԽՇԾԾՇՇԼ ԰ԽՊԹԪՁԻՊՇՆ ԢԭԞՊԽԻՇՅՅԽՆԼՋ԰ԽՊԹԪՁԻՊՇՆն ՌՀՊՇՍԿՀՇՍՌ

ՈՊԽԽՐՈՇՋՍՊԽ
ԹԾՌԽՊԫԣՋՌԹԿԽԹՆԼ

ԼՍՊՁՆԿՌՀԽԽՆՌՁՊԽԼԼԽԾՁՆՁՌՁՎԽՋՌՍԼՑԦԾ

԰ՇՍՊԻԽՇԾԾՇՇԼ ԰ԽՊԹԪՁԻՊՇՆնԲ԰Ԟ

ԪՇՆՌԿՇՅԽՊՑՎՁՄՄԽԭԞ

Page 12 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԦՇԼՁԼԽԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆԼՁԽՌ
ՁԾՃՆՇՏՆ

ԫՇՌՊԽՈՇՊՌԽԼ  ԹՆՇՌՀԽՊԼՁԽՌՁՋՍՋԽԼՌՀԽՋՌՍԼՑՊԽՈՇՊՌՋՀՇՍՄԼ

ՈՊՇՎՁԼԽԹՆԹՄՑՋՁՋՇԾՁՇԼՁԼԽԻՇՆՌԽՆՌԹՆԼՈՇՌԽՆՌՁԹՄ

ԻՇՆՌԹՅՁՆԹՆՌՋԹՆԼՌՀԽԼՁԽՌՋՀՇՍՄԼ

ԼԽՅՇՆՋՌՊԹՌԽԽՉՍԹՄՈԽՊԾՇՊՅԹՆԻԽՌՇ԰ԽՊԹ

ԪՁԻՊՇՆն 

ԣՊԽՉՍԽՆԻՑՇԾԾԽԽԼՁՆԿ ԱՀՊԽԽՌՁՅԽՋՈԽՊԼԹՑ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾԽԽԼՁՆԿՇԻԻՍՊԹՌՄԽԹՋՌ

ՌՏՁԻԽՈԽՊԼԹՑ

ԡԽՌԹՁՄՋՇՆԾԽԽԼՁՆԿՊԽԿՁՅԽ ԱՀԽԾԽԽԼՁՆԿՊԽԿՁՅԽՏԹՋ

ՅԿՄԹՊՎԹԼԹՑԹՆԼՁՆԻՊԽԹՋԽԼՌՇՅԿՄԹՊՎԹԼԹՑԺՑՌՀԽԽՆԼՇԾՌՀԽՌԽՋՌ

ԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌԾՇՇԼՊԹՌՁՇՆՋԼՍՊՁՆԿՌՀԽ

ՈՊԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼԺԽՁՆԻՊԽԹՋԽԼԹՄՇՆԿՏՁՌՀ

ՄԹՊՎԹՄԿՊՇՏՌՀՌՇԹՈՈՊՇՐՁՅԹՌԽՄՑ

ՅԿՄԹՊՎԹԼԹՑԺՑՌԽՋՌՁՆՁՌՁԹՌՁՇՆԢԭԞԹՆԼ

ԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌԾՇՇԼՊԹՌՁՇՆՋՁՆԻՊԽԹՋԽ

ԾՊՇՅՅԿՄԹՊՎԹԼԹՑԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
԰ՌՍԼՑ

ԡԹՑՌՇՅԿՄԹՊՎԹԼԹՑՁՆՌՀԽՄԹՋՌՏԽԽՃ

ՇԾՌՀԽՌԽՋՌ
԰ՌՍԼՑԡԹՑ

Page 13 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԠԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԦՆԾՇՊՅԹՌՁՇՆՇՆՌՀԽԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԹՆԼԱԽՋՌԳԽՋՋԽՄԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱՑՈԽՇԾԽՐՈՇՋՍՊԽ ԣՄՇՏՌՀՊՇՍԿՀ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԹԾՄՇՏՌՀՊՇՍԿՀ

ՋՑՋՌԽՅ

ԱՑՈԽՇԾԾՄՇՏՌՀՊՇՍԿՀԼՁՄՍՌՁՇՆՋՑՋՌԽՅ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԠՇՆՌՁՆՍՇՍՋԾՄՇՏԼՁՄՍՌԽՊ ԦՆՌԽՊՅՁՌՌԽՆՌԾՄՇՏՈՊՇՈՇՊՌՁՇՆԹՄԼՁՄՍՌԽՊՋՇՊ

ԻՇՆՌՁՆՍՇՍՋԾՄՇՏՋԽՊՁԹՄԼՁՄՍՌԽՊՋԹՊԽ

ՊԽԻՇՅՅԽՆԼԽԼ

ԣՄՇՏՌՀՊՇՍԿՀՊԹՌԽ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԻԹՅԩՅՁՆԺԹՋԽԼՇՆԹԩ

ԾՁՄՄՎՇՄՍՅԽԹՆԼՎՇՄՍՅԽԹԼԼՁՌՁՇՆՋՈԽՊԼԹՑ

ԱՀԽԽՋՌՁՅԹՌԽԼԾՄՇՏՊԹՌԽՈՊՇՎՁԼԽԼԻՇՅՈՄԽՌԽՎՇՄՍՅԽՊԽՈՄԹԻԽՅԽՆՌԹՈՈՊՇՐՁՅԹՌԽՄՑԽՎԽՊՑՀՇՍՊՋ

ԯԽԻՇՅՅԽՆԼԽԼԾՄՇՏՌՀՊՇՍԿՀՊԹՌԽՁՋ

ՅԩՅՁՆ
ԻՇՅՈՄԽՌԽՎՇՄՍՅԽՊԽՈՄԹԻԽՅԽՆՌԻԹ

ԽՎԽՊՑՀՊՋ

 ԞԼԼՁՌՁՇՆԹՄԿՍՁԼԹՆԻԽԾՇՊԹՉՍԹՌՁԻՌԽՋՌԼԽՋՁԿՆՁՋՄՇԻԹՌԽԼՁՆԬԠ԰ԭԭԤՍՁԼԽՄՁՆԽ԰ՈԽԻՁԹՄԠՇՆՋՁԼԽՊԹՌՁՇՆՋԾՇՊԠՇՆԼՍԻՌՁՆԿԞՉՍԹՌՁԻԩԹԺՇՊԹՌՇՊՑ԰ՌՍԼՁԽՋ

Page 14 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊԾՄՇՏՌՀՊՇՍԿՀՋՑՋՌԽՅՋ
ՁԾԹՈՈՄՁԻԹԺՄԽ

԰ՁՆԿՄԽՌԽՋՌՋՌՇԻՃՋՇՄՍՌՁՇՆՏԹՋԼԽՄՁՎԽՊԽԼՌՇՅՁՐՁՆԿԻՀԹՅԺԽՊՋԹՋՋՁԿՆԽԼՌՇԽԹԻՀՌՊԽԹՌՅԽՆՌ԰ՌՇԻՃՋՇՄՍՌՁՇՆՏԹՋԼՁՄՍՌԽԼՏՁՌՀՏԽՄՄՏԹՌԽՊՁՆՌՀԽՅՁՐՁՆԿԻՀԹՅԺԽՊՋՌՇՇԺՌԹՁՆԽԹԻՀՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆԱՀԽՈՊՇՈՇՊՌՁՇՆՇԾՌԽՋՌՋՇՄՍՌՁՇՆԼԽՄՁՎԽՊԽԼՌՇԽԹԻՀՊԽՈՄՁԻԹՌԽՌԽՋՌԻՀԹՅԺԽՊՏԹՋԻՀԽԻՃԽԼՈՊՁՇՊՌՇՌՀԽՌԽՋՌԹՆԼԹՈՈՊՇՐՁՅԹՌԽՄՑՏԽԽՃՄՑՌՇԽՆՋՍՊԽԾՄՇՏՊԹՌԽՋՎԹՊՁԽԼԺՑՆՇՅՇՊԽՌՀԹՆչՇԾՌՀԽՅԽԹՆԾՄՇՏՊԹՌԽԾՇՊՌՀԽՊԽՈՄՁԻԹՌԽՋԡԽՄՁՎԽՊՑՇԾՌԽՋՌՋՇՄՍՌՁՇՆՋՌՇՌՀԽՌԽՋՌԻՀԹՅԺԽՊՋՏԹՋՁՆՁՌՁԹՌԽԼԽՁԿՀՌԼԹՑՋՈՊՁՇՊՌՇՌՀԽՁՆՌՊՇԼՍԻՌՁՇՆՇԾՌՀԽՌԽՋՌՇՊԿԹՆՁՋՅՋ

ԯԽԻՇՅՅԽՆԼԽԼՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊ

ԾՄՇՏՌՀՊՇՍԿՀՋՑՋՌԽՅՋԪՁՐՁՆԿԻՀԹՅԺԽՊՁՋ

ՊԽԻՇՅՅԽՆԼԽԼԺՍՌՆՇՌՊԽՉՍՁՊԽԼԞԽՊԹՌՁՇՆ

ՁՋՆՇՌՊԽԻՇՅՅԽՆԼԽԼԾՇՊՅՁՐՁՆԿԞ

ԼԽՅՇՆՋՌՊԹՌՁՇՆՌՀԹՌՌՀԽՌԽՋՌՋՇՄՍՌՁՇՆՁՋ

ԻՇՅՈՄԽՌԽՄՑՅՁՐԽԼԺԽԾՇՊԽՁՆՌՊՇԼՍԻԽԼՁՆՌՇՌՀԽ

ՌԽՋՌՋՑՋՌԽՅՁՋՊԽԻՇՅՅԽՆԼԽԼԱՀԽ

ՊԽԻՇՅՅԽՆԼԽԼԾՄՇՏՋՈՄՁՌՌՁՆԿԹԻԻՍՊԹԻՑՁՋ

ՏՁՌՀՁՆ

ԯԽՆԽՏԹՄՈԽՊՁՇԼԾՇՊՋՌԹՌՁԻՊԽՆԽՏԹՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫՇՌԹՈՈՄՁԻԹԺՄԽ ԦԾՋՌԹՌՁԻՊԽՆԽՏԹՄՁՋՍՋԽԼԢԭԞՊԽԻՇՅՅԽՆԼՋ

ՀՊՊԽՆԽՏԹՄՊԽՆԽՏԹՄՈԽՊՁՇԼՁՋ

ՊԽԻՇՅՅԽՆԼԽԼՆՇՌՌՇԽՐԻԽԽԼՀՇՍՊՋ

Page 15 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԽՊԹՌՁՇՆ! ԫՇ ԢԭԞՊԽԻՇՅՅԽՆԼՋՅԹՁՆՌԹՁՆՁՆԿԼՁՋՋՇՄՎԽԼ

ՇՐՑԿԽՆԻՇՆԻԽՆՌՊԹՌՁՇՆՋ ԹՁՊՋԹՌՍՊԹՌՁՇՆ


 ՅԿԩԞԽՊԹՌՁՇՆՅԹՑԺԽՅԹՁՆՌԹՁՆԽԼ

ՌՀՊՇՍԿՀԺՍԺԺՄԽՊՋԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՇՋԽՌ

ԺՍԺԺՄԽՊՋԹՌՄԽՎԽՄՋՌՀԹՌԼՇՆՇՌԻԹՍՋԽՋՌՊԽՋՋ

ՇՆՌՀԽՌԹԼՈՇՄԽՋ

԰ՇՍՊԻԽՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊ ԣՊԽՋՀՏԹՌԽՊԾՊՇՅԹՅԽՌԽՊԼԽԽՈ

ՏԽՄՄՄՇԻԹՌԽԼՇՆՌՀԽԴՁՄԼՄՁԾԽԦՆՌԽՊՆԹՌՁՇՆԹՄԩՌԼ԰ՁՌԽ

ԡՁՄՍՌՁՇՆՏԹՌԽՊՏԹՋՈՊԽՈԹՊԽԼԺՑՈԹՋՋՁՆԿՌՀԽՏԽՄՄՏԹՌԽՊՌՀՊՇՍԿՀԹՋԹՆԼԾՁՄՌԽՊՌՇՊԽՅՇՎԽՈԹՊՌՁԻՄԽՋԿՊԽԹՌԽՊՌՀԹՆսՅԹՆԼՌՀԽՆՈՍՅՈՁՆԿՁՌՁՆՌՇԹՋՌՇՊԹԿԽՌԹՆՃՏՀԽՊԽՁՌՏԹՋԹԽՊԹՌԽԼԱՀԽՏԹՌԽՊՏԹՋԾՁՄՌԽՊԽԼՌՇսՅՌՇՊԽՅՇՎԽԾՁՆԽՈԹՊՌՁԻՄԽՋԹՆԼՏԹՋՈԹՋՋԽԼՌՀՊՇՍԿՀԹՆՍՄՌՊԹՎՁՇՄԽՌՋՌԽՊՁՄՁՒԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՆԹՌՍՊԹՄՇՊՊԽԻՇՆՋՌՁՌՍՌԽԼ

ՏԹՌԽՊՁՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՆԹՌՍՊԹՄՏԹՌԽՊ

ԺԽՋՌԽՊՁՄՁՒԽԼՏՁՌՀԲԳԹՆԼՌԽՋՌԽԼԾՇՊ

ՈԽՋՌՁԻՁԼԽՋՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊ

ՈՇՋՋՁԺՄԽԻՇՆՌԹՅՁՆԹՆՌՋՁՆԻՄՍԼՁՆԿՃՆՇՏՆ

ՋՍԺՋՌՊԹՌԽՋՇԾՌՀԽՁՇԼՁՆԽՌՊԹՆՋՈՇՊՌԽՊՇԾՌՀԽ

ՌՀՑՊՇՁԼԿՄԹՆԼ
ԽԿԾՄՍՇՊՁԼԽԻՀՄՇՊԹՌԽ

ՈԽՊԻՀՄՇՊԹՌԽԬԢԠԡԹԻԻԽՈՌՋԹՆՑՏԹՌԽՊՁՆ

ՏՀՁԻՀՌՀԽՌԽՋՌՋՈԽԻՁԽՋՋՀՇՏԻՇՆՌՊՇՄՋՍՊՎՁՎԹՄ

ԹՌՄԽԹՋՌԹՋԿՇՇԼԹՋՁՆԼՁԻԹՌԽԼՁՆՌՀԽՌԽՋՌ

ԿՍՁԼԽՄՁՆԽ

Page 16 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋԼՁՄՍՌՁՇՆՏԹՌԽՊԹՆԹՄՑՒԽԼԾՇՊՈԽՋՌՁԻՁԼԽՋՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊԻՇՆՌԹՅՁՆԹՆՌՋ!

ԶԽՋ ԡՁՄՍՌՁՇՆՏԹՌԽՊՏԹՋԹՆԹՄՑՒԽԼԾՇՊ

ՋՈԽԻՁԾՁԻԻՇՆԼՍԻՌԹՆԻԽՀԹՊԼՆԽՋՋԹՄՃԹՄՁՆՁՌՑՈԥՌՇՌԹՄՇՊԿԹՆՁԻԻԹՊԺՇՆՈԽՋՌՁԻՁԼԽՋՇՊԿԹՆՁԻՋԹՆԼՅԽՌԹՄՋ

ԦՇԼՁԼԽՋՍՈՈՄԽՅԽՆՌԹՌՁՇՆՁՆՏԹՌԽՊ!

ԫՇՈՊԽՄՁՅՁՆԹՊՑԹՆԹՄՑՋՁՋՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊՁՆԼՁԻԹՌԽԼԹՆՁՇԼՁԼԽԻՇՆԻԽՆՌՊԹՌՁՇՆՇԾԻԹՌՇսԿԩ

ԦԾՊԽԻՇՆՋՌՁՌՍՌԽԼՏԹՌԽՊՁՋՍՋԽԼՇՊՁԾ

ԺԹԻՃԿՊՇՍՆԼՄԽՎԽՄՋՇԾՁՇԼՁԼԽՁՆՆԹՌՍՊԹՄՏԹՌԽՊ

ԹՊԽՄԽՋՋՌՀԹՆսԿԩՁՇԼՁԼԽ

ՋՍՈՈՄԽՅԽՆՌԹՌՁՇՆՁՋՊԽԻՇՅՅԽՆԼԽԼԱՀՁՋ

ՋՍՈՈՄԽՅԽՆՌԹՌՁՇՆՁՋՁՆԹԼԼՁՌՁՇՆՌՇՌՀԽ

ՊԽԻՇՅՅԽՆԼԽԼԼՁԽՌԹՊՑՋՇՍՊԻԽՇԾՁՇԼՁԼԽ


ԽԿՁՆ԰ԽՊԹԪՁԻՊՇՆ

ԱԽՋՌՎԽՋՋԽՄՌՑՈԽՅԹՌԽՊՁԹՄՋ ԱԽՋՌԻՀԹՅԺԽՊՋՏԽՊԽԿՄԹՋՋԹՉՍԹՊՁԹ ԢԭԞ ԹՆԼ ԬԢԠԡ ՊԽԻՇՅՅԽՆԼ ՌՀԹՌ

ՏԹՌԽՊԻՇՆՌԹԻՌ ՈՇՊՌՁՇՆՋ ՇԾ ՌՀԽ ՋՑՋՌԽՅ ՆՇՌ

ԻՇՅՈՊՇՅՁՋԽ ՌՀԽ ՋՌՍԼՑ 
ԽԿ ԹՄՄ ԿՄԹՋՋ

ՎԽՋՋԽՄՋՇՊԿՄԹՋՋՎԽՋՋԽՄՋՏՁՌՀՋՌԹՁՆՄԽՋՋՋՌԽԽՄ

ԾՊԹՅԽՋԹՊԽԹԻԻԽՈՌԹԺՄԽԽՐԹՅՈՄԽՋ

ԱԽՋՌՎԽՋՋԽՄՋՁՒԽ ԰ՈԽԻՁԾՁԻԼՁՅԽՆՋՁՇՆՋՏԽՊԽՆՇՌ

ՊԽՈՇՊՌԽԼԱՀԽՌՇՌԹՄՎՇՄՍՅԽՏԹՋԩ

ԣՁՄՄՎՇՄՍՅԽ ԻԹԩ

Page 17 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋՇՆԽՐՈՇՋՍՊԽՋՑՋՌԽՅ

ԢՐՈՇՋՍՊԽՏԹՋԻՇՆԼՍԻՌԽԼՁՆԹՌԽՅՈԽՊԹՌՍՊԽԻՇՆՌՊՇՄՄԽԼԽՆՎՁՊՇՆՅԽՆՌԹՄԻՀԹՅԺԽՊՌՇՅԹՁՆՌԹՁՆՌՀԽՌԽՋՌՋՇՄՍՌՁՇՆՌԽՅՈԽՊԹՌՍՊԽՋԹՌ±ոԠ

 ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԴԹՌԽՊԮՍԹՄՁՌՑԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋՁՆՌՀԽԱԽՋՌ԰ՑՋՌԽՅ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ

ԪԽԹՋՍՊԽՅԽՆՌ

ԦՆՌԽՊՎԹՄ

ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԥԹՊԼՆԽՋՋ
ՅԿԩԹՋԠԹԠԬ    ԴԽԽՃՄՑ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՀԹՊԼՆԽՋՋՌՇ

ՅԿԩԹՋԠԹԠԬ

Ոԥ    ԴԽԽՃՄՑ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՈԥչ

ՁՆՌԽՊՊԽՈՄՁԻԹՌԽԹՆԼՁՆՌԽՊՌՊԽԹՌՅԽՆՌ

ԼՁԾԾԽՊԽՆՌՁԹՄՋՋՀՇՍՄԼՆՇՌԽՐԻԽԽԼ

ԡՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ՅԿԩ    ԴԽԽՃՄՑ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ԡԬ

 ՅԿԩ
 ԹՁՊՋԹՌՍՊԹՌՁՇՆԬԢԠԡ

ՊԽԻՇՅՅԽՆԼՋԡԬԻՇՆԻԽՆՌՊԹՌՁՇՆ ՅԿԩ


 ԹՁՊՋԹՌՍՊԹՌՁՇՆ

Page 18 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ

ԪԽԹՋՍՊԽՅԽՆՌ

ԦՆՌԽՊՎԹՄ

ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՅՈԽՊԹՌՍՊԽ   

ԱԽՅՈԽՊԹՌՍՊԽՏԹՋ

ԻՇՆՌՁՆՍՇՍՋՄՑԹՆԼ

ՊԽԻՇՊԼԽԼՏԽԽՃՄՑ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌԽՅՈԽՊԹՌՍՊԽչՇԠ

ՁՆՌԽՊՊԽՈՄՁԻԹՌԽԹՆԼՁՆՌԽՊՌՊԽԹՌՅԽՆՌ

ԼՁԾԾԽՊԽՆՌՁԹՄՋՋՀՇՍՄԼՆՇՌԽՐԻԽԽԼՇԠ

ԦՇԼՁԼԽ

ԳԹՄՍԽՆՇՌՊԽՈՇՊՌԽԼԤԩԭԻՇՅՈՄՁԹՆԻԽՋՌԹՌԽՅԽՆՌՁՆԼՁԻԹՌԽՋՌՀԹՌՈՊԽՄՁՅՁՆԹՊՑԹՆԹՄՑՋՁՋՇԾՏԹՌԽՊՁՇԼՁԼԽԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽՆՇՌՈԽՊԾՇՊՅԽԼԹԻԻՇՊԼՁՆԿՌՇ

Ԥԩԭ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՉՍԹՌՁԻՁՇԼՁԼԽՊԹՆԿԽ

-սԿԩ
ՋՍՈՈՄԽՅԽՆՌԹՄՁՇԼՁԼԽՋՀՇՍՄԼՆՇՌ

ԽՐԻԽԽԼսԿԩ

Page 19 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ

ԪԽԹՋՍՊԽՅԽՆՌ

ԦՆՌԽՊՎԹՄ

ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞՅՅՇՆՁԹ ԫՇՌՊԽՈՇՊՌԽԼ ԤԽՆԽՊԹՄՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋԾՇՊԾՊԽՉՍԽՆԻՑՇԾ

ՅԽԹՋՍՊԽՅԽՆՌՋԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌ

ՏԹՌԽՊՉՍԹՄՁՌՑՈԹՊԹՅԽՌԽՊՋԺԽՅԽԹՋՍՊԽԼՁՆԹ

ԻՇՆՌՊՇՄԹՆԼԹՌՇՆԽՌԽՋՌՁՌԽՅԻՇՆԻԽՆՌՊԹՌՁՇՆ

ԹՌՄԽԹՋՌՏԽԽՃՄՑԦՆՋՌԹՌՁԻՊԽՆԽՏԹՄՋՑՋՌԽՅՋ

ՏԹՌԽՊՉՍԹՄՁՌՑՈԹՊԹՅԽՌԽՊՋՁՆԻՄՍԼՁՆԿ

ԹՅՅՇՆՁԹՋՀՇՍՄԼԺԽՅԽԹՋՍՊԽԼՂՍՋՌՈՊՁՇՊՌՇ

ՊԽՆԽՏԹՄԦՆԹԼԼՁՌՁՇՆԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌ

ԡԬԺԽՅԽԹՋՍՊԽԼԹՌԽԹԻՀԻՇՆԻԽՆՌՊԹՌՁՇՆԹՌ

ՄԽԹՋՌՏԽԽՃՄՑԹՆԼՌՀԹՌՌԽՅՈԽՊԹՌՍՊԽԹՊԽ

ՅԽԹՋՍՊԽԼԻՇՆՌՁՆՍՇՍՋՄՑԬԢԠԡ

ՊԽԻՇՅՅԽՆԼՋՌՀԹՌ ԡԬԹՆԼՌԽՅՈԽՊԹՌՍՊԽԺԽ

ՅԽԹՋՍՊԽԼԹՌՄԽԹՋՌՏԽԽՃՄՑԹՆԼՌՀԹՌՈԥԹՆԼ

ՀԹՊԼՆԽՋՋԺԽՅԽԹՋՍՊԽԼԹՌՄԽԹՋՌԹՌՌՀԽ

ԺԽԿՁՆՆՁՆԿԹՆԼԽՆԼՇԾՌՀԽՌԽՋՌ

ԣՄՍՇՊՁԼԽ ԫՇՌՊԽՈՇՊՌԽԼԭԽՊԻՀՄՇՊԹՌԽ ԫՇՌՊԽՈՇՊՌԽԼԠՀՄՇՊԹՌԽ ԫՇՌՊԽՈՇՊՌԽԼ԰ՈԽԻՁԾՁԻԠՇՆԼՍԻՌԹՆԻԽ
ս԰ԻՅ    ԴԽԽՃՄՑ

Page 20 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

 ԡ԰ՌՍԼՑԡԽՋՁԿՆԹՆԼԞԼԼՁՌՁՇՆԹՄԢՐՈԽՊՁՅԽՆՌԹՄԠՇՆԼՁՌՁՇՆՋ

ԱԹԺՄԽԯԹՆԿԽԣՁՆԼՁՆԿ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ
ՁԾԞՈՈՄՁԻԹԺՄԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋԹՊԹՆԿԽԾՁՆԼԽՊԻՇՆԼՍԻՌԽԼ! ԶԽՋԦԾՑԽՋՏՀԹՌՏԹՋՌՀԽՅԽՌՀՇԼԾՇՊԼԽՌԽՊՅՁՆՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽՊԹՆԿԽԾՁՆԼԽՊ!

ԱՀԽՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽՊԹՆԿԽԾՁՆԼԽՊՏԹՋԺԹՋԽԼՇՆՌՀԽՏԹՌԽՊՋՇՄՍԺՁՄՁՌՑՇԾԭԠԫԟ
ՅԿԩԹՌոԠ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌՀԽ

ՌԽՋՌԻՇՅՈՇՍՆԼՅԿԩՇՊԼԽՅՇՆՋՌՊԹՌԽՋ

ԹԼԽՉՍԹՌԽԽՎՁԼԽՆԻԽՇԾՌՇՐՁԻՁՌՑ
ԽԿ

ՅՇՊՌԹՄՁՌՑՏՀՁԻՀԽՎԽՊԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋՄՇՏԽՋՌ

԰ՈԽԻՁԽՋ ԵԽՆՇՈՍՋՄԹԽՎՁՋԩՁԾԽՋՌԹԿԽ ԫԣՋՌԹԿԽԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ

Page 21 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ ԞՊԹՆԿԽԾՁՆԼՁՆԿՋՌՍԼՑՏԹՋ

ԻՇՆԼՍԻՌԽԼՏՁՌՀՌԹԼՈՇՄԽՋՁՆՋՁՆԿՄԽՊԽՈՄՁԻԹՌԽՋՇԾՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾԹՆԼՅԿԹՁԩԪՇՊՌԹՄՁՌՑՏԹՋՁՆԺՇՌՀՌՀԽԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋԱՀԽՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆԾՇՊՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌՏԹՋԺԹՋԽԼՇՆՇԾՌՀԽԽՋՌՁՅԹՌԽԼԼԹՑԩԠ

ՅԿԹՁԩ

ԱԹԺՄԽԡԽԾՁՆՁՌՁՎԽ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՌՀԽ ԼՍՊԹՌՁՇՆ ՇԾ ՌՀԽ

ԼԽԾՁՆՁՌՁՎԽՌԽՋՌԺԽԼԹՑՋ

Page 22 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԪԽՌՀՇԼԾՇՊՋԽՄԽԻՌՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԯԹՆԿԽԾՁՆԼԽՊ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌՀԽ

ՌԽՋՌԻՇՅՈՇՍՆԼՅԿԩՇՊԼԽՅՇՆՋՌՊԹՌԽՋ

ԹԼԽՉՍԹՌԽԽՎՁԼԽՆԻԽՇԾՌՇՐՁԻՁՌՑ
ԽԿ

ՅՇՊՌԹՄՁՌՑՏՀՁԻՀԽՎԽՊԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋՄՇՏԽՋՌ

ԯԽԾԽՊԽՆԻԽՋՌՍԼՑԻՁՌԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫՇՌԹՈՈՄՁԻԹԺՄԽ

԰ԽՈԹՊԹՌՁՇՆՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ  ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ՌՀԽ ՅԹՐՁՅՍՅ

ԻՇՆԻԽՆՌՊԹՌՁՇՆ ՋԽՈԹՊԹՌՁՇՆ ԺԽ  ԹՆԼ ՌՀԽ

ՅՁՆՁՅՍՅԺԽ

ԫՍՅԺԽՊՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ ԱՀՊԽԽՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋՈՄՍՋԹՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՇԾ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹՆԼԹԻՇՆՌՊՇՄՈՄՍՋՋՇՄՎԽՆՌ

ԻՇՆՌՊՇՄՁԾԹՈՈՊՇՈՊՁԹՌԽ

ԞՊԽՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹԼՂՍՋՌԽԼԾՇՊՈՍՊՁՌՑ!

ԫՇ 

ԦՆԼՁԻԹՌԽՌՀԽՌՑՈԽՇԾՎԹՄՍԽՋՈՊԽՋԽՆՌԽԼԾՇՊՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ԱՁՅԽՏԽՁԿՀՌԽԼԹՎԽՊԹԿԽ 

Page 23 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԩՁՅՁՌՇԾՉՍԹՆՌՁԾՁԻԹՌՁՇՆ
ԩԬԮ ՅԿԹՁԩ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՇՊԻՀԽՅՁԻԹՄՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽՄՇՏՌՀԽԩԬԮԹՆԹՄՑՋԽՋԺԽ

ԻՇՆԼՍԻՌԽԼՇՆՌՀԽՋՌՇԻՃՋՇՄՍՌՁՇՆՋ

ԩԽՎԽՄՇԾԼԽՌԽԻՌՁՇՆ
ԩԬԡ ԫՇՌՊԽՈՇՊՌԽԼԣՊԽՉՍԽՆԻՑՇԾՅԽԹՋՍՊԽՅԽՆՌ ԞՈՈՊՇՐՁՅԹՌԽՄՑԼԹՑՋ  ԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՌԽՋՌՁՌԽՅԻՇՆԻԽՆՌՊԹՌՁՇՆ

ԺԽՅԽԹՋՍՊԽԼՁՆՇՆԽՌԹՆՃԹՌԽԹԻՀՌՊԽԹՌՅԽՆՌ

ՄԽՎԽՄԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆԹՆԼԽՎԽՊՑՏԽԽՃ

ՌՀԽՊԽԹԾՌԽՊ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆԻՇՆՌՊՇՄ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆՋՇՄՎԽՆՌԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫՇՌԹՈՈՄՁԻԹԺՄԽ  ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԽՍՋԽՇԾԹ

ԻՇՆԻՍՊՊԽՆՌՋՇՄՎԽՆՌԻՇՆՌՊՇՄՏՀԽՆԹՋՇՄՍԺՁՄՁՒՁՆԿ

ԹԿԽՆՌՁՋՍՋԽԼԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՈԽՊՌԽՋՌՁՌԽՅՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

ԫՍՅԺԽՊՇԾՄԹՊՎԹԽՈԽՊՌՊԽԹՌՅԽՆՌԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

 

ԴԹՋԹՋՇՄՎԽՆՌՍՋԽԼ! ԫՇ԰ՇՄՎԽՆՌՌՑՈԽ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԫՇՌԹՈՈՄՁԻԹԺՄԽ ԰ԹՌՍՊԹՌՇՊԻՇՄՍՅՆՋՍՋԽԼ

Page 24 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԪԹՐՁՅՍՅՋՇՄՎԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫՇՌԹՈՈՄՁԻԹԺՄԽ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՋՇՄՎԽՆՌՆՇՌԽՐԻԽԽԼ

ՅՄԩԬԢԠԡՊԽԻՇՅՅԽՆԼՋՌՀԹՌՋՇՄՎԽՆՌ

ՀԹՎԽՆՇԽԾԾԽԻՌՇՆՋՍՊՎՁՎԹՄՆՇՊՈՊՇԼՍԻԽԹՆՑ

ՇՌՀԽՊԹԼՎԽՊՋԽԽԾԾԽԻՌՋԹՆԼՌՀԹՌԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՆՇՌԺԽԿՊԽԹՌԽՊՌՀԹՆՅՄԩ

ԴԹՋԹՈՇՋՁՌՁՎԽԻՇՆՌՊՇՄՍՋԽԼ! ԫՇԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԫՇՌԹՈՈՄՁԻԹԺՄԽ ԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄԻՇՆԻԽՆՌՊԹՌՁՇՆ
Ջ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫՇՌԹՈՈՄՁԻԹԺՄԽ 

ԭՀՇՌՇՈԽՊՁՇԼ ՀՊՋՄՁԿՀՌ

ՀՊՋԼԹՊՃ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՈՀՇՌՇՈԽՊՁՇԼ


ՄՁԿՀՌԼԹՊՃ

ԩՁԿՀՌՁՆՌԽՆՋՁՌՑԹՌՏԹՌԽՊ0ՋՋՍՊԾԹԻԽ -ԨՄՍՐՅԽԹՆ

ՇԾԨՄՍՐ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՄՁԿՀՌՁՆՌԽՆՋՁՌՑ-ԨՄՍՐ


ԹՌՏԹՌԽՊ0ՋՋՍՊԾԹԻԽ

 ԥՍՌԻՀՁՆՋՇՆԱԥ԰ՀՁՄՄԹԺԽԽՊԫԴՁՆՌԽՊԪԧԭՁԻՃԾՇՊԼԡԟ
ԞԻՍՌԽԹՆԼԻՀՊՇՆՁԻԽԾԾԽԻՌՋՇԾԻԹՊՊՁԽՊՋՇՄՎԽՆՌՋՁՆԹՉՍԹՌՁԻՇՊԿԹՆՁՋՅՋԞԻՊՁՌՁԻԹՄՊԽՎՁԽՏԯԽՎՁԽՏ

ԞՉՍԹՌՁԻԱՇՐՁԻՇՄՇԿՑՈՈ-

 ԬԢԠԡ
ԤՍՁԼԹՆԻԽԡՇԻՍՅԽՆՌՇՆԞՉՍԹՌՁԻԱՇՐՁԻՁՌՑԱԽՋՌՁՆԿՇԾԡՁԾԾՁԻՍՄՌ԰ՍԺՋՌԹՆԻԽՋԹՆԼԪՁՐՌՍՊԽՋԢՆՎՁՊՇՆՅԽՆՌԹՄԥԽԹՄՌՀԹՆԼ԰ԹԾԽՌՑԭՍԺՄՁԻԹՌՁՇՆՋ԰ԽՊՁԽՋ

ՇՆԱԽՋՌՁՆԿԹՆԼԞՋՋԽՋՋՅԽՆՌԫՇԭԹՊՁՋԣՊԹՆԻԽ

Page 25 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ ԫՇՌԹՈՈՄՁԻԹԺՄԽ ԱՀԽՌԽՋՌՋՇՄՍՌՁՇՆՋՏԽՊԽԻՄԽԹՊԹՆԼԻՇՄՇՊՄԽՋՋ

ՏՁՌՀՆՇԽՎՁԼԽՆԻԽՇԾՈՊԽԻՁՈՁՌԹՌՁՇՆՋՍՊԾԹԻԽԾՁՄՅՋՇՊՍՆԼՁՋՋՇՄՎԽԼՅԹՌԽՊՁԹՄ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԱՊԽԹՌՅԽՆՌԠՇՆԻԽՆՌՊԹՌՁՇՆՋՁՆՌՀԽԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑՏՁՌՀԭԠԫԟՌԽԻՀՆՁԻԹՄ

ԱՊԽԹՌՅԽՆՌԦԡ

ԫՇՅՁՆԹՄ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԱԴԞԪԽԹՋՍՊԽԼ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԪԽԹՆԠԳ
 ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ   ԫԞ ԫԞ ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌՌԽՋՌՁՌԽՅ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽՅԹՁՆՌԹՁՆԽԼԹՌԹԻՇԽԾԾՁԻՁԽՆՌՇԾ

ՎԹՊՁԹՌՁՇՆ
ԠԳ

ԱՊԽԹՌՅԽՆՌ    ԫԞԱՊԽԹՌՅԽՆՌ    ԫԞԱՊԽԹՌՅԽՆՌ    ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԠԳԠՇԽԾԾՁԻՁԽՆՌՇԾՎԹՊՁԹՌՁՇՆԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ

 ԠԹՄԻՍՄԹՌԽԼԺՑԯԽՎՁԽՏԽՊ     

 ԢԬԺՋԽՊՎԹՌՁՇՆՋ

ԟՁՇՄՇԿՁԻԹՄԢՆԼՈՇՁՆՌՋ ԡԹՑԫԣՋՌԹԿԽՏԽՌՏԽՁԿՀՌ԰ԳԩԥԩԩՆՇՊՅԹՄՁՒԽԼԥԩԩ

Page 26 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

        ԡԹՑԫԣՋՌԹԿԽՏԽՌՏԽՁԿՀՌ԰ԳԩԥԩԩՆՇՊՅԹՄՁՒԽԼԥԩԩՌՀՑՊՇՁԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑ

        ԡԹՁՄՑՅՇՊՌԹՄՁՌՑԹՆԼԻՄՁՆՁԻԹՄՋՁԿՆՋ

ԴԽՊԽՊԹՏ
ՁՆԼՁՎՁԼՍԹՄԼԹՌԹՈՊՇՎՁԼԽԼ!ԶԽՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՇԺՋԽՊՎԹՌՁՇՆՋՇԾՅՇՊՌԹՄՁՌՑԹՆԼԻՄՁՆՁԻԹՄՋՁԿՆՋՇԻԻՍՊԼԹՁՄՑԹՌԹՅՁՆՁՅՍՅՇՌՀԽՊՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽՊԽԻՇՅՅԽՆԼԽԼԹՋԾՇՄՄՇՏՋԫԣ

ԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽ
ԡԹՑՋԹՆԼԹՆՑԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌՁՆԼՁԻԹՌԽԼԺՑՌԹԼՈՇՄԽՋՌՀԹՌԻԹՆՆՇՌԺԽԹՋՋՁԿՆԽԼԹՆԫԣՋՌԹԿԽ
ԡԹՑՋԹՆԼ

ՀՁՆԼՄՁՅԺՄԽՆԿՌՀ
ԡԹՑՋԹՆԼՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
ԡԹՑՋԹՆԼԺՇԼՑՏԽՁԿՀՌ
ՌԽՋՌՁՆՁՌՁԹՌՁՇՆԾՇՊՇՈՌՁՇՆԹՄՋՁՒԽԺԹՋԽԼՄԹՊՎԹՄՋԽՄԽԻՌՁՇՆԹՆԼՌՀՑՊՇՁԼ

ԿՄԹՆԼԿՊՇՋՋՈԹՌՀՇՄՇԿՑԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑ
ԡԹՑԫՇՌԽՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՑՋԽԻՌՁՇՆՇԾՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԹՄՋՇՁՆԻՄՍԼԽՋՌՀՑՊՇՁԼԿՊՇՋՋՈԹՌՀՇՄՇԿՑՇԺՋԽՊՎԹՌՁՇՆՋ

Page 27 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԦԦ ԯԢ԰ԲԩԱ԰ԞԫԡԡԦ԰ԠԲ԰԰ԦԬԫ

Ԟ ԯԽՋՍՄՌՋ

ԞԾՌԽՊԼԹՑՋՇԾԽՐՈՇՋՍՊԽՅԽԹՆՋՍՊՎՁՎԹՄՏԹՋՊԽՈՇՊՌԽԼՄՑՁՆԺՇՌՀՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՌՀԽ

ԱԴԞՅԽԹՋՍՊԽԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈԹՆԼՁՆՌՀԽԱԴԞՅԽԹՋՍՊԽԼԹՆԼ

ՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԟՑՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆՅԽԹՆՋՍՊՎՁՎԹՄՏԹՋՊԽՈՇՊՌԽԼՄՑՁՆԺՇՌՀՌՀԽՆԽԿԹՌՁՎԽ

ԻՇՆՌՊՇՄԹՆԼՌՀԽԱԴԞՅԽԹՋՍՊԽԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆՌՀԽԱԴԞՅԽԹՋՍՊԽԼ

ՌՊԽԹՌՅԽՆՌԿՊՇՍՈԹՆԼՁՆՌՀԽԱԴԞՅԽԹՋՍՊԽԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈԦՆՌՀԽ

ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՊՇՍՈՇՆԽՌԹԼՈՇՄԽՏԹՋՁՆԻՁԼԽՆՌԹՄՄՑՃՁՄՄԽԼԼՍՊՁՆԿՋՁՈՀՇՆՁՆԿԹՆԼՌՀԽՋՌՍԼՑԹՍՌՀՇՊՋԼՁԼՆՇՌ

ԻՇՆՋՁԼԽՊՌՀՁՋԼԽԹՌՀՁՆՋՍՊՎՁՎԹՄԻԹՄԻՍՄԹՌՁՇՆՋԹԻՌՍԹՄՋՍՊՎՁՎԹՄԼԹՌԹ
ՁՆԻՄՍԼՁՆԿՁՆԻՁԼԽՆՌԹՄԼԽԹՌՀՋԹՊԽՈՊԽՋԽՆՌԽԼ

ԺԽՄՇՏՁՆԱԹԺՄԽ

ԱԹԺՄԽԩԹՊՎԹՄԪՇՊՌԹՄՁՌՑՁՆԵԽՆՇՈՍՋՄԹԽՎՁՋ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԩԹՊՎԹՄԪՇՊՌԹՄՁՌՑ

ԡԹՑ ԡԹՑ

ԫ ԪՇՊՌԹՄՁՌՑ ԪՇՊՌԹՄՁՌՑ ԫ ԪՇՊՌԹՄՁՌՑ ԪՇՊՌԹՄՁՌՑ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ      

      

      

      

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



 ԰ԹՅՈՄԽՋՁՒԽԹՆԼԻՍՅՍՄԹՌՁՎԽՅՇՊՌԹՄՁՌՑՎԹՄՍԽՋԹՌԡԹՑՈՊՁՇՊՌՇՁՆՌԽՊՁՅՋԹԻՊՁԾՁԻԽ



 ԫՍՅԺԽՊՇԾՁՆԼՁՎՁԼՍԹՄՌԹԼՈՇՄԽՋՈԽՊՌՊԽԹՌՅԽՆՌ

ԟՑԡԹՑՌՀԽՅԽԼՁԹՆԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՏԹՋԾՇՊՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼԹՄՄՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ


ԱԹԺՄԽԞՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆՌՀԽՅԽԼՁԹՆԼԽՎԽՄՇՈՅԽՆՌՋՌԹԿԽՏԹՋԾՇՊՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼ

ԾՇՊԹՄՄՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ

Page 28 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԩԹՊՎԹՄԡԽՎԽՄՇՈՅԽՆՌՁՆԵԽՆՇՈՍՋՄԹԽՎՁՋ-ԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽԹՆԼԞՋՑՆԻՀՊՇՆՇՍՋԡԽՎԽՄՇՈՅԽՆՌ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽ

ԡԹՑ ԡԹՑ

Ն

ԪԽԼՁԹՆ

԰ՌԹԿԽ

ԞՋՑՆԻՀՊՇՆՇՍՋ Ն

ԪԽԼՁԹՆ

԰ՌԹԿԽ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ      

      

      

      

ԱՀԽԡԹՑՆՇՊՅԹՄՁՒԽԼԥԩԩԹՎԽՊԹԿԽԼՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈ


ԱԹԺՄԽԫՇՊՅԹՄՁՒԽԼԥԩԩՏԹՋՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈԹՆԼՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈԱՀԽՋՌՍԼՑԹՍՌՀՇՊՊԽՈՇՊՌԽԼՌՀԹՌՌՀԽՅԽԹՆՆՇՊՅԹՄՁՒԽԼԥԩԩՇՆԡԹՑՏԹՋՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ՁՆՌՀԽԱԴԞՅԽԹՋՍՊԽԼԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԹՆԼՁՆՌՀԽԱԴԞՅԽԹՋՍՊԽԼ

ՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈ

Page 29 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԩԹՊՎԹՄԡԽՎԽՄՇՈՅԽՆՌՁՆԵԽՆՇՈՍՋՄԹԽՎՁՋ-ԥՁՆԼԩՁՅԺԩԽՆԿՌՀ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԥՁՆԼԩՁՅԺԩԽՆԿՌՀ
ԥԩԩ

ԡԹՑ ԡԹՑ

Ն ԪԽԹՆ


ՅՅ

չ԰ԡ

ԥԩԩ

԰Գԩ Ն ԪԽԹՆ
ՅՅ

չ԰ԡ

ԥԩԩ

԰Գԩ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ        

        

        

        

ԞԺԺՊԽՎՁԹՌՁՇՆՋ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ



 ԰ՍՅՅԹՊՑՊԽՋՍՄՌՋԾՇՊՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰ԳԩԹՊԽՈՊԽՋԽՆՌԽԼՁՆՌՀԽՆԽՐՌՌԹԺՄԽ
ԱԹԺՄԽ

ԡԹՑ԰ԳԩԹՎԽՊԹԿԽԼՅՅՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈԹՆԼՅՅ

ԹՆԼՅՅՁՆՌՀԽԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽԟՑԡԹՑ԰Գԩ

ԹՎԽՊԹԿԽԼՅՅՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼԹՆԼՅՅՁՆՌՀԽԹՆԼ

ՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ

ԡԹՑՏԽՌՏԽՁԿՀՌԹՎԽՊԹԿԽԼԿՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼԹՆԼԿՁՆՌՀԽ

ԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ
ԱԹԺՄԽԡԹՑՏԽՌՏԽՁԿՀՌԹՎԽՊԹԿԽԼԿ

ՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼԹՆԼԿՁՆՌՀԽԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑ

Page 30 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԩԹՊՎԹՄԤՊՇՏՌՀՁՆԵԽՆՇՈՍՋՄԹԽՎՁՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞ

ՅԽԹՋՍՊԽԼ%

԰ՆՇՍՌԳԽՆՌԩԽՆԿՌՀ
԰Գԩ ԟՇԼՑԴԽՁԿՀՌ

ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ

Ն ԪԽԹՆ


ՅՅ

չ԰ԡ Ն ԪԽԹՆ


ՅՅ

չ԰ԡ Ն ԪԽԹՆ


Կ

չ԰ԡ Ն ԪԽԹՆ


Կ

չ԰ԡ

ԫԽԿԹՌՁՎԽ

ԠՇՆՌՊՇՄ

           

            

            

            

ԞԺԺՊԽՎՁԹՌՁՇՆՋ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ



 ԞՄՋՇՊԽԾԽՊՊԽԼՌՇԹՋ՟ՏԽՌՏԽՁԿՀՌՠՁՆՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽ

ԞԻԻՇՊԼՁՆԿՌՇՌՀԽՈԹՌՀՇՄՇԿՁՋՌ0ՋՊԽՈՇՊՌՏՀԽՆԻՇՅՈԹՊԽԼՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՊՇՍՈՌՀԽՀՁԿՀԽՋՌՌՊԽԹՌՅԽՆՌԿՊՇՍՈ

ԻՇՆՌԹՁՆԽԼՅՇՊԽԹՆՁՅԹՄՋՌՀԹՌՋՀՇՏԽԼՅՁՄԼԿՄԹՆԼԹՌՊՇՈՀՑ
ԹՆԼՋԽՎԽՊԽԿՄԹՆԼՀՑՈԽՊՌՊՇՈՀՑ
ՌՀԹՆՌՀԽՆԽԿԹՌՁՎԽ

ԻՇՆՌՊՇՄԿՊՇՍՈԠՇՆԻՇՅՁՌԹՆՌՄՑՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԹՄՋՇՋՀՇՏԽԼՅՇՊԽԹՆՁՅԹՄՋՏՁՌՀՅՁՄԼԾՇՄՄՁԻՄԽՋՁՒԽԼԽԻՊԽԹՋԽ


ԹՆԼՅՇԼԽՊԹՌԽՋԽՎԽՊԽԾՇՄՄՁԻՄԽՋՁՒԽՁՆԻՊԽԹՋԽ
ՌՀԹՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԿՊՇՍՈԥՇՏԽՎԽՊԹԻԻՇՊԼՁՆԿՌՇԽՐԹԻՌ

ՇՆԽՋՁԼԽԼԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼՌԽՋՌՋԻՇՆԼՍԻՌԽԼԺՑՌՀԽՋՌՍԼՑԹՍՌՀՇՊՌՀԽՋԽՎԽՊՁՌՑՋԻՇՊԽՋՁՆՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ

ԽՐՈՇՋԽԼՌՇՌՀԽՌԽՋՌՋՍԺՋՌԹՆԻԽՏԽՊԽՆՇՌՋՁԿՆՁԾՁԻԹՆՌՄՑԼՁԾԾԽՊԽՆՌԾՊՇՅՋԽՎԽՊՁՌՑՋԻՇՊԽՋՊԽԻՇՊԼԽԼԾՇՊՌՀԽԻՇՆՌՊՇՄԿՊՇՍՈ

ԣՁՆԼՁՆԿՋԾՇՊԾՇՄՄՁԻՍՄԹՊՀՑՈԽՊՌՊՇՈՀՑԹՆԼՀՑՈԽՊՈՄԹՋՁԹԹՆԼՇՌՀԽՊԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼԽԼՉՍԹՄՁՌԹՌՁՎԽՇԺՋԽՊՎԹՌՁՇՆՋՏԽՊԽ

ՆՇՌՊԽՈՇՊՌԽԼԺՍՌՌՀԽՈԹՌՀՇՄՇԿՁՋՌԼԽՋԻՊՁԺԽԼՇՌՀԽՊԾՁՆԼՁՆԿՋՏՀՁԻՀԹՊԽՋՀՇՏՆՁՆԱԹԺՄԽ



Page 31 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԤՊՇՋՋԭԹՌՀՇՄՇԿՑԹՆԼԥՁՋՌՇՈԹՌՀՇՄՇԿՑՇԾՌՀԽԱՀՑՊՇՁԼԤՄԹՆԼՁՆԵԽՆՇՈՍՋՄԹԽՎՁՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞ

ՅԽԹՋՍՊԽԼ%

ԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԱՀՑՊՇՁԼԤՄԹՆԼ

ԥՑՈԽՊՌՊՇՈՀՑ

ԱՀՑՊՇՁԼԤՄԹՆԼ

ԞՌՊՇՈՀՑ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՌՊՇՈՀՑ

ԣՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՈՄԹՋՁԹ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ         

        

        

        

         

        

        

        

         

        

        

        

         

        

        

        



 ԱՀՑՊՇՁԼԿՄԹՆԼԿՊՇՋՋՈԹՌՀՇՄՇԿՑԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՄԼ

ԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԬԢԠԡԫՇԾՇՊՊԽԾԽՊԽՆԻԽ

Page 32 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԞԼԼՁՌՁՇՆԹՄԱՀՑՊՇՁԼԤՄԹՆԼԥՁՋՌՇՈԹՌՀՇՄՇԿՑԬԺՋԽՊՎԹՌՁՇՆՋՁՆԵԽՆՇՈՍՋՄԹԽՎՁՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԮՍԹՄՁՌԹՌՁՎԽԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԣՇՄՄՁԻՍՄԹՊԩՍՅԽՆ

ԞՊԽԹ
ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՄԽԹՋՑՅՅԽՌՊՑ

ՁՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊ԰ՁՒԽ


ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊ԰ՁՒԽ


ԡԽԻՊԽԹՋԽ

ԤՄԹՆԼԞՋՑՅՅԽՌՊՑ

ԦՆԻՊԽԹՋԽ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ ԫ ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ           

          

                    

           

          

                    

           

          

                    

Page 33 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԮՍԹՄՁՌԹՌՁՎԽԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԣՇՄՄՁԻՍՄԹՊԩՍՅԽՆ

ԞՊԽԹ
ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՄԽԹՋՑՅՅԽՌՊՑ

ՁՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊ԰ՁՒԽ


ԦՆԻՊԽԹՋԽ

ԣՇՄՄՁԻՍՄԹՊ԰ՁՒԽ


ԡԽԻՊԽԹՋԽ

ԤՄԹՆԼԞՋՑՅՅԽՌՊՑ

ԦՆԻՊԽԹՋԽ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ ԫ ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

           

          

                    

 ԱՀՑՊՇՁԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՁՋԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԬԢԠԡԫՇԾՇՊՊԽԾԽՊԽՆԻԽ԰ՅԹՄՄՋՁՒԽՏԹՋՆՇՌԽԼՁՆՇՆԽՌԹԼՈՇՄԽՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՁՆՇՆԽՌԹԼՈՇՄԽՁՆՌՀԽՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈԱԹՁՄԻՍՊՎԹՌՍՊԽՏԹՋՈՊԽՋԽՆՌՁՆ

ԹՆԼՇԾՌՀԽՌԹԼՈՇՄԽՋՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՌՀԽԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑԹՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ

Page 34 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԠՄՁՆՁԻԹՄ԰ՁԿՆՋՁՆԵԽՆՇՈՍՋՄԹԽՎՁՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԠՄՁՆՁԻԹՄ԰ՁԿՆՋ

ԱՑՈԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ

԰ՅԹՄՄՋՁՒԽ





԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ



԰ՅԹՄՄՋՁՒԽ





԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ



԰ՅԹՄՄՋՁՒԽ





԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ



԰ՅԹՄՄՋՁՒԽ





԰ՈՁՆԹՄԻՍՊՎԹՌՍՊԽ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ

 ԰ԽՎԽՊՁՌՑ

 ԫՇՌԽՌՀԹՌԹՋՑՆԻՀՊՇՆՇՍՋԼԽՎԽՄՇՈՅԽՆՌ
ՍՆԹԺՄԽՌՇՋՌԹԿԽՁՋՊԽՈՇՊՌԽԼՈՊԽՎՁՇՍՋՄՑՁՆԱԹԺՄԽ

  ԰ԽՎԽՊՁՌՑՋԻՇՊԽՋԾՇՊՋՈՁՆԹՄԻՍՊՎԹՌՍՊԽԹՊԽՊԽՈՇՊՌԽԼՀԽՊԽԹՋԹՋՋՁԿՆԽԼԺՑՌՀԽՋՌՍԼՑԹՍՌՀՇՊ

Page 35 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԟ ԰ՌՍԼՑԞՍՌՀՇՊ0ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

ԣՇՊԹՄՄՉՍԹՆՌՁՌԹՌՁՎԽԽՆԼՈՇՁՆՌՋ
ԥԩԩ԰ԳԩՏԽՌՏԽՁԿՀՌՌՀԹՌԾՇՄՄՇՏԽԼԹՅՇՆՇՌՇՆՁԻԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽ

ՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌԽՋՌՏԹՋԹՈՈՄՁԽԼՁՆԹՋՌԽՈԼՇՏՆՅԹՆՆԽՊՌՇԽՋՌԹԺՄՁՋՀՋՁԿՆՁԾՁԻԹՆՌՌՊԽԹՌՅԽՆՌԽԾԾԽԻՌՋ

ԣՇՊԻՇՆՌՁՆՍՇՍՋԽՆԼՈՇՁՆՌՋՌՀԹՌՏԽՊԽՆՇՌԻՇՆՋՁՋՌԽՆՌՏՁՌՀԹՅՇՆՇՌՇՆՁԻՊԽՋՈՇՆՋԽՌՀԽԼԹՌԹՏԽՊԽԽՎԹՄՍԹՌԽԼ

ԾՇՊՆՇՊՅԹՄՁՌՑ
԰ՀԹՈՁՊՇԴՁՄՃ0ՋՌԽՋՌԹՆԼՀՇՅՇԿԽՆԽՁՌՑ
ԩԽՎԽՆԽ0ՋՌԽՋՌԦԾԹԼԹՌԹՋԽՌՏԹՋԾՇՍՆԼՌՇՀԹՎԽԹ

ՆՇՆՆՇՊՅԹՄԼՁՋՌՊՁԺՍՌՁՇՆՇՊԹՀԽՌԽՊՇԿԽՆԽՇՍՋԼՁՋՌՊՁԺՍՌՁՇՆՇԾՎԹՊՁԹՆԻԽԹՆՇՊՅԹՄՁՒՁՆԿՎԹՊՁԹՆԻԽՋՌԹԺՁՄՁՒՁՆԿ

ՌՊԹՆՋԾՇՊՅԹՌՁՇՆՏԹՋՍՋԽԼԦԾՌՀԽՌՊԹՆՋԾՇՊՅԹՌՁՇՆԹԻՀՁԽՎԽԼՆՇՊՅԹՄՁՌՑԹՆԼԽՉՍԹՄՎԹՊՁԹՆԻԽԼԹՌԹՏԽՊԽՌԽՋՌԽԼ

ՍՋՁՆԿԡՍՆՆԽՌՌ0ՋՌԽՋՌԦԾՌՀԽԼԹՌԹՏԽՊԽՆՇՊՅԹՄՄՑԼՁՋՌՊՁԺՍՌԽԼՏՁՌՀՍՆԽՉՍԹՄՎԹՊՁԹՆԻԽԹԾՌԽՊՌՀԽՌՊԹՆՋԾՇՊՅԹՌՁՇՆ

ՌՀԽԱԹՅՀԹՆԽԡՍՆՆԽՌՌ
ԱՌԽՋՌՇՊՌՀԽԪԹՆՆԴՀՁՌՆԽՑԴՁՄԻՇՐՇՆԲՌԽՋՌՏԽՊԽՍՋԽԼՌՇԽՎԹՄՍԹՌԽՌՀԽԼԹՌԹ

ԴՀԽՊԽ ՆՇ ՆՇՊՅԹՄՁՒՁՆԿ ՌՊԹՆՋԾՇՊՅԹՌՁՇՆ ԻՇՍՄԼ ԺԽ ԾՇՍՆԼ ՌՀԽ ԪԹՆՆԴՀՁՌՆԽՑԴՁՄԻՇՐՇՆ Բ ՌԽՋՌ ՍՋՁՆԿ Թ

ԟՇՆԾԽՊՊՇՆՁԥՇՄՅԹԼՂՍՋՌՅԽՆՌՌՇՌՀԽՈՎԹՄՍԽՋՏԹՋՍՋԽԼՌՇԽՎԹՄՍԹՌԽՌՀԽԼԹՌԹՋԽՌՋ

Ԟ ԠՇԻՀՊԹՆԞՊՅՁՌԹԿԽ ՌԽՋՌ ՏԹՋ ԹՈՈՄՁԽԼ ՁԾ ՌՀԽ ԼԹՌԹ ՋԽՌ ՀԹԼ Թ ԻՇՆՋՁՋՌԽՆՌ ԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽ

ԞՄՌԽՊՆԹՌՁՎԽՄՑ ՆՇՆՅՇՆՇՌՇՆՁԻ ՅՇՊՌԹՄՁՌՑ ԼԹՌԹ ՋԽՌՋ ՏԽՊԽ ԽՎԹՄՍԹՌԽԼ ՍՋՁՆԿ ԣՁՋՀԽՊ0Ջ ԢՐԹԻՌ ՌԽՋՌ ՏՁՌՀ Թ

ԟՇՆԾԽՊՊՇՆՁԥՇՄՅԹԼՂՍՋՌՅԽՆՌԦՆՌՀԽԽՎԽՆՌՅԽԼՁԹՆՎԹՄՍԽՋԻՇՍՄԼՆՇՌԺԽԼԽՌԽՊՅՁՆԽԼՊԽՈՄՁԻԹՌԽՅԽԹՆՋՌԹԿԽ

ՎԹՄՍԽՋ ՏԽՊԽ ՍՋԽԼ ԹՆԼ ԽՎԹՄՍԹՌԽԼ ՍՋՁՆԿ ԡՍՆՆԽՌՌ0Ջ ՌԽՋՌ ԠՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽ ՅՇՆՇՌՇՆՁԻՁՌՑ ՏԹՋ

ԹՋՋԽՋՋԽԼՎՁՋՍԹՄՄՑԾՊՇՅՌՀԽՊԽՈՄՁԻԹՌԽԹՆԼՌՊԽԹՌՅԽՆՌՅԽԼՁԹՆՋՇՊՅԽԹՆՋԦԾՋՇՅԽՇԾՌՀԽՋԽՈՊՇԻԽԼՍՊԽՋՏԽՊԽ

ՆՇՌԹՈՈՊՇՈՊՁԹՌԽԾՇՊՌՀԽՊԽՋՈԽԻՌՁՎԽԼԹՌԹՋԽՌՌՀԽՆՌՀԽԬԢԠԡԠՍՊՊԽՆՌԞՈՈՊՇԹԻՀԽՋՁՆՌՀԽ԰ՌԹՌՁՋՌՁԻԹՄԞՆԹՄՑՋՁՋ

ՇԾԢԻՇՌՇՐՁԻՁՌՑԡԹՌԹԞԤՍՁԼԹՆԻԽՌՇԞՈՈՄՁԻԹՌՁՇՆՏԹՋԻՇՆՋՍՄՌԽԼ
ԬԢԠԡԠԢԱԦ԰ԠՇՅՈՊԽՀԽՆՋՁՎԽ

ԢՆՎՁՊՇՆՅԽՆՌԹՄԱՇՐՁԻՁՌՑԦՆԾՇՊՅԹՌՁՇՆ԰ՑՋՌԽՅԱԪ
ԦՎԽՋԳԽՊՋՁՇՆՋՇԾՌՏԹՊԽՏԹՋՍՋԽԼՌՇՈԽՊԾՇՊՅ

ԹՄՄՋՌԹՌՁՋՌՁԻԹՄԻՇՅՈՍՌԹՌՁՇՆՋ

ԞՄՄՋՌԹՌՁՋՌՁԻԹՄԻՇՆԻՄՍՋՁՇՆՋՏԽՊԽՅԹԼԽԹՌՌՀԽՄԽՎԽՄՇԾԻԽՊՌԹՁՆՌՑԽՐԻԽՈՌ ՁՆՌՀԽԻԹՋԽՇԾՌՀԽԺԹՋՁԻ

ԹՋՋՍՅՈՌՁՇՆՌԽՋՌՋՋՍԻՀԹՋ԰ՀԹՈՁՊՇԴՁՄՃՋ0ԱԽՋՌԹՆԼԟԹՊՌՄԽՌՌ0ՋԱԽՋՌՁՆՏՀՁԻՀՌՀԽՄԽՎԽՄՇԾԻԽՊՌԹՁՆՌՑՏԹՋ

ԹՈՈՄՁԽԼ

ԡՍՆՆԽՌՌ0ՋՌԽՋՌՁՆԼՁԻԹՌԽԼԹՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԼԽԻՊԽԹՋԽՁՆԡԹՑՏԽՌՏԽՁԿՀՌՁՆՌՀԽՀՁԿՀԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽԻՇՆՌՊՇՄԿՊՇՍՈ
Ո ՏՀՁԻՀՏԹՋԻՇՆՋՁԼԽՊԽԼՌՇԺԽ

ՁՆՌՀԽՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԞՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԼԽԻՊԽԹՋԽՁՆ԰ԳԩՇՆԡԹՑՏԹՋ

ՁԼԽՆՌՁԾՁԽԼՁՆՌՀԽՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ
Ո

ԹԻԻՇՊԼՁՆԿՌՇԺՇՌՀՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹԱՊԽՆԼՌԽՋՌԹՆԼԡՍՆՆԽՌՌ	ՋՌԽՋՌԞՋՄՁԿՀՌՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌ

Page 36 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԼԽԻՊԽԹՋԽՁՆԥԩԩՏԹՋՇԺՋԽՊՎԽԼՁՆՌՀԽՅՁԼԼՄԽԻՇՆԻԽՆՌՊԹՌՁՇՆՌՊԽԹՌՅԽՆՌԿՊՇՍՈԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ

ԻՇՆՌՊՇՄԹԻԻՇՊԼՁՆԿՌՇԡՍՆՆԽՌՌ0ՋՌԽՋՌ
ՈԱՀՁՋԼԽԻՊԽԹՋԽՏԹՋՆՇՌԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋՁՎԽԹՆԼՌՀՍՋ

ՆՇՌԻՇՆՋՁԼԽՊԽԼՌՇԺԽՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԞՋՄՁԿՀՌՌՀՇՍԿՀՋՁԿՆՁԾՁԻԹՆՌՌՊԽՆԼ
ՈՁՆՅԽԼՁԹՆԡԹՑ

ԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՋՁՆՌՀԽՅՁԼԼՄԽԹՆԼՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՄԹՌՁՎԽՌՇՌՀԽԻՇՆՌՊՇՄՏԹՋ

ՁԼԽՆՌՁԾՁԽԼԹԻԻՇՊԼՁՆԿՌՇՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼՌԽՋՌ ԴՀՁՄԽՌՀԽՅԽԼՁԹՆՋՌԹԿԽՏԹՋՁՆԹՄՄՌՀՊԽԽ

ՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՇՆԡԹՑՌՀԽՊԽՏԽՊԽԼՁԾԾԽՊԽՆԻԽՋՁՆՌՀԽԼՁՋՌՊՁԺՍՌՁՇՆՇԾԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՋԹՅՇՆԿ

ՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ
ԞՈՈԽՆԼՁՐԣՇՊՁՆՋՌԹՆԻԽՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼՄՇՏԽՋՌՌՊԽԹՌՅԽՆՌԿՊՇՍՈՀԹԼ

ԹՆԼՌԹԼՈՇՄԽՋՊԽՋՈԽԻՌՁՎԽՄՑԹՌՋՌԹԿԽՏՀՁՄԽՌՀԽՅՁԼԹՆԼՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՀԹԼԹՆԼՌԹԼՈՇՄԽՋ

ԹՌՋՌԹԿԽՊԽՋՈԽԻՌՁՎԽՄՑ

ԱԹՁՄԻՍՊՎԹՌՍՊԽ
ՁՆԻՄՍԼՁՆԿԹՄՄՋԽՎԽՊՁՌՑԿՊԹԼԽՋԹՋՋՁԿՆԽԼԺՑՌՀԽՋՌՍԼՑԹՍՌՀՇՊՏԹՋՈՊԽՋԽՆՌՁՆ

ԹՆԼ ՇԾՌԹԼՈՇՄԽՋՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼԹՄՄՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ

 ԠԯԽՎՁԽՏԽՊ0ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

԰ՌԹՌՁՋՌՁԻԹՄԪԽՌՀՇԼՋԞՄՄԼԹՌԹՏԽՊԽՌԽՋՌԽԼԾՇՊՆՇՊՅԹՄՁՌՑՍՋՁՆԿ԰ՀԹՈՁՊՇԴՁՄՃՋՌԽՋՌ
ĮԹՆԼԾՇՊ

ՀՇՅՇԿԽՆԽՁՌՑՇԾՎԹՊՁԹՆԻԽՋՍՋՁՆԿԽՁՌՀԽՊԩԽՎԽՆԽ0ՋՇՊԟԹՊՌՄԽՌՌ0ՋՌԽՋՌ
ĮԞՄՄԽՆԼՈՇՁՆՌՋՅԽՌՌՀԽ

ԹՋՋՍՅՈՌՁՇՆՋՇԾՈԹՊԹՅԽՌՊՁԻՋՌԹՌՁՋՌՁԻՋԹՆԼՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿԡՍՆՆԽՌՌ0ՋԪՍՄՌՁՈՄԽԠՇՅՈԹՊՁՋՇՆՌԽՋՌՏՁՌՀ

ՌՀԽԽՐԻԽՈՌՁՇՆՇԾԡԹՑԫՇՊՅԹՄՁՒԽԼԥԩԩԹՆԼԡԹՑԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽԱՀԽՋԽՆՇՆՈԹՊԹՅԽՌՊՁԻՋՌԹՌՁՋՌՁԻՋ

ՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿՌՀԽԪԹՆՆԴՀՁՌՆԽՑԲԱՏՇՋԹՅՈՄԽԱԽՋՌԞՋՍԿԿԽՋՌՁՎԽՁՆԻՊԽԹՋՁՆԿ

ԻՇՆԻԽՆՌՊԹՌՁՇՆԼԽՈԽՆԼԽՆՌՌՊԽՆԼՏԹՋՆՇՌԽԼԾՇՊԡԹՑԫՇՊՅԹՄՁՒԽԼԥԩԩԼԹՌԹԞԼԽԻՊԽԹՋՁՆԿ

ԻՇՆԻԽՆՌՊԹՌՁՇՆԼԽՈԽՆԼԽՆՌՌՊԽՆԼՏԹՋՆՇՌԽԼԡԹՑ԰ԳԩԹՆԼԹՋՍԿԿԽՋՌՁՎԽԼԽԻՊԽԹՋՁՆԿՌՊԽՆԼՏԹՋՇԺՋԽՊՎԽԼ

ԾՇՊԡԹՑԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽԱՀԽԫԬԞԢԠԩԬԞԢԠԾՇՊՌՀԽՋԽԽՆԼՈՇՁՆՌՋՏԽՊԽԻՇՆԾՁՊՅԽԼՍՋՁՆԿԺՇՌՀ

ՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹԹՆԼԴՁՄՄՁԹՅ0ՋՌԽՋՌՋԱՀԽՋԽԹՆԹՄՑՋԽՋՏԽՊԽԻՇՆԼՍԻՌԽԼՍՋՁՆԿԠԢԱԦ԰ԹՆԼ

ԺԹԻՃԽՆԼՋԽՌՌՁՆԿՋՁՅՈՄԽՅԽՆՌԽԼԺՑԢԣԢԡՇՆ

 ԠՇՆԻՄՍՋՁՇՆՋ

ԬՆԡԹՑՌՀԽՊԽՎՁԽՏԽՊ0ՋԹՆԹՄՑՋՁՋԼԽՌԽԻՌԽԼԹՋՁԿՆՁԾՁԻԹՆՌՊԽԼՍԻՌՁՇՆՁՆ԰ԳԩԹՆԼՏԽՌՏԽՁԿՀՌԹՌՌՀԽՀՁԿՀԽՋՌ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄ
ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՈՊԽՄԹՌՁՎԽՌՇՌՀԽԻՇՆՌՊՇՄԺՍՌՆՇԽԾԾԽԻՌՋՏԽՊԽԼԽՌԽԻՌԽԼՇՆ

ԹՆՑԽՆԼՈՇՁՆՌՋԹՌԡԹՑ԰ՄՁԿՀՌՑԽՌՋՁԿՆՁԾՁԻԹՆՌԽԾԾԽԻՌՋՇՆՅԽԼՁԹՆԡԹՑԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՏԽՊԽԾՇՍՆԼ

ԾՇՊԹՄՄՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ
ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՈԱՀՇՍԿՀՌՀԽՅԽԼՁԹՆԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՏԹՋ

Page 37 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԾՇՊԹՄՄՌՀՊԽԽՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՇՆԡԹՑՌՀԽԼԹՌԹՋՍԿԿԽՋՌՌՀԹՌԼՁԾԾԽՊԽՆԻԽՋԽՐՁՋՌՁՆՌՀԽԼՁՋՌՊՁԺՍՌՁՇՆ

ՇԾԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՋԹՅՇՆԿՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՏՀՁԻՀԹՊԽՁՆԼՁԻԹՌՁՎԽՇԾԼԽՄԹՑԽԼԼԽՎԽՄՇՈՅԽՆՌԱՀԽ

ՁՆԻՁԼԽՆԻԽԹՆԼՋԽՎԽՊՁՌՑՇԾՌՀՑՊՇՁԼԿՊՇՋՋՈԹՌՀՇՄՇԿՑԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑ
ԾՇՄՄՁԻՍՄԹՊՋՁՒԽԾՁՆԼՁՆԿՋՏԹՋՎՁՋՍԹՄՄՑ

ԼԽՌԽՊՅՁՆԽԼՌՇԺԽԿՊԽԹՌԽՊԹՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄԹՄՌՀՇՍԿՀՌՀԽՋՌՍԼՑԹՍՌՀՇՊՁՆԼՁԻԹՌԽԼՌՀԹՌՌՀԽԼՁԾԾԽՊԽՆԻԽ

ՁՆՋԻՇՊԽՋՏԹՋՆՇՌՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌ

Page 38 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԡԽՎԽՄՇՈՅԽՆՌԹՄԹՆԼԱՀՑՊՇՁԼԤՊՇՋՋԭԹՌՀՇՄՇԿՑԥՁՋՌՇՈԹՌՀՇՄՇԿՑ ԢՆԼՈՇՁՆՌՋՁՆՌՀԽԞԪԞՏՁՌՀԭԠԫԟԱԽԻՀՆՁԻԹՄ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԫԣԡԽՎԽՄՇՈՅԽՆՌԹՄ԰ՌԹԿԽ ԥՁՆԼԩՁՅԺԩԽՆԿՌՀ ԞՋՑՆԻՀՊՇՆՇՍՋ

ԡԽՎԽՄՇՈՅԽՆՌ

ԱՀՑՊՇՁԼԤՊՇՋՋԹՆԼ

ԥՁՋՌՇՈԹՌՀՇՄՇԿՑ

ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ

ԪԽԼՁԹՆ Ո ԪԽԼՁԹՆ Ո ԡՁԾԾ Ո



ԡՁԾԾ

Ո



ԡՁԾԾ

Ո



ԡՁԾԾ

Ո

ԱՊԽԹՌՅԽՆՌԯԽՄԹՌԽԼ

ԢԾԾԽԻՌՋ!
ԶԽՋԫՇ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ  ԫԞ  ԫԞ  ԫԞ  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ         ԫԞ ԫԞ ԫԞ ԫԞ ԫՇ         ԫԞ ԫԞ ԫԞ ԫԞ ԫՇ         ԫԞ ԫԞ ԫԞ ԫԞ ԶԽՋ԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ

ԡՍՆՆԽՌՌ

ԧՇՆԻՃՀԽԽՊԽ

ԱԽՊՋՈՌՊԹ

ԧՇՆԻՃՀԽԽՊԽԱԽՊՋՈՌՊԹ ԡՍՆՆԽՌՌ ԫԞ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄԠՇՆԻՄՍՋՁՇՆՋՊԽԿԹՊԼՁՆԿՀՁՋՌՇՈԹՌՀՇՄՇԿՑՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼ

ԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ ԥՁՆԼՄՁՅԺՄԽՆԿՌՀՁՋՆՇՊՅԹՄՁՒԽԼՌՇՋՆՇՍՌՎԽՆՌՄԽՆԿՌՀ
԰Գԩ ԟԹՋԽԼ ՇՆ ՎՁՋՍԹՄ ԹՋՋԽՋՋՅԽՆՌ ՇԾ ՁՆԻՁԼԽՆԻԽ ԹՆԼ ՋԽՎԽՊՁՌՑ ԼԹՌԹ ՀՇՏԽՎԽՊ ՌՀԽ ՋՌՍԼՑ ԹՍՌՀՇՊ ՊԽՈՇՊՌԽԼ ՌՀԹՌՌՀԽ ԼՁԾԾԽՊԽՆԻԽՋՏԽՊԽ ՆՇՌ ՋՌԹՌՁՋՌՁԻԹՄՄՑ ՋՁԿՆՁԾՁԻԹՆՌ


ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՈ 

 ԞՄՌՀՇՍԿՀԹՆՇՆՈԹՊԹՅԽՌՊՁԻՌԽՋՌՏՇՍՄԼԺԽԹՈՈՊՇՈՊՁԹՌԽՌՇԹՋՋԽՋՋՅԽԼՁԹՆՎԹՄՍԽՋԾՇՊԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՁՆՌՀՁՋԻԹՋԽՁՌՏՇՍՄԼՆՇՌԺԽԽՐՈԽԻՌԽԼՌՇՑՁԽՄԼԼՁԾԾԽՊԽՆՌՇՎԽՊԹՄՄԻՇՆԻՄՍՋՁՇՆՋ

ԹՋԻՇՅՈԹՊԽԼՌՇԡՍՆՆԽՌՌ0ՋՌԽՋՌԺԽԻԹՍՋԽՌՀԽՊԽՏԹՋՆՇԼՁԾԾԽՊԽՆՌՁՆՌՊԽԹՌՅԽՆՌՅԽԼՁԹՆՎԹՄՍԽՋ

Page 39 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԱԹԺՄԽԤՊՇՏՌՀԢՆԼՈՇՁՆՌՋՁՆՌՀԽԞԪԞՏՁՌՀԭԠԫԟԱԽԻՀՆՁԻԹՄ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

԰ՆՇՍՌԳԽՆՌԩԽՆԿՌՀ ԟՇԼՑԴԽՁԿՀՌ

ԡԹՑ ԡԹՑ ԡԹՑ ԡԹՑ

ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ  ԫԞ  ԫԞ  ԫԞ  ԫԞ

        

        

        

԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ ԧՇՆԻՃՀԽԽՊԽ

ԱԽՊՋՈՌՊԹ

ԡՍՆՆԽՌՌ ԡՍՆՆԽՌՌ ԡՍՆՆԽՌՌ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ

Ԣ԰ՌՍԼՑԡԽԾՁԻՁԽՆԻՁԽՋ

 ԱՀԽԠԳՇԾՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋԽՐԻԽԽԼԽԼՇՎԽՊՌՀԽԼԹՑՋՌՍԼՑ
ԠԳՊԹՆԿԽԼԾՊՇՅ

-ԞՋԹՊԽՋՍՄՌՌՀԽՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼԹՆԼԽՐՈՊԽՋՋԽԼՌՇՐՁԻՁՌՑՎԹՄՍԽՋՍՋՁՆԿԱԴԞ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

 ԱԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋԼԽԻՊԽԹՋԽԼԹԾՌԽՊՌՀԽԹԼԼՁՌՁՇՆՇԾՇՊԿԹՆՁՋՅՋՇՆԡԹՑՏՀՁԻՀՏԹՋԹՌՌՊՁԺՍՌԽԼ

ՌՇՌՀԽԹԾԾՁՆՁՌՑՇԾՌՀԽՌԽՋՌՅԹՌԽՊՁԹՄՌՇԺՁՆԼՌՇԿՄԹՋՋՌԹՆՃՋԾՇՇԼՌԹԼՈՇՄԽՋԹՆԼԽՐԻՊԽՌԽԼՇՊԿԹՆՁԻ

ՅԹՌՌԽՊ

ԱՀԽՊԽՅԹՁՆՁՆԿՈԽՊԾՇՊՅԹՆԻԽԹՆԼՎԹՄՁԼՁՌՑԻՊՁՌԽՊՁԹՏԽՊԽՋԹՌՁՋԾՁԽԼ

ԣԯԽՎՁԽՏԽՊ0ՋԠՇՅՅԽՆՌՋ

ԱՀԽՊԽՎՁԽՏԽՊ0ՋՊԽՋՍՄՌՋԹՊԽՊԽՈՇՊՌԽԼՁՆՌՀԽԢՐԽԻՍՌՁՎԽ԰ՍՅՅԹՊՑԹՆԼԠՇՆԻՄՍՋՁՇՆՋՋԽԻՌՁՇՆՋՇԾՌՀՁՋԡԢԯԦՆ

ԿԽՆԽՊԹՄՌՀԽՊԽՎՁԽՏԽՊ0ՋՊԽՋՍՄՌՋԹԿՊԽԽԼՏՁՌՀՌՀԽՋՌՍԼՑԹՍՌՀՇՊՋ0ՀՇՏԽՎԽՊՌՀԽՋՌՍԼՑԹՍՌՀՇՊՋ0ԹՆԹՄՑՋՁՋՇՆՄՑ

Page 40 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԱՇՐՁԻՁՌՑՇԾԭԠԫԟՌՇԞՅՈՀՁԺՁԹՆՋԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽՇԾ

ԼԽՌԽԻՌԽԼԽԾԾԽԻՌՋՇՆԼԹՑԼԽՎԽՄՇՈՅԽՆՌՋՌԹԿԽԹՌՌՀԽՅՁԼԼՄԽԹՆԼՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆՄԽՎԽՄՋՏՀՁՄԽՌՀԽ

ՊԽՎՁԽՏԽՊ0ՋԹՆԹՄՑՋՁՋԼԽՌԽԻՌԽԼԼԽՄԹՑԽԼԽԾԾԽԻՌՋԹՌԹՄՄՌՊԽԹՌԽԼՄԽՎԽՄՋ

ԱՀԽՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼՌՀԽՌՁՅԽՏԽՁԿՀՌԽԼԹՎԽՊԹԿԽ
ԱԴԞԻՇՆԻԽՆՌՊԹՌՁՇՆՋՍՋՁՆԿՌՀԽԾՇՄՄՇՏՁՆԿԽՉՍԹՌՁՇՆ

ՏՀԽՊԽ

ԠԱԴԞՁՋՌՀԽՌՁՅԽՏԽՁԿՀՌԽԼԹՎԽՊԹԿԽԻՇՆԻԽՆՌՊԹՌՁՇՆ

ԠՂՁՋՌՀԽԻՇՆԻԽՆՌՊԹՌՁՇՆՅԽԹՋՍՊԽԼԹՌՌՁՅԽՁՆՌԽՊՎԹՄՂ
ՂՆ

ՌՂՁՋՌՀԽՆՍՅԺԽՊՇԾՀՇՍՊՋ
ՇՊԼԹՑՋՇՊՏԽԽՃՋՍՆՁՌՋՍՋԽԼՂՍՋՌՆԽԽԼՌՇԺԽԻՇՆՋՁՋՌԽՆՌՁՆՌՀԽԽՉՍԹՌՁՇՆՇԾ

ՌՀԽՌԽՋՌԹՌՌՁՅԽՁՆՌԽՊՎԹՄՂ


ԽԿՌՀՇՍՊՋ
ՌԽՋՌՁՆՁՌՁԹՌՁՇՆՌՀՇՍՊՋՌՀՇՍՊՋ

ԦԦԦ ԯԢԣԢԯԢԫԠԢ԰

ԤՊՁՅԨԠԽՌԹՄԱՀՑՊՇՁԼԥՁՋՌՇՈԹՌՀՇՄՇԿՑԞՋՋԽՋՋՅԽՆՌՋԾՇՊՌՀԽԞՅՈՀՁԺՁԹՆԪԽՌԹՅՇՊՈՀՇՋՁՋԞՋՋԹՑՌՇԡԽՌԽԻՌ

ԱՀՑՊՇՁԼԞԻՌՁՎԽ԰ՍԺՋՌԹՆԻԽՋԱՇՐՁԻՇՄԭԹՌՀՇՄ

ԫՁԽՍՏՃՇՇՈԭԡԹՆԼԣԹԺԽՊԧԫՇՊՅԹՄԱԹԺՄԽՋՇԾԵԽՆՇՈՍՋՄԹԽՎՁ
ԡԹՍԼՁՆԤԹՊՄԹՆԼԭՍԺՄՁՋՀՁՆԿԩՇՆԼՇՆ



( ) ( ) ( ) ( )

n

nn

nn

n

n

TWA t

tt

CC

tt

CC

tt

CC

tt

CC

C

1

1

21

21

12

12

01

01

2 2 2 2 −

−

−

−  ̧ − 1

·  ̈

©

§ +  ̧ +− 1

·  ̈

©

§ +  ̧ +− 1

·  ̈

©

§ +  ̧ +− 1

·  ̈

©

§ +

=

Page 41 of 207
DATA EVALUATION RECORD

PENTACHLORONITROBENZENE (PCNB) 

Study Type: OCSPP 890.1150, Androgen Receptor Binding Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-36-2012 (MRID 48946801) 

Prepared for

Health Effects Division

Office of Pesticide Programs

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by

Dynamac Corporations

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer Signature:

Scott D. Studenberg, Ph.D., D.A.B.T. Date: 12/3/2012

Secondary Reviewer Signature:

Michelle J. Sharpe-Kass, M.S. Date: 12/4/2012

Program Manager: Signature:

Jack D. Early, M.S. Date: 12/13//2012

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 12/13/2012

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by Dynamac Corporation personnel. 

Page 42 of 207
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 43 of 207
PCN B I 056502 

Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) I Page I of 17 

OCSPP 890.1150/ OECD None 

Primary Reviewer: Deborah Smegal 

Health Effects Division 

Secondary Reviewer: Greg Akerman, Ph.D. 

Health Effects Division 

Sigoi~Lr Date; ~---_...~?fi!LZ-~~..L.--­ Signature: ... 4~~,4~· ======--

Date: G; /j.. 'TI 1crTemplate version 0812011 

DATA EVALUATION RECORD 

STUDY TYPE: Androgen Receptor Binding Assay Using Rat Prostate Cytosol (AR); OCSPP 

890.1150 

PC CODE: 056502 DP BARCODE: D407069 

TXR#: 0056474 CAS No.: 82-68-8 

TEST MATERIAL (PURITY): PCNB (95.6% a.i.) 

SYNONYMS: 1,2,3,4,5-pentachloro-6-nitrobenzene, quintozene 

CITATION: Matthews, A. (2012). PCNB Technical: Androgen Receptor Binding (Rat 

Prostate Cytosol). Huntingdon Life Sciences, Huntingdon, Cambridgeshire, UK. 

Laboratory Study No.: BDG0128, July 26, 2012. MRID 48946801. 

Unpublished. 

SPONSOR: AMV AC Chemical Corp., 4695 MacArthur Court, Suite 1200, Newport Beach, 

CA 92660-1706 

TEST ORDER #: EDSP-056502-105 

EXECUTIVE SUMMARY: In an androgen receptor (AR) binding assay (MRID 48946801), 

prostate cytosol from Sprague-Dawley rats was used as the source of AR to conduct binding 

experiments. Prior to conducting the competitive binding experiments, a saturation binding 

experiment was conducted to demonstrate that the AR in the rat prostate cytosol was present in 

reasonable numbers and was functioning with appropriate affinity for the radiolabeled reference 

androgen ([3H]-R1881). The competitive binding experiment was conducted to measure the 

binding of a single concentration of [3H]-Rl 881 (I nM) in the presence of increasing 

concentrations (logarithmic increase from 10- 10 to 10-3

.s M) of PCNB (95.6% a.i.). Ethanol was 

used as the solvent vehicle at a final assay concentration of 3%. The highest soluble 

concentration for PNCB was 10-3.

5 M. Three valid independent runs were performed, and each 

run included dexamethasone as a weak positive control, and R 1881 as the ligand reference 

standard. 

For the saturation binding assay, the appropriate protein concentration was determined to be 4.67 

mg/mL as it bound 24% of the [3H]-R1881. The mean Kd for [

3

H]-R1881was1.6246±0.3283 

nM, and the mean estimated Bmax was 0.1805±0.0199 nM for the prepared rat prostate cytosol. 

The Kd was within the guideline recommended range of 0.03 to 1.5 nM for two of the three runs, 

but the Kd for Run 2 (2.2810±0.2936 nM) was above the recommended range. 

Page 44 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 2 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

The protein concentration for the competitive binding assay was determined to be 2.0 mg/mL as 

it bound 13% of the [3

H]-R1881 at 1 nM. Across all three valid runs, the estimated mean IC50

was 1.95 × 10−9 M for R1881 and 1.01 × 10−4 M for the weak positive control, dexamethasone. 

The corresponding log IC50 values for R1881 and dexamethasone were −8.72 and −4.00 M, 

respectively. The mean relative binding affinity (RBA) for dexamethasone compared to R1881 

was 0.0019%, for a log RBA of −4.72%. Three valid assay runs were completed out of a total of 

eight runs; five of the runs were appropriately rejected as they failed to meet various 

performance or acceptance criteria. 

For PCNB, the minimum mean specific binding of [3H]-R1881 to the AR was 64, 83 and 80% in 

the three valid runs, which corresponded to an equivocal classification (50-75% [3H]-R1881 

binding) for the first valid run and non-binder (>75% [

3

H]-R1881 binding) in the other two valid 

runs. 

Based on the results from the three runs, PCNB is classified as a Non-Binder in the Androgen 

Receptor Binding Assay. 

 

The assay satisfies the EDSP Tier 1 Test Order requirements for an Androgen Receptor Binding 

Assay (OCSPP 890.1150). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, Flagging, and 

Quality Assurance statements were provided. 

Page 45 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 3 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Huntingdon Life Sciences

Location: Huntingdon, Cambridgeshire, UK

Study Director: A. Matthews

Other Personnel: B. Mann, Assistant Study Scientist; S. Bate, Senior Statistician

Study Period: February 10, 2012 – July 26, 2012

2. Test substance: PCNB

Description: Off-white to dark tan crystalline solid or powder

Source: AMVAC Chemical Corp.

Lot #: 107030L052

Purity: 95.6% a.i. (Expiry July 2016)

Solubility: Soluble in ethanol up to 50 mM

Volatility: Not reported

Stability: Not reported

Storage conditions: Away from direct sunlight in a closed container at room temperature

CAS #: 82-68-8

Molecular weight: 295.3

Structure:

Cl

Cl

Cl

Cl

Cl

NO2

3. Non-labeled ligand: R1881

Supplier: Steraloids

Catalog # E3164-000

Batch #: B1023 (expiry June 2014)

Purity: 98.8%

CAS #: 965-93-5

4. Radioactive ligand: [

3

H]-R1881

Supplier: Perkin-Elmer

Catalog #: NET-590

Batch #: 679512, 1582134

Radiochemical purity: Not reported

Specific activity: 85.1 μCi/nmol

Concentration of stock: 1 mCi/mL

5. Weak Positive control: Dexamethasone

Supplier: Sigma-Aldrich

Catalog # D-1756

Batch #: 1419230 (expiry Nov 2013)

Purity: 98.9%

CAS # : 50-02-2

6. Solvent/vehicle control: Ethanol

Justification for choice of solvent: Not reported; ethanol is the recommended solvent for the AR Binding assay.

Final Concentration: 3%

Page 46 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 4 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

B. METHODS 

1. Preparation of Rat Prostate Cytosol: Trimmed prostate tissue was collected from 60 male 

Sprague-Dawley [CD(Crl:CD(SD))] rats that were purchased from Charles River

Laboratories. Animals were 80-90 days old at the time of euthanasia, and rats had been 

castrated approximately 24 hours prior to tissue harvest. The tissues were placed into icecold low salt buffer, on ice, immediately after collection. The study authors did not report 

prostate weights, but tissues were homogenized in ice-cold (4°C) low salt TEDG (Tris, 

sodium molybdate, EDTA, DTT, glycerol) + PMSF (phenylmethylsulfonyl fluoride) buffer, 

pH 7.4. Homogenates were centrifuged for 30 minutes at 30,000 × g, discarding the 

resulting pellets. Protein concentration of the cytosol was determined to be 7.126 mg/mL 

using the Bradford method. Cytosol was divided into aliquots (volume not reported) and 

stored at -75°C for up to 90 days until use. 

 The appropriate protein concentration that would give binding of 25-35% of the total 

[

3

H]-R1881 in the saturation binding assay was determined by combining the following 

components in silanized glass tubes: triamcinolone acetonide (60 μM, 50 μL); [3

H]-R1881 

(10 nM, 7.5 μL); and non-radiolabelled R1881 (1 nM, 7.5 μL). After evaporation of the 

solvent, varying cytosolic protein concentrations (1.8 to 2.14 mg/300 μL) were diluted with 

TEDG+PMSF buffer in the initial incubation. A second incubation range of 1.4 to 

2.0 mg/300 μL followed the initial incubation. All samples were run in triplicate. The tubes 

were maintained at 4°C, vortex mixed, and incubated in a rotary mixer at 15 rpm for 20 

hours.

2. Saturation (Radioligand) Binding Experiment: A saturation binding experiment 

measuring total and non-specific binding of [3H]-R1881 was performed to demonstrate that 

the AR was present in reasonable concentrations and had the appropriate affinity for the 

native ligand. The conditions for the saturation binding are summarized in Table 1. 

TABLE 1. Summary of Conditions for Saturation Binding Experimenta

Source of receptor Rat prostate cytosol 

Concentration of radioligand (as serial dilutions) 0.25-10 nM

Concentration of non-labeled ligand (100X [radioligand]) 25-1000 nM

Concentration of receptor Sufficient to bind 25 to 35% of 

radioligand at 0.1 mg/mLb

Temperature 4oC 

Incubation time 20 hours 

Composition of assay buffer Tris 1 M (pH 7.4)

EDTA 200 mM 

Sodium molybdate 1 M

Glycerol 10%

Phenylmethylsulfonyl fluoride 100 mM 

DTT 0.154 mg/mL

a Data were obtained from pages 14-16 of the study report.

b 1.4 mg/assay tube

Page 47 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 5 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

The study report did not state whether or not the specific activity of the stock solution of 

[

3

H]-R1881 was adjusted for decay over time. Additionally, although two different batches 

of [

3

H]-R1881 (with the same specific activity) were used over the course of the assay, the 

use dates for each batch were not reported. Serial dilutions of [3H]-R1881 were prepared in 

TEDG + PMSF buffer to achieve final concentrations of 0.25, 0.5, 0.7, 1, 1.5, 2.5, 5, and 

10 nM. Solutions of non-labeled R1881 were prepared in a similar manner to achieve 

concentrations that were 100-fold greater than each respective radiolabeled concentration to 

result in final concentrations of 25, 50, 70, 100, 150, 250, 500, and 1000 nM. For each 

batch of cytosol, the optimal protein concentration was determined by testing serial amounts 

of protein per tube, using 10 nM [3H]-R1881 (7.5 μL), until a concentration was reached 

that bound approximately 25-35% of the total radioactivity added. Each assay consisted of 

three non-concurrent runs, and each run contained three concurrent replicates at each 

concentration (Table 2). 

TABLE 2. Saturation Binding Experiment Runa

Total bindingb Non-specific 

bindingc

Radioligand aloned Assay Components

NR NR --- TEDG + PMSF buffer

10 μL 10 μL 10 μL [

3

H]-R1881 (8 serial dilutions)e

--- 10 μL --- Non-labeled R1881 (8 serial dilutions, 100× 

each respective labeled concentration)f

300 μL 300 μL --- Prostate cytosol (diluted to appropriate conc.)

300 μL 300 μL 10 μL Total volume in each assay tube

a Data were obtained from page 15 of the study report. Tube numbers corresponding to assay conditions 

were not provided.

b Total binding = [

3

H]-R1881 bound to AR 

c Non-specific binding = [3

H]-R1881 and 100-fold greater non-labeled bound to AR 

d Total [

3

H]-R1881 alone for dpm determination at each concentration

e Final concentrations of [3

H]-R1881 = 0.25, 0.5, 0.7, 1, 1.5, 2.5, 5, and 10 nM. 

f Final concentrations of non-labeled R1881 = 25, 50, 70, 100, 150, 250, 500, and 1000 nM. 

Tubes were incubated with gentle vortexing for 20 hours at 4°C. To separate bound from 

free [

3

H]-R1881, a 60% hydroxyapatite (HAP) slurry was added to 100-μL portions of each 

reaction mixture and vortexed at 5-minute intervals over 20 minutes, followed by 

centrifugation at 600 × g for 3 minutes at 4°C. Subsequently, the contents of each tube were 

washed four times as follows: 50 mM Tris buffer was added, vortexed, centrifuged for 

3 minutes at 600 x g, and the supernatant decanted and discarded. Ethanol was then added 

to the HAP pellet remaining in each tube to extract the [

3

H]-R1881, followed by vortexing 

over a 10-minute period, and centrifugation for 10 min at 600 × g. An aliquot of supernatant 

from each tube (1 mL) was radioassayed by liquid scintillation counting. The temperature 

was maintained at 4oC throughout the assay prior to extraction with ethanol. 

3. Competitive Binding Experiment: A summary of the experiment conditions for the 

competitive binding experiment is presented in Table 3. 

Page 48 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 6 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

TABLE 3. Summary of Conditions for Competitive Binding Experimenta

Source of receptor Rat Prostate Cytosol 

Concentration of radioligand 1 nM 

Concentration of receptor Sufficient to bind 10 to 15% of 

radioligand at 2.0 mg/mLb

Concentration of PCNB (as serial dilutions) 10−10 to 10−3.5 M

Temperature 4°C 

Incubation time 20 hours 

Composition of assay buffer Tris 1 M (pH 7.4)

EDTA 200 mM 

Glycerol 10% 

Phenylmethylsulfonyl fluoride 100 mM 

DTT 0.154 mg/mL 

a Data were obtained from pages 15, 16, and 19 of the study report.

b 0.6 mg/assay tube 

PCNB was initially determined to be soluble in ethanol at up to 30 mM, but precipitation 

was noted after spiking 10 μL of this PCNB stock solution into 300 μL of prostate cytosol. 

The highest achievable concentration of PCNB in cytosol was determined to be 1 × 10−3.5

M. On the day of the assay, the specific activity of the stock solution [3H]-R1881 was not 

reported, and it was not reported to have been adjusted for decay over time. [3

H]-R1881 

was diluted in TEDG + PMSF buffer to achieve a final concentration of 1 nM. Serial 

dilutions of PCNB, weak positive control (dexamethasone), and reference material (nonlabeled R1881) were prepared to achieve the concentrations shown in Table 4. Each assay 

consisted of three runs, and each run contained three replicates at each concentration (except 

for six replicates of the solvent control and non-specific binding), resulting in a total of 75 

tubes/run. 

Page 49 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 7 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

TABLE 4. Molar (M) concentrations in Competitive Binding Assay Runa,b

PCNB

Weak Positive control Reference Chemical

Solvent Control 

Ethanolc Dexamethasone Non-labeledR1881

Tubes 1-3, 73-75 Tubes 25-48d Tubes 49-72d Tubes 4-24d

10−10 10−10 10−11

10−9 10−9 10−10

10−8 10−8 10−9

10−7 10−7 10−8

10−6 10−6 10−7

10−5 10−5 10−6 (NSB)e

10−4 10−4 -

10−3.5 10−3 -

a

 Data were obtained from pages 19 and 70-81 of the study report. 

b Each tube contains: 10μL of the PCNB, positive control, negative control, solvent control, or non-labeled 

R1881; 390 μL of TEDG + PMSF buffer with [3

H]-R1881; and 100 μL of prostate cytosol (with AR), for a 

total of 500 μL.

c Solvent was ethanol (3%).

d Each concentration of each chemical was run in triplicate, except for the solvent control and non-specific 

binding, for a total of 75 tubes per run. Tube numbers were not provided, but were assigned by reviewer 

based on data spreadsheets on pages 51-59.

e Tubes 19-24

Tubes were incubated and processed as described previously for the saturation binding 

experiment. An aliquot of supernatant from each tube (1 mL) was radioassayed by liquid 

scintillation counting. The temperature was maintained at 4oC throughout the assay prior to 

extraction with ethanol. 

4. Data Analysis: For the saturation binding experiment, total binding and non-specific 

binding data were modeled via non-linear regression with PROC NLIN SAS 9.1.3 (SAS 

Institute 2002). For the competitive binding assay, similar methods of nonlinear regression 

were used to fit a curve (for R1881, dexamethasone, and PCNB) to the Hill equation 

formula which incorporated log IC50 as a parameter to be estimated. For parameters 

reported from the saturation binding experiment (Kd and Bmax) and competitive binding 

experiment (log IC50 and RBA), mean and standard deviation were calculated for each run 

and mean and standard error were calculated for the composite three runs with Microsoft 

Excel (Microsoft Corporation, Redmond, WA).

5. Definitions: 

a. Classification of test material 

If the data fit a 4-parameter nonlinear regression model, the test chemical is classified as:

Binder: The average curve for the test chemical across runs crosses 50% of radioligand 

bound. 

Equivocal: The average lowest portion of curves across runs is between 50% and 75% 

Page 50 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 8 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

radioligand binding (i.e. radioligand displacement is at least 25% but less than 50%), or the 

curve falls outside the range for the weak positive control (-0.6 to -1.4). 

Non-Binder: The average lowest portion of curves across runs is greater than 75% activity 

(i.e. less than 25% displacement of radioligand), or the data do not fit the model. 

Untestable: If the test compound is not soluble above 1×10-6 M and the binding curve does 

not cross 50%, the chemical is judged to be untestable. 

b. Descriptors for receptor binding

Bmax: maximal binding capacity

Kd: dissociation constants

IC50: Concentration of the test substance at which 50% of radioligand is displaced from the AR 

by the competitor

Relative Binding Affinity (%RBA): (IC50 of R1881 ÷ IC50 of test substance) × 100

Log RBA: Log10 (IC50 of R1881 ÷ IC50 of test substance)

II. RESULTS

A. SATURATION BINDING EXPERIMENT: The appropriate protein concentration for 

the saturation binding assay was determined to be 1.4 mg/300 μL (4.67 mg/mL) as it bound 

24% of the [

3

H]-R1881, just below the Guideline specified range of 25-35% binding. The 

results from the three saturation binding assays are summarized in Table 5 and shown 

graphically in Figures 1-6. The mean Kd for [

3

H]-R1881 was 1.6246±0.3283 nM, and the 

mean estimated Bmax was 0.1805±0.0199 nM for the prepared rat prostate cytosol. The Kd

was within the expected range of 0.03 to 1.5 nM for two of the three runs, but outside the 

range for Run 2 (2.2810±0.2936 nM), and the mean Kd (1.6246 nM) was also slightly above 

the recommended Guideline range. The data were fit to a linear Scatchard plot in all three

runs; visual observation indicates a moderate degree of scatter. Confidence in these 

numbers is high due to the minimal variation among runs. 

TABLE 5. Saturation Binding Experiment of R1881 with Androgen Receptor from Rat Prostate Cytosola

Parameter Run 1 Run 2 Run 3 Mean±SEM

r

2 (unweighted) NR NR NR NA

Bmax (nM) 0.1426±0.0107 0.2102±0.0111 0.1887±0.0110 0.1805±0.0199

Bmax (fmol/100 μg protein) 10.1864 15.0108 13.4772 12.8915±1.4231

Kd (nM) 1.3131±0.2647 2.2810±0.2936 1.2798±0.2117 1.6246±0.3283

a Data were obtained from page 30 of the study report. 

r

2 Goodness of fit (calculated by reviewers). 

SEM Standard Error. 

NR Not reported.

NA Not Applicable. 

Page 51 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 9 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

FIGURE 1. Specific, non-specific, and total binding of [3H]-R1881 to the androgen 

receptor during the Saturation Binding Experiment (Run 1). 

FIGURE 2. Specific, non-specific, and total binding of [3H]-R1881 to the androgen 

receptor during the Saturation Binding Experiment (Run 1).

 

Page 52 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 10 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

FIGURE 3. Specific, non-specific, and total binding of [3H]-R1881 to the androgen 

receptor during the Saturation Binding Experiment (Run 1).

FIGURE 4. Scatchard plot for the Saturation Binding Experiment (Run 1). 

Page 53 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 11 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

FIGURE 5. Scatchard plot for the Saturation Binding Experiment (Run 2). 

FIGURE 6. Scatchard plot for the Saturation Binding Experiment (Run 3). 

Page 54 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 12 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

B. COMPETITIVE BINDING EXPERIMENT: The appropriate protein concentration for 

the competitive binding assay was determined to be 0.6 mg/300 μL (2.0 mg/mL) as it bound 

13% of the [3H]-R1881, which was within the Guideline range of 10-15% binding. 

The results from the three competitive binding assays are shown in Table 6, summarized in 

Table 7, and shown graphically in Figures 7-9. The goodness-of fit (r2) values for each run 

were not reported. The mean log IC50 was −8.72 M for R1881 and −4.00 M for the weak 

positive control. 

The study author reported estimated log IC50 values for PCNB, however it was noted that

the calculated log IC50 estimates for PCNB were not reliable because the confidence limits 

(not reported) were large. PCNB did not reduce [3H]-R1881 binding by ≥50% at any 

concentration up to 10-3.5 M, therefore an IC50 value for PCNB was not calculated. The 

mean RBA was 0.0019% for the weak positive control, and could not be calculated for 

PCNB. Variability of the data within each run for R1881 and dexamethasone were low; 

therefore, the confidence in these numbers is high. Three valid assay runs were completed 

out of eight runs in total. The five remaining runs were rejected as they failed to meet 

various performance or acceptance criteria. PCNB is demonstrated equivocal binding (25-

50% reduction in [3

H]-R1881 binding), in Run 1 but was classified as a non-binder (<25% 

reduction in [3

H]-R1881 binding) in Runs 2 and 3. Overall, based on the results of the three 

valid runs, PCNB is classified as a non-binder in this assay. 

TABLE 6. Mean Specific Binding (%) of [3H]-R1881 in the Presence of R1181, Dexamethasone and PCNB for 

the Three Valid Competitive Binding Experimentsa

Chemical

Concen. 

(M)

Mean Specific Binding by Run

Run 1 Run 2 Run 3 Mean SE

R1881

(positive control)

−11 103 100 108 104 2.3

−10 110 102 97 103 3.8

−9 72 68 58 66 4.2

−8 21 14 20 18 2.2

−7 2 3 2 2 0.3

Dexamethasone 

(weak positive control)

−10 93 111 90 98 6.6

−9 103 95 114 104 5.5

−8 115 88 100 101 7.8

−7 100 106 108 105 2.4

−6 101 100 114 105 4.5

−5 100 103 94 99 2.6

−4 54 49 49 51 1.7

−3 12 13 19 15 2.2

PCNB −10 92 98 84 91 4.1

−9 82 97 77 85 6.0

−8 82 96 91 90 4.1

−7 92 96 101 96 2.6

−6 89 103 92 95 4.3

−5 100 100 105 102 1.7

−4 64 83 80 76 5.9

−3.5 66 92 90 83 8.4

a Data were obtained from pages 51-59 of the study report.

b The mean and Standard Error (SE) of specific binding across all three runs were calculated by the reviewer.

Page 55 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 13 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

TABLE 7. Competitive Binding Assay of PCNB with Androgen Receptor from Rat Prostate Cytosola

Parameter Run 1 Run 2 Run 3 Mean ± SEM c

r

2 (unweighted) R1881 NR NR NR NA

Dexamethasone NR NR NR NA

PCNB NR NR NR NA

Log IC50 (M) R1881 −8.60 −8.73 −8.83 −8.72 ± 0.067

Dexamethasone −3.96 −4.01 −4.03 −4.00 ± 0.022

PCNB NAb NAb NAb NAb

IC50 (M)c R1881 2.53 × 10−9 1.85 × 10−9 1.48 × 10−9 1.95× 10−9 (±0.31)

Dexamethasone 1.10 × 10−4 9.89 × 10−5 9.29 × 10−5 1.01 × 10−4 (±0.051)

PCNB NA NA NA NA

Log RBAc Dexamethasone -4.64 -4.73 -4.80 -4.72 ± 0.05

PCNB NA NA NA NA

RBA (%)c Dexamethasone 0.0023 0.0019 0.0016 0.0019 ± 0.0002

PCNB NA NA NA NA

a Data were obtained from pages 31-33 of the study report, and were converted to M equivalents by the reviewer. 

b Although log IC50 values were estimated for PCNB by the study author, they are not included because 

radiolabeled ligand binding was not reduced by PCNB by ≥50%.

c All values are reviewer-calculated from the log IC50 values reported in the study report. For means expressed 

in scientific notation, the SE values in parentheses are presented in the same order of magnitude as the mean 

value.

r

2 Goodness of fit

SEM Standard Error

RBA (%) Relative binding affinity

NR Not reported

NA Not applicable

Page 56 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 14 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

FIGURE 7. Plot of 4-parameter fitted curve during the Competitive Binding Experiment 

(Run 1).

FIGURE 8. Plot of 4-parameter fitted curve during the Competitive Binding Experiment 

(Run 2).

Page 57 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 15 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

FIGURE 9. Plot of 4-parameter fitted curve during the Competitive Binding Experiment 

(Run 3).

C. PERFORMANCE CRITERIA: To ensure that the competitive binding assay functioned

properly, each run was evaluated with the following criteria (Table 8): 

TABLE 8. Criteriona Tolerance 

Limit(s)

Value Yes No

R1881 fitted curve parameters

Loge residual SD

Top (% binding) 82 to 114 99.1 to 105.9 X

Bottom (% binding) −2 to 2 1.104 to 1.794 X

Hill Slope (log10(M)-1) −1.2 to −0.8 -1.174 to -0.890 X

Weak Positive control (Dexamethasone) fitted curve parameters

Loge residual SD

Top (% binding) 87 to 106 97.3 to 101.9 X

Bottom (% binding) −12 to12 7.369 to 15.65 Xb,c

Hill Slope (log10(M)-1) −1.4 to −0.6 -8.947 to -1.179 Xb

Solvent concentration

Ethanol ≤3% 3% X

Ligand Depletion <10-15% 1-2% X

a

 Data were obtained from pages 30, 31, and 70-81 of the study report.

b Run 2

c Run 3

NA Not applicable

Page 58 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 16 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

The data for R1881 met the acceptance criteria described in the Guideline. The study author

stated that the data for weak positive control, dexamethasone, met the acceptance criteria 

described in the guideline, with the following exceptions: in Run 2, bottom plateau level 

upper limit was 12.672 (target was -12 to 12); in Run 2, Hill slope was -8.947 (target 

was -1.4 to -0.6); and in Run 3, bottom plateau level upper limit was 15.654 (target was 

target was -12 to 12). 

Additionally, the curve for the reference material showed that increasing concentrations of 

unlabeled R1881 displaced [3

H]-R1881 in a manner consistent with one-site binding, as 

indicated by a descent from 97-110% to 14-21% binding over approximately a 100-fold 

increase in concentration of the test chemical (i.e., 1.65 to 2 log units). 

PCNB was tested over a concentration range that fully defined the top of the curve. In the 

second and third valid assay runs, the percent binding at the top plateau was generally 

within 25 percentage points of the value for the lowest concentration of the R1881 standard, 

although inter-assay variation was high. The results of the first assay run were equivocal 

and did not meet this criterion. 

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: With unlabeled R1881, the average curve across 

the three valid tests crossed 50% and an IC50 was obtained for every run. Therefore, R1881 

is classified as being a 'binder' with the androgen receptor. With dexamethasone, the 

average curve across the three valid tests crossed 50% and an IC50 was obtained for every 

run. Therefore, dexamethasone is classified as being a 'binder' with the androgen receptor. 

The mean RBA for dexamethasone was 0.0019% and with a log RBA of −2.72%. 

The curve for the test compound, PCNB, did not cross 75% binding in two of the three valid 

tests, but did cross 75% in the first test. Although an IC50 was calculated for PCNB in every 

run, these values were not considered to be reliable estimates as the confidence limits were 

very large. As PCNB is classified as equivocal in the first valid test and a non-binder for the 

second and third valid tests, overall PCNB is classified as being a non-binder with the AR. 

The data obtained from R1881 and the weak positive control were generally in line with the 

ranges provided in the Guideline. Although not all the performance criteria for the weak 

positive control were met for every valid test, the results with dexamethasone showed that 

the assay was sensitive to weakly active chemicals. 

B. AGENCY COMMENTS: The protein concentration for the saturation binding assay was 

determined to be 4.67 mg/mL as it bound 24% of the [

3

H]-R1881, which is just below the 

Guideline range of 25-35%. The mean Kd for [

3

H]-R1881 was 1.6246 nM, and the mean 

estimated Bmax was 0.1805 nM for the prepared rat prostate cytosol. The Kd was within the 

expected range of 0.03 to 1.5 nM for two of the three runs, but was above the recommended 

Kd in Run 2 (2.2810 nM). The mean Kd for all three runs (1.6246 nM) was also slightly 

above the Guideline recommended range. 

 The protein concentration for the competitive binding assay was determined to be 2.0 

mg/mL as it bound 13% of 1 nM of [3H]-R1881. An estimated mean IC50 for PCNB could 

Page 59 of 207
Androgen Receptor Binding Assay (Rat Prostate Cytosol) (2011) / Page 17 of 17

PCNB / 056502 OCSPP 890.1150/ OECD None

not be determined as it did not result in 50% displacement of [

3

H]-R1881 from the AR. The 

mean log IC50 was −8.72 M for R1881 and −4.00 M for the weak positive control. The 

mean RBA was 0.0019% for the weak positive control, but an RBA could not be calculated 

for PCNB. Variability within each run with R1881 and dexamethasone was low; therefore, 

the confidence in these numbers is high. 

Three valid assay runs were completed out of a total of eight runs. Five of the runs were 

appropriately rejected as they failed to meet various performance or acceptance criteria (e.g.,

non-specific binding too high, drift in the final solvent control values relative to the initial 

values, performance criteria not met for the weak positive control). Continued issues with 

the performance criteria for dexamethasone were observed in valid Runs 2 and 3. For 

PCNB, the minimum mean specific binding of [3H]-R1881 to the AR was 64, 83 and 80% in 

the three valid runs, which corresponded to an equivocal classification (50-75% binding) for 

the first valid run and non-binder (>75% binding) in the other two valid runs. 

 

C. STUDY DEFICIENCIES: The following deficiencies were noted that did not have an 

adverse effect on the results, interpretation or conclusions of this study: 

• The calculated Kd for Run 2, and the mean Kd, were above the recommended guideline 

range in the saturation binding experiment.

• Several performance criteria were not met for dexamethasone. 

• The radiochemical purity of [

3

H]-R1881, and the calculated specific activity values 

(adjusted for decay) on each day of use, were not reported. 

Page 60 of 207
DATA EVALUATION RECORD

PCNB

Study Type: OCSPP 890.1200, Aromatase Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-26-2012 (MRID 48916701) 

Prepared for

Health Effects Division

Office of Pesticide Programs

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by

CSS-Dynamac Corporation

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Michelle Sharpe-Kass, M.S. Date: 10/11/2012

Secondary Reviewer: Signature:

Scott D. Studenberg, Ph.D., D.A.B.T. Date: 10/13/2012

Program Manager: Signature:

Jack D. Early, M.S. Date: 10/17/2012

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 10/17/2012

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 61 of 207
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 62 of 207
PCNB I 056502 

Primary Reviewer"'--: -=D"-'e"""'b"""o"""'ra=h"""S=m=e=g=a"""l ___ ___ _ 

Health Effects Division 

Secondary Reviewer: Greg Akerman, Ph.D. 

Health Effects Division 

Signature: 

Date: 

DATA EVALUATION RECORD 

STUDY TYPE: Aromatase (Human Recombinant); OCSPP 890.1200 

-~z!; Template version 10/2011 

PC CODE: 056502 DP BARCO DE: D4053 72 

TXR#: 0056474 CAS No.: 82-68-8 

TEST MATERIAL (PURITY): PCNB (95.6% a.i.) 

SYNONYMS: 1, 2, 3, 4, 5-pentachloro-6-nitrobenzene, Quintozene 

CITATION: Foster, J.R. (2012) PCNB Technical: Aromatase (Human Recombinant) Assay. 

Huntingdon Life Sciences Ltd., Huntingdon, Cambridgeshire, England. 

Laboratory Report No.: BDG0124, June 15, 2012. MRID 48916701. 

Unpublished. 

SPONSOR: AMVAC Chemical Corporation, 4695 MacArthur Court, Suite 1200, Newport 

Beach, CA 

TEST ORDER#: EDSP-056502-105 

EXECUTIVE SUMMARY: In an in vitro aromatase (CYP19) assay (MRID 48916701), 

PCNB (95.6% a.i. Lot # 107030L052) was incubated with human recombinant aromatase and 

tritiated androstenedione ([I P-3H(N)]-androst-4-ene-3, 17-dione; [3H]-ASDN) in SI% ethanol at 

log concentrations from 10-10 to 10-4 M for 15 minutes to assess the potential of PCNB to inhibit 

aromatase activity. 

Aromatase activity was determined by measuring the amount of tritiated water produced at the 

end of a 15-minute incubation for each concentration of chemical. Tritiated water was quantified 

using liquid scintillation counting (LSC). Three runs were conducted and each run included a 

full activity control, a background activity control, a positive control series (10- 10 to 10-5 M) 

using a known inhibitor (4-hydroxyandrostenedione; 4-0H ASDN; formestane), and the test 

chemical series (10- 10 to 10-4 M) with three repetitions per concentration. 

Aromatase activity in the full activity controls ranged from 0.251 to 0.340 nmol·mgprotein-1 ·rnin-1 for the three test runs, with a mean and standard deviation of0.297 ± 0.044 

nmol·mg-protein- 1

·min- 1

• Activity in the background controls ranged from 0.38 to 1.78% and 

averaged 0.78% of the full control activity. The response of the full activity controls and 

background controls was generally acceptable for each run. 

Page 63 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 2 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

For the positive control substance (4-OH ASDN), aromatase results were generally within the 

recommended ranges for the top of the curve, bottom curve, Hill slope, log IC50, and %CV for 

replicates of each concentration within runs. The estimated mean log IC50 for 4-OH ASDN was

−7.39 M and the mean Hill slope was −0.955.

For PCNB, aromatase activity averaged 0.286 ± 0.051 nmol∙mg-protein−1∙min−1 at the lowest 

tested concentration of 10−10 M and 0.275 ± 0.038 nmol∙mg-protein−1∙min−1 at the highest tested 

concentration of 10−4 M. Aromatase activity ranged from 92.5 to 98.9% of the full activity 

control at PCNB concentrations from 10−10 to 10−4 M. Although the study author used the 4-

parameter nonlinear regression model to extrapolate possible log IC50 and Hill slope values for 

PCNB (−1.23 M and −0.465, respectively), these values are not supported by the experimental 

data and are well outside the bounds of the tested concentrations. 

Based on the data from the average response curve, PCNB is classified as a Non-inhibitor of 

aromatase activity in this assay. 

The assay satisfies the EDSP Tier 1 Test Order requirements for an Aromatase assay (OCSPP 

890.1200). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, Flagging, and

Quality Assurance statements were provided. 

Page 64 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 3 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Huntingdon Life Sciences Ltd.

Location: Cambridgeshire, England

Study Director: J. R. Foster

Other Personnel: M. C. Jordan, Technical Specialist 

 J. D. Holding, Consultant Pharmacokineticist

 S. J. Bartlett, Lead Scientist

Study Period: February 3, 2012 through June 15, 2012

2. Test Substance: PCNB

Description: Technical, light brown powder

Source: AMVAC Chemical Corporation, CA

Lot/Batch #: 107030L052, Expiration date July 2016

Purity: 95.6%

Volatility: NR

Storage conditions: In a closed container, away from direct sunlight, at room temperature

Stability: Approximately 4 years

Solvent: Ethanol

Solubility (in test solvent): 10 –2 M in Ethanol

Highest Concentration Tested: 10 –4 M

Molecular weight: 295.3

CAS #: 82-68-8

Structure:

Cl

Cl

Cl

Cl

Cl

NO2

3. Non-Labeled Substrate: Androstenedione (ASDN)

CAS # : 63-05-8

Source (catalog #): Sigma (46033)

Lot/Batch # (expiration date): SZB931XV (Nov 13, 2014)

Purity: 99.1

4. Radiolabeled Substrate: 1-β [

3

H(N)]-Androst-4-ene-3,17-dione; ([

3

H]ASDN)

Source (catalog #): American Radiolabeled Chemicals, Inc. (ART 1673)

Lot/Batch # (expiration date): 110512 (not reported)

Radiochemical Purity (Supplier): 99%

Specific activity: 26.3 Ci/μmol (on date of use)

Radiochemical Purity (In-lab 

determination):

99.6-99.0%

5. Positive Control: 4-hydroxyandrostenedione (4-OH ASDN; Formestane)

CAS # 566-48-3

Source (catalog #): Sigma (F552)

Lot/Batch # (expiration date): 081K2133 (Nov 24, 2014)

Purity: 99.6 %

Page 65 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 4 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

6. Solvent (Vehicle Control): Ethanol

Lot/Batch # (expiration date): BDH/VWR, Catalog # 20821.321 (not reported)

Justification for choice of solvent Solubility

Final concentration ≤1% of final assay volume

7. Test Microsomes: Human recombinant aromatase (CYP19) microsomes

Source (catalog #): Gentest/BD Biosciences (456260)

Lot/Batch # (expiration date): 03897 (February 2014)

Protein concentration: 7.4 mg protein per mL 

Cytochrome C reductase activity: 290 nmole cytochrome c reduced/mg protein/minute 

Aromatase activity: 6 pmol/(min × pmol P450); 0.81 nmol∙mg-protein−1∙min−1

B. METHODS

1. Assay Components and Preparations: A mixture of non-labeled and radiolabeled 

[

3

H]ASDN was prepared such that the final concentration of ASDN in the assay was 

approximately 100 nM, and the amount of tritium added to each incubation tube was 

approximately 0.1 μCi in a volume of 100 μL. 

PCNB stock solutions were prepared such that the total volume of each test chemical 

formulation used per assay was ≤1% of the total assay volume to minimize the potential for 

the solvent to inhibit the enzyme. Selection of the solvent, ethanol, was based upon the 

solubility of PCNB in the solution following addition of the buffer. 

A stock solution of the positive control substance, 4-OH ASDN, was formulated in ethanol. 

Fresh dilutions of the stock solution were prepared in the same solvent as the stock solution 

on the day of use. Dilutions were prepared such that the target concentrations of the 

positive control substance (0.1–10,000 nM; Table 4) were achieved by the addition of 10 μL 

of the dilution for a final assay volume of 1 mL.

Human recombinant microsomes were purchased from Gentest through BD Biosciences,

and stored at ≤−75oC. Microsomes were thawed and sub-aliquoted before being refrozen at 

–75°C. 

Other assay components sodium phosphate buffer, propylene glycol, and NADPH are 

reported in Table 1. 

TABLE 1. Assay Components and Conditionsa

Assay Factor Values

0.1M sodium phosphate buffer (pH 7.4)

Microsomal Protein 0.0037 mg/mL 

NADPH 6 mM

[3H]ASDN 2μM

Propylene Glycol 5%

Temperature 37°C

Incubation Time 15 min

a Data were obtained from page 15-16 of the study report

Page 66 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 5 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

2. Suitability Assessments: The protein concentration of the microsomes was supplied by the 

vendor (BD Gentest; 7.4 mg/mL). Aromatase activity in each lot of human recombinant 

microsomes was demonstrated to be sufficient for analysis of PCNB. The aromatase 

activity was calculated to be 0.81 nmol∙mg-protein−1∙min−1, which was greater than the 

minimum acceptable aromatase activity of 0.1 nmol∙mg-protein−1∙min−1. 

3. Aromatase Assay: Each assay run contained 4 tubes for the full enzyme activity and 

background activity controls, respectively, and a full concentration curve in triplicate for the 

positive control and PCNB. The aromatase assay was conducted according to the 

procedures described in OCSPP 890.1200 (Section h, pp. 9-10). 

The amount of 3

H2O in the aqueous fraction was quantified for each assay tube by LSC, and 

aromatase activity was reported in units of nmol∙mg-protein−1∙min−1. 

4. Demonstration of Proficiency: Proficiency testing of the CYP19 aromatase assay was 

conducted as part of study CWM39 (Report title: Validation of the Aromatase (Human 

Recombinant) Assay Performed Using a Hamilton STAR Robot). Each of the proficiency 

chemicals (atrazine, econazole, fenarimol and nitrofen) were incubated alongside the 

positive control inhibitor (formestane) on 3 separate occasions. 

a. Positive Control

(1) Initial Demonstration of Laboratory Proficiency: The positive control data met the 

following criteria:

• Mean aromatase activity in the absence of an inhibitor was at least 0.1 nmol∙mgprotein−1∙min−1. 

• Mean background control activity was ≤15% of the full activity control.

• Coefficient of variation (CV) for replicates within each sample type and concentration 

of 4-OH ASDN was <15%, with one exception (see B.4.b.), and the log IC50 values 

were within historical laboratory ranges (although below the lower limit of the 

performance criteria). 

• Performance criteria (Table 2) were generally met, and served as guidance in 

identifying runs that provided parameters in the preferred ranges. 

(2) Demonstration of Proficiency of New Technician for Conducting Assay (when 

applicable): The positive control data met the criteria as listed in section (i) of OCSPP 

890.1200, except for log IC50 of -7.74 M which was slightly less than the guideline range (-

7.3 to 7.0 M). 

TABLE 2. Performance Criteria for the Positive Control (Formestane; 4-OH ASDN)a

Parameter Lower Limit Criteria Upper Limit Criteria Actual Lower Limit Actual Upper Limit

Slope −1.2 −0.8 –1.010 –0.812

Top (%) 90 110 90.1 107.2

Bottom (%) −5 +6 0.1 1.1

Log IC50 (M) −7.3 −7.0 –7.74 –7.30

a Data were obtained from page 54 of the study report.

Page 67 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 6 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

b. Proficiency Chemicals: The full activity control was greater than 100 pmol/min/mg 

protein for all 12 runs conducted, ranging from 193.6 to 496.8 pmol/min/mg protein. The 

background activity control was <15% of the mean full activity control for all twelve runs 

conducted, ranging from -0.5% to 0.6% of full activity control. Of the twelve runs with 

proficiency chemicals and positive control, the positive control was run in triplicate on three

occasions and in duplicate for the remaining nine occasions. The %CV between replicates

was <15% for all the runs with formestane run in triplicate. Of the remaining nine runs with 

formestane run in duplicate, six of the runs had a %CV of <15%. The three runs that had 

replicates with a percent CV >15% were at no more than two concentrations of positive 

control and for these runs log IC50 values were calculated to be –7.61, –7.65 and –7.32 M, 

which were within the range achieved by this laboratory (Table 3). These runs were 

therefore deemed acceptable.

Proficiency chemicals were run in triplicate on all occasions. However, on one occasion 

during a run with the proficiency chemical fenarimol, a hardware error was noted on the 

Hamilton STAR robot. The error occurred during the addition of [3H] androstenedione to a 

single replicate only. This led to the results being based on duplicate fenarimol incubations 

for this run only. The %CV between replicates was <15% for all data points with 

proficiency chemicals.

During proficiency testing, the positive control (formestane) met the criteria in the EPA

Guideline with the exception of the log IC50 range (Table 2).

TABLE 3. Proficiency Chemicals

Compound CAS# Class Concentrations

Econazole 24169-02-6 Inhibitor 10 –11 to 10 –6

Fenarimol 60168-88-9 Inhibitor 10 –9 to 10 –4

Nitrofen 1836-75-5 Inhibitor 10 –10 to 10 –4.5

Atrazine 1912-24-9 Non-inhibitor 10 –9 to 10 –3.5

5. Determination of Aromatase Activity with Test Chemical(s): The response of aromatase 

activity to the presence of eight concentrations of PCNB per run, in triplicate, was tested 

during three independent runs (Table 4). After completion of the first run, the data were 

reviewed and no adjustments to the test chemical concentrations were deemed necessary. 

Page 68 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 7 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

TABLE 4. Test Chemical Study Design for each Test Runa

Sample Type Repetitions 

(Tubes) Description

Reference or 

Test Chemical 

(M)

Full Activity Control 4 All test componentsb plus solvent vehicle N/A

Bkgd Activity Control 4 Same as above without NADPH N/A

4-OH ASDN Conc 1 2 All test components plus 4-OH ASDN 1×10−5

4-OH ASDN Conc 2 2 All test components plus 4-OH ASDN 1×10−6

4-OH ASDN Conc 3 2 All test components plus 4-OH ASDN 1×10−6.5

4-OH ASDN Conc 4 2 All test components plus 4-OH ASDN 1×10−7

4-OH ASDN Conc 5 2 All test components plus 4-OH ASDN 1×10−7.5

4-OH ASDN Conc 6 2 All test components plus 4-OH ASDN 1×10−8

4-OH ASDN Conc 7 2 All test components plus 4-OH ASDN 1×10−9

4-OH ASDN Conc 8 2 All test components plus 4-OH ASDN 1×10−10

PCNB Conc 1 3 All test components plus PCNB 1×10−4

PCNB Conc 2 3 All test components plus PCNB 1×10−4.5

PCNB Conc 3 3 All test components plus PCNB 1×10−5

PCNB Conc 4 3 All test components plus PCNB 1×10−6

PCNB Conc 5 3 All test components plus PCNB 1×10−7

PCNB Conc 6 3 All test components plus PCNB 1×10−8

PCNB Conc 7 3 All test components plus PCNB 1×10−9

PCNB Conc 8 3 All test components plus PCNB 1×10−10

a Data were obtained from page 15 of the study report.

b The complete assay contained buffer, propylene glycol, microsomal protein, [3H]ASDN, and NADPH. 

C. DATA ANALYSIS

1. Raw Data: Raw data were converted to aromatase activity (nmol∙mg-protein−1∙min−1) and 

percent control for the positive control, proficiency chemicals and test chemical(s). The 

following raw data and calculated endpoints for each run were included in the report 

(Table 5). 

TABLE 5. Raw and Calculated Dataa

Raw/Calculated Data Included (X)

DPM/mL for each portion of extracted aqueous incubation mixture X

Average DPM/mL for each aqueous portion (after extraction) X

Total DPM for each aqueous portion (after extraction) X

The total DPM present in the assay tube at initiation X

The percentage of substrate converted to product X

Total DPM after extraction corrected for background X

Aromatase activity expressed in nmol∙mg protein−1∙min−1 X

Average aromatase activity in the full activity control tubes X

Percentage of control activity remaining in the presence of various inhibitor concentrations X

a Data were obtained from pages 26-43 of the study report.

DPM Disintegrations per minute

2. Statistical Methods: Mean% control activities were calculated. The response curve was

fitted by weighted least squares nonlinear regression analysis with WinNonlin Pro v 5.0. A 

4-parameter logistic dose response curve was fitted by weighted least-squares non-linear 

regression analysis, with weights equal to 1/(% control activity). 

Page 69 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 8 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

3. Interpretation of Results: Interpretation of the assay results was based on the average of 

three runs, using the categories presented in Table 6. 

TABLE 6. Interpretation of Results

Criteria Interpretation

Data fit 4-parameter nonlinear 

regression model

Average curve across runs crossed 50%a Inhibitor

Average lowest portion of curves across runs is 

between 50% and 75% activityb

Equivocal

Average lowest portion of curves across runs is greater 

than 75% activityb

Non-inhibitor

Data do not fit model ---

a Ordinarily, an inhibition curve will fall from 90% to 10% over 2 log units with a slope near −1. Unusually steep curves 

may indicate protein denaturing or solubility issues. If the slope of the curve is steeper than −2.0, the result is classified as 

equivocal.

b If the test compound was not soluble above 10−6 M and the inhibition curve does not cross 50%, the chemical is typically 

determined to be untestable in the aromatase assay. 

II. RESULTS

A. CONTROL ACTIVITY: Aromatase activity in the full activity controls ranged from 

0.251 to 0.340 nmol∙mg-protein−1∙min−1 for the three test runs, with a mean and standard 

deviation of 0.297 ± 0.044 nmol∙mg-protein−1∙min−1. Activity in the background controls 

ranged from 0.38 to 1.78% and averaged 0.78% of the full activity control. The individual 

values generally fell in the range of −0.5% to 1.0% of the full control activity, and the 

response of the full activity controls and background controls was considered acceptable for 

each run. 

B. POSITIVE CONTROL: For the positive control substance (4-OH ASDN), aromatase 

activity averaged 0.278 ± 0.031 nmol∙mg-protein−1∙min−1 at the lowest tested concentration 

10−10 M and 0.0018 ± 0.0003 nmol∙mg-protein−1

∙min−1 at the highest tested concentration 

10−5

 M. The mean aromatase activity of the positive control (expressed as % full control 

activity) for each concentration tested across all three runs is presented in Table 7, along 

with the overall standard deviation (SD), standard error of the mean (SEM) and % 

coefficient of variance (CV). Inhibition response curves for the positive control from each

run are shown in Figure 1, and the average inhibition response curve across all runs is 

shown in Figure 2. These results were generally within the recommended ranges for the 

%CV, top of the curve, bottom curve, Hill slope and log IC50. 

Page 70 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 9 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

TABLE 7. Effect of PCNB on Aromatase Activity (as percent of control) from Three Independent Runsa

Chemical

Concen. 

(Log M) # Runs Overall Mean Overall SD Overall SEM Overall %CV

4-OH ASDN 

(positive control)

−5 3 0.62 0.16 0.09 26.1

−6 3 6.20 0.61 0.35 9.8

−6.5 3 13.45 0.53 0.31 3.9

−7 3 34.38 0.67 0.38 1.9

−7.5 3 56.9 2.58 1.49 4.5

−8 3 81.3 1.45 0.84 1.8

−9 3 95.0 5.64 3.25 5.9

−10 3 93.3 4.38 2.53 4.7

PCNB −4 3 92.5 0.70 0.41 0.8

−4.5 3 95.7 1.93 1.12 2.0

−5 3 94.0 1.61 0.93 1.7

−6 3 98.8 1.58 0.91 1.6

−7 3 98.9 0.57 0.33 0.6

−8 3 97.3 4.33 2.50 4.4

−9 3 99.3 2.42 1.40 2.4

−10 3 95.2 4.49 2.59 4.7

a Data were obtained from page 50 of the study report, and calculated by reviewers from pages 23-25 of the study report.

SD Standard Deviation

SEM Standard Error of the Mean

CV Coefficient of Variance 

C. TEST SUBSTANCE: For PCNB, aromatase activity averaged 0.286 ± 0.051 nmol∙mgprotein−1

∙min−1, or 95.2% of the full activity control at the lowest tested concentration 

10−10 M, and 0.275 ± 0.038 nmol∙mg-protein−1∙min−1, or 92.5% of the full activity control at 

the highest tested concentration 10−4 M. The mean aromatase activity of PCNB (expressed

as %full control activity) for each concentration tested across all three runs is presented in 

Table 7, along with the overall SD, SEM and % CV. Inhibition response curves for PCNB

from each run are shown in Figure 1, and the average inhibition response curve across all 

runs is shown in Figure 2. 

Page 71 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 10 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

FIGURE 1. Inhibition Response Curves for PCNB and 4-OH ASDN From Each Test 

Run. 

Page 72 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 11 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

FIGURE 2. Mean Inhibition Response Curve for PCNB and 4-OH ASDN. 

Although inhibition of aromatase activity was <10% at concentrations up to 10 −4

 M, the 

study author utilized the 4-parameter regression model to extrapolate log IC50 and Hill slope

values for PCNB (Table 8). For PCNB, the extrapolated log IC50 values ranged from 

−0.044 to −2.07 M and averaged –1.23 M; these values are well outside the performance 

boundaries of the assay and are not supported by the experimental data. For the positive 

Page 73 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 12 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

control 4-OH ASDN, the log IC50 averaged –7.39 M. The average slope of the 

concentration response curve was –0.465 for PCNB and −0.955 for 4-OH ASDN. 

TABLE 8. Effect of PCNB on Aromatase Activity (as Percent of Control) From Independent Runsa

Chemical Run 1 Run 2 Run 3 Mean SEM %CV

Log IC50 (M)

PCNB b –2.07 –1.57 –0.044 –1.23 0.61 86

4-OH ASDN –7.53 –7.30 –7.34 –7.39 0.07 1.6

Hill Slope

PCNB b –0.691 –0.465 –0.239 –0.465 0.13 48

4-OH ASDN –0.955 –0.958 –0.951 –0.955 0.002 0.42

a Data were obtained from page 51 of the study report, SEM and %CV for all runs were calculated by the reviewer. 

b Although the study author calculated values for PCNB using the 4-parameter curve model, this is of limited use as they 

are well outside the boundaries of the experimental data. 

SEM Standard error of the mean

NA Not applicable; log IC50 and Hill slope could not be calculated. 

Based on the data from the average response curve and the criteria listed above in Table 8, 

PCNB is classified as a non-inhibitor of aromatase activity under the conditions of this 

assay.

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATORS CONCLUSIONS: PCNB Technical was calculated to have a mean

log IC50 (mol/L) of –1.23 ± 1.06 M with a range from –2.07 to –0.044 M. The positive 

control 4-OH ASDN was calculated to have a mean log IC50 (mol/L) of –7.39 ±0.12 with a 

range from –7.53 to –7.30. Two of these log IC50 values (–7.53 and –7.34) were marginally 

outside the Guideline suggested range (–7.3 to –7.0), but were consistent with previous 

laboratory findings. The mean slope of the 4-OH ASDN dose response curve from the 3 

runs averaged –0.955 ± 0.004 and ranged from –0.958 to –0.951, which were within the 

Guideline range (–1.2 to –0.8). The top of the 4-OH ASDN dose response curve ranged 

between 89% and 98% of the mean full activity control and the bottom of the dose response 

curve ranged between 0.5% and 0.8%. Except for one instance where the top of the dose 

response curve was 89%, these results meet the criteria stated in the EPA Guideline. Except 

for one data point, which had a CV of 17.3% (Run 1; 10–6.5 M), the percent CV between 

replicates was <15% for all 4-OH ASDN data points within each run. The addition of 4-OH 

ASDN to the assay resulted in almost total inhibition of the enzyme activity at the highest 

concentration (10−4 M) used.

The lowest measured data point of the average dose response curve for PCNB was 90.4% of 

the full activity control. Based on these finding, PCNB is classified as a non-inhibitor of 

CYP19 aromatase activity. 

B. AGENCY COMMENTS: Aromatase activity in the full activity controls ranged from 

0.251-0.3397 nmol∙mg-protein−1∙min−1 for the three test runs, with a mean and standard 

deviation of 0.297 ± 0.039 nmol∙mg-protein−1∙min−1. Activity in the background controls 

averaged 0.0023 ± 0.0018 nmol∙mg-protein−1∙min−1, or 0.78±0.41% of the full activity 

Page 74 of 207
Aromatase (Human Recombinant) Assay (2012) / Page 13 of 13

PCNB / 056502 OCSPP 890.1200 / OECD None

control. The response of the full activity controls and background controls were generally 

acceptable for each run.

For the positive control substance (4-OH ASDN), aromatase results were generally within 

the recommended ranges for the top of the curve, bottom curve, Hill slope, log IC50, and 

%CV for replicates of each concentration within runs. The estimated mean log IC50 for 

4-OH ASDN averaged −7.39 M and the mean Hill slope was −0.955.

For PCNB, aromatase activity averaged 0.286 ± 0.051 nmol∙mg-protein−1∙min−1 at the 

lowest tested concentration 10−10 M and 0.275 ± 0.038 nmol∙mg-protein−1∙min−1 at the 

highest tested concentration 10−4 M. 

The lowest portion of the response curve across all runs was greater than 75% activity at all 

concentrations, therefore PCNB is classified as a non-inhibitor of aromatase activity.

C. STUDY DEFICIENCIES: The following deficiencies were noted that are not considered 

to have had an adverse impact on the results, interpretation or conclusions of this study: 

• Information on data analysis was not provided 

Page 75 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽ

ԡԹՌԹԯԽՉՍՁՊԽՅԽՆՌ    ԢԭԞ

ԢԭԞ

ԢԭԞ

ԱԽՋՌԪԹՌԽՊՁԹՄ  ԭԠԫԟԱԽԻՀՆՁԻԹ

ԠՇՅՅՇՆԫԹՅԽ ԭԠԫԟԱԽԻՀՆՁԻԹ

ԠՀԽՅՁԻԹՄԫԹՅԽ  ԦԲԭԞԠ  

 ԠԞ԰ԫԹՅԽ 

ԠԞ԰ԫՇ 

԰ՑՆՇՆՑՅՋ 

ԢԭԞԭԠԠՇԼԽ

ԭՊՁՅԹՊՑԯԽՎՁԽՏԽՊ ԧՇՀՆԪԹՊՌՇՆԭ

ԢՆՎՁՊՇՆՅԽՆՌԹՄ԰ԻՁԽՆՌՁՋՌԠԡԪ԰ՅՁՌՀ

԰ԽԻՇՆԼԹՊՑԯԽՎՁԽՏԽՊ
ՋԱԽՊՁ԰ԪՑԽ

ԢՆՎՁՊՇՆՅԽՆՌԹՄ԰ԻՁԽՆՌՁՋՌԠԡԪ԰ՅՁՌՀ

ԭՊՁՅԹՊՑԯԽՎՁԽՏԽՊ ԢԼՏԹՊԼ԰ԻՇՄՄՇՆ

ԱՇՐՁԻՇՄՇԿՁՋՌԲ԰ԢԭԞԬԭԭԢԣԢԡԢԯ

԰ԽԻՇՆԼԹՊՑԯԽՎՁԽՏԽՊԢՄՁՒԹԺԽՌՀ
ԯՁՄԽ

ԟՁՇՄՇԿՁՋՌԲ԰ԢԭԞԬԭԭԢԣԢԡԢԯԟԳ

ԞԼԼՁՌՁՇՆԹՄԯԽՎՁԽՏԽՊԠԹՌՀԽՊՁՆԽԞՍԺԽ

԰ԽՆՁՇՊ԰ԻՁԽՆՌՁՋՌԲ԰ԢԭԞԬԭԭԢԣԢԡ

ԡԹՌԽԢՎԹՄՍԹՌՁՇՆԠՇՅՈՄԽՌԽԼ#ԼԼՅՅ

ԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀ

ԢԭԞԪԯԦԡ

ԭԹԿԽ  οԾ 

ԞԡԭԟԹՊԻՇԼԽ 

ԞԪԯԦԡ   

ԞԤՍՁԼԽՄՁՆԽ  

    ԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹ

Մ    ԭՍՊՁՌՑ
 

Մ

ԫՇՌՊԽՈՇՊՌԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ



ԭԽՆՌԹԻՀՄՇՊՇՆՁՌՊՇԺԽՆՒԽՆԽ



ԭՀԡ    ԡԹՌԽ

Հ

ԽՊՋԭՀԡ   ԡԹՌԽ

Հ

ՆԭՀԡ    ԡԹՌԽ 
ՆՇՄՇՆԿԽՊ

ԯԟԦԳ

ԽՑԡՇՆՇՎԹՆ   ԡԹՌԽ

ԳԦ

ԽԽ     ԡԹՌԽ

ԡԢԯԟԦԳ

ՅՅՑՑՑՑ%

ԭԠԫԟ

ԫՍՅԺԽՊ

ԹՑ

ՊՏՁՌՀԢԭԞ

Digitally signed by Elizabeth 

Donovan 

DN: cn=Elizabeth Donovan, 

o=EPA, ou=EFED, 

email=donovan.elizabeth@epa.

gov, c=US 

Date: 2015.06.10 09:03:15 -04'00'

Page 76 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԠԦԱԞԱԦԬԫ԰ԻՀՆԽՁԼԽՊ԰ԷԨԥԪԹՊՌՁՆԱԷԨԽՆԼԹՄՄԹՆԼԥԬԨՊՍԽԿԽՊԭԠԫԟԱԽԻՀՆՁԻԹՄԣՁՋՀ԰ՀՇՊՌԱԽՊՅ

ԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀՌՀԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋԲՆՈՍԺՄՁՋՀԽԼՋՌՍԼՑՈԽՊԾՇՊՅԽԼԺՑ

ԴՁՄԼՄՁԾԽԦՆՌԽՊՆԹՌՁՇՆԹՄԩՌԼԢԹՋՌՇՆԪԹՊՑՄԹՆԼԩԹԺՇՊԹՌՇՊՑՊԽՈՇՊՌՆՍՅԺԽՊԞԞ԰ՌՍԼՑՋՈՇՆՋՇՊԽԼԺՑ

ԞՅՎԹԻԠՀԽՅՁԻԹՄԠՇՊՈՇՊԹՌՁՇՆԫԽՏՈՇՊՌԟԽԹԻՀԠԹՄՁԾՇՊՆՁԹ԰ՌՍԼՑԻՇՅՈՄԽՌԽԼԧԹՆՍԹՊՑ

ԡՁՋԻՄԹՁՅԽՊԱՀԽԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋՁՆՌՀՁՋԡԢԯՌԽՅՈՄԹՌԽԹՊԽՇԾԾԽՊԽԼԹՋԹԿԽՆԽՊԹՄՊԽԾԽՊԽՆԻԽՌՇԹՁԼՁՆՈՊԽՈԹՊԹՌՁՇՆ

ՇԾՌՀԽԡԢԯԱՀԽՈՍՊՈՇՋԽՇԾՌՀԽՋԽՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋՁՋՆՇՌՌՇՋԽՊՎԽԹՋՋՍԺՋՌՁՌՍՌԽԾՇՊՌՀԽԱԽՋՌԤՍՁԼԽՄՁՆԽՋՆՇՊՌՇՈՊՇՎՁԼԽ

ԹՆՑԿՍՁԼԹՆԻԽՇՆՀՇՏՌՀԽՋՌՍԼՑՋՀՇՍՄԼԺԽԻՇՆԼՍԻՌԽԼ

ԫՇՌԽԱՀԽԲ԰ԢԭԞԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅ
Ԣԡ԰ԭԱՁԽՊՋԻՊԽԽՆՁՆԿԺԹՌՌԽՊՑՁՋԻՇՅՈՊՁՋԽԼՇԾԽՄԽՎԽՆ

ՋԻՊԽԽՆՁՆԿԹՋՋԹՑՋՁՆՌԽՆԼԽԼՌՇՁԼԽՆՌՁԾՑԹԻՀԽՅՁԻԹՄ0ՋՄՁՃԽՄՑԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՁԽՁՌՋՈՇՌԽՆՌՁԹՄՌՇՁՆՌԽՊԹԻՌՏՁՌՀ

ՌՀԽԽՋՌՊՇԿԽՆԹՆԼՊՇԿԽՆՇՊՌՀՑՊՇՁԼ
ԢԞՇՊԱՈԹՌՀՏԹՑՋԱՀԽՊՇԺՍՋՌՆԽՋՋՇԾՌՀԽԱՁԽՊԺԹՌՌԽՊՑՁՋԺԹՋԽԼՇՆ

ՌՀԽՋՌՊԽՆԿՌՀՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄԹՋՋԹՑՌՇՁԼԽՆՌՁԾՑՈՇՌԽՆՌՁԹՄԽՆԼՇԻՊՁՆԽԺՁՇԹԻՌՁՎՁՌՑՏՁՌՀԻՇՅՈՄԽՅԽՆՌԹՊՑԽՆԼՈՇՁՆՌՋ

ՏՁՌՀՁՆՌՀԽԹՋՋԹՑՏՀԽՊԽԹՎԹՁՄԹԺՄԽԹՆԼՊԽԼՍՆԼԹՆԻՑԹԻՊՇՋՋՌՀԽԺԹՌՌԽՊՑԱՀՍՋՌՀԽՊԽՋՍՄՌՋՇԾԽԹԻՀՁՆԼՁՎՁԼՍԹՄ

ԹՋՋԹՑՋՀՇՍՄԼՆՇՌԺԽԻՇՆՋՁԼԽՊԽԼՁՆՁՋՇՄԹՌՁՇՆԺՍՌՊԹՌՀԽՊՋՀՇՍՄԼԺԽԻՇՆՋՁԼԽՊԽԼՁՆՌՀԽԻՇՆՌԽՐՌՇԾՇՌՀԽՊԹՋՋԹՑՋ

ՁՆՌՀԽԺԹՌՌԽՊՑԹՋՏԽՄՄԹՋԬՌՀԽՊ԰ԻՁԽՆՌՁԾՁԻԹՄՄՑԯԽՄԽՎԹՆՌԦՆԾՇՊՅԹՌՁՇՆ
Ԭ԰ԯԦԦՆՇՊԼԽՊՌՇԼԽՌԽՊՅՁՆԽՁԾԹԻՀԽՅՁԻԹՄ

ՀԹՋՌՀԽՈՇՌԽՆՌՁԹՄՌՇՁՆՌԽՊԹԻՌՏՁՌՀՌՀԽԢԞՇՊԱՈԹՌՀՏԹՑՋԹԴԽՁԿՀՌՇԾԢՎՁԼԽՆԻԽ
ԴՇԢԽՎԹՄՍԹՌՁՇՆՇԾԱՁԽՊ

ԹՋՋԹՑՊԽՋՍՄՌՋՁՆԻՇՅԺՁՆԹՌՁՇՆՏՁՌՀՌՀԽԾՁՆԼՁՆԿՋՁՆՌՀԽԬ԰ԯԦՋՀՇՍՄԼԺԽՍՆԼԽՊՌԹՃԽՆ
ՊԽԾԽՊՌՇՌՀԽԴՇԢ

ԡՇԻՍՅԽՆՌ

ԢԵԢԠԲԱԦԳԢ԰ԲԪԪԞԯԶ

ԱՀԽԼԹՑՋՀՇՊՌՌԽՊՅՊԽՈՊՇԼՍԻՌՁՇՆԹՋՋԹՑՇԾԭԠԫԟՏՁՌՀԾԹՌՀԽԹԼՅՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋՏԹՋԻՇՆԼՍԻՌԽԼ

ՍՆԼԽՊԾՄՇՏՌՀՊՇՍԿՀԻՇՆԼՁՌՁՇՆՋԞԼՍՄՌԾՁՋՀ
ՅԹՄԽՋԹՆԼԾԽՅԹՄԽՋԿՊՇՍՈԿՊՇՍՈՋՌՊԽԹՌՅԽՆՌ+ՅՇՆՌՀՋՇՄԼ

ՏԽՊԽԽՐՈՇՋԽԼՌՇՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾԭԠԫԟ
ՈՍՊՁՌՑՇԾ
ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՆԼ

ՅԿԹՁԩՅԽԹՆՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽ
ԩԬԮԻՇՆՌՊՇՄԹՆԼ

ՅԿԹՁԩԯԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼՌՁՅԽՏԽՁԿՀՌԽԼԹՎԽՊԹԿԽ
ԱԴԞԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽ

ԹՆԼՅԿԹՁԩԱՀԽՌԽՋՌՋՑՋՌԽՅՏԹՋՅԹՁՆՌԹՁՆԽԼԹՌՌՇոԠԹՆԼԹՈԥՇԾՌՇ

ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԹՄՄԽԾԾԽԻՌՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄ

԰ՍՊՎՁՎԹՄՏԹՋՁՆԹՄՄՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԹՆԼԹՄՄԾՁՋՀԹՈՈԽԹՊԽԼՆՇՊՅԹՄԹՆԼՀԽԹՄՌՀՑՌՀՊՇՍԿՀՇՍՌՌՀԽԽՐՈՇՋՍՊԽ

ՈԽՊՁՇԼՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆՇԾՌՏՇԾԽՅԹՄԽՋՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՏՀՇԹՈՈԽԹՊԽԼՌՇԺԽԽԿԿԺՇՍՆԼԬՆԽԾԽՅԹՄԽ

Page 77 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ՏԹՋՇԺՋԽՊՎԽԼՌՇԺԽԽԿԿԺՇՍՆԼԾՊՇՅԡԹՑՋՌՇՏՀՁՄԽՌՀԽՇՌՀԽՊԾԽՅԹՄԽՏԹՋՇԺՋԽՊՎԽԼՌՇԺԽԽԿԿԺՇՍՆԼՇՆԡԹՑՋ

ԹՆԼԭԠԫԟԽՐՈՇՋՍՊԽՏԹՋԹՋՋՇԻՁԹՌԽԼՏՁՌՀԹԻՇՆԻԽՆՌՊԹՌՁՇՆԼԽՈԽՆԼԽՆՌՁՆԻՊԽԹՋԽՁՆԺՇԼՑՏԽՁԿՀՌՁՆԾԽՅԹՄԽ

ԾՁՋՀՏՁՌՀՋՁԿՆՁԾՁԻԹՆՌՈՊՇՅՇՌՁՇՆՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ԣԽԻՍՆԼՁՌՑ ԽՐԻԽԽԼԽԼ  ԽԿԿՋԾԽՅԹՄԽԼԹՑ ՁՆ ԽԹԻՀ ՇԾ ՌՀԽ ԻՇՆՌՊՇՄ ՊԽՈՄՁԻԹՌԽՋ 
ՅԽԹՆ 

ԽԿԿՋԾԽՅԹՄԽԼԹՑՊԽՈՄՁԻԹՌԽՊԹՆԿԽԹՄՌՀՇՍԿՀԽԹԻՀՊԽՈՄՁԻԹՌԽՁՆԻՄՍԼԽԼՇՊԼԹՑՈԽՊՁՇԼՋՏՁՌՀՇՍՌ

ՋՈԹՏՆՁՆԿԣԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋՁՆԻՇՆՌՊՇՄՋՏԹՋԭԠԫԟՋՁԿՆՁԾՁԻԹՆՌՄՑԼԽԻՊԽԹՋԽԼԾԽԻՍՆԼՁՌՑԺՑ
Ո

ԹՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆԾԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋՏԹՋԻՇՅՈԹՊԹԺՄԽԺԽՌՏԽԽՆՌՀԽԻՇՆՌՊՇՄԹՆԼՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈՋԭՄԹՋՅԹՎՁՌԽՄՄՇԿԽՆՁՆ
ԳԱԤՄԽՎԽՄՋՁՆՅԹՄԽԹՆԼԾԽՅԹՄԽԾՁՋՀՏԽՊԽՍՆԹԾԾԽԻՌԽԼԹՌԹՄՄՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՊԽՄԹՌՁՎԽ

ՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԫՇՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՋՇՆԿՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑՏԽՊԽՇԺՋԽՊՎԽԼՁՆՅԹՄԽԾՁՋՀԹՌԹՆՑ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄՀՇՏԽՎԽՊՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՋՏԽՊԽՆՇՌԽԼՁՆԾԽՅԹՄԽՋԹՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄԱՀԽՊԽՏԹՋ

ԹՆՁՆԻՊԽԹՋԽՁՆՅԽԼՁԹՆԿՇՆԹԼԹՄՋՌԹԿՁՆԿ
ՎՋՁՆԻՇՆՌՊՇՄԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄԽԾԾԽԻՌՋՁՆԻՄՍԼԽԼԼԽԻՊԽԹՋԽԼ

ՈՇՋՌՇՎՍՄԹՌՇՊՑ ԾՇՄՄՁԻՄԽՋ ԹՆԼ ՁՆԻՊԽԹՋԽԼ ՇՇԻՑՌԽ ԹՌՊԽՋՁԹ Ԟ ՋՁԿՆՁԾՁԻԹՆՌ ԻՇՆԻԽՆՌՊԹՌՁՇՆԼԽՈԽՆԼԽՆՌ ՁՆԻՊԽԹՋԽ ՁՆ

ԿՇՆԹԼՇՋՇՅԹՌՁԻՁՆԼԽՐ
Ԥ԰ԦՏԹՋՇԺՋԽՊՎԽԼՁՆՅԹՄԽԾՁՋՀՁՆՌՀԽՅՁԼԹՆԼՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ
ĹԹՆԼ

ՈԹՆԼԹՆԼՁՆԾԽՅԹՄԽԾՁՋՀՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈ
ĹՈԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹԫՍՈՌՁԹՄ

ՌՍԺԽՊԻՄԽՋԻՇՊԽՏԹՋՍՆԹԾԾԽԻՌԽԼԺՑԭԠԫԟԽՐՈՇՋՍՊԽՁՆՅԹՄԽՋՆՇՌՍԺԽՊԻՄԽՋՏԽՊԽՇԺՋԽՊՎԽԼՇՆԾԽՅԹՄԽՋ

ԱՀԽԿՍՁԼԽՄՁՆԽՎԹՄՁԼՁՌՑԹՆԼՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹՏԽՊԽԿԽՆԽՊԹՄՄՑՅԽՌ ԱՀՁՋԹՋՋԹՑՋԹՌՁՋԾՁԽՋՌՀԽԢԡ԰ԭԱՁԽՊԱԽՋՌ

ԬՊԼԽՊՊԽՉՍՁՊԽՅԽՆՌԾՇՊԹԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ
ԬԠ԰ԭԭԤՍՁԼԽՄՁՆԽ

ԯԽՋՍՄՌՋ԰ՑՆՇՈՋՁՋ

ԱԽՋՌՇՊԿԹՆՁՋՅԹԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆՅՇՆՌՀՋ

ԪԽԹՆԺՇԼՑՏԽՁԿՀՌԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆԿԾՇՊՅԹՄԽՋԿԾՇՊԾԽՅԹՄԽՋ

ԪԽԹՆՄԽՆԿՌՀԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆԫՇՌՊԽՈՇՊՌԽԼ

ԱԽՋՌՌՑՈԽԣՄՇՏՌՀՊՇՍԿՀ

Page 78 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԯԽՈՊՇԼՍԻՌՁՎԽԹՆԼԥԭԤԢԾԾԽԻՌՋՁՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ
ԣ԰ԱԯԞՏՁՌՀԭԠԫԟ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞ

ՅԽԹՋՍՊԽԼ%

ԣԽԻՍՆԼՁՌՑ

ԣԽՊՌ

԰ՍԻԻԽՋՋ

ԱՍԺԽՊԻՄԽ԰ԻՇՊԽ Ԥ԰Ԧ ԤՇՆԹԼԹՄԥՁՋՌՇ ԭՄԹՋՅԹԳԱԤ ԭՄԹՋՅԹԱ ԭՄԹՋՅԹԢ

Ԫ ԣ Ԫ ԣ Ԫ ԣ Ԫ ԣ Ԫ ԣ Ԫ ԣ

 ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫԞ ԫԞ ԫԞ ԫԞ ԫՇ ԫՇ ԫՇ ԫՇ ԶԽՋ ԫՇ ԫՇ ԫՇ ԫՇ ԫՇ ԫԞ ԫԞ ԫԞ ԫԞ ԶԽՋ ԫՇ ԫՇ ԫՇ ԶԽՋ ԶԽՋ ԫՇ ԶԽՋ ԫՇ ԫՇ ԫԞ ԫԞ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԢȕԽՋՌՊԹԼՁՇՄԣԣԽՅԹՄԽԣԽՊՌԣԽՊՌՁՄՁՒԹՌՁՇՆԤ԰ԦԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐԥՁՋՌՇԥՁՋՌՇՈԹՌՀՇՄՇԿՑԪԪԹՄԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԱԱԽՋՌՇՋՌԽՊՇՆԽԳԱԤԳՁՌԽՄՄՇԿԽՆՁՆ

 Ԟ՟ՑԽՋՠՁՆԼՁԻԹՌԽՋԹՋՁԿՆՁԾՁԻԹՆՌԼՁԾԾԽՊԽՆԻԽԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄՍՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼ

 ԱՀԽԻՊՁՌԽՊՁԹԾՇՊՋՁԿՆՁԾՁԻԹՆԻԽԹՊԽԼԽՋԻՊՁԺԽԼՁՆՌՀԽԯԽՎՁԽՏԽՊ0ՋԞՆԹՄՑՋՁՋԹՆԼ԰ՌԹՌՁՋՌՁԻԹՄԳԽՊՁԾՁԻԹՌՁՇՆՋԽԻՌՁՇՆՋՇԾՌՀԽԡԢԯԠՇՆԻՄՍՋՁՇՆՋՊԽԿԹՊԼՁՆԿՀՁՋՌՇՈԹՌՀՇՄՇԿՑՅԹՑԺԽՀԽԹՎՁՄՑ

ՏԽՁԿՀՌԽԼԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

Page 79 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

Ԧ ԪԞԱԢԯԦԞԩ԰ԞԫԡԪԢԱԥԬԡ԰ 

ԤՍՁԼԽՄՁՆԽԣՇՄՄՇՏԽԼԱՀՁՋՋՌՍԼՑՏԹՋԻՇՆԼՍԻՌԽԼԾՇՄՄՇՏՁՆԿԿՍՁԼԽՄՁՆԽՋՇՍՌՄՁՆԽԼՁՆՌՀԽԲ԰ԢԭԞ԰ԽՊՁԽՋ-

ԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅԱԽՋՌԤՍՁԼԽՄՁՆԽՋԬԠ԰ԭԭԫՍՅԺԽՊ

ԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑԹՆԼՌՀԽԬԢԠԡԤՍՁԼԽՄՁՆԽՋԾՇՊԱԽՋՌՁՆԿՇԾ

ԠՀԽՅՁԻԹՄՋԤՍՁԼԽՄՁՆԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑԱՀԽԾՇՄՄՇՏՁՆԿ

ԼԽՎՁԹՌՁՇՆՋՏԽՊԽՆՇՌԽԼ

 ԯԽՋՁԼՍԹՄԻՀՄՇՊՁՆԽԹՆԼՍՆՁՇՆՁՒԽԼԹՅՅՇՆՁԹԻՇՆԻԽՆՌՊԹՌՁՇՆՋՁՆՌՀԽԼՁՄՍՌՁՇՆՏԹՌԽՊՏԽՊԽՆՇՌՊԽՈՇՊՌԽԼ

 ԬՆԡԹՑԹԼՁՄՍՌԽՊՅԹՄԾՍՆԻՌՁՇՆՇԻԻՍՊՊԽԼՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈԞԼԼՁՌՁՇՆԹՄՋԹՅՈՄԽՋՏԽՊԽ

ՌԹՃԽՆՇՆԡԹՑԹՋՋՇՇՆԹՋՌՀԽՈՊՇԺՄԽՅՏԹՋԼՁՋԻՇՎԽՊԽԼԹՆԼՌՀԽՈՊՇԺՄԽՅՏԹՋՊԽՈԹՁՊԽԼ԰ԹՅՈՄԽՋ

ՏԽՊԽԹՄՋՇՌԹՃԽՆՇՆԡԹՑՌՇԻՇՆԾՁՊՅԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹԾՌԽՊՌՀԽԼՁՄՍՌԽՊՅԹՄԾՍՆԻՌՁՇՆԱՀԽՁՆՌԽՊՊՍՈՌՁՇՆ

ՁՆԼԽՄՁՎԽՊՑՏԹՋՋՀՇՊՌՁՆԼՍՊԹՌՁՇՆ
ՀՇՍՊՋԞՆԹՄՑՌՁԻԹՄՊԽԻՇՎԽՊՁԽՋՏԽՊԽՇԾՆՇՅՁՆԹՄՇՆ

ԡԹՑԹՆԼՇԾՆՇՅՁՆԹՄՇՆԡԹՑԱՀԽՋԽԹՆԹՄՑՌՁԻԹՄՊԽՋՍՄՌՋՏԽՊԽՆՇՌՁՆԻՄՍԼԽԼՁՆՅԽԹՆ

ՅԽԹՋՍՊԽԼԻԹՄԻՍՄԹՌՁՇՆՋ

ԱՀԽԼՁՄՍՌԽՊՅԹՄԾՍՆԻՌՁՇՆԹՆԼԹՋՋՇԻՁԹՌԽԼՁՅՈԹԻՌՋՇՆՌԽՋՌՋՍԺՋՌԹՆԻԽԻՇՆԻԽՆՌՊԹՌՁՇՆՋՁՆՌՊՇԼՍԻԽՋՍՆԻԽՊՌԹՁՆՌՑՁՆՌՇ

ՌՀԽՁՆՌԽՊՈՊԽՌԹՌՁՇՆՇԾԽՐՈՇՋՍՊԽԹՋՋՇԻՁԹՌԽԼՏՁՌՀԽԾԾԽԻՌՋՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈԥՇՏԽՎԽՊՌՀԽՋՌՍԼՑՁՋ

ՇՌՀԽՊՏՁՋԽԿԽՆԽՊԹՄՄՑՋՇՍՆԼ

ԠՇՅՈՄՁԹՆԻԽ԰ՁԿՆԽԼԹՆԼԼԹՌԽԼԫՇԡԹՌԹԠՇՆԾՁԼԽՆՌՁԹՄՁՌՑԤԩԭԹՆԼԮՍԹՄՁՌՑԞՋՋՍՊԹՆԻԽՋՌԹՌԽՅԽՆՌՋՏԽՊԽ

ՈՊՇՎՁԼԽԼԱՀՁՋՋՌՍԼՑՏԹՋԻՇՆԼՍԻՌԽԼՁՆԻՇՅՈՄՁԹՆԻԽՏՁՌՀԤՇՇԼԩԹԺՇՊԹՌՇՊՑԭՊԹԻՌՁԻԽ԰ՌԹՆԼԹՊԼՋԹՋՈՍԺՄՁՋՀԽԼԺՑ

ՌՀԽԲ԰ԢՆՎՁՊՇՆՅԽՆՌԹՄԭՊՇՌԽԻՌՁՇՆԞԿԽՆԻՑ
ԠԣԯԭԹՊՌՋԹՆԼԹՆԼԬԢԠԡԭՊՁՆԻՁՈՄԽՋՇԾԤՇՇԼ

ԩԹԺՇՊԹՌՇՊՑԭՊԹԻՌՁԻԽ
ԢԫԳԪԠԠԥԢԪ
ՏՁՌՀՌՀԽԾՇՄՄՇՏՁՆԿԽՐԻԽՈՌՁՇՆՋՈԽՊՁՇԼՁԻԹՆԹՄՑՋԽՋՇԾՏԹՌԽՊԾՇՊ

ՈՇՌԽՆՌՁԹՄԻՇՆՌԹՅՁՆԹՆՌՋՏԽՊԽՆՇՌՈԽՊԾՇՊՅԽԼԹԻԻՇՊԼՁՆԿՌՇԤՇՇԼԩԹԺՇՊԹՌՇՊՑԭՊԹԻՌՁԻԽ԰ՌԹՆԼԹՊԼՋԺՍՌՏԽՊԽ

ՈԽՊԾՇՊՅԽԼՍՋՁՆԿԹԻԽՊՌՁԾՁԽԼՄԹԺՇՊԹՌՇՊՑԹՆԼՋՌԹՆԼԹՊԼԲ԰ԢԭԞԹՆԹՄՑՌՁԻԹՄՅԽՌՀՇԼՋԹՆԼՌՀԽԻՀԹՊԹԻՌԽՊՁՒԹՌՁՇՆՇԾ

ՌՀԽՌԽՋՌՋՍԺՋՌԹՆԻԽԹՆԼՌՀԽՋՌԹԺՁՄՁՌՑՇԾՌՀԽՌԽՋՌՋՍԺՋՌԹՆԻԽՍՆԼԽՊՌՀԽԻՇՆԼՁՌՁՇՆՋՇԾՋՌՇՊԹԿԽԹՌՌՀԽՌԽՋՌՋՁՌԽԹՊԽ

ՌՀԽՊԽՋՈՇՆՋՁԺՁՄՁՌՑՇԾՌՀԽ԰ՈՇՆՋՇՊ

Ԟ ԱԽՋՌԪԹՌԽՊՁԹՄ   ԭԠԫԟԱԽԻՀՆՁԻԹՄ

Page 80 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԡԽՋԻՊՁՈՌՁՇՆ    ԩՁԿՀՌԺՊՇՏՆՈՇՏԼԽՊ

ԩՇՌԫՇԟԹՌԻՀԫՇ ԩ

ԢՐՈՁՊԹՌՁՇՆԡԹՌԽ  

ԭՍՊՁՌՑ    

ԦՅՈՍՊՁՌՁԽՋ   ԫՇՆԽՊԽՈՇՊՌԽԼ

԰ՌԹԺՁՄՁՌՑՇԾԠՇՅՈՇՍՆԼ ԫՇՌՊԽՈՇՊՌԽԼԥՇՏԽՎԽՊՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼԱԴԞԻՇՆԻԽՆՌՊԹՌՁՇՆՋՑՁԽՄԼԽԼ

ՊԽԻՇՎԽՊՁԽՋՇԾՇԾՆՇՅՁՆԹՄ

԰ՌՇՊԹԿԽԠՇՆԼՁՌՁՇՆՋՇԾ 

ԱԽՋՌԠՀԽՅՁԻԹՄՋ  ԰ՌՇՊԽԼՍՆԼԽՊԹՅԺՁԽՆՌԻՇՆԼՁՌՁՇՆՋ

Page 81 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԟ ԱԽՋՌԬՊԿԹՆՁՋՅ

ԱԹԺՄԽԤԽՆԽՊԹՄԦՆԾՇՊՅԹՌՁՇՆԞԺՇՍՌՌՀԽԱԽՋՌ԰ՈԽԻՁԽՋԹՆԼԞԻԻՄՁՅԹՌՁՇՆ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

԰ՈԽԻՁԽՋԻՇՅՅՇՆՆԹՅԽ ԣԹՌՀԽԹԼԪՁՆՆՇՏ ԢԭԞՊԽԻՇՅՅԽՆԼՋԾԹՌՀԽԹԼՅՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋ

ՈՊՇՅԽՄԹՋ ԰ՈԽԻՁԽՋՋԻՁԽՆՌՁԾՁԻՆԹՅԽ ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

԰ՈԽԻՁԽՋՋՌՊԹՁՆ
ՁԾՋՌԹՌԽԼ ԫՇՌՊԽՈՇՊՌԽԼԴԽՊԽԾՁՋՀՇԺՌԹՁՆԽԼԾՊՇՅԹՋՁՆԿՄԽՄԹԺՇՊԹՌՇՊՑՋՌՇԻՃ!

ԶԽՋ ԰ՌՇԻՃԻՍՄՌՍՊԽՏԹՋՇՊՁԿՁՆԹՄՄՑՇԺՌԹՁՆԽԼԾՊՇՅ

ԬՋԹԿԽԠԹՌԾՁՋՀԽՊՁԽՋԦՆԻ
ԬՋԹԿԽԟԽԹԻՀԪՁՋՋՇՍՊՁ

ԢԭԞ ՊԽԻՇՅՅԽՆԼՋ ՌՀԹՌ ԾՁՋՀ ԺԽ ԾՊՇՅ Թ ՋՁՆԿՄԽ

ՄԹԺՇՊԹՌՇՊՑՋՌՇԻՃ

ԴԽՊԽԹԻԻՄՁՅԹՌՁՇՆԻՇՆԼՁՌՁՇՆՋՋԹՅԽԹՋԼԽԾՁՆՁՌՁՎԽՌԽՋՌ!

ԶԽՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՁՋՀԺԽԹԻԻՄՁՅԹՌԽԼՍՆԼԽՊ

ՏԹՌԽՊՉՍԹՄՁՌՑԹՆԼՁՄՄՍՅՁՆԹՌՁՇՆԻՇՆԼՁՌՁՇՆՋՌՀԹՌԹՊԽ

ՋՁՅՁՄԹՊՌՇՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԞԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼ ՅՇՆՌՀՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՌՏՇՏԽԽՃ

ԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼԫՇՌԽՌՀԹՌՌՀԽԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼ

ՁՋԼՁԾԾԽՊԽՆՌԾՊՇՅՌՀԽՋՍԺՋԽՉՍԽՆՌՁՆՋՁՌՍ

ՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽ

Page 82 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՀԽԹՄՌՀ ԡՍՊՁՆԿՌՀԽՏԽԽՃՋՈՊՁՇՊՌՇ

ՌՀԽՋՌԹՊՌՇԾՌՀԽՌԽՋՌԾՁՋՀՋՀՇՏԽԼՆՇՋՁԿՆՋՇԾԼՁՋԽԹՋԽՇՊՋՌՊԽՋՋԹՆԼՆՇՅՇՊՌԹՄՁՌՁԽՋՏԽՊԽՇԺՋԽՊՎԽԼ

ԣՁՋՀԼՁԼՆՇՌՊԽԻԽՁՎԽԹՆՑՌՊԽԹՌՅԽՆՌԾՇՊԼՁՋԽԹՋԽԼՍՊՁՆԿՌՀԽԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼՌՀԽՌՏՇՏԽԽՃՈՊԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼՇՊՌՀԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՅՇՊՌԹՄՁՌՑԼՍՊՁՆԿՌՀԽԼԹՑՋ

ՈՊՁՇՊՌՇՌՀԽՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽԺԽՄԽՋՋՌՀԹՆՇԾ

ՌՀԽԻՍՄՌՍՊԽՈՇՈՍՄԹՌՁՇՆԦԾՅՇՊՌԹՄՁՌՑԼՍՊՁՆԿՌՀԽՋԽ

ԼԹՑՋՁՋԿՊԽԹՌԽՊՌՀԹՆԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌ

ՌՀԽԾՁՋՀԺԽՊԽՂԽԻՌԽԼԦԾՅՇՊՌԹՄՁՌՑՁՋԺԽՌՏԽԽՆ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՁՋՀԺԽՀԽՄԼԹՆՇՌՀԽՊԼԹՑՋ 

ԦԾՅՇՊՌԹՄՁՌՁԽՋԿՊԽԹՌԽՊՌՀԹՆՇԻԻՍՊԼՍՊՁՆԿՌՀՁՋ

ԽՐՌԽՆԼԽԼԹԻԻՄՁՅԹՌՁՇՆՈԽՊՁՇԼԢԭԞՊԽԻՇՅՅԽՆԼՋ

ՌՀԹՌՌՀԽԾՁՋՀՆՇՌԺԽՍՋԽԼ

ԱՑՈԽՇԾԾՇՇԼ ԠՇՅՅԽՊԻՁԹՄԾՄԹՃԽԾՇՇԼ

ՋՍՈՈՄԽՅԽՆՌԽԼՏՁՌՀԺՊՁՆԽՋՀՊՁՅՈՆԹՍՈՄՁՁ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՁՋՀԺԽԾԽԼԾՊՇՒԽՆԺՊՁՆԽ

ՋՀՊՁՅՈՌՏՁԻԽՈԽՊԼԹՑՌՇՈՊՇՅՇՌԽԹԻՌՁՎԽՊԽՈՊՇԼՍԻՌՁՇՆ

ԹՆԼՅԹՁՆՌԹՁՆԺՇԼՑԻՇՆԼՁՌՁՇՆ

԰ՇՍՊԻԽՇԾԾՇՇԼ ԣՄԹՃԽԾՇՇԼ԰ԽՊԹԫՇՊՌՀ

ԞՅԽՊՁԻԹ
ԪՇՆՌԿՇՅԽՊՑՎՁՄՄԽ

ԭԞԟՊՁՆԽՋՀՊՁՅՈԟՊՁՆԽ԰ՀՊՁՅՈԡՁՊԽԻՌ
ԬԿԼԽՆԲԱ

ԣՊԽՉՍԽՆԻՑՇԾԾԽԽԼՁՆԿ ՌՁՅԽՋԼԹՑ

Page 83 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆԾԽԽԼՁՆԿ ԣՁՋՀՏԽՊԽԾԽԼԹՌԹՋՍԾԾՁԻՁԽՆՌ

ՊԹՌԽՌՇՈՊՇՅՇՌԽԹԻՌՁՎԽՊԽՈՊՇԼՍԻՌՁՇՆԹՆԼՅԹՁՆՌԹՁՆԺՇԼՑԻՇՆԼՁՌՁՇՆ

ԣՁՋՀՏԽՊԽՆՇՌԾԽԼԾՇՊԹՌՄԽԹՋՌՀՇՍՊՋՈՊՁՇՊՌՇՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆՌՇԹՄՄՇՏԾՇՊԻՄԽԹՊԹՆԻԽՇԾՌՀԽԼՁԿԽՋՌՁՎԽՌՊԹԻՌՋԺԽԾՇՊԽՌԽՊՅՁՆԹՄՏԽՁԿՀՌՅԽԹՋՍՊԽՅԽՆՌՋՏԽՊԽՅԹԼԽԲՆԽԹՌԽՆԾՇՇԼԹՆԼԾԽԻԹՄՅԹՌԽՊՁԹՄՏԽՊԽՊԽՅՇՎԽԼԾՊՇՅՌՀԽՌԽՋՌԻՀԹՅԺԽՊՋԺՑՋՁՈՀՇՆՁՆԿԼԹՁՄՑ

ԱԹԺՄԽԣՁՋՀ԰ԽՄԽԻՌՁՇՆԹՆԼԭՊԽԢՐՈՇՋՍՊԽԭԽՊԾՇՊՅԹՆԻԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԿԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ ՅՇՆՌՀՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՊՇԼՍԻՌՁՎԽՄՑՅԹՌՍՊԽ
ՋԽՐՍԹՄՄՑ

ԼՁՅՇՊՈՀՁԻԾՁՋՀՅՇՆՌՀՋՇՄԼ

Page 84 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԪԽԹՆՏԽՁԿՀՌՇԾՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

Կ ԟԹՋԽԼՇՆՋՍԺՋԹՅՈՄԽ
Ն ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌ ԹՋՍԺՋԹՅՈՄԽՇԾԾՁՋՀԺԽ

ՏԽՁԿՀԽԼԺԽԾՇՊԽՌՀԽՌԽՋՌՌՇԽՋՌՁՅԹՌԽՌՀԽՅԽԹՆՏԽՁԿՀՌ

ԾՇՊԽԹԻՀՋԽՐԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՌՀԽՁՆԼՁՎՁԼՍԹՄ

ՏԽՁԿՀՌՇԾԽԹԻՀԾՁՋՀՋԽՄԽԻՌԽԼԾՇՊՌՀԽՌԽՋՌԺԽՏՁՌՀՁՆ

չՇԾՌՀԽԽՋՌՁՅԹՌԽԼՅԽԹՆԾՇՊԽԹԻՀՋԽՐ

ԯԹՆԿԽՇԾՁՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋ
ՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ ԦՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋՏԽՊԽՊԽՈՇՊՌԽԼՄՑՏՁՌՀՁՆչ

ՇԾՌՀԽՅԽԹՆ

ԪԽԹՆՏԽՁԿՀՌՇԾԾԽՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

Կ ԟԹՋԽԼՇՆՋՍԺՋԹՅՈՄԽ
Ն

ԯԹՆԿԽՇԾՁՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋ
ԾԽՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ ԦՆԼՁՎՁԼՍԹՄՏԽՁԿՀՌՋՏԽՊԽՊԽՈՇՊՌԽԼՄՑՏՁՌՀՁՆչ

ՇԾՌՀԽՅԽԹՆ

ԪԽԹՆՄԽՆԿՌՀՇԾՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ

ԪԽԹՆՄԽՆԿՌՀՇԾԾԽՅԹՄԽՋԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ
ՁԾԼԽՌԽՊՅՁՆԽԼ

ԫՇՌՊԽՈՇՊՌԽԼ

ԡՍՊԹՌՁՇՆՇԾՈՊԽԽՐՈՇՋՍՊԽՈՀԹՋԽ  ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՇԾԼԹՑՋԴԽՊԽՈՊԽԽՐՈՇՋՍՊԽԻՇՆԼՁՌՁՇՆՋՁԼԽՆՌՁԻԹՄՌՇՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ!

ԶԽՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՈՊԽԽՐՈՇՋՍՊԽԻՇՆԼՁՌՁՇՆՋ

ՁՆԻՄՍԼՁՆԿՌԽՅՈԽՊԹՌՍՊԽՈՀՇՌՇՈԽՊՁՇԼԾԽԽԼՁՆԿԽՌԻ

ԺԽՁԼԽՆՌՁԻԹՄՌՇԼԽԾՁՆՁՌՁՎԽՌԽՋՌԻՇՆԼՁՌՁՇՆՋ

Page 85 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԫՍՅԺԽՊՇԾՈՊԽԽՐՈՇՋՍՊԽՌԹՆՃՋ  ԞԼԼՁՌՁՇՆԹՄՊԽՈՄՁԻԹՌԽՋՏԽՊԽԽՋՌԹԺՄՁՋՀԽԼՋՇՌՀԹՌ

ԺՊԽԽԼՁՆԿԿՊՇՍՈՋՏՁՌՀԹՈՊՇՎԽՆՀՁՋՌՇՊՑՇԾՋՈԹՏՆՁՆԿՏՇՍՄԼԺԽԹՎԹՁՄԹԺՄԽԾՇՊՌՀԽԽՐՈՇՋՍՊԽՈՀԹՋԽՇԾՌՀԽՌԽՋՌ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԹԼԼՁՌՁՇՆԹՄՌԹՆՃՋՋԽՌՍՈԹՌՌՀԽ

ԺԽԿՁՆՆՁՆԿՇԾՈՊԽԽՐՈՇՋՍՊԽՏՁՄՄԽՆՋՍՊԽՌՀԹՌՋՍԾԾՁԻՁԽՆՌ

ՊԽՈՄՁԻԹՌԽՋՏՁՌՀՌՀԽԻՇՊՊԽԻՌՋԽՐՊԹՌՁՇԹՊԽԹՎԹՁՄԹԺՄԽԾՇՊ

ՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԫՍՅԺԽՊՇԾՅԹՄԽՋՈԽՊՌԹՆՃ ԫՍՅԺԽՊՇԾԾԽՅԹՄԽՋՈԽՊՌԹՆՃ ԭՊԽԽՐՈՇՋՍՊԽԾԽԻՍՆԼՁՌՑ

 ԽԿԿՋԾԽՅԹՄԽ

ՊԽՈՊՇԼՍԻՌՁՎԽԼԹՑՊԽՈՄՁԻԹՌԽ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՈՊԽԽՐՈՇՋՍՊԽԾԽԻՍՆԼՁՌՑՁՆ

ԽԹԻՀՊԽՈՄՁԻԹՌԽ
ՌԹՆՃՋԽՄԽԻՌԽԼԾՇՊՍՋԽՁՆՌՀԽ

ԼԽԾՁՆՁՌՁՎԽՌԽՋՌԺԽԹՌՄԽԹՋՌ

ԽԿԿՋԾԽՅԹՄԽՊԽՈՊՇԼՍԻՌՁՎԽԼԹՑՊԽՈՄՁԻԹՌԽԼՍՊՁՆԿ

ՌՀԽԼԹՑՋՈՊՁՇՊՌՇՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԫՍՅԺԽՊՇԾՋՈԹՏՆՋԼՍՊՁՆԿՈՊԽԽՐՈՇՋՍՊԽ

 ՌՁՅԽՋՁՆԼԹՑՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՋՈԹՏՆՁՆԿՇԻԻՍՊԹՌՄԽԹՋՌ

ՌՏՁԻԽՁՆՌՀԽԼԹՑՋՈՊՁՇՊՌՇՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

Page 86 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՈՊԽԽՐՈՇՋՍՊԽ ԱՀԽԿՊՇՍՈՋՏԽՊԽՊԹՆՃԽԼ

ԾՊՇՅՄՇՏՌՇՀՁԿՀԾԽԻՍՆԼՁՌՑԹՆԼՌՀԽՌՇՈՈԽՊԾՇՊՅՁՆԿՋՈԹՏՆՁՆԿԿՊՇՍՈՋՏԽՊԽՋԽՄԽԻՌԽԼԱՀԽՌՇՈԾՇՍՊՈԽՊԾՇՊՅԽՊՋՏԽՊԽՊԹՆԼՇՅՄՑԹՋՋՁԿՆԽԼՌՇՇՆԽՊԽՈՄՁԻԹՌԽԾՇՊԽԹԻՀՌՊԽԹՌՅԽՆՌԱՀԽՆԽՐՌԾՇՍՊՈԽՊԾՇՊՅԽՊՋՏԽՊԽՊԹՆԼՇՅՄՑԹՋՋՁԿՆԽԼՌՇԹՋԽԻՇՆԼՊԽՈՄՁԻԹՌԽԾՇՊԽԹԻՀՌՊԽԹՌՅԽՆՌԹՆԼԻՇՆՌՊՇՄԹՆԼՋՇՇՆ

Page 87 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

Ԡ ԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԦՆԾՇՊՅԹՌՁՇՆՇՆՌՀԽԢՐՈՇՋՍՊԽ԰ՑՋՌԽՅԹՆԼԱԽՋՌԳԽՋՋԽՄԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱՑՈԽՇԾԽՐՈՇՋՍՊԽ ԣՄՇՏՌՀՊՇՍԿՀ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԹԾՄՇՏՌՀՊՇՍԿՀ

ՋՑՋՌԽՅԞՋՆՇՌԽԼՁՆՌՀԽԠՇՊՊԽԻՌՁՇՆՋԹՆԼ

ԠՄԹՊՁԾՁԻԹՌՁՇՆՋԼՇԻՍՅԽՆՌ ՌՀԽՍՋԽՇԾԹՋՌԹՌՁԻ

ՊԽՆԽՏԹՄՋՑՋՌԽՅՁՋՆՇՌՊԽԻՇՅՅԽՆԼԽԼԾՇՊՌՀՁՋ

ԹՋՋԹՑ

ԱՑՈԽՇԾԾՄՇՏՌՀՊՇՍԿՀԼՁՄՍՌՁՇՆՋՑՋՌԽՅ

ԠՇՆՌՁՆՍՇՍՋԾՄՇՏ ԦՆՌԽՊՅՁՌՌԽՆՌԾՄՇՏՈՊՇՈՇՊՌՁՇՆԹՄԼՁՄՍՌԽՊՋՇՊ

ԻՇՆՌՁՆՍՇՍՋԾՄՇՏՋԽՊՁԹՄԼՁՄՍՌԽՊՋԹՊԽ

ՊԽԻՇՅՅԽՆԼԽԼ

ԣՄՇՏՌՀՊՇՍԿՀՊԹՌԽ ՅԩՅՁՆ ԠԹՄԻՍՄԹՌԽԼԺԹՋԽԼՇՆԾՁՄՄՎՇՄՍՅԽ
ԩԹՆԼ

ՎՇՄՍՅԽԹԼԼՁՌՁՇՆՋՈԽՊԼԹՑ

ԯԽԻՇՅՅԽՆԼԽԼԾՄՇՏՌՀՊՇՍԿՀՊԹՌԽՁՋՅԩՅՁՆ


ԩՀՊՇՊԹՌՄԽԹՋՌՌՇՌԹՄՎՇՄՍՅԽԽՐԻՀԹՆԿԽՋ

ՈԽՊԼԹՑ

Բ԰ԢՆՎՁՊՇՆՅԽՆՌԹՄԭՊՇՌԽԻՌՁՇՆԞԿԽՆԻՑ
ԢԭԞ
ԠՇՊՊԽԻՌՁՇՆՋԹՆԼԠՄԹՊՁԾՁԻԹՌՁՇՆՋՇՆԱԽԻՀՆՁԻԹՄԞՋՈԽԻՌՋՇԾՌՀԽԱԽՋՌԤՍՁԼԽՄՁՆԽՋԾՇՊՌՀԽԢՆԼՇԻՊՁՆԽԡՁՋՊՍՈՌՇՊ԰ԻՊԽԽՆՁՆԿԭՊՇԿՊԹՅ

ԱՁԽՊԞՋՋԹՑՋ
ԬԠ԰ԭԭԱԽՋՌԤՍՁԼԽՄՁՆԽ԰ԽՊՁԽՋԪԹՊԻՀԬԾԾՁԻԽՇԾԠՀԽՅՁԻԹՄ԰ԹԾԽՌՑԹՆԼԭՇՄՄՍՌՁՇՆԭՊԽՎԽՆՌՁՇՆ
ԬԠ԰ԭԭԴԹՋՀՁՆԿՌՇՆԡԠ


ՀՌՌՈՏՏՏԽՈԹԿՇՎԽՆԼՇՈՍԺՋԹՋՋԹՑՎԹՄՁԼԹՌՁՇՆԻՄԹՊՁԾՁԻԹՌՁՇՆԼՇԻՈԼԾ

ԞԼԼՁՌՁՇՆԹՄԿՍՁԼԹՆԻԽԾՇՊԹՉՍԹՌՁԻՌԽՋՌԼԽՋՁԿՆՁՋՄՇԻԹՌԽԼՁՆԬԠ԰ԭԭԤՍՁԼԽՄՁՆԽ԰ՈԽԻՁԹՄԠՇՆՋՁԼԽՊԹՌՁՇՆՋԾՇՊԠՇՆԼՍԻՌՁՆԿԞՉՍԹՌՁԻԩԹԺՇՊԹՌՇՊՑ԰ՌՍԼՁԽՋ

Page 88 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԡԽՌԹՁՄՋՇՆՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊԾՄՇՏՌՀՊՇՍԿՀՋՑՋՌԽՅՋ

ԣՄՍՁԼՅԽՌԽՊՁՆԿՈՍՅՈՋՏԽՊԽՍՋԽԼՌՇԼԽՄՁՎԽՊՎՇՄՍՅԽՋՇԾԹՋՁՆԿՄԽՌԽՋՌՋՍԺՋՌԹՆԻԽՋՌՇԻՃՋՇՄՍՌՁՇՆՌՇՅՁՐՁՆԿԻՀԹՅԺԽՊՋԹՋՋՁԿՆԽԼՌՇԽԹԻՀՌՊԽԹՌՅԽՆՌ԰ՌՇԻՃՋՇՄՍՌՁՇՆՋՏԽՊԽԼՁՄՍՌԽԼՏՁՌՀՏԽՄՄՏԹՌԽՊՁՆՅՁՐՁՆԿԻՀԹՅԺԽՊՋՁՆՇՊԼԽՊՌՇՇԺՌԹՁՆՌՀԽԼԽՋՁՊԽԼՆՇՅՁՆԹՄՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՈՊՁՇՊՌՇԼԽՄՁՎԽՊՑՌՇՌՀԽՌԽՋՌԻՀԹՅԺԽՊՋԣՄՇՏՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊՏԹՋԻՇՆՌՊՇՄՄԽԼՍՋՁՆԿՊՇՌԹՅԽՌԽՊՋ

ԤԽՆԽՊԹՄՇՈԽՊԹՌՁՇՆՇԾՌՀԽԽՐՈՇՋՍՊԽՋՑՋՌԽՅՏԹՋԻՀԽԻՃԽԼՎՁՋՍԹՄՄՑԹՌՄԽԹՋՌՌՏՇՌՁՅԽՋՈԽՊԼԹՑԼՍՊՁՆԿՌՀԽՌԽՋՌԹՆԼԹՌՄԽԹՋՌՇՆԻԽՇՆՌՀԽԾՁՊՋՌԹՆԼՄԹՋՌԼԹՑՇԾՌՀԽՌԽՋՌ

ԯԽԻՇՅՅԽՆԼԽԼՌՇՐՁԻԹՆՌՅՁՐՁՆԿԾՇՊԾՄՇՏՌՀՊՇՍԿՀ

ՋՑՋՌԽՅՋԪՁՐՁՆԿԻՀԹՅԺԽՊՁՋՊԽԻՇՅՅԽՆԼԽԼ

ԺՍՌՆՇՌՊԽՉՍՁՊԽԼԞԽՊԹՌՁՇՆՁՋՆՇՌ

ՊԽԻՇՅՅԽՆԼԽԼԾՇՊՅՁՐՁՆԿԞԼԽՅՇՆՋՌՊԹՌՁՇՆ

ՌՀԹՌՌՀԽՌԽՋՌՋՇՄՍՌՁՇՆՁՋԻՇՅՈՄԽՌԽՄՑՅՁՐԽԼԺԽԾՇՊԽ

ՁՆՌՊՇԼՍԻԽԼՁՆՌՇՌՀԽՌԽՋՌՋՑՋՌԽՅՁՋՊԽԻՇՅՅԽՆԼԽԼ

ԱՀԽՊԽԻՇՅՅԽՆԼԽԼԾՄՇՏՋՈՄՁՌՌՁՆԿԹԻԻՍՊԹԻՑՁՋ

ՏՁՌՀՁՆ

ԞԽՊԹՌՁՇՆ! ԫՇ ԢԭԞՊԽԻՇՅՅԽՆԼՋԹԽՊԹՌՁՇՆՁԾԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆ

ՊԽԹԻՀԽՋՅԿԩ
ՋԹՌՍՊԹՌՁՇՆ

Page 89 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

԰ՇՍՊԻԽՇԾԼՁՄՍՌՁՇՆՏԹՌԽՊ ԬԺՌԹՁՆԽԼԾՊՇՅԹՏԽՄՄ

ԹՈՈՊՇՐՁՅԹՌԽՄՑՅԽՌԽՊՋԼԽԽՈՄՇԻԹՌԽԼՇՆՋՁՌԽԴԽՄՄՏԹՌԽՊՏԹՋՈԹՋՋԽԼՌՀՊՇՍԿՀԹՋԹՆԼԾՁՄՌԽՊՌՇՊԽՅՇՎԽՈԹՊՌՁԻՄԽՋԿՊԽԹՌԽՊՌՀԹՆ+սՅԹՆԼՈՍՅՈԽԼՁՆՌՇԹՋՌՇՊԹԿԽՌԹՆՃՏՀԽՊԽՁՌՏԹՋԹԽՊԹՌԽԼԭՊՁՇՊՌՇՍՋԽՏԹՌԽՊՏԹՋԾՁՄՌԽՊԽԼՌՇսՅՌՇՊԽՅՇՎԽԾՁՆԽՈԹՊՌՁԻՄԽՋԹՆԼՏԹՋՈԹՋՋԽԼՌՀՊՇՍԿՀԹԲԳՋՌԽՊՁՄՁՒԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՆԹՌՍՊԹՄՇՊՊԽԻՇՆՋՌՁՌՍՌԽԼՏԹՌԽՊ

ՁՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՆԹՌՍՊԹՄՏԹՌԽՊԺԽ

ՋՌԽՊՁՄՁՒԽԼՏՁՌՀԲԳԹՆԼՌԽՋՌԽԼԾՇՊՈԽՋՌՁԻՁԼԽՋ

ՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊՈՇՋՋՁԺՄԽԻՇՆՌԹՅՁՆԹՆՌՋ

ԬԢԠԡԹԻԻԽՈՌՋԹՆՑՏԹՌԽՊՁՆՏՀՁԻՀՌՀԽՌԽՋՌ

ՋՈԽԻՁԽՋՋՀՇՏԻՇՆՌՊՇՄՋՍՊՎՁՎԹՄԹՌՄԽԹՋՌԹՋԿՇՇԼԹՋ

ՁՆԼՁԻԹՌԽԼՁՆՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽ

ԴԹՋԼՁՄՍՌՁՇՆՏԹՌԽՊԹՆԹՄՑՒԽԼԾՇՊՈԽՋՌՁԻՁԼԽՋՀԽԹՎՑՅԽՌԹՄՋԹՆԼՇՌՀԽՊԻՇՆՌԹՅՁՆԹՆՌՋ!

ԶԽՋ԰ԽԽԯԽՎՁԽՏԽՊ0ՋԠՇՅՅԽՆՌՋ

ԱԽՋՌՎԽՋՋԽՄՌՑՈԽՅԹՌԽՊՁԹՄՋ ԤՄԹՋՋ ԢԭԞԹՆԼԬԢԠԡՊԽԻՇՅՅԽՆԼՌՀԹՌՏԹՌԽՊԻՇՆՌԹԻՌ

ՈՇՊՌՁՇՆՋՇԾՌՀԽՋՑՋՌԽՅՆՇՌԻՇՅՈՊՇՅՁՋԽՌՀԽՋՌՍԼՑ


ԽԿԹՄՄԿՄԹՋՋՎԽՋՋԽՄՋՇՊԿՄԹՋՋՎԽՋՋԽՄՋՏՁՌՀ

ՋՌԹՁՆՄԽՋՋՋՌԽԽՄԾՊԹՅԽՋԹՊԽԹԻԻԽՈՌԹԺՄԽ

ԽՐԹՅՈՄԽՋ

ԱԽՋՌՎԽՋՋԽՄՋՁՒԽ ԩ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԩՌԽՋՌԻՀԹՅԺԽՊՋ


ԽԿՐՐԻՅ

Page 90 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԣՁՄՄՎՇՄՍՅԽ ԩ ԢԭԞՊԽԻՇՅՅԽՆԼՋԩՋՇՄՍՌՁՇՆՈԽՊՌԹՆՃ԰ՈԹՏՆՁՆԿՋՍԺՋՌՊԹՌԽՅԹՌԽՊՁԹՄ ԰ԽՅՁԻՁՊԻՍՄԹՊՋԽԻՌՁՇՆՋՇԾ

ԭԳԠ

ԱՀՊԽԽՋՈԹՏՆՁՆԿՋՍԺՋՌՊԹՌԽՋՏԽՊԽԽՋՌԹԺՄՁՋՀԽԼՁՆԽԹԻՀԻՀԹՅԺԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԽԹԻՀՌԹՆՃԻՇՆՌԹՁՆՌՀՊԽԽ

ՋԽՅՁԻՁՊԻՍՄԹՊՋՈԹՏՆՁՆԿՋՍԺՋՌՊԹՌԽՋԽԿԹԿԽԼ

ԭԳԠՈՁՈԽԻՅՁՆՄԽՆԿՌՀՋՈՄՁՌՄԽՆԿՌՀՏՁՋԽ ԰ՈԹՏՆՁՆԿՋՍԺՋՌՊԹՌԽՋՁՒԽ ԻՅ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋՇՆԽՐՈՇՋՍՊԽ

ՋՑՋՌԽՅ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԴԹՌԽՊԮՍԹՄՁՌՑԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋՁՆՌՀԽԱԽՋՌ԰ՑՋՌԽՅ

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ ԪԽԹՋՍՊԽՅԽՆՌԦՆՌԽՊՎԹՄ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՅՈԽՊԹՌՍՊԽ
ոԠ   

ԪԽԹՋՍՊԽԼՏԽԽՃՄՑՁՆ

ԽԹԻՀԻՀԹՅԺԽՊ

ԱԽՅՈԽՊԹՌՍՊԽԹՄՋՇՏԹՋ

ՅՇՆՁՌՇՊԽԼԻՇՆՌՁՆՍՇՍՋՄՑ

ՁՆՇՆԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ

ՊԽՈՄՁԻԹՌԽԼՍՊՁՆԿՌՀԽ

ԽՐՈՇՋՍՊԽՈԽՊՁՇԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌԽՅՈԽՊԹՌՍՊԽչՇԠ

ՁՆՌԽՊՊԽՈՄՁԻԹՌԽԹՆԼՁՆՌԽՊՌՊԽԹՌՅԽՆՌԼՁԾԾԽՊԽՆՌՁԹՄՋ

ՋՀՇՍՄԼՆՇՌԽՐԻԽԽԼՇԠ

Ոԥ   

ԪԽԹՋՍՊԽԼՏԽԽՃՄՑՁՆ

ԽԹԻՀԻՀԹՅԺԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՈԥՌՇ

ԡՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ՅԿԩ    ԪԽԹՋՍՊԽԼՏԽԽՃՄՑՁՆ

ԽԹԻՀԻՀԹՅԺԽՊ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆ
ԡԬ 

ՅԿԩ
 ԹՁՊՋԹՌՍՊԹՌՁՇՆ

Page 91 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ ԪԽԹՋՍՊԽՅԽՆՌԦՆՌԽՊՎԹՄ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱՇՌԹՄԹՄՃԹՄՁՆՁՌՑ
ՅԿԩԹՋԠԹԠԬ   

ԪԽԹՋՍՊԽԼՁՆՇՆԽ

ՊԽՈՄՁԻԹՌԽՌԽՋՌԻՀԹՅԺԽՊ

ՇԾՌՀԽԻՇՆՌՊՇՄԹՆԼ

ՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՏԽԽՃՄՑ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՇՌԹՄԹՄՃԹՄՁՆՁՌՑ ՅԿԩԹՋ

ԠԹԠԬ

ԥԹՊԼՆԽՋՋ
ՅԿԩԹՋԠԹԠԬ   

ԪԽԹՋՍՊԽԼՁՆՇՆԽ

ՊԽՈՄՁԻԹՌԽՌԽՋՌԻՀԹՅԺԽՊ

ՇԾՌՀԽԻՇՆՌՊՇՄԹՆԼ

ՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՏԽԽՃՄՑ

ԱՇՌԹՄՇՊԿԹՆՁԻԻԹՊԺՇՆ
ՅԿԩ   

ԣՇՍՊՏԽԽՃՈԽՊՁՇԼ

ՁՅՅԽԼՁԹՌԽՄՑՈՊՁՇՊՌՇՌՀԽ

ՌԽՋՌ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՇՌԹՄՇՊԿԹՆՁԻԻԹՊԺՇՆՁՆ

ԼՁՄՍՌՁՇՆՏԹՌԽՊԺԽՅԿԩ

ԲՆՁՇՆՁՒԽԼԹՅՅՇՆՁԹ


μԿԩ ԫՇՌԯԽՈՇՊՌԽԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՍՆՁՇՆՁՒԽԼԹՅՅՇՆՁԹՁՆ

ՌՀԽԼՁՄՍՌՁՇՆՏԹՌԽՊԺԽ

μԿԩ

ԯԽՋՁԼՍԹՄԻՀՄՇՊՁՆԽ


μԿԩ ԫՇՌԯԽՈՇՊՌԽԼ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՊԽՋՁԼՍԹՄԻՀՄՇՊՁՆԽՁՆ

ԼՁՄՍՌՁՇՆՏԹՌԽՊԺԽμԿԩ

Page 92 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԪՁՆՁՅՍՅ ԪԹՐՁՅՍՅ ԪԽԹՆ ԪԽԹՋՍՊԽՅԽՆՌԦՆՌԽՊՎԹՄ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

԰ՈԽԻՁԾՁԻԠՇՆԼՍԻՌԹՆԻԽ
ս԰ԻՅ   

ԪԽԹՋՍՊԽԼՁՆՇՆԽ

ՊԽՈՄՁԻԹՌԽՌԽՋՌԻՀԹՅԺԽՊ

ՇԾՌՀԽԻՇՆՌՊՇՄԹՆԼ

ՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՏԽԽՃՄՑ

ԤԽՆԽՊԹՄՊԽԻՇՅՅԽՆԼԹՌՁՇՆՋԾՇՊԾՊԽՉՍԽՆԻՑՇԾ

ՅԽԹՋՍՊԽՅԽՆՌՋԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌ

ՌԽՅՈԽՊԹՌՍՊԽՈԥԹՆԼԼՁՋՋՇՄՎԽԼՇՐՑԿԽՆԺԽ

ՅԽԹՋՍՊԽԼՁՆԹՄՄՌԽՋՌՌԹՆՃՋԹՌՄԽԹՋՌՏԽԽՃՄՑԹՆԼ

ՌՀԹՌՀԹՊԼՆԽՋՋԹՆԼԹՄՃԹՄՁՆՁՌՑԺԽՅԽԹՋՍՊԽԼՁՆ

ԻՇՆՌՊՇՄՋԹՆԼՁՆՇՆԽՌԹՆՃԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆԹՌՄԽԹՋՌՏԽԽՃՄՑԦՆԹԼԼՁՌՁՇՆ

ԻՇՆՌՁՆՍՇՍՋՌԽՅՈԽՊԹՌՍՊԽՅՇՆՁՌՇՊՁՆԿՇԾԹՌՄԽԹՋՌ

ՇՆԽՌԹՆՃՁՋԽՆԻՇՍՊԹԿԽԼ

ԡ ԰ՌՍԼՑԡԽՋՁԿՆԹՆԼԞԼԼՁՌՁՇՆԹՄԢՐՈԽՊՁՅԽՆՌԹՄԠՇՆԼՁՌՁՇՆՋ

ԱԹԺՄԽԯԹՆԿԽԣՁՆԼՁՆԿ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ
ՁԾԞՈՈՄՁԻԹԺՄԽ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԴԹՋԹՊԹՆԿԽԾՁՆԼԽՊԻՇՆԼՍԻՌԽԼ! ԶԽՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋԻՇՆԼՍԻՌՁՆԿԹՊԹՆԿԽԾՁՆԼԽՊՁԾ

ՀՇՍՊԩԠԼԹՌԹԾՇՊՌՀԽԾԹՌՀԽԹԼՅՁՆՆՇՏԹՊԽ

ՍՆԹՎԹՁՄԹԺՄԽ

Page 93 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԦԾՑԽՋՏՀԹՌՏԹՋՌՀԽՅԽՌՀՇԼԾՇՊԼԽՌԽՊՅՁՆՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽՊԹՆԿԽԾՁՆԼԽՊ!

ԟԹՋԽԼՇՆՌՀԽՊԽՈՇՊՌԽԼՏԹՌԽՊՋՇՄՍԺՁՄՁՌՑՇԾՌՀԽՌԽՋՌՅԹՌԽՊՁԹՄ
ՅԿԩ"ոԠԹՆԼՌՀԽՊԽՈՇՊՌԽԼԩԠԾՇՊՊԹՁՆԺՇՏՌՊՇՍՌԹՆԼԺՄՍԽԿՁՄՄՏՀՁԻՀՊԹՆԿԽԼԾՊՇՅՅԿԩ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆԺԽՋԽՄԽԻՌԽԼԺԹՋԽԼՇՆՌՇՐՁԻՁՌՑԼԹՌԹԾՇՊ

ՇՌՀԽՊԾՁՋՀՋՌՍԼՁԽՋՇՊՋՈԽԻՁԽՋՁԾԹՎԹՁՄԹԺՄԽ

ԬՌՀԽՊՏՁՋԽԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌՀԽՌԽՋՌ

ԻՇՅՈՇՍՆԼՇՊՅԿԩ
ՏՀՁԻՀԽՎԽՊՁՋՄՇՏԽՊՁՋ

ԹՈՈՊՇՈՊՁԹՌԽ

԰ՈԽԻՁԽՋ ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋԩՁԾԽՋՌԹԿԽ ԞԼՍՄՌՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՊԹՆԿԽԾՁՆԼՁՆԿՌԽՋՌՋԺԽ

ՈԽՊԾՇՊՅԽԼՏՁՌՀԾՁՋՀՇԾՋՁՅՁՄԹՊԹԿԽԹՆԼՋՁՒԽՌՇՌՀՇՋԽ

ՌՀԹՌՏՇՍՄԼԺԽՍՌՁՄՁՒԽԼՁՆՌՀԽՌԽՋՌ

ԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՀՇՍՊԽՐՈՇՋՍՊԽ

Page 94 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ ԱՀԽՌԽՋՌՏԹՋԻՇՆԼՍԻՌԽԼ

ՏՁՌՀՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋՇԾ
ՆԽԿԹՌՁՎԽԹՆԼՋՇՄՎԽՆՌԻՇՆՌՊՇՄՋԹՆԼՅԿԹՁԩ

ԫՇՅՇՊՌԹՄՁՌՁԽՋՏԽՊԽՇԺՋԽՊՎԽԼՁՆՌՀԽԻՇՆՌՊՇՄՋՇՊԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՅՇՊՌԹՄՁՌՑՁՆՌՀԽՅԿԹՁԩԿՊՇՍՈՏԹՋԩԽՌՀԹՊԿՑՋՍՊԾԹԻՁՆԿՄՇՋՋՇԾԽՉՍՁՄՁԺՊՁՍՅԹՆԼՄՑՁՆԿՇՆՌՀԽԺՇՌՌՇՅՇԾՌՀԽԻՀԹՅԺԽՊՏԽՊԽՇԺՋԽՊՎԽԼՁՆՌՀՁՋԿՊՇՍՈԢԿԿՈՊՇԼՍԻՌՁՇՆՏԹՋՇԺՋԽՊՎԽԼԼՍՊՁՆԿՌՀԽԼԹՑՌԽՋՌՁՆՌՀԽԻՇՆՌՊՇՄՋԹՆԼԹՆԼՅԿԹՁԩԿՊՇՍՈՋԫՇԽԿԿՈՊՇԼՍԻՌՁՇՆՏԹՋՇԺՋԽՊՎԽԼՁՆՌՀԽՅԿԹՁԩԿՊՇՍՈԹՆԼՇՆՄՑՇՆԽՋՈԹՏՆՏԹՋՇԺՋԽՊՎԽԼՁՆՌՀԽՀՁԿՀԽՋՌԿՊՇՍՈԞԼԹՑԩԠՎԹՄՍԽՇԾՅԿԹՁԩ

ՏԹՋԻԹՄԻՍՄԹՌԽԼԹՆԼԹՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆՇԾՅԿԹՁԩՏԹՋՋԽՄԽԻՌԽԼԾՇՊՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԢԭԞՊԽԻՇՅՅԽՆԼՋԻՇՆԼՍԻՌՁՆԿԹՊԹՆԿԽԾՁՆԼԽՊՏՁՌՀ

ԾՁՎԽՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋՈՄՍՋԹԻՇՆՌՊՇՄ
ՋՁՐՌՇՌԹՄ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄՋՏՁՌՀԾՇՍՊԾԽՅԹՄԽՋԹՆԼՌՏՇՅԹՄԽՋ

ՈԽՊԽՐՈՇՋՍՊԽՌԹՆՃ
ԾՁՋՀՌՇՌԹՄԱՀԽՆՍՅԺԽՊՇԾ

ՅՇՊՌԹՄՁՌՁԽՋՌՀԹՌՇԻԻՍՊՅԹՑԺԽՍՋԽԼՌՇԼԽՎԽՄՇՈԹ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋԽԻՍՊՎԽ

ԟԹՋԽԼՍՈՇՆՌՀԽՊԽՋՍՄՌՋՌՀԽՀՁԿՀԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՌՀԹՌԼՇԽՋՆՇՌՊԽՋՍՄՌՁՆՁՆԻՊԽԹՋԽԼՅՇՊՌԹՄՁՌՑՇՊՋՁԿՆՋ

ՇԾՇՎԽՊՌՅՇՊԺՁԼՁՌՑԻՇՅՈԹՊԽԼՌՇԻՇՆՌՊՇՄՋՇՊՌՀԽ

ԼԽՊՁՎԽԼՀՊԩԠՅԹՑԺԽՋԽՄԽԻՌԽԼԹՋՌՀԽՀՁԿՀԽՋՌ

ԽՐՈՇՋՍՊԽԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽԼԹՑՌԽՋՌ

Page 95 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԡԽԾՁՆՁՌՁՎԽ԰ՌՍԼՑԠՇՆԼՁՌՁՇՆՋ

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԱԽՋՌԼՍՊԹՌՁՇՆ ԼԹՑՋ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽԼՍՊԹՌՁՇՆՇԾՌՀԽԼԽԾՁՆՁՌՁՎԽ

ՌԽՋՌԺԽԼԹՑՋ

ԪԽՌՀՇԼԾՇՊՋԽՄԽԻՌՁՆԿՌՀԽՀՁԿՀԽՋՌՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՁՆՌՀԽԼԽԾՁՆՁՌՁՎԽՌԽՋՌ

ԯԹՆԿԽԾՁՆԼԽՊ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՀՁԿՀԽՋՌՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋԽՁՌՀԽՊՌՀԽՋՇՄՍԺՁՄՁՌՑՄՁՅՁՌՇԾՌՀԽՌԽՋՌ

ԻՇՅՈՇՍՆԼՅԿԩՇՊԼԽՅՇՆՋՌՊԹՌԽՋԹԼԽՉՍԹՌԽ

ԽՎՁԼԽՆԻԽՇԾՌՇՐՁԻՁՌՑ
ԽԿՌՀԽՀՇՍՊԩԠ

ՏՀՁԻՀԽՎԽՊԻՇՆԻԽՆՌՊԹՌՁՇՆՁՋՄՇՏԽՋՌ

ԯԽԾԽՊԽՆԻԽՋՌՍԼՑԻՁՌԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫԞ

԰ԽՈԹՊԹՌՁՇՆՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ  ԢԭԞՋՍԿԿԽՋՌՋՌՀԹՌԹԻՇՆԻԽՆՌՊԹՌՁՇՆՋԽՈԹՊԹՌՁՇՆՇԾ

ԺԽՌՏԽԽՆ
ՇՊՌՀՊԽԽԾՇՄԼԹՆԼ
ՇՊՌԽՆԾՇՄԼ

ՁՋՋԻՁԽՆՌՁԾՁԻԹՄՄՑԹԻԻԽՈՌԹԺՄԽ 

ԫՍՅԺԽՊՇԾՌԽՋՌԻՇՆԻԽՆՌՊԹՌՁՇՆՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋԹՅՁՆՁՅՍՅՇԾԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ԹՆԼԹԻՇՆՌՊՇՄՈՄՍՋՋՇՄՎԽՆՌԻՇՆՌՊՇՄՁԾԹՈՈՊՇՈՊՁԹՌԽ

ԞՊԽՆՇՅՁՆԹՄԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹԼՂՍՋՌԽԼ

ԾՇՊՈՍՊՁՌՑ!

ԶԽՋ 

ԦՆԼՁԻԹՌԽՌՀԽՌՑՈԽՇԾՎԹՄՍԽՋՈՊԽՋԽՆՌԽԼԾՇՊՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

ԪԽԹՆՅԽԹՋՍՊԽԼ ԱՀԽՊԽՎՁԽՏԽՊԹՄՋՇԻԹՄԻՍՄԹՌԽԼՌՀԽՌՁՅԽՏԽՁԿՀՌԽԼ

ԹՎԽՊԹԿԽ
ԱԴԞԻՇՆԻԽՆՌՊԹՌՁՇՆՋ

Page 96 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԩՁՅՁՌՇԾՉՍԹՆՌՁԾՁԻԹՌՁՇՆ
ԩԬԮ ՅԿԹՁԩ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԾՇՊԻՀԽՅՁԻԹՄՌԽՋՌ

ԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽՄՇՏՌՀԽԩԬԮԹՆԹՄՑՋԽՋԺԽ

ԻՇՆԼՍԻՌԽԼՇՆՌՀԽՋՌՇԻՃՋՇՄՍՌՁՇՆՋ

ԩԽՎԽՄՇԾԼԽՌԽԻՌՁՇՆ
ԩԬԡ ԫՇՌՊԽՈՇՊՌԽԼԣՊԽՉՍԽՆԻՑՇԾՅԽԹՋՍՊԽՅԽՆՌ ԰ԹՅՈՄԽՋՏԽՊԽԻՇՄՄԽԻՌԽԼԾՇՊ

ԹՆԹՄՑՋՁՋՇՆԡԹՑՋԹՆԼ

ԦՌՁՋՊԽԻՇՅՅԽՆԼԽԼՌՀԹՌՌԽՋՌՁՌԽՅԻՇՆԻԽՆՌՊԹՌՁՇՆԺԽ

ՅԽԹՋՍՊԽԼՈՊՁՇՊՌՇՌՀԽԹԼԼՁՌՁՇՆՇԾԾՁՋՀՁՆԹՄՄՌԹՆՃՋԹՆԼ

ԹՌՄԽԹՋՌՏԽԽՃՄՑՌՀԽՊԽԹԾՌԽՊՁՆՌՏՇՊԽՈՄՁԻԹՌԽՋՈԽՊ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

ԴԹՋՌՀԽՊԹՆԼՇՅՁՒԽԼԻՇՅՈՄԽՌԽԺՄՇԻՃԼԽՋՁԿՆՍՋԽԼ!

ԶԽՋ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌԹՄՄԾՁՋՀԺԽՊԹՆԼՇՅՄՑ

ԹՋՋՁԿՆԽԼՌՇՌԹՆՃՋԼՍՊՁՆԿՈՊԽԽՐՈՇՋՍՊԽԱԹՆՃՋԹՊԽ

ՌՀԽՆՊԹՆՃԽԼԹԻԻՇՊԼՁՆԿՌՇՈՊԽԽՐՈՇՋՍՊԽԾԽԻՍՆԼՁՌՑ

ԹՆԼՌՀԽՌԹՆՃՋՏՁՌՀՌՀԽՀՁԿՀԽՋՌԾԽԻՍՆԼՁՌՑԹՊԽ

ՊԹՆԼՇՅՄՑԹՋՋՁԿՆԽԼՌՇԹԼԽԾՁՆՁՌՁՎԽՌԽՋՌՌՊԽԹՌՅԽՆՌԹՆԼ

ԺՄՇԻՃԾՁՊՋՌԢԹԻՀԺՄՇԻՃԻՇՆՌԹՁՆՋՇՆԽՊԽՈՄՁԻԹՌԽՇԾ

ԽԹԻՀՌՊԽԹՌՅԽՆՌՁՆԻՄՍԼՁՆԿԻՇՆՌՊՇՄՋ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆԻՇՆՌՊՇՄ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՁՆՋՇՄՎԽՆՌԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫԞ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԽՍՋԽՇԾԹԻՇՆԻՍՊՊԽՆՌՋՇՄՎԽՆՌ

ԻՇՆՌՊՇՄՏՀԽՆԹՋՇՄՍԺՁՄՁՒՁՆԿԹԿԽՆՌՁՋՍՋԽԼԢԭԞ

ՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

Page 97 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԫՍՅԺԽՊՇԾՊԽՈՄՁԻԹՌԽՋՈԽՊՌԽՋՌՁՌԽՅՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋՊԽՈՄՁԻԹՌԽՋ

ԫՍՅԺԽՊՇԾՅԹՄԽԾՁՋՀՈԽՊՊԽՈՄՁԻԹՌԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋՅԹՄԽՋՈԽՊՊԽՈՄՁԻԹՌԽ 

ԫՍՅԺԽՊՇԾԾԽՅԹՄԽԾՁՋՀՈԽՊՊԽՈՄՁԻԹՌԽԹՌՌԽՋՌՁՆՁՌՁԹՌՁՇՆ

  ԢԭԞՊԽԻՇՅՅԽՆԼՋԾԽՅԹՄԽՋՈԽՊՊԽՈՄՁԻԹՌԽ

ԴԹՋԹՋՇՄՎԽՆՌՍՋԽԼ! ԫՇ԰ՇՄՎԽՆՌՌՑՈԽ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԫԞԪԹՐՁՅՍՅՋՇՄՎԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫԞ  ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌՀԽՋՇՄՎԽՆՌՆՇՌԽՐԻԽԽԼ

ՅՄԩԬԢԠԡՊԽԻՇՅՅԽՆԼՋՌՀԹՌՋՇՄՎԽՆՌՀԹՎԽՆՇ

ԽԾԾԽԻՌՇՆՋՍՊՎՁՎԹՄՆՇՊՈՊՇԼՍԻԽԹՆՑՇՌՀԽՊԹԼՎԽՊՋԽ

ԽԾԾԽԻՌՋԹՆԼՌՀԹՌԻՇՆԻԽՆՌՊԹՌՁՇՆՆՇՌԺԽԿՊԽԹՌԽՊՌՀԹՆ

ՅՄԩ



ԴԹՋԹՈՇՋՁՌՁՎԽԻՇՆՌՊՇՄՍՋԽԼ! ԫՇԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄ
ՁԾԹՈՈՄՁԻԹԺՄԽ ԫԞ

ԥՍՌԻՀՁՆՋՇՆԱԥ԰ՀՁՄՄԹԺԽԽՊԫԴՁՆՌԽՊԪԧԭՁԻՃԾՇՊԼԡԟ
ԞԻՍՌԽԹՆԼԻՀՊՇՆՁԻԽԾԾԽԻՌՋՇԾԻԹՊՊՁԽՊՋՇՄՎԽՆՌՋՁՆԹՉՍԹՌՁԻՇՊԿԹՆՁՋՅՋԞԻՊՁՌՁԻԹՄՊԽՎՁԽՏԯԽՎՁԽՏԞՉՍԹՌՁԻԱՇՐՁԻՇՄՇԿՑ

ՈՈ-

ԬԢԠԡ
ԤՍՁԼԹՆԻԽԡՇԻՍՅԽՆՌՇՆԞՉՍԹՌՁԻԱՇՐՁԻՁՌՑԱԽՋՌՁՆԿՇԾԡՁԾԾՁԻՍՄՌ԰ՍԺՋՌԹՆԻԽՋԹՆԼԪՁՐՌՍՊԽՋԢՆՎՁՊՇՆՅԽՆՌԹՄԥԽԹՄՌՀԹՆԼ԰ԹԾԽՌՑԭՍԺՄՁԻԹՌՁՇՆՋ԰ԽՊՁԽՋՇՆԱԽՋՌՁՆԿԹՆԼ

ԞՋՋԽՋՋՅԽՆՌԫՇԭԹՊՁՋԣՊԹՆԻԽ

Page 98 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԭԹՊԹՅԽՌԽՊ ԳԹՄՍԽ
Ջ ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԭՇՋՁՌՁՎԽԻՇՆՌՊՇՄԻՇՆԻԽՆՌՊԹՌՁՇՆ
Ջ
ՁԾԹՈՈՄՁԻԹԺՄԽ

ԫԞ 

ԭՀՇՌՇՈԽՊՁՇԼ ՀՊՋՄՁԿՀՌ

ՀՊՋԼԹՊՃ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՈՀՇՌՇՈԽՊՁՇԼ
ՄՁԿՀՌԼԹՊՃ

ԩՁԿՀՌՁՆՌԽՆՋՁՌՑԹՌՏԹՌԽՊ0ՋՋՍՊԾԹԻԽ ՄՍՐ ԢԭԞՊԽԻՇՅՅԽՆԼՋՄՁԿՀՌՁՆՌԽՆՋՁՌՑ-ՄՍՐ
ԹՌ

ՏԹՌԽՊ0ՋՋՍՊԾԹԻԽ

ԞԼԼՁՌՁՇՆԹՄԼԽՌԹՁՄՋ ԫԞ

ԱԹԺՄԽ԰ՍՅՅԹՊՑՇԾԱՊԽԹՌՅԽՆՌԠՇՆԻԽՆՌՊԹՌՁՇՆՋՁՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԱՊԽԹՌՅԽՆՌԦԡ

ԫՇՅՁՆԹՄ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԪԽԹՋՍՊԽԼ

ԠՇՆԻԽՆՌՊԹՌՁՇՆ


ՅԿԹՁԩ

ԪԽԹՆԠԳ
 ԡԽՌԹՁՄՋՇՊԯԽՅԹՊՃՋ ԤՍՁԼԽՄՁՆԽԯԽԻՇՅՅԽՆԼԹՌՁՇՆՋ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ  ԩԬԮ ԫԞ ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՌԽՋՌՁՌԽՅԻՇՆԻԽՆՌՊԹՌՁՇՆՋԺԽ

ՅԹՁՆՌԹՁՆԽԼԹՌԹԻՇԽԾԾՁԻՁԽՆՌՇԾՎԹՊՁԹՌՁՇՆ
ԠԳ ԱՊԽԹՌՅԽՆՌ    ԱԴԞ

ԱՊԽԹՌՅԽՆՌ    ԱԴԞԱՊԽԹՌՅԽՆՌ    ԱԴԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԠԳԠՇԽԾԾՁԻՁԽՆՌՇԾՎԹՊՁԹՌՁՇՆ

ԩԬԮՅԿԹՁԩ

Page 99 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

Ԣ ԬԺՋԽՊՎԹՌՁՇՆՋ

ԟՁՇՄՇԿՁԻԹՄԢՆԼՈՇՁՆՌՋ  ԣԽԻՍՆԼՁՌՑԾԽՊՌՁՄՁՌՑՆՍՈՌՁԹՄՌՍԺԽՊԻՄԽՋԻՇՊԽՋԺՇԼՑՏԽՁԿՀՌՄԽՆԿՌՀԳԱԤԻՇՆԻԽՆՌՊԹՌՁՇՆՋԤ԰ԦԴԽՊԽՊԹՏ
ՁՆԼՁՎՁԼՍԹՄԼԹՌԹՈՊՇՎՁԼԽԼ! ԶԽՋ

ԢԭԞՊԽԻՇՅՅԽՆԼՋՌՀԹՌՇԺՋԽՊՎԹՌՁՇՆՋՇԾՋՍՊՎՁՎԹՄԾԽԻՍՆԼՁՌՑԾԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋՋԽԻՇՆԼԹՊՑՋԽՐԻՀԹՊԹԻՌԽՊՁՋՌՁԻՋԹՆԼՇՌՀԽՊԻՄՁՆՁԻԹՄՋՁԿՆՋՇԻԻՍՊԹՌՄԽԹՋՌԼԹՁՄՑԞՌՌԽՋՌ

ՌԽՊՅՁՆԹՌՁՇՆ
ԡԹՑԹԼԼՁՌՁՇՆԹՄՇԺՋԽՊՎԹՌՁՇՆՋՁՆԻՄՍԼԽԺՇԼՑՏԽՁԿՀՌԹՆԼՄԽՆԿՌՀՆՍՈՌՁԹՄՌՍԺԽՊԻՄԽՋԻՇՊԽԿՇՆԹԼԹՄՋՌԹԿՁՆԿԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՈՄԹՋՅԹՎՁՌԽՄՄՇԿԽՆՁՆԹՆԼ

ՈՄԹՋՅԹՋԽՐՋՌԽՊՇՁԼՋ
ՌԽՋՌՇՋՌԽՊՇՆԽԹՆԼȕԽՋՌՊԹԼՁՇՄՁԾՅԽԹՋՍՊԽԼԤՇՆԹԼՇՋՇՅԹՌՁԻՁՆԼԽՐ
Ԥ԰ԦՁՋԻԹՄԻՍՄԹՌԽԼՍՋՁՆԿԹՊԹՌՁՇՇԾԿՇՆԹԼՏԽՁԿՀՌՌՇԺՇԼՑՏԽՁԿՀՌ
ԿՇՆԹԼ

ՏԽՁԿՀՌՌՇՌՀԽՆԽԹՊԽՋՌՅԿԺՇԼՑՏԽՁԿՀՌՁՆՅԿՐԹՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ

ԠՄՁՆՁԻԹՄՋՁԿՆՋՇԾՇՎԽՊՌՌՇՐՁԻՁՌՑՅԹՑՁՆԻՄՍԼԽ
ԺՍՌԹՊԽՆՇՌՄՁՅՁՌԽԼՌՇՀԽՅՇՊՊՀԹԿԽԻԽՋՋԹՌՁՇՆՇԾԾԽԽԼՁՆԿԹՆԼՇՌՀԽՊԹԺՆՇՊՅԹՄԺԽՀԹՎՁՇՊ

ԦԦ ԯԢ԰ԲԩԱ԰ԞԫԡԡԦ԰ԠԲ԰԰ԦԬԫ

Ԟ ԯԽՋՍՄՌՋ

ԪԽԹՆՅԹՄԽԹՆԼԾԽՅԹՄԽՋՍՊՎՁՎԹՄՏԽՊԽՁՆՌՀԽԻՇՆՌՊՇՄԹՆԼԱԴԞԹՆԼՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԹՌՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆ
ԱԹԺՄԽ



Page 100 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԞԼՍՄՌԣՁՋՀ԰ՍՊՎՁՎԹՄՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ 

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն ԰ՍՊՎՁՎՁՆԿ ԰ՍՊՎՁՎԹՄ Ն ԰ՍՊՎՁՎՁՆԿ ԰ՍՊՎՁՎԹՄ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ                        

ԩԬԮՅԿԹՁԩ

ԟՑՌԽՋՌՌԽՊՅՁՆԹՌՁՇՆՌՀԽԿՊՇՍՈՅԽԹՆՋՇԾՅԹՄԽՄԽՆԿՌՀՊԹՆԿԽԼԾՊՇՅՌՇՅՅԹՆԼՌՀԽԿՊՇՍՈՅԽԹՆՋՇԾԾԽՅԹՄԽՄԽՆԿՌՀՊԹՆԿԽԼԾՊՇՅՌՇՅՅ
ԱԹԺՄԽԤՊՇՍՈՅԽԹՆՋԾՇՊՏԽՌՏԽՁԿՀՌՁՆՅԹՄԽՋՊԹՆԿԽԼԾՊՇՅԿՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՌՇԿՁՆՌՀԽԱԴԞՅԿԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈ

ՏՀՁՄԽԾԽՅԹՄԽՏԽՁԿՀՌՊԹՆԿԽԼԾՊՇՅՌՇԿ

Page 101 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽ԰ՁՒԽԹՌԱԽՋՌԱԽՊՅՁՆԹՌՁՇՆՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԟՇԼՑԴԽՁԿՀՌ ԩԽՆԿՌՀ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն

ԪԽԹՆ


Կ

չ԰ԡ Ն

ԪԽԹՆ


Կ

չ԰ԡ Ն

ԪԽԹՆ


ՅՅ

չ԰ԡ Ն

ԪԽԹՆ


ՅՅ

չ԰ԡ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ

           

                                    

ԩԬԮՅԿԹՁԩ

Page 102 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԪԽԹՆԾԽԻՍՆԼՁՌՑՎԹՄՍԽՋՏԽՊԽԹՆԼԽԿԿՋԾԽՅԹՄԽՊԽՈՊՇԼՍԻՌՁՎԽԼԹՑՁՆՌՀԽԱԴԞԹՆԼՅԿ

ԹՁԩՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՋՈԽԻՌՁՎԽՄՑԥՇՏԽՎԽՊԾԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋՏԹՋՁՆԹՄՄԿՊՇՍՈՋԞՄՌՀՇՍԿՀ

ԾԽԻՍՆԼՁՌՑՁՆՌՀԽԻՇՆՌՊՇՄԿՊՇՍՈԽՐԻԽԽԼԽԼԽԿԿՋԾԽՅԹՄԽԼԹՑՁՆԽԹԻՀՇԾՌՀԽՊԽՈՄՁԻԹՌԽՋԽԹԻՀՊԽՈՄՁԻԹՌԽՁՆԻՄՍԼԽԼ

ՇՊԼԹՑՈԽՊՁՇԼՋՏՁՌՀՇՍՌՋՈԹՏՆՁՆԿ

ԱԹԺՄԽԣԽԻՍՆԼՁՌՑԹՆԼԣԽՊՌՁՄՁՒԹՌՁՇՆ԰ՍԻԻԽՋՋՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԣԽԻՍՆԼՁՌՑ ԣԽՊՌՁՄՁՒԹՌՁՇՆ԰ՍԻԻԽՋՋ


ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ չ չ

 չ չ

 չ չ

 չ չ

ԣԽԻՍՆԼՁՌՑՁՋԻԹՄԻՍՄԹՌԽԼԹՋՌՀԽՆՍՅԺԽՊՇԾԽԿԿՋՈԽՊՋՍՊՎՁՎՁՆԿԾԽՅԹՄԽՈԽՊՊԽՈՊՇԼՍԻՌՁՎԽԼԹՑՈԽՊՊԽՈՄՁԻԹՌԽ



ԣԽՊՌՁՄՁՒԹՌՁՇՆՋՍԻԻԽՋՋ
ՁՋԻԹՄԻՍՄԹՌԽԼԹՋՌՀԽՆՍՅԺԽՊՇԾԽՅԺՊՑՇՋԼՁՎՁԼԽԼԺՑՌՀԽՆՍՅԺԽՊՇԾԽԿԿՋՅՍՄՌՁՈՄՁԽԼԺՑ

ԩԬԮՅԿԹՁԩ

ԪԽԼՁԹՆՅԹՄԽՌՍԺԽՊԻՄԽՋԻՇՊԽՋՊԹՆԿԽԼԾՊՇՅԹՈՈՊՇՐՁՅԹՌԽՄՑՌՇ
ԱԹԺՄԽԫՇՌՍԺԽՊԻՄԽՋՏԽՊԽՆՇՌԽԼՇՆ

ԾԽՅԹՄԽՋ

ԱԹԺՄԽԫՍՈՌՁԹՄԱՍԺԽՊԻՄԽ԰ԻՇՊԽՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն ԪԽԼՁԹՆԱՍԺԽՊԻՄԽ

԰ԻՇՊԽ Ն ԪԽԼՁԹՆԱՍԺԽՊԻՄԽ԰ԻՇՊԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ    

    

    

    

ԩԬԮՅԿԹՁԩ

Page 103 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԪԽԹՆՅԹՄԽԤ԰ԦՁՆԻՊԽԹՋԽԼԾՊՇՅՁՆՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՌՇՁՆՌՀԽԱԴԞՅԿԹՁԩՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈ
ԱԹԺՄԽ԰ՁՅՁՄԹՊՄՑՅԽԹՆԾԽՅԹՄԽԤ԰ԦՁՆԻՊԽԹՋԽԼԾՊՇՅՁՆՌՀԽԻՇՆՌՊՇՄՌՇԹՌՌՀԽՀՁԿՀԽՋՌ

ՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

ԱԹԺՄԽԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐ
Ԥ԰ԦՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն ԪԽԹՆԤ԰Ԧ




չ԰ԡ Ն ԪԽԹՆԤ԰Ԧ




չ԰ԡ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ      

      

      

      

ԤՇՆԹԼՇՋՇՅԹՌՁԻՁՆԼԽՐ
ՁՋԻԹՄԻՍՄԹՌԽԼԹՋԿՇՆԹԼՏԽՁԿՀՌ
ՌՇՌՀԽՆԽԹՊԽՋՌՅԿԺՇԼՑՏԽՁԿՀՌ
ՅԿՐ

ԩԬԮՅԿԹՁԩ

ԪԽԼՁԹՆՅԹՄԽԿՇՆԹԼԹՄՋՌԹԿԽՊԹՆԿԽԼԾՊՇՅՌՇԹՆԼՏԹՋԻՇՅՈԹՊԹԺՄԽԺԽՌՏԽԽՆՌՀԽԻՇՆՌՊՇՄԹՆԼՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈՋ
ԱԹԺՄԽԠՇՆՎԽՊՋԽՄՑՅԽԼՁԹՆԾԽՅԹՄԽԿՇՆԹԼՋՌԹԿԽՁՆԻՊԽԹՋԽԼԾՊՇՅՁՆՌՀԽԻՇՆՌՊՇՄՌՇՁՆՌՀԽ

ՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈ

Page 104 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԤՇՆԹԼԹՄ԰ՌԹԿՁՆԿՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ
ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն ԪԽԼՁԹՆ԰ՌԹԿԽ Ն ԪԽԼՁԹՆ԰ՌԹԿԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ    

    

    

    



ԱՀԽԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼՋՌՀԽԾՇՄՄՇՏՁՆԿԿՇՆԹԼԹՄՋՌԹԿՁՆԿՋԻԹՄԽԾՇՊՅԹՄԽԾԹՌՀԽԹԼՅՁՆՆՇՏՍՆԼԽՎԽՄՇՈԽԼԽԹՊՄՑ

ՋՈԽՊՅԹՌՇԿԽՆՁԻՅՁԼՋՈԽՊՅԹՌՇԿԽՆՁԻՄԹՌԽՋՈԽՊՅԹՌՇԿԽՆՁԻՋՈԽՆՌ



ԱՀԽԿՍՁԼԽՄՁՆԽՊԽԻՇՅՅԽՆԼՋՌՀԽԾՇՄՄՇՏՁՆԿԿՇՆԹԼԹՄՋՌԹԿՁՆԿՋԻԹՄԽԾՇՊԾԽՅԹՄԽԾԹՌՀԽԹԼՅՁՆՆՇՏՍՆԼԽՎԽՄՇՈԽԼԽԹՊՄՑ

ԼԽՎԽՄՇՈՅԽՆՌՅՁԼԼԽՎԽՄՇՈՅԽՆՌՄԹՌԽԼԽՎԽՄՇՈՅԽՆՌՄԹՌԽԼԽՎԽՄՇՈՅԽՆՌՀՑԼՊԹՌԽԼՈՇՋՌՇՎՍՄԹՌՇՊՑ

ԩԬԮՅԿԹՁԩ

ԱԽՋՌԽՋՋՀՇՏԽԼՆՇՀՁՋՌՇՄՇԿՁԻԹՄՄՑԽՎՁԼԽՆՌԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՄԹՌԽԼԻՀԹՆԿԽՋՁՆՌՀԽՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՄԹՌՁՎԽՌՇՌՀԽ

ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՌՀՇՍԿՀՅՁՆՁՅԹՄԿՊԹՆՍՄՇՅԹՌՇՍՋՁՆԾՄԹՅՅԹՌՁՇՆՏԹՋՇԺՋԽՊՎԽԼՁՆԾՁՋՀՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈ


ԱԹԺՄԽՋԹՆԼԱՀԽՊԽՏԽՊԽՆՇՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՋՁՆՇՎԹՊՁԽՋՁՆՌՀԽՄՇՏԹՆԼՅՁԼԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆՇԾԹՋՄՁԿՀՌՍՈՏԹՊԼՋՀՁԾՌՁՆՌՀԽՅԽԼՁԹՆ

ԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՇԾՌՀԽՇՎԹՊՁԽՋՁՆՌՀԽՅՁԼՌՊԽԹՌՅԽՆՌԿՊՇՍՈ
ԱԹԺՄԽՋԹՆԼԥՁԿՀՋԽՎԽՊՁՌՑՋԻՇՊԽՋԾՇՊ

ԼԽԻՊԽԹՋԽԼՈՇՋՌՇՎՍՄԹՌՇՊՑԾՇՄՄՁԻՄԽՋՏԽՊԽԹՄՋՇՇԺՋԽՊՎԽԼՁՆՌՀՁՋՌՊԽԹՌՅԽՆՌԿՊՇՍՈՏՀՁԻՀԹՊԽԹՆՇՊՅԹՄՇԻԻՍՊՊԽՆԻԽ

ՁՆՋՌԹԿԽԹՆԼՇՎԹՊՁԽՋԱՀԽՊԽԾՇՊԽԼՁԾԾԽՊԽՆԻԽՋԾՊՇՅՌՀԽԻՇՆՌՊՇՄՏԽՊԽԹՌՌՊՁԺՍՌԽԼՌՇԹԿՊԽԹՌԽՊՆՍՅԺԽՊՇԾՇՎԹՊՁԽՋ

ՁՆՌՀՁՋԿՊՇՍՈԹՌՋՌԹԿԽԹՆԼԱՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՋՏԽՊԽՆՇՌԽԼՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՏՁՌՀԹ

ՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌՁՆԻՊԽԹՋԽՁՆԾԽՅԹՄԽԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽԱՀԽՊԽԹՄՋՇՏԹՋԹՆՁՆԻՊԽԹՋԽՁՆՋԽՎԽՊԽՇՇԻՑՌԽ

ԹՌՊԽՋՁԹՁՆՇԾՌՀԽԾՁՋՀԹՌՌՀՁՋՄԽՎԽՄԻՇՅՈԹՊԽԼՌՇՇՆՄՑՇԾՁՆՌՀԽԻՇՆՌՊՇՄԣՍՊՌՀԽՊՌՀԽՊԽՏԹՋԹՋՁԿՆՁԾՁԻԹՆՌ

ՁՆԻՊԽԹՋԽՁՆՌՀԽՆՍՅԺԽՊՇԾՋԽՎԽՊԽՈՇՋՌԹՌՊԽՌՁԻԾՇՄՄՁԻՄԽՋԱՀԽՋԽՁՆԻՊԽԹՋԽՋՁՆԼՁԻԹՌԽՌՀԹՌՌՀԽՆՍՅԺԽՊՇԾՎՁԹԺՄԽ

ՋՈԹՏՆԽԼՇՇԻՑՌԽՋՈՊՇԼՍԻԽԼԺՑՌՀԽՋԽՇՎԹՊՁԽՋՏԹՋՋՁԿՆՁԾՁԻԹՆՌՄՑԼՁՅՁՆՁՋՀԽԼՏՀՁԻՀՏԹՋԻՇՆԾՁՊՅԽԼԺՑՄՇՏ

ԾԽԻՍՆԼՁՌՑԱՀԽՊԽՏԹՋԹՄՋՇԹՋՁԿՆՁԾՁԻԹՆՌՁՆԻՊԽԹՋԽՁՆՁՆՌՊԹՎԹՋԻՍՄԹՊՁՆՌԽՊՋՌՁՌՁԹՄՈՊՇՌԽՁՆԹԻԽՇՍՋԾՄՍՁԼՋԽԽՆՁՆՇԾՌՀԽ

ԾԽՅԹՄԽՋԹՌՌՀԽՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆ

Page 105 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑՁՆԪԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ 


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆԻՊԽԹՋԽԼ

ԭՊՇՈՇՊՌՁՇՆՇԾ

԰ՈԽՊՅԹՌՇԿՇՆՁԹ

ԭՊԽՋԽՆԻԽՇԾ

ԱԽՋՌՁՋԬՎԹ

ԦՆԻՊԽԹՋԽԼ

ԱԽՋՌՁԻՍՄԹՊ

ԡԽԿԽՆԽՊԹՌՁՇՆ

ԦՆՌԽՊՋՌՁՌՁԹՄԠԽՄՄ

ԥՑՈԽՊՌՊՇՈՀՑ

ԥՑՈԽՊՈՄԹՋՁԹ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԠՇՆՌՊՇՄ
ԩԬԮ         

        

        

        

        

         

        

        

        

        

         

        

        

        

        

         

        

        

        

        

 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼ

ԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԞՈՈԽՆԼՁՐԢՇԾՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԾՇՊՊԽԾԽՊԽՆԻԽ

ԩԬԮՅԿԹՁԩ

Page 106 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԞԼԼՁՌՁՇՆԹՄԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑԬԺՋԽՊՎԹՌՁՇՆՋՁՆԪԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ 


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԡԽԻՊԽԹՋԽԼ

ԭՊՇՈՇՊՌՁՇՆՇԾ

԰ՈԽՊՅԹՌՇԿՇՆՁԹ

ԦՆԻՊԽԹՋԽԼԳԹՋԻՍՄԹՊ

ՇՊԦՆՌԽՊՋՌՁՌՁԹՄ

ԭՊՇՌԽՁՆԹԻԽՇՍՋԣՄՍՁԼ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԤՇՆԹԼ

ԡԽՎԽՄՇՈՅԽՆՌ

ԞՄՌԽՊԽԼԭՊՇՈՇՊՌՁՇՆՋՇԾ

԰ՈԽՊՅԹՌՇԻՑՌԽՋՇՊ

԰ՈԽՊՅԹՌՁԼՋ

ԤՊԹՆՍՄՇՅԹՌՇՍՋ

ԦՆԾՄԹՅՅԹՌՁՇՆ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ           

          

                              

           

          

                              

           

          

                              

Page 107 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱՊԽԹՌՅԽՆՌ 


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԡԽԻՊԽԹՋԽԼ

ԭՊՇՈՇՊՌՁՇՆՇԾ

԰ՈԽՊՅԹՌՇԿՇՆՁԹ

ԦՆԻՊԽԹՋԽԼԳԹՋԻՍՄԹՊ

ՇՊԦՆՌԽՊՋՌՁՌՁԹՄ

ԭՊՇՌԽՁՆԹԻԽՇՍՋԣՄՍՁԼ

ԞՋՑՆԻՀՊՇՆՇՍՋ

ԤՇՆԹԼ

ԡԽՎԽՄՇՈՅԽՆՌ

ԞՄՌԽՊԽԼԭՊՇՈՇՊՌՁՇՆՋՇԾ

԰ՈԽՊՅԹՌՇԻՑՌԽՋՇՊ

԰ՈԽՊՅԹՌՁԼՋ

ԤՊԹՆՍՄՇՅԹՌՇՍՋ

ԦՆԾՄԹՅՅԹՌՁՇՆ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

           

          

                              

 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԞՈՈԽՆԼՁՐԢՇԾՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽ

ԾՇՊՊԽԾԽՊԽՆԻԽ

ԩԬԮՅԿԹՁԩ

Page 108 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑՁՆԣԽՅԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ 


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆԻՊԽԹՋԽԼԬՇԻՑՌԽ

ԞՌՊԽՋՁԹ

ԭԽՊՁԾՇՄՄՁԻՍՄԹՊԠԽՄՄ

ԥՑՈԽՊՈՄԹՋՁԹ

ԥՑՈԽՊՌՊՇՈՀՑ

ԡԽԻՊԽԹՋԽԼԶՇՄՃ

ԣՇՊՅԹՌՁՇՆ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ       

      

      

      

      

       

      

      

      

      

       

      

      

      

      

       

      

      

      

      



 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼ

ԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԞՈՈԽՆԼՁՐԢՇԾՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԾՇՊՊԽԾԽՊԽՆԻԽ

ԩԬԮՅԿԹՁԩ

Page 109 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԞԼԼՁՌՁՇՆԹՄԤՇՆԹԼԹՄԥՁՋՌՇՈԹՌՀՇՄՇԿՑԬԺՋԽՊՎԹՌՁՇՆՋՁՆԣԽՅԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋ

ՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ 


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԞԼԼՁՌՁՇՆԹՄԡՁԹԿՆՇՋՌՁԻԬԺՋԽՊՎԹՌՁՇՆՋ

԰ԽՎԽՊՁՌՑ

ԦՆՌԽՊՋՌՁՌՁԹՄ

ԣՁԺՊՇՋՁՋ

ԢԿԿԡԽԺՊՁՋՁՆ

ԬՎՁԼՍԻՌ

ԤՊԹՆՍՄՇՅԹՌՇՍՋ

ԦՆԾՄԹՅՅԹՌՁՇՆ

ԡԽԻՊԽԹՋԽԼ

ԭՇՋՌԬՎՍՄԹՌՇՊՑ

ԣՇՄՄՁԻՄԽՋ

Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ


ԩԬԮ

        

        

        

        

        

         

        

        

        

        

         

        

        

        

        

         

        

        

        

        



 ԤՇՆԹԼԹՄՀՁՋՌՇՈԹՌՀՇՄՇԿՑԼՁԹԿՆՇՋՌՁԻՇԺՋԽՊՎԹՌՁՇՆՋԹՊԽԿՊԹԼԽԼ-ԺԹՋԽԼՇՆՋԽՎԽՊՁՌՑԫՇՌՊԽՅԹՊՃԹԺՄԽԪՁՆՁՅԹՄԪՁՄԼ

ԪՇԼԽՊԹՌԽ԰ԽՎԽՊԽ԰ԽԽԞՈՈԽՆԼՁՐԢՇԾՌՀԽՌԽՋՌԿՍՁԼԽՄՁՆԽԾՇՊՊԽԾԽՊԽՆԻԽ

ԩԬԮՅԿԹՁԩ

Page 110 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԪԽԹՆՅԹՄԽԹՆԼԾԽՅԹՄԽԳԱԤԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏԽՊԽՀՁԿՀՄՑՎԹՊՁԹԺՄԽԹՆԼՏԽՊԽԻՇՅՈԹՊԹԺՄԽԺԽՌՏԽԽՆՌՀԽԻՇՆՌՊՇՄ

ԹՆԼԹՄՄՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ
ԱԹԺՄԽ

ԱԹԺՄԽԭՄԹՋՅԹԳՁՌԽՄՄՇԿԽՆՁՆՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԭՄԹՋՅԹԳՁՌԽՄՄՇԿԽՆՁՆ
ԳԱԤ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն ԪԽԹՆ


ՆԿՅԩՈՄԹՋՅԹ

չ԰ԡ Ն ԪԽԹՆ


ՆԿՅԩՈՄԹՋՅԹ

չ԰ԡ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ     Ր Ր

     Ր Ր

     Ր Ր

     Ր Ր

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ

ԩԬԮՅԿԹՁԩ

Page 111 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

 ԱԹԺՄԽԭՄԹՋՅԹ԰ԽՐ԰ՌԽՊՇՁԼՋՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ  ԫՇՌՅԽԹՋՍՊԽԼ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԭՄԹՋՅԹԱԽՋՌՇՋՌԽՊՇՆԽ
Ա ԭՄԹՋՅԹ

ȕԽՋՌՊԹԼՁՇՄ
Ԣ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ ԪԹՄԽՋ ԣԽՅԹՄԽՋ

Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ Ն

ԪԽԹՆ


ՆԿՅԩ

ՈՄԹՋՅԹ

չ԰ԡ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ  ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԫԡԫՇՌԼԽՌԽՊՅՁՆԽԼ԰ԡ԰ՌԹՆԼԹՊԼԼԽՎՁԹՌՁՇՆ

ԩԬԮՅԿԹՁԩ

Page 112 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԞՄՄԾՁՋՀԹՈՈԽԹՊԽԼՆՇՊՅԹՄԹՆԼՀԽԹՄՌՀՑՌՀՊՇՍԿՀՇՍՌՌՀԽԽՐՈՇՋՍՊԽՈԽՊՁՇԼՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆՇԾՌՏՇԾԽՅԹՄԽՋՏՀՇԹՈՈԽԹՊԽԼՌՇԺԽԽԿԿԺՇՍՆԼՁՆՌՀԽՀՁԿՀԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՌՊԽԹՌՅԽՆՌԿՊՇՍՈ
ԱԹԺՄԽԬՆԽԾԽՅԹՄԽՏԹՋՇԺՋԽՊՎԽԼՌՇԺԽԽԿԿԺՇՍՆԼԾՊՇՅԡԹՑՋՌՇՏՀՁՄԽՌՀԽՇՌՀԽՊԾԽՅԹՄԽՏԹՋՇԺՋԽՊՎԽԼՌՇԺԽԽԿԿԺՇՍՆԼՇՆԡԹՑՋԹՆԼ

ԱԹԺՄԽ԰ԽԻՇՆԼԹՊՑ԰ԽՐԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋԹՆԼԠՄՁՆՁԻԹՄ԰ՁԿՆՋՁՆԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

԰ԽԻՇՆԼԹՊՑ԰ԽՐԠՀԹՊԹԻՌԽՊՁՋՌՁԻՋԹՆԼԠՄՁՆՁԻԹՄ԰ՁԿՆՋ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ

ԱՑՈԽ Ն ԦՆԻՁԼԽՆԻԽ ԱՑՈԽ Ն ԦՆԻՁԼԽՆԻԽ

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ ԫՇՆԽ   ԫՇՆԽ  

 ԫՇՆԽ   ԫՇՆԽ  

 ԫՇՆԽ   ԫՇՆԽ  

 ԫՇՆԽ  

ԫՇՆԽ





ԢԿԿԺՇՍՆԼ 

ԩԬԮՅԿԹՁԩ

Page 113 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԟ ԰ՌՍԼՑԞՍՌՀՇՊ0ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

԰ՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋԽՋՏԽՊԽՈԽՊԾՇՊՅԽԼՇՆՋՍՊՎՁՎԹՄՏԽՌՏԽՁԿՀՌՌՇՌԹՄՄԽՆԿՌՀԾԽԻՍՆԼՁՌՑԾԽՊՌՁՄՁՌՑԤ԰ԦՈՄԹՋՅԹ

ԳԱԤԻՇՆԻԽՆՌՊԹՌՁՇՆՋՌՍԺԽՊԻՄԽՋԻՇՊԽՋՁՆԻՁԼԽՆԻԽԹՆԼՋԽՎԽՊՁՌՑՇԾԿՇՆԹԼԹԺՆՇՊՅԹՄՁՌՁԽՋԹՆԼԿՇՆԹԼ

ԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽԪԽԹՋՍՊԽՅԽՆՌՋՇԾԳԱԤԻՇՆԻԽՆՌՊԹՌՁՇՆՋԹՊԽՁՆՀԽՊԽՆՌՄՑՎԹՊՁԹԺՄԽԹՆԼԺՇՐՈՄՇՌՋՇԾՄՇԿ

ՌՊԹՆՋԾՇՊՅԽԼԳԱԤՎԹՄՍԽՋՏԽՊԽՍՋԽԼՌՇՁԼԽՆՌՁԾՑՈՇՌԽՆՌՁԹՄՇՍՌՄՁԽՊՋ
ԱՍՃԽՑ0ՋՅԽՌՀՇԼԫՇՇՍՌՄՁԽՊՋՏԽՊԽ

ԽՐԻՄՍԼԽԼԾՊՇՅԹՆԹՄՑՋԽՋՁՆՌՀՁՋՋՌՍԼՑԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՆՇՌԽԼՌՀԽՍՆՁՌՇԾՋՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋՁՋՏԹՋՌՀԽ

ՊԽՈՄՁԻԹՌԽՌԽՋՌԻՀԹՅԺԽՊԪԹՄԽՋԹՆԼԾԽՅԹՄԽՋՏԽՊԽԹՆԹՄՑՒԽԼՋԽՈԹՊԹՌԽՄՑԾՇՊԽԹԻՀԽՆԼՈՇՁՆՌՏՀԽՆԹՈՈՊՇՈՊՁԹՌԽ

ԞՄՄԽՆԼՈՇՁՆՌՋՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿՌՏՇԻՇՅՈՄԽՅԽՆՌԹՊՑՋՌԹՌՁՋՌՁԻԹՄԹՈՈՊՇԹԻՀԽՋԦԾՊԽՋՈՇՆՋԽՋԹՈՈԽԹՊԽԼՌՇ

ԺԽՅՇՆՇՌՇՆՁԻԹՋՌԽՈԼՇՏՆԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼՌԽՋՌՏԹՋՍՋԽԼՌՇԽՎԹՄՍԹՌԽՈՇՋՋՁԺՄԽՌՊԽՆԼՋՁՆՌՀԽ

ՊԹՆՃՋՇԾՊԽՈՄՁԻԹՌԽՅԽԹՆՋՌՇԼԽՌԽՊՅՁՆԽԻՇՆԻԽՆՌՊԹՌՁՇՆՊԽՋՈՇՆՋՁՎԽՌՊԽՆԼՋԹՅՇՆԿՌՀԽՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋԞՄՄ

ԽՆԼՈՇՁՆՌՋԽՐԻԽՈՌԾՇՊՋՍՊՎՁՎԹՄԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՋԽՎԽՊՁՌՑՋԻՇՊԽՋԹՆԼՋՌԹԿԽՋԹՄՋՇՏԽՊԽԹՆԹՄՑՒԽԼԺՑ

ՈԽՊԾՇՊՅՁՆԿՈԹՁՊՏՁՋԽԻՇՅՈԹՊՁՋՇՆՋՍՋՁՆԿԡՍՆՆԽՌՌ0ՋՅՍՄՌՁՈՄԽԻՇՅՈԹՊՁՋՇՆՌԽՋՌՌՇԼԽՌԽՊՅՁՆԽՏՀՁԻՀՌՊԽԹՌՅԽՆՌ

ԿՊՇՍՈՋԼՁԾԾԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑԾՊՇՅՌՀԽԻՇՆՌՊՇՄԡԹՌԹԾՇՊԽՆԼՈՇՁՆՌՋԹՆԹՄՑՒԽԼԺՑԡՍՆՆԽՌՌ0ՋՌԽՋՌՏԽՊԽԾՁՊՋՌ

ԽՎԹՄՍԹՌԽԼԾՇՊՆՇՊՅԹՄՁՌՑՍՋՁՆԿ԰ՀԹՈՁՊՇԴՁՄՃ0ՋՌԽՋՌԹՆԼԾՇՊՀՇՅՇԿԽՆԽՁՌՑՇԾՎԹՊՁԹՆԻԽՍՋՁՆԿԩԽՎԽՆԽ0ՋՌԽՋՌ


ĮԞՄՄԼԹՌԹՏՁՌՀՌՀԽԽՐԻԽՈՌՁՇՆՇԾԳԱԤԾՇՊՌՀՁՋՋՌՍԼՑՈԹՋՋԽԼՌՀԽԹՋՋՍՅՈՌՁՇՆՋՇԾՆՇՊՅԹՄՁՌՑԹՆԼ

ՀՇՅՇԿԽՆԽՁՌՑՇԾՎԹՊՁԹՆԻԽԱՀԽԳԱԤԼԹՌԹՏԽՊԽՄՇԿՌՊԹՆՋԾՇՊՅԽԼԹՆԼՈԹՋՋԽԼՌՀԽԹՋՋՍՅՈՌՁՇՆՋՇԾՆՇՊՅԹՄՁՌՑ

ԹՆԼՀՇՅՇԿԽՆԽՁՌՑՇԾՎԹՊՁԹՆԻԽ

԰ՍՊՎՁՎԹՄԼԹՌԹԹՆԼՀՁՋՌՇՈԹՌՀՇՄՇԿՑՋԽՎԽՊՁՌՑՋԻՇՊԽՋԹՆԼՋՌԹԿԽՋՏԽՊԽՆՇՌԹՅԽՆԹԺՄԽՌՇՌՀԽՋՌԹՌՁՋՌՁԻԹՄՅԽՌՀՇԼՋ

ՍՋԽԼԾՇՊԹՆԹՄՑՋՁՋՇԾՇՌՀԽՊԽՆԼՈՇՁՆՌՋԦՆՈԹՊՌՁԻՍՄԹՊՌՀԽՅՇՋՌՋՍՁՌԹԺՄԽՍՆՁՌՇԾՋՌԹՌՁՋՌՁԻԹՄԹՆԹՄՑՋՁՋԾՇՊՌՀԽՋԽ

ԽՆԼՈՇՁՆՌՋՏԹՋՌՀԽՁՆԼՁՎՁԼՍԹՄԹՆՁՅԹՄԱՀԽՊԽԾՇՊԽՋՍՊՎՁՎԹՄՏԹՋԹՆԹՄՑՒԽԼՍՋՁՆԿՌՀԽՋՌԽՈԼՇՏՆ

ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼՌԽՋՌԹՆԼԣՁՋՀԽՊՋԢՐԹԻՌԱԽՋՌԥՁՋՌՇՈԹՌՀՇՄՇԿՑՋԽՎԽՊՁՌՑՋԻՇՊԽՋԹՆԼՋՌԹԿԽՋՇԾ

ՁՆԼՁՎՁԼՍԹՄՋՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿՌՀԽՋՌԽՈԼՇՏՆԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼՌԽՋՌ

ԞՄՄԹՆԹՄՑՋԽՋՍՆՄԽՋՋՇՌՀԽՊՏՁՋԽՆՇՌԽԼՏԽՊԽԻՇՆԼՍԻՌԽԼԹՌĮՏՁՌՀ԰Ԟ԰ՋՇԾՌՏԹՊԽ

ԱՀԽՋՌՍԼՑԹՍՌՀՇՊՋՊԽՈՇՊՌԽԼՆՇՌՊԽԹՌՅԽՆՌՊԽՄԹՌԽԼԽԾԾԽԻՌՋՇՆԹՆՑԽՆԼՈՇՁՆՌՁՆՄՇՏԹՆԼՅՁԼԻՇՆԻԽՆՌՊԹՌՁՇՆ

ՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԦՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՌՀԽՊԽՏԹՋԹԼԽԻՊԽԹՋԽՁՆ

ԾԽԻՍՆԼՁՌՑԹՆՁՆԻՊԽԹՋԽՁՆԾԽՅԹՄԽՏԽՌՏԽՁԿՀՌԹՆԼԹՆՁՆԻՊԽԹՋԽՁՆՅԹՄԽԹՆԼԾԽՅԹՄԽԤ԰ԦԥՁՋՌՇՄՇԿՁԻԹՄԾՁՆԼՁՆԿՋ

ՁՆՌՀԽՇՎԹՊՁԽՋՁՆՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՁՆԻՄՍԼԽԼԹՆՁՆԻՊԽԹՋԽՁՆՌՀԽՅԽԼՁԹՆԼԽՎԽՄՇՈՅԽՆՌԹՄՋՌԹԿԽՀՁԿՀԽՊ

ՋԽՎԽՊՁՌՑՋԻՇՊԽՋԾՇՊԼԽԻՊԽԹՋԽԼՈՇՋՌՇՎՍՄԹՌՇՊՑԾՇՄՄՁԻՄԽՋՁՆԻՊԽԹՋԽԼՇՇԻՑՌԽԹՌՊԽՋՁԹՁՆԻՊԽԹՋԽԼՆՍՅԺԽՊՇԾ

Page 114 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ՈՇՋՌԹՌՊԽՌՁԻԾՇՄՄՁԻՄԽՋԹՆԼՁՆԻՊԽԹՋԽՁՆՁՆՌՊԹՎԹՋԻՍՄԹՊՁՆՌԽՊՋՌՁՌՁԹՄՈՊՇՌԽՁՆԹԻԽՇՍՋԾՄՍՁԼԱՀԽՋՌՍԼՑԹՍՌՀՇՊՋ

ՋՍԿԿԽՋՌՌՀԹՌՌՀԽՀՁՋՌՇՈԹՌՀՇՄՇԿՁԻԹՄԾՁՆԼՁՆԿՋԹՆԼՁՆԻՊԽԹՋԽԼԤ԰ԦՁՆԾԽՅԹՄԽԾՁՋՀԹՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄ

ԹՊԽԻՇՆՋՁՋՌԽՆՌՏՁՌՀՌՀԽՊԽԼՍԻԽԼԾԽԻՍՆԼՁՌՑՇԺՋԽՊՎԽԼԹՌՌՀՁՋՄԽՎԽՄԹՆԼԹՊԽՄՁՃԽՄՑԼՍԽՌՇԿԽՆԽՊԹՄՌՇՐՁԻՁՌՑՊԹՌՀԽՊ

ՌՀԹՆՌՇԹՆԽՆԼՇԻՊՁՆԽԽԾԾԽԻՌ

Ԡ ԯԽՎՁԽՏԽՊ0ՋԞՆԹՄՑՋՁՋԹՆԼԠՇՆԻՄՍՋՁՇՆՋ

԰ՌԹՌՁՋՌՁԻԹՄԪԽՌՀՇԼՋԣԽՅԹՄԽԹՆԼՅԹՄԽԺՇԼՑՏԽՁԿՀՌԾԽՅԹՄԽԹՆԼՅԹՄԽԤ԰ԦԹՆԼԾԽՅԹՄԽԳԱԤԽՐՀՁԺՁՌԽԼ

ՅՇՆՇՌՇՆՁԻՌՊԽՆԼՋԹՆԼՏԽՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՌՊԽՆԼՌԽՋՌ
ՇՆԽՋՁԼԽԼ

ԼՁՊԽԻՌՁՇՆԹՄՄՑԼԽՈԽՆԼԽՆՌՇՆՌՀԽՊԽՋՈՇՆՋԽԣԽՅԹՄԽԹՆԼՅԹՄԽՄԽՆԿՌՀԾԽՊՌՁՄՁՌՑԾԽԻՍՆԼՁՌՑՅԹՄԽՌՍԺԽՊԻՄԽ

ՋԻՇՊԽՋԹՆԼՅԹՄԽԳԱԤԼՁԼՆՇՌԽՐՀՁԺՁՌՅՇՆՇՌՇՆՁԻՌՊԽՆԼՋԹՆԼՏԽՊԽԹՆԹՄՑՒԽԼԾՇՊՆՇՊՅԹՄՁՌՑ
԰ՀԹՈՁՊՇԴՁՄՃ0Ջ

ĮԹՆԼՀՇՅՇԿԽՆԽՁՌՑՇԾՎԹՊՁԹՆԻԽ
ԟԹՊՌՄԽՌՌ0ՋĮԞՄՄԽՐԻԽՈՌՅԹՄԽԳԱԤՅԽՌՌՀԽԹՋՋՍՅՈՌՁՇՆՋ

ՇԾԞԫԬԳԞԹՆԼՏԽՊԽՌՀԽՊԽԾՇՊԽԹՆԹՄՑՒԽԼՍՋՁՆԿԡՍՆՆԽՌՌ0ՋՅՍՄՌՁՈՄԽԻՇՅՈԹՊՁՋՇՆՌԽՋՌԪԹՄԽԳԱԤՏԹՋԹՆԹՄՑՒԽԼ

ՍՋՁՆԿՌՀԽԪԹՆՆԴՀՁՌՆԽՑԲԱՏՇ԰ԹՅՈՄԽՌԽՋՌԞՄՄԹՆԹՄՑՋԽՋՏԽՊԽԻՇՆԼՍԻՌԽԼՍՋՁՆԿԠԢԱԦ԰ՎՏՁՌՀ

ԺԹԻՃԽՆԼԼԹՌԹԺԹՋԽՋԽՌՌՁՆԿՋՁՅՈՄԽՅԽՆՌԽԼԺՑԢԣԢԡՇՆԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋՏԽՊԽ

ԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ

ԠՇՆԻՄՍՋՁՇՆՋԱՀԽՊԽՏԽՊԽՋՁԿՆՁԾՁԻԹՆՌՁՆԻՊԽԹՋԽՋՁՆԾԽՅԹՄԽԺՇԼՑՏԽՁԿՀՌ
ՁՆԻՊԽԹՋԽ

ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՈԹՆԼԾԽՅԹՄԽԤ԰Ԧ
ՁՆԻՊԽԹՋԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՈՁՆՌՀԽ

ՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԪԹՄԽԤ԰ԦՏԹՋՋՁԿՆՁԾՁԻԹՆՌՄՑՁՆԻՊԽԹՋԽԼԾՊՇՅՌՀԽ

ՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄԹՌՌՀԽՅՁԼԹՆԼՀՁԿՀՌՊԽԹՌՅԽՆՌԿՊՇՍՈՋ
ՁՆԻՊԽԹՋԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹՈ

ԣԽԻՍՆԼՁՌՑՏԹՋՋՁԿՆՁԾՁԻԹՆՌՄՑՊԽԼՍԻԽԼԹՌՌՀԽՀՁԿՀՌՊԽԹՌՅԽՆՌՄԽՎԽՄՊԽՄԹՌՁՎԽՌՇՌՀԽՆԽԿԹՌՁՎԽԻՇՆՌՊՇՄ


ՊԽԼՍԻՌՁՇՆԡՍՆՆԽՌՌ0ՋՈ

Page 115 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԯԽՈՊՇԼՍԻՌՁՎԽԹՆԼԥԭԤԢՆԼՈՇՁՆՌՋԾՇՊԪԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋՁՆՌՀԽԣ԰ԱԯԞՏՁՌՀԭԠԫԟ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԱՍԺԽՊԻՄԽ԰ԻՇՊԽ Ԥ԰Ԧ

ԤՇՆԹԼԹՄ

԰ՌԹԿՁՆԿԹՆԼ

ԥՁՋՌՇ

ԭՄԹՋՅԹԳԱԤ ԭՄԹՋՅԹԱ ԭՄԹՋՅԹԢ

ԪԽԼՁԹՆ Ո ԡՁԾԾ Ո

ԢԾԾԽԻՌ!


ԶԽՋԫՇ

ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ

 ԫԞ  ԫԞ ԫՇ  ԫԞ

ԫԞ ԫԞ ԫԞ ԫԞ

     ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ     ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ     ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ ԡՍՆՆԽՌ ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ ԫԞ ԪԹՆՆԴՀՁՌՆԽՑԲ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԢȕԽՋՌՊԹԼՁՇՄԤ԰ԦԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐԥՁՋՌՇԥՁՋՌՇՈԹՌՀՇՄՇԿՑԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԱԱԽՋՌՇՋՌԽՊՇՆԽԳԱԤԳՁՌԽՄՄՇԿԽՆՁՆ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋԹՆԼՈԽՊԻԽՆՌ
ԼՁԾԾԽՊԽՆԻԽՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄԠՇՆԻՄՍՋՁՇՆՋՊԽԿԹՊԼՁՆԿՀՁՋՌՇՈԹՌՀՇՄՇԿՑ

ՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌ

Ո

 ԞՄՌՀՇՍԿՀԹՆՇՆՈԹՊԹՅԽՌՊՁԻՌԽՋՌՏՇՍՄԼԺԽԹՈՈՊՇՈՊՁԹՌԽՌՇԹՋՋԽՋՋՅԽԼՁԹՆՎԹՄՍԽՋԾՇՊՌՍԺԽՊԻՄԽՋԻՇՊԽՁՆՌՀՁՋԻԹՋԽՁՌՏՇՍՄԼՆՇՌԺԽԽՐՈԽԻՌԽԼՌՇՑՁԽՄԼԼՁԾԾԽՊԽՆՌՇՎԽՊԹՄՄԻՇՆԻՄՍՋՁՇՆՋ

ԹՋԻՇՅՈԹՊԽԼՌՇԡՍՆՆԽՌՌ0ՋՌԽՋՌ

ԩԬԮՅԿԹՁԩ

Page 116 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԯԽՈՊՇԼՍԻՌՁՎԽԹՆԼԥԭԤԢՆԼՈՇՁՆՌՋԾՇՊԣԽՅԹՄԽԣԹՌՀԽԹԼԪՁՆՆՇՏ
ԭՁՅԽՈՀԹՄԽՋՈՊՇՅԽՄԹՋՁՆՌՀԽԣ԰ԱԯԞՏՁՌՀԭԠԫԟ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԣԽԻՍՆԼՁՌՑ ԣԽՊՌ԰ՍԻԻԽՋՋ

ԱՍԺԽՊԻՄԽ

԰ԻՇՊԽ

Ԥ԰Ԧ

ԤՇՆԹԼԹՄ԰ՌԹԿՁՆԿԹՆԼ

ԥՁՋՌՇ

ԭՄԹՋՅԹԳԱԤ ԭՄԹՋՅԹԱ ԭՄԹՋՅԹԢ



ԡՁԾԾ

Ո



ԡՁԾԾ

Ո ԪԽԼՁԹՆ Ո ԡՁԾԾ Ո ԢԾԾԽԻՌ!
ԶԽՋԫՇ ԡՁԾԾ Ո



ԡՁԾԾ

Ո



ԡՁԾԾ

Ո

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ

 ԫԞ  ԫԞ ԫԞ ԫԞ  ԫԞ ԫՇ  ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

     ԫԞ ԫԞ   ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ   ԫՇ   ԫԞ ԫԞ ԫԞ ԫԞ     ԫԞ ԫԞ   ԶԽՋ   ԫԞ ԫԞ ԫԞ ԫԞ԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ ԡՍՆՆԽՌՌ ԡՍՆՆԽՌՌ ԫԞ ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ ԫԞ ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ ԫԞ ԫԞ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԢȕԽՋՌՊԹԼՁՇՄԣԽՊՌԣԽՊՌՁՄՁՒԹՌՁՇՆԤ԰ԦԤՇՆԹԼՇ԰ՇՅԹՌՁԻԦՆԼԽՐԥՁՋՌՇԥՁՋՌՇՈԹՌՀՇՄՇԿՑԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽԱԱԽՋՌՇՋՌԽՊՇՆԽԳԱԤԳՁՌԽՄՄՇԿԽՆՁՆ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼԽԾԾԽԻՌՋԹՆԼՈԽՊԻԽՆՌ
ԼՁԾԾԽՊԽՆԻԽՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊԻՇՆՌՊՇՄԠՇՆԻՄՍՋՁՇՆՋՊԽԿԹՊԼՁՆԿՀՁՋՌՇՈԹՌՀՇՄՇԿՑ

ՅԹՑԺԽՀԽԹՎՁՄՑՏԽՁԿՀՌԽԼԺՑՌՀԽԽՐՈԽՊՌՇՈՁՆՁՇՆՇԾԹԺՇԹՊԼԻԽՊՌՁԾՁԽԼՈԹՌՀՇՄՇԿՁՋՌ

 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌ

Ո

ԩԬԮՅԿԹՁԩ

Page 117 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԱԹԺՄԽԤՊՇՏՌՀԢՆԼՈՇՁՆՌՋՁՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑ
ԣ԰ԱԯԞՏՁՌՀԭԠԫԟ

ԱՊԽԹՌՅԽՆՌ


ՅԿԹՁԩ

#ԱԴԞՅԽԹՋՍՊԽԼ%

ԟՇԼՑԴԽՁԿՀՌ ԩԽՆԿՌՀ

ԪԹՄԽՋ ԣԽՅԹՄԽՋ ԪԹՄԽՋ ԣԽՅԹՄԽՋ

ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո ԡՁԾԾ Ո

ԫԽԿԹՌՁՎԽԠՇՆՌՊՇՄ
ԩԬԮ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ ԫԞ

        

        

        

԰ՌԹՌՁՋՌՁԻԹՄԱԽՋՌ ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ ԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ ԡՍՆՆԽՌՌ ԡՍՆՆԽՌՌ

ԞԺԺՊԽՎՁԹՌՁՇՆՋԡՁԾԾԡՁԾԾԽՊԽՆԻԽԫԞԫՇՌԹՈՈՄՁԻԹԺՄԽ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՁՆԼՁԻԹՌԽԼՈԽՊԻԽՆՌ
ԼՁԾԾԽՊԽՆԻԽՋԹՊԽՊԽՈՇՊՌԽԼԺԹՋԽԼՇՆԻՇՅՈԹՊՁՋՇՆՌՇՌՀԽՆԽԿԹՌՁՎԽ
ԻՄԽԹՆՏԹՌԽՊ

ԻՇՆՌՊՇՄ



 ԲՆՄԽՋՋՇՌՀԽՊՏՁՋԽՋՈԽԻՁԾՁԽԼԽԾԾԽԻՌՋԹՊԽԻՇՆՋՁԼԽՊԽԼՋՌԹՌՁՋՌՁԻԹՄՄՑՋՁԿՆՁԾՁԻԹՆՌԹՌՈ

ԩԬԮՅԿԹՁԩ

ԡ ԰ՌՍԼՑԡԽԾՁԻՁԽՆԻՁԽՋ

ԞՄՌՀՇՍԿՀՌՀԽՊԽՏԽՊԽՅՁՆՇՊԼԽՎՁԹՌՁՇՆՋԾՊՇՅՌՀԽԿՍՁԼԽՄՁՆԽԹՋՆՇՌԽԼՁՆՌՀԽԪԹՌԽՊՁԹՄՋԹՆԼԪԽՌՀՇԼՋՋԽԻՌՁՇՆՇԾՌՀԽ

ԡԢԯՌՀԽՋՌՍԼՑՅԽՌԹՄՄՎԹՄՁԼՁՌՑԹՆԼՈԽՊԾՇՊՅԹՆԻԽԻՊՁՌԽՊՁԹԱՀԽԼԽՎՁԹՌՁՇՆՋՆՇՌԽԼԼՁԼՆՇՌՁՅՈԹԻՌՌՀԽԹԺՁՄՁՌՑՌՇ

ՁՆՌԽՊՈՊԽՌՌՀԽՊԽՋՍՄՌՋՇԾՌՀՁՋՋՌՍԼՑ

Ԣ ԯԽՎՁԽՏԽՊ0ՋԠՇՅՅԽՆՌՋ

ԱՀԽՊԽՎՁԽՏԽՊ0ՋՊԽՋՍՄՌՋՏԽՊԽԺԹՋԽԼՇՆՌՀԽՌՁՅԽՏԽՁԿՀՌԽԼԹՎԽՊԹԿԽ
ԱԴԞԻՇՆԻԽՆՌՊԹՌՁՇՆՋՏՀԽՊԽԹՋՌՀԽՋՌՍԼՑ

ԹՍՌՀՇՊՋՊԽՈՇՊՌԽԼՊԽՋՍՄՌՋԺԹՋԽԼՇՆՅԽԹՆՅԽԹՋՍՊԽԼԻՇՆԻԽՆՌՊԹՌՁՇՆՋԱՀԽՊԽԾՇՊԽՌՀԽՊԽՎՁԽՏԽՊ0ՋՊԽՋՍՄՌՋԹՊԽ

ՊԽՈՇՊՌԽԼՁՆՌՀԽԢՐԽԻՍՌՁՎԽ԰ՍՅՅԹՊՑՋԽԻՌՁՇՆՇԾՌՀՁՋԡԢԯԱՀԽՊԽՎՁԽՏԽՊ0ՋԻՇՆԻՄՍՋՁՇՆՊԽԿԹՊԼՁՆԿՅԹՄԽԤ԰ԦՏԹՋ

ՅՇՊԽՋԽՆՋՁՌՁՎԽՌՀԹՆՌՀԽՋՌՍԼՑԹՍՌՀՇՊ0ՋԺԽԻԹՍՋԽՌՀԽՊԽՎՁԽՏԽՊՊԽՄՁԽԼՇՆՌՀԽՊԽՋՍՄՌՇԾՌՀԽԧՇՆԻՃՀԽԽՊԽԱԽՊՈՋՌՊԹ

ՌԽՋՌԿՁՎԽՆՌՀԽՅՇՆՇՌՇՆՁԻՁՆԻՊԽԹՋԽԽՐՀՁԺՁՌԽԼԺՑՌՀԽՅԽԼՁԹՆՎԹՄՍԽՋԬՌՀԽՊՌՀԹՆՌՀՁՋԼՁԾԾԽՊԽՆԻԽՌՀԽՋՌԹՌՁՋՌՁԻԹՄ

ՊԽՋՍՄՌՋՇԾԾԽՊԽԼԺՑՌՀԽՊԽՎՁԽՏԽՊ0ՋԹՆԹՄՑՋՁՋԹԿՊԽԽԼՏՁՌՀՌՀԽՋՌՍԼՑԹՍՌՀՇՊ0ՋԱՀԽՋՌՍԼՑԹՍՌՀՇՊՀՇՏԽՎԽՊԹՌՌՊՁԺՍՌԽԼ

Page 118 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԽԾԾԽԻՌՋՇՆԤ԰ԦԹՆԼՀՁՋՌՇՄՇԿՁԻԹՄԾՁՆԼՁՆԿՋՌՇՊԽԼՍԻԽԼԾԽԻՍՆԼՁՌՑԹՆԼՌԽՋՌՅԹՌԽՊՁԹՄՌՇՐՁԻՁՌՑՊԹՌՀԽՊՌՀԹՆՌՀԽՁՅՈՄՁԻԹՌՁՇՆ

ՇԾՈՇՋՋՁԺՄԽԥԤԱԹՐՁՋՁՆՌԽՊԾԽՊԽՆԻԽ

ԱՀԽՊԽՎՁԽՏԽՊԻԹՄԻՍՄԹՌԽԼՌՀԽԱԴԞԻՇՆԻԽՆՌՊԹՌՁՇՆՋՍՋՁՆԿՌՀԽԾՇՄՄՇՏՁՆԿԽՉՍԹՌՁՇՆ

ՏՀԽՊԽ

ԠԱԴԞՁՋՌՀԽՌՁՅԽՏԽՁԿՀՌԽԼԹՎԽՊԹԿԽԻՇՆԻԽՆՌՊԹՌՁՇՆ

ԠՂՁՋՌՀԽԻՇՆԻԽՆՌՊԹՌՁՇՆՅԽԹՋՍՊԽԼԹՌՌՁՅԽՁՆՌԽՊՎԹՄՂ
ՂՆ

ՌՂՁՋՌՀԽՆՍՅԺԽՊՇԾՀՇՍՊՋ
ՇՊԼԹՑՋՇՊՏԽԽՃՋՍՆՁՌՋՍՋԽԼՂՍՋՌՆԽԽԼՌՇԺԽԻՇՆՋՁՋՌԽՆՌՁՆՌՀԽԽՉՍԹՌՁՇՆՇԾՌՀԽ

ՌԽՋՌԹՌՌՁՅԽՁՆՌԽՊՎԹՄՂ
ԽԿՌՀՇՍՊՋ
ՌԽՋՌՁՆՁՌՁԹՌՁՇՆՌՀՇՍՊՋՌՀՇՍՊՋ

ԤՄԹՋՋՋԹՌՍՊԹՌՇՊԻՇՄՍՅՆՋՏԽՊԽՈՊԽՈԹՊԽԼԾՇՊՌՀԽԼԽՄՁՎԽՊՑՇԾԭԠԫԟԢԹԻՀԿՄԹՋՋԻՇՄՍՅՆ
ՠԦԡՐՠԩՏԹՋՈԹԻՃԽԼ

ՏՁՌՀԹՈՈՊՇՐՁՅԹՌԽՄՑՠՇԾՅՁԻՊՇՆԿՄԹՋՋՏՇՇՄՌՀԹՌՏԹՋՈՊԽՏԹՋՀԽԼՏՁՌՀՊԽԹԿԽՆՌԿՊԹԼԽԹԻԽՌՇՆԽԹՆԼԻՇԹՌԽԼ

ՏՁՌՀԹԻՇՆԻԽՆՌՊԹՌԽԼՋՌՇԻՃՋՍՋՈԽՆՋՁՇՆՇԾԭԠԫԟԞՎԹԻՍՍՅՈՍՅՈՏԹՋՍՋԽԼՌՇԽՆՋՍՊԽՌՀԽՋՇՄՍՌՁՇՆԽՎԽՆՄՑԻՇԹՌԽԼ

ՌՀԽԿՄԹՋՋՏՇՇՄԹՆԼՌՀԽԻՇՄՍՅՆՏԹՋՎԹԻՍՍՅԼՊՁԽԼՌՇՊԽՅՇՎԽՌՀԽԹԻԽՌՇՆԽԬՆԻԽՌՀԽԹԻԽՌՇՆԽՏԹՋՊԽՅՇՎԽԼ

ՌՀԽԻՇՄՍՅՆՏԹՋՏՊԹՈՈԽԼՁՆԹՄՍՅՁՆՍՅԾՇՁՄԹՆԼՋՌՇՊԽԼՊԽԾՊՁԿԽՊԹՌԽԼՍՆՌՁՄՍՋԽԱԽՆԻՇՄՍՅՆՋՏԽՊԽՍՋԽԼՌՇՈՊԽՈԹՊԽ

ՌՀԽՈՊՁՅԹՊՑՋՌՇԻՃՋՇՄՍՌՁՇՆԾՇՊՌՀԽԼՍՊԹՌՁՇՆՇԾՌՀԽՋՌՍԼՑ԰ՁՆԻԽՌՀԽԻՇՄՍՅՆՋՏԽՊԽՋՌԹԺՄԽԾՇՊԹՌՄԽԹՋՌԼԹՑՋ

ԻՇՄՍՅՆՋՏԽՊԽՊԽՈՄԹԻԽԼՇՆԹՏԽԽՃՄՑԺԹՋՁՋ

ԯԽՋՍՄՌՋԾՊՇՅՌՀԽՈԽՊՁՇԼՁԻՋԻՊԽԽՆՁՆԿԹՆԹՄՑՋՁՋՇԾՌՀԽԼՁՄՍՌՁՇՆՏԹՌԽՊՁՆԼՁԻԹՌԽԼՌՀԽՈՊԽՋԽՆԻԽՇԾՌՀԽԾՇՄՄՇՏՁՆԿ

ԹՆԹՄՑՌԽՋ ԻԹՄԻՁՍՅ 
ՅԿԩ ԻՀՄՇՊՁԼԽ 
ՅԿԩԾՄՍՇՊՁԼԽ 
ՅԿԩՅԹԿՆԽՋՁՍՅ 
ՅԿԩ

ՈՇՌԹՋՋՁՍՅ
ՅԿԩՋՇԼՁՍՅ
ՅԿԩԹՆԼՋՍՄԾԹՌԽ
ՅԿԩ

ԱՀԽՁՆՄՁԾԽՈՇՊՌՁՇՆՇԾՌՀԽԼԽԾՁՆՁՌՁՎԽՌՇՐՁԻՁՌՑՌԽՋՌՏԹՋԻՇՆԼՍԻՌԽԼԾՊՇՅ԰ԽՈՌԽՅԺԽՊՌՇԬԻՌՇԺԽՊ

( ) ( ) ( ) ( )

n

nn

nn

n

n

TWA t

tt

CC

tt

CC

tt

CC

tt

CC

C

1

1

21

21

12

12

01

01

2 2 2 2 −

−

−

−  ̧ − 1

·  ̈

©

§ +  ̧ +− 1·  ̈

©

§ +  ̧ +− 1·  ̈

©

§ +  ̧ +− 1·  ̈

©

§ +

=

Page 119 of 207
ԡԹՌԹԢՎԹՄՍԹՌՁՇՆԯԽԻՇՊԼՇՆՌՀԽԣՁՋՀ԰ՀՇՊՌԱԽՊՅԯԽՈՊՇԼՍԻՌՁՇՆԞՋՋԹՑՏՁՌՀԭԠԫԟ

ԢԭԞԪԯԦԡԫՍՅԺԽՊ

ԭԹԿԽ  οԾ 

ԦԦԦ ԯԢԣԢԯԢԫԠԢ԰

ԨԽՆԼԹՄՄԱԷԹՆԼԴԟԫՁՐՇՆԞՆԹՄՑՌՁԻԹՄԪԽՌՀՇԼԳԽՊՁԾՁԻԹՌՁՇՆԾՇՊՌՀԽԡԽՌԽՊՅՁՆԹՌՁՇՆՇԾԭԠԫԟԱԽԻՀՆՁԻԹՄՁՆ

ԣՊԽՋՀՏԹՌԽՊԴՁՄԼՄՁԾԽԦՆՌԽՊՆԹՌՁՇՆԹՄԭՊՇՂԽԻՌԫՍՅԺԽՊԠԲՆՈՍԺՄՁՋՀԽԼՊԽՈՇՊՌՈՊԽՈԹՊԽԼԾՇՊԞՅՎԹԻԠՀԽՅՁԻԹՄ

ԠՇՊՈՇՊԹՌՁՇՆԪԹՑ

ԱՍՃԽՑԧԴԢՐՈՄՇՊԹՌՇՊՑԡԹՌԹԞՆԹՄՑՋՁՋԯԽԹԼՁՆԿԪԞԞԼԼՁՋՇՆԴԽՋՄԽՑ

ԱՀԽ԰Ԟ԰԰ՑՋՌԽՅԾՇՊԴՁՆԼՇՏՋԳԽՊՋՁՇՆ԰Ԟ԰ԦՆՋՌՁՌՍՌԽԦՆԻԠԹՊՑԫՇՊՌՀԠԹՊՇՄՁՆԹ

Page 120 of 207
CETIS Summary Report Report Date: 28 Aug-13 18:05 (p 1 of 5)

Test Code: 056502 49042102 | 03-9257-0391

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Sample ID: 17-8324-7209

Sample Date: 26 Sep-12

Receive Date: 17 Oct-12

Code: 49042102

Sample Age: NA

Source: AMVAC Chemical Corporation

Station:

Client: CDM Smith

Material: Pentachloronitrobenzene (PCNB) Project: Endocrine Disruptor Screening Progra

flow-through 056502 49042102

056502 49042102

Batch Note:

Sample Note:

Comparison Summary

Analysis ID Endpoint NOEL LOEL TOEL PMSD TU Method

00-3675-8381 Fecundity 6.9 74.42 22.66 42.9% Dunnett Multiple Comparison Test

09-2176-9624 FemaleBodyWt 6.9 74.42 22.66 NA Jonckheere-Terpstra Step-Down Test

05-8240-6262 FemaleBodyWt 6.9 74.42 22.66 10.1% Dunnett Multiple Comparison Test

18-0020-9072 FemaleGSI 6.9 74.42 22.66 NA Jonckheere-Terpstra Step-Down Test

05-2068-8500 FemaleGSI 74.42 >74.42 NA 35.4% Dunnett Multiple Comparison Test

03-2266-2722 FemaleLength 74.42 >74.42 NA 4.61% Dunnett Multiple Comparison Test

14-3841-1363 FemaleVTG 74.42 >74.42 NA NA Jonckheere-Terpstra Step-Down Test

21-3503-7035 FemaleVTG 74.42 >74.42 NA 87.8% Dunnett Multiple Comparison Test

07-0436-1675 Fertility 74.42 >74.42 NA 5.42% Dunnett Multiple Comparison Test

06-5938-6080 MaleBodyWt 74.42 >74.42 NA NA Jonckheere-Terpstra Step-Down Test

01-8011-0904 MaleBodyWt 74.42 >74.42 NA 20.7% Dunnett Multiple Comparison Test

02-9170-5609 MaleGSI 0.635 6.9 2.093 NA Jonckheere-Terpstra Step-Down Test

07-6895-8495 MaleGSI 6.9 74.42 22.66 49.1% Dunnett Multiple Comparison Test

09-4547-8918 MaleLength 74.42 >74.42 NA 6.46% Dunnett Multiple Comparison Test

18-3354-6518 MaleMedianTubercleScore 74.42 >74.42 NA 23.3% Dunnett Multiple Comparison Test

14-6379-8478 MaleVTG 74.42 >74.42 NA 342.0% Mann-Whitney U Two-Sample Test

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 121 of 207
CETIS Summary Report Report Date: 28 Aug-13 18:05 (p 2 of 5)

Test Code: 056502 49042102 | 03-9257-0391

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

Fecundity Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 18.6 13.1 24.2 16.4 23.8 1.74 3.49 18.7% 0.0%

0.635 4 17.1 8.47 25.7 10.1 22 2.71 5.42 31.7% 8.31%

6.9 4 21.7 16.1 27.3 18.6 26.7 1.75 3.51 16.2% -16.5%

74.42 4 6.1 -0.524 12.7 1.3 11.1 2.08 4.16 68.2% 67.3%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleBodyWt Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 1.19 1.09 1.28 1.11 1.24 0.0307 0.0614 5.18% 0.0%

0.635 4 1.23 1.08 1.37 1.12 1.34 0.0452 0.0904 7.38% -3.38%

6.9 4 1.22 1.16 1.27 1.17 1.26 0.0185 0.037 3.04% -2.53%

74.42 4 1.31 1.22 1.39 1.23 1.34 0.0253 0.0507 3.88% -10.1%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleGSI Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 13.2 10.8 15.5 12 15.1 0.724 1.45 11.0% 0.0%

0.635 4 15.3 13.6 17 13.7 16 0.531 1.06 6.96% -16.2%

6.9 4 14.8 10.8 18.9 12.9 18.6 1.28 2.56 17.2% -12.9%

74.42 4 17.8 11.8 23.8 13 22 1.89 3.79 21.3% -35.2%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleLength Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 47.3 45.6 49 46.3 48.8 0.54 1.08 2.28% 0.0%

0.635 4 47.7 45.3 50.2 46.8 50 0.767 1.53 3.22% -0.9%

6.9 4 47.3 46.2 48.3 46.3 47.8 0.333 0.665 1.41% 0.05%

74.42 4 48.4 46.6 50.3 47.5 49.8 0.572 1.14 2.36% -2.43%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

FemaleVTG Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 1.90E+7 8.61E+5 3.72E+7 9.65E+6 3.37E+7 5.71E+6 1.14E+7 60.0% 0.0%

0.635 4 1.68E+7 1.80E+6 3.18E+7 8.50E+6 3.03E+7 4.71E+6 9.43E+6 56.1% 11.8%

6.9 4 1.39E+7 5.59E+6 2.22E+7 8.96E+6 2.00E+7 2.62E+6 5.23E+6 37.6% 26.9%

74.42 4 1.33E+7 5.26E+5 2.60E+7 5.84E+6 2.42E+7 4.00E+6 8.01E+6 60.4% 30.3%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

Fertility Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 97.4 94.6 100 95 98.7 0.873 1.75 1.79% 0.0%

0.635 4 97.9 95.4 100 95.9 99.2 0.784 1.57 1.6% -0.49%

6.9 4 97.5 93.5 102 94.2 99.6 1.26 2.53 2.59% -0.13%

74.42 4 96 89.1 103 89.6 99 2.19 4.37 4.55% 1.41%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

MaleBodyWt Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 2.5 2.24 2.76 2.3 2.68 0.0821 0.164 6.57% 0.0%

0.635 4 2.6 2.23 2.97 2.4 2.9 0.116 0.231 8.89% -4.2%

6.9 4 2.6 2.14 3.05 2.27 2.92 0.143 0.286 11.0% -4.0%

74.42 4 2.84 2.26 3.43 2.44 3.21 0.183 0.367 12.9% -13.8%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

MaleGSI Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 1.25 0.716 1.78 0.9 1.7 0.167 0.334 26.8% 0.0%

0.635 4 1.77 1.32 2.22 1.44 2.11 0.142 0.283 16.0% -41.7%

6.9 4 1.77 1.3 2.24 1.47 2.05 0.148 0.295 16.6% -42.1%

74.42 4 1.99 1.4 2.58 1.48 2.35 0.186 0.372 18.7% -59.3%

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 122 of 207
CETIS Summary Report Report Date: 28 Aug-13 18:05 (p 3 of 5)

Test Code: 056502 49042102 | 03-9257-0391

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

MaleLength Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 58.9 57.2 60.5 57.5 60 0.515 1.03 1.75% 0.0%

0.635 4 58.1 57.4 58.9 57.5 58.5 0.239 0.479 0.82% 1.27%

6.9 4 58.4 53.8 62.9 55 61 1.43 2.87 4.91% 0.85%

74.42 4 59.9 55.8 64 57 62.5 1.28 2.56 4.28% -1.7%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

MaleMedianTubercleScore Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 25.4 22 28.8 24 28.5 1.07 2.14 8.42% 0.0%

0.635 4 23.8 21.5 26 22 25.5 0.722 1.44 6.08% 6.4%

6.9 4 27 18.3 35.7 22 34.5 2.75 5.49 20.3% -6.4%

74.42 4 23.6 21.3 25.9 22 25.5 0.718 1.44 6.08% 6.9%

C-μg ai/L Control Type Count Mean Min Max Std Err Std Dev CV%

MaleVTG Summary

95% LCL 95% UCL %Effect

0 Negative Control 4 1780 -2610 6170 271 5920 1380 2760 155.0% 0.0%

0.635 4 1830 -1700 5370 378 5120 1110 2220 121.0% -3.07%

6.9 4 664 -176 1510 133 1350 264 528 79.5% 62.7%

74.42 4 3790 -5830 13400 218 12800 3020 6050 160.0% -113.0%

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 123 of 207
CETIS Summary Report Report Date: 28 Aug-13 18:05 (p 4 of 5)

Test Code: 056502 49042102 | 03-9257-0391

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

C-μg ai/L Control Type

Fecundity Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 16.6 16.4 17.8 23.8

0.635 20.7 10.1 22 15.6

6.9 20.2 21.4 26.7 18.6

74.42 4.6 7.4 11.1 1.3

C-μg ai/L Control Type

FemaleBodyWt Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 1.24 1.23 1.11 1.16

0.635 1.21 1.34 1.12 1.23

6.9 1.21 1.26 1.17 1.22

74.42 1.34 1.32 1.23 1.33

C-μg ai/L Control Type

FemaleGSI Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 12.1 13.4 12 15.1

0.635 16 15.6 13.7 15.8

6.9 14.2 18.6 13.7 12.9

74.42 17 19.1 13 22

C-μg ai/L Control Type

FemaleLength Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 48.8 46.8 47.3 46.3

0.635 47.3 50 46.8 46.8

6.9 47.8 46.3 47.5 47.5

74.42 49.8 49 47.5 47.5

C-μg ai/L Control Type

FemaleVTG Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 9.65E+6 1.03E+7 2.25E+7 3.37E+7

0.635 1.32E+7 1.52E+7 8.50E+6 3.03E+7

6.9 1.65E+7 8.96E+6 1.02E+7 2.00E+7

74.42 5.84E+6 9.12E+6 1.39E+7 2.42E+7

C-μg ai/L Control Type

Fertility Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 97.3 95 98.7 98.7

0.635 99.2 95.9 97.4 99.1

6.9 99.4 97 99.6 94.2

74.42 97.1 99 98.5 89.6

C-μg ai/L Control Type

MaleBodyWt Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 2.57 2.44 2.68 2.3

0.635 2.67 2.4 2.44 2.9

6.9 2.73 2.92 2.27 2.47

74.42 2.44 3.09 3.21 2.63

C-μg ai/L Control Type

MaleGSI Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 1.15 1.7 1.24 0.9

0.635 2.11 1.67 1.85 1.44

6.9 2.05 2 1.47 1.57

74.42 2.15 2.35 1.48 1.97

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 124 of 207
CETIS Summary Report Report Date: 28 Aug-13 18:05 (p 5 of 5)

Test Code: 056502 49042102 | 03-9257-0391

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

C-μg ai/L Control Type

MaleLength Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 60 59 59 57.5

0.635 58.5 57.5 58 58.5

6.9 60.5 61 55 57

74.42 58.5 62.5 61.5 57

C-μg ai/L Control Type

MaleMedianTubercleScore Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 24 28.5 25 24

0.635 24 22 25.5 23.5

6.9 34.5 27.5 24 22

74.42 23.5 25.5 23.5 22

C-μg ai/L Control Type

MaleVTG Detail

Rep 1 Rep 2 Rep 3 Rep 4

0 Negative Control 5.92E+3 4.32E+2 4.98E+2 2.71E+2

0.635 1.20E+3 6.33E+2 5.12E+3 3.78E+2

6.9 1.35E+3 1.33E+2 7.81E+2 3.95E+2

74.42 7.31E+2 2.18E+2 1.28E+4 1.38E+3

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 125 of 207
Report Date: 28 Aug-13 18:02 (p 1 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:57

Analysis ID: 00-3675-8381 Endpoint: Fecundity CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.519 2.68 8 6 0.9156 CDF Non-Significant Effect

6.9 1.03 2.68 8 6 0.6179 CDF Non-Significant Effect

74.42* 4.21 2.68 8 6 0.0033 CDF Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 42.9% 6.9 74.42 22.66

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 555.8919 185.2973 3 10.4 0.0012 Significant Effect

Error 213.6575 17.80479 12

Total 769.5494 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 0.723 11.3 0.8677 Equal Variances

Distribution Shapiro-Wilk W Normality 0.915 0.841 0.1386 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

Fecundity Summary

0 Negative Control 4 18.6 13.1 24.2 17.2 16.4 23.8 1.74 18.7% 0.0%

0.635 4 17.1 8.47 25.7 18.2 10.1 22 2.71 31.7% 8.31%

6.9 4 21.7 16.1 27.3 20.8 18.6 26.7 1.75 16.2% -16.5%

74.42 4 6.1 -0.524 12.7 6 1.3 11.1 2.08 68.2% 67.3% Centered Untransformed

 Rankits

-1

-2

-3

-4

-5

-6

-7

0

1

2

3

4

5

6

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

Fecundity

 C-μg ai/L

Reject Null

Reject Null

0

5

10

15

20

25

30

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 126 of 207
Report Date: 28 Aug-13 18:02 (p 2 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:56

Analysis ID: 05-8240-6262 Endpoint: FemaleBodyWt CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.898 2.68 0.119 6 0.7040 CDF Non-Significant Effect

6.9 0.674 2.68 0.119 6 0.8405 CDF Non-Significant Effect

74.42* 2.69 2.68 0.119 6 0.0490 CDF Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 10.1% 6.9 74.42 22.66

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 0.03150002 0.01050001 3 2.65 0.0966 Non-Significant Effect

Error 0.04760001 0.003966668 12

Total 0.07910003 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 2.19 11.3 0.5344 Equal Variances

Distribution Shapiro-Wilk W Normality 0.976 0.841 0.9287 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

FemaleBodyWt Summary

0 Negative Control 4 1.19 1.09 1.28 1.19 1.11 1.24 0.0307 5.18% 0.0%

0.635 4 1.23 1.08 1.37 1.22 1.12 1.34 0.0452 7.38% -3.38%

6.9 4 1.22 1.16 1.27 1.22 1.17 1.26 0.0185 3.04% -2.53%

74.42 4 1.31 1.22 1.39 1.33 1.23 1.34 0.0253 3.88% -10.1% Centered Untransformed

 Rankits

-0.04

-0.08

-0.12

0.00

0.04

0.08

0.12

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

FemaleBodyWt

 C-μg ai/L

Reject Null

Reject Null

0.0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 127 of 207
Report Date: 28 Aug-13 18:02 (p 3 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 18:00

Analysis ID: 09-2176-9624 Endpoint: FemaleBodyWt CETIS Version: CETISv1.8.7

Analysis: Nonparametric-Control vs Ord. Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical Ties P-Value Decision(α:5%)

Jonckheere-Terpstra Step-Down Test

DF P-Type

Negative Control 0.635 0.438 1.64 1 -2 0.3309 Asymp Non-Significant Effect

6.9 0.442 1.64 2 -2 0.3294 Asymp Non-Significant Effect

74.42* 1.92 1.64 2 -2 0.0272 Asymp Significant Effect

Data Transform Zeta Alt Hyp Trials Seed NOEL LOEL TOEL TU

Untransformed NA C < T NA NA 6.9 74.42 22.66

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 0.03150002 0.01050001 3 2.65 0.0966 Non-Significant Effect

Error 0.04760001 0.003966668 12

Total 0.07910003 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 2.19 11.3 0.5344 Equal Variances

Distribution Shapiro-Wilk W Normality 0.976 0.841 0.9287 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

FemaleBodyWt Summary

0 Negative Control 4 1.19 1.09 1.28 1.19 1.11 1.24 0.0307 5.18% 0.0%

0.635 4 1.23 1.08 1.37 1.22 1.12 1.34 0.0452 7.38% -3.38%

6.9 4 1.22 1.16 1.27 1.22 1.17 1.26 0.0185 3.04% -2.53%

74.42 4 1.31 1.22 1.39 1.33 1.23 1.34 0.0253 3.88% -10.1% Centered Untransformed

 Rankits

-0.04

-0.08

-0.12

0.00

0.04

0.08

0.12

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

FemaleBodyWt

 C-μg ai/L

0.0

0.2

0.4

0.6

0.8

1.0

1.2

1.4

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 128 of 207
Report Date: 28 Aug-13 18:02 (p 4 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:55

Analysis ID: 05-2068-8500 Endpoint: FemaleGSI CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 1.22 2.68 4.66 6 0.4959 CDF Non-Significant Effect

6.9 0.979 2.68 4.66 6 0.6511 CDF Non-Significant Effect

74.42 2.66 2.68 4.66 6 0.0516 CDF Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 35.4% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 43.7825 14.59417 3 2.42 0.1165 Non-Significant Effect

Error 72.29501 6.024584 12

Total 116.0775 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 4.69 11.3 0.1958 Equal Variances

Distribution Shapiro-Wilk W Normality 0.955 0.841 0.5664 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

FemaleGSI Summary

0 Negative Control 4 13.2 10.8 15.5 12.8 12 15.1 0.724 11.0% 0.0%

0.635 4 15.3 13.6 17 15.7 13.7 16 0.531 6.96% -16.2%

6.9 4 14.8 10.8 18.9 13.9 12.9 18.6 1.28 17.2% -12.9%

74.42 4 17.8 11.8 23.8 18 13 22 1.89 21.3% -35.2% Centered Untransformed

 Rankits

-1

-2

-3

-4

-5

0

1

2

3

4

5

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

FemaleGSI

 C-μg ai/L

Reject Null

Reject Null

0

5

10

15

20

25

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 129 of 207
Report Date: 28 Aug-13 18:02 (p 5 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 18:00

Analysis ID: 18-0020-9072 Endpoint: FemaleGSI CETIS Version: CETISv1.8.7

Analysis: Nonparametric-Control vs Ord. Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Jonckheere-Terpstra Step-Down Test

DF P-Type

Negative Control 0.635 15 NA -2 0.1061 Exact Non-Significant Effect

6.9 1.25 1.64 1 -2 0.1061 Asymp Non-Significant Effect

74.42* 2.1 1.64 1 -2 0.0177 Asymp Significant Effect

Data Transform Zeta Alt Hyp Trials Seed NOEL LOEL TOEL TU

Untransformed NA C < T NA NA 6.9 74.42 22.66

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 43.7825 14.59417 3 2.42 0.1165 Non-Significant Effect

Error 72.29501 6.024584 12

Total 116.0775 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 4.69 11.3 0.1958 Equal Variances

Distribution Shapiro-Wilk W Normality 0.955 0.841 0.5664 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

FemaleGSI Summary

0 Negative Control 4 13.2 10.8 15.5 12.8 12 15.1 0.724 11.0% 0.0%

0.635 4 15.3 13.6 17 15.7 13.7 16 0.531 6.96% -16.2%

6.9 4 14.8 10.8 18.9 13.9 12.9 18.6 1.28 17.2% -12.9%

74.42 4 17.8 11.8 23.8 18 13 22 1.89 21.3% -35.2% Centered Untransformed

 Rankits

-1

-2

-3

-4

-5

0

1

2

3

4

5

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

FemaleGSI

 C-μg ai/L

0

5

10

15

20

25

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 130 of 207
Report Date: 28 Aug-13 18:02 (p 6 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:54

Analysis ID: 03-2266-2722 Endpoint: FemaleLength CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.523 2.68 2.18 6 0.9139 CDF Non-Significant Effect

6.9 0.0308 2.68 2.18 6 1.0000 CDF Non-Significant Effect

74.42 1.42 2.68 2.18 6 0.3876 CDF Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 4.61% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 3.612502 1.204167 3 0.913 0.4637 Non-Significant Effect

Error 15.825 1.31875 12

Total 19.4375 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 1.69 11.3 0.6395 Equal Variances

Distribution Shapiro-Wilk W Normality 0.873 0.841 0.0306 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

FemaleLength Summary

0 Negative Control 4 47.3 45.6 49 47 46.3 48.8 0.54 2.28% 0.0%

0.635 4 47.7 45.3 50.2 47 46.8 50 0.767 3.22% -0.9%

6.9 4 47.3 46.2 48.3 47.5 46.3 47.8 0.333 1.41% 0.05%

74.42 4 48.4 46.6 50.3 48.3 47.5 49.8 0.572 2.36% -2.43% Centered Untransformed

 Rankits

-0.5

-1.0

0.0

0.5

1.0

1.5

2.0

2.5

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

FemaleLength

 C-μg ai/L

Reject Null

Reject Null

0

10

20

30

40

50

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 131 of 207
Report Date: 28 Aug-13 18:02 (p 7 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:54

Analysis ID: 21-3503-7035 Endpoint: FemaleVTG CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.359 2.68 2E+07 6 0.9686 CDF Non-Significant Effect

6.9 0.822 2.68 2E+07 6 0.7526 CDF Non-Significant Effect

74.42 0.926 2.68 2E+07 6 0.6859 CDF Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 87.8% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 8.581012E+13 2.860337E+13 3 0.368 0.7774 Non-Significant Effect

Error 9.324587E+14 7.770489E+13 12

Total 1.018269E+15 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 1.54 11.3 0.6736 Equal Variances

Distribution Shapiro-Wilk W Normality 0.91 0.841 0.1181 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

FemaleVTG Summary

0 Negative Control 4 1.90E+7 8.61E+5 3.72E+7 16400000 9.65E+6 3.37E+7 5.71E+6 60.0% 0.0%

0.635 4 1.68E+7 1.80E+6 3.18E+7 14200000 8.50E+6 3.03E+7 4.71E+6 56.1% 11.8%

6.9 4 1.39E+7 5.59E+6 2.22E+7 13400000 8.96E+6 2.00E+7 2.62E+6 37.6% 26.9%

74.42 4 1.33E+7 5.26E+5 2.60E+7 11500000 5.84E+6 2.42E+7 4.00E+6 60.4% 30.3% Centered Untransformed

 Rankits

-2.0E+06

-4.0E+06

-6.0E+06

-8.0E+06

-1.0E+07

0.0E+00

2.0E+06

4.0E+06

6.0E+06

8.0E+06

1.0E+07

1.2E+07

1.4E+07

1.6E+07

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

FemaleVTG

 C-μg ai/L

Reject Null

Reject Null

0.0E+00

5.0E+06

1.0E+07

1.5E+07

2.0E+07

2.5E+07

3.0E+07

3.5E+07

4.0E+07

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 132 of 207
Report Date: 28 Aug-13 18:02 (p 8 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 18:00

Analysis ID: 14-3841-1363 Endpoint: FemaleVTG CETIS Version: CETISv1.8.7

Analysis: Nonparametric-Control vs Ord. Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Jonckheere-Terpstra Step-Down Test

DF P-Type

Negative Control 0.635 9 NA -2 0.4429 Exact Non-Significant Effect

6.9 28 NA -2 0.3090 Exact Non-Significant Effect

74.42 58 NA -2 0.1910 Exact Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed NOEL LOEL TOEL TU

Untransformed NA C > T NA NA 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 8.581012E+13 2.860337E+13 3 0.368 0.7774 Non-Significant Effect

Error 9.324587E+14 7.770489E+13 12

Total 1.018269E+15 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 1.54 11.3 0.6736 Equal Variances

Distribution Shapiro-Wilk W Normality 0.91 0.841 0.1181 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

FemaleVTG Summary

0 Negative Control 4 1.90E+7 8.61E+5 3.72E+7 16400000 9.65E+6 3.37E+7 5.71E+6 60.0% 0.0%

0.635 4 1.68E+7 1.80E+6 3.18E+7 14200000 8.50E+6 3.03E+7 4.71E+6 56.1% 11.8%

6.9 4 1.39E+7 5.59E+6 2.22E+7 13400000 8.96E+6 2.00E+7 2.62E+6 37.6% 26.9%

74.42 4 1.33E+7 5.26E+5 2.60E+7 11500000 5.84E+6 2.42E+7 4.00E+6 60.4% 30.3% Centered Untransformed

 Rankits

-2.0E+06

-4.0E+06

-6.0E+06

-8.0E+06

-1.0E+07

0.0E+00

2.0E+06

4.0E+06

6.0E+06

8.0E+06

1.0E+07

1.2E+07

1.4E+07

1.6E+07

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

FemaleVTG

 C-μg ai/L

0.0E+00

5.0E+06

1.0E+07

1.5E+07

2.0E+07

2.5E+07

3.0E+07

3.5E+07

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 133 of 207
Report Date: 28 Aug-13 18:02 (p 9 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:53

Analysis ID: 07-0436-1675 Endpoint: Fertility CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.241 2.68 5.28 6 0.9899 CDF Non-Significant Effect

6.9 0.0635 2.68 5.28 6 0.9998 CDF Non-Significant Effect

74.42 0.698 2.68 5.28 6 0.8268 CDF Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 5.42% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 7.926877 2.642292 3 0.341 0.7964 Non-Significant Effect

Error 93.0875 7.757292 12

Total 101.0144 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 3.62 11.3 0.3055 Equal Variances

Distribution Shapiro-Wilk W Normality 0.883 0.841 0.0437 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

Fertility Summary

0 Negative Control 4 97.4 94.6 100 98 95 98.7 0.873 1.79% 0.0%

0.635 4 97.9 95.4 100 98.3 95.9 99.2 0.784 1.6% -0.49%

6.9 4 97.5 93.5 102 98.2 94.2 99.6 1.26 2.59% -0.13%

74.42 4 96 89.1 103 97.8 89.6 99 2.19 4.55% 1.41% Centered Untransformed

 Rankits

-1

-2

-3

-4

-5

-6

-7

0

1

2

3

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

Fertility

 C-μg ai/L

Reject Null

Reject Null

0

20

40

60

80

100

120

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 134 of 207
Report Date: 28 Aug-13 18:02 (p 10 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:50

Analysis ID: 01-8011-0904 Endpoint: MaleBodyWt CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.545 2.68 0.517 6 0.9045 CDF Non-Significant Effect

6.9 0.519 2.68 0.517 6 0.9156 CDF Non-Significant Effect

74.42 1.79 2.68 0.517 6 0.2244 CDF Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 20.7% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 0.2577 0.08590001 3 1.16 0.3658 Non-Significant Effect

Error 0.8899 0.07415833 12

Total 1.1476 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 1.7 11.3 0.6363 Equal Variances

Distribution Shapiro-Wilk W Normality 0.947 0.841 0.4437 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

MaleBodyWt Summary

0 Negative Control 4 2.5 2.24 2.76 2.51 2.3 2.68 0.0821 6.57% 0.0%

0.635 4 2.6 2.23 2.97 2.56 2.4 2.9 0.116 8.89% -4.2%

6.9 4 2.6 2.14 3.05 2.6 2.27 2.92 0.143 11.0% -4.0%

74.42 4 2.84 2.26 3.43 2.86 2.44 3.21 0.183 12.9% -13.8% Centered Untransformed

 Rankits

-0.1

-0.2

-0.3

-0.4

-0.5

0.0

0.1

0.2

0.3

0.4

0.5

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

MaleBodyWt

 C-μg ai/L

Reject Null

Reject Null

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 135 of 207
Report Date: 28 Aug-13 18:02 (p 11 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:58

Analysis ID: 06-5938-6080 Endpoint: MaleBodyWt CETIS Version: CETISv1.8.7

Analysis: Nonparametric-Control vs Ord. Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical Ties P-Value Decision(α:5%)

Jonckheere-Terpstra Step-Down Test

DF P-Type

Negative Control 0.635 0.438 1.64 1 -2 0.3309 Asymp Non-Significant Effect

6.9 0.66 1.64 1 -2 0.2545 Asymp Non-Significant Effect

74.42 1.45 1.64 1 -2 0.0731 Asymp Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed NOEL LOEL TOEL TU

Untransformed NA C < T NA NA 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 0.2577 0.08590001 3 1.16 0.3658 Non-Significant Effect

Error 0.8899 0.07415833 12

Total 1.1476 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 1.7 11.3 0.6363 Equal Variances

Distribution Shapiro-Wilk W Normality 0.947 0.841 0.4437 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

MaleBodyWt Summary

0 Negative Control 4 2.5 2.24 2.76 2.51 2.3 2.68 0.0821 6.57% 0.0%

0.635 4 2.6 2.23 2.97 2.56 2.4 2.9 0.116 8.89% -4.2%

6.9 4 2.6 2.14 3.05 2.6 2.27 2.92 0.143 11.0% -4.0%

74.42 4 2.84 2.26 3.43 2.86 2.44 3.21 0.183 12.9% -13.8% Centered Untransformed

 Rankits

-0.1

-0.2

-0.3

-0.4

-0.5

0.0

0.1

0.2

0.3

0.4

0.5

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

MaleBodyWt

 C-μg ai/L

0.0

0.5

1.0

1.5

2.0

2.5

3.0

3.5

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 136 of 207
Report Date: 28 Aug-13 18:02 (p 12 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:49

Analysis ID: 07-6895-8495 Endpoint: MaleGSI CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 2.28 2.68 0.613 6 0.1017 CDF Non-Significant Effect

6.9 2.3 2.68 0.613 6 0.0980 CDF Non-Significant Effect

74.42* 3.24 2.68 0.613 6 0.0184 CDF Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 49.1% 6.9 74.42 22.66

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 1.188275 0.3960917 3 3.79 0.0401 Significant Effect

Error 1.2529 0.1044083 12

Total 2.441175 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 0.246 11.3 0.9698 Equal Variances

Distribution Shapiro-Wilk W Normality 0.965 0.841 0.7516 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

MaleGSI Summary

0 Negative Control 4 1.25 0.716 1.78 1.19 0.9 1.7 0.167 26.8% 0.0%

0.635 4 1.77 1.32 2.22 1.76 1.44 2.11 0.142 16.0% -41.7%

6.9 4 1.77 1.3 2.24 1.79 1.47 2.05 0.148 16.6% -42.1%

74.42 4 1.99 1.4 2.58 2.06 1.48 2.35 0.186 18.7% -59.3% Centered Untransformed

 Rankits

-0.1

-0.2

-0.3

-0.4

-0.5

-0.6

0.0

0.1

0.2

0.3

0.4

0.5

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

MaleGSI

 C-μg ai/L

Reject Null

Reject Null

0.0

0.5

1.0

1.5

2.0

2.5

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 137 of 207
Report Date: 28 Aug-13 18:02 (p 13 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:58

Analysis ID: 02-9170-5609 Endpoint: MaleGSI CETIS Version: CETISv1.8.7

Analysis: Nonparametric-Control vs Ord. Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Jonckheere-Terpstra Step-Down Test

DF P-Type

Negative Control 0.635 14 NA -2 0.0571 Exact Non-Significant Effect

6.9* 36 NA -2 0.0463 Exact Significant Effect

74.42* 74 NA -2 0.0075 Exact Significant Effect

Data Transform Zeta Alt Hyp Trials Seed NOEL LOEL TOEL TU

Untransformed NA C < T NA NA 0.635 6.9 2.093

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 1.188275 0.3960917 3 3.79 0.0401 Significant Effect

Error 1.2529 0.1044083 12

Total 2.441175 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 0.246 11.3 0.9698 Equal Variances

Distribution Shapiro-Wilk W Normality 0.965 0.841 0.7516 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

MaleGSI Summary

0 Negative Control 4 1.25 0.716 1.78 1.19 0.9 1.7 0.167 26.8% 0.0%

0.635 4 1.77 1.32 2.22 1.76 1.44 2.11 0.142 16.0% -41.7%

6.9 4 1.77 1.3 2.24 1.79 1.47 2.05 0.148 16.6% -42.1%

74.42 4 1.99 1.4 2.58 2.06 1.48 2.35 0.186 18.7% -59.3% Centered Untransformed

 Rankits

-0.1

-0.2

-0.3

-0.4

-0.5

-0.6

0.0

0.1

0.2

0.3

0.4

0.5

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

MaleGSI

 C-μg ai/L

0.0

0.5

1.0

1.5

2.0

2.5

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 138 of 207
Report Date: 28 Aug-13 18:02 (p 14 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:49

Analysis ID: 09-4547-8918 Endpoint: MaleLength CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.529 2.68 3.8 6 0.9116 CDF Non-Significant Effect

6.9 0.353 2.68 3.8 6 0.9701 CDF Non-Significant Effect

74.42 0.705 2.68 3.8 6 0.8227 CDF Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 6.46% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 7.1875 2.395833 3 0.596 0.6297 Non-Significant Effect

Error 48.25 4.020833 12

Total 55.4375 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 7.87 11.3 0.0487 Equal Variances

Distribution Shapiro-Wilk W Normality 0.958 0.841 0.6302 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

MaleLength Summary

0 Negative Control 4 58.9 57.2 60.5 59 57.5 60 0.515 1.75% 0.0%

0.635 4 58.1 57.4 58.9 58.3 57.5 58.5 0.239 0.82% 1.27%

6.9 4 58.4 53.8 62.9 58.8 55 61 1.43 4.91% 0.85%

74.42 4 59.9 55.8 64 60 57 62.5 1.28 4.28% -1.7% Centered Untransformed

 Rankits

-0.5

-1.0

-1.5

-2.0

-2.5

-3.0

-3.5

0.0

0.5

1.0

1.5

2.0

2.5

3.0

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

MaleLength

 C-μg ai/L

Reject Null

Reject Null

0

10

20

30

40

50

60

70

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 139 of 207
Report Date: 28 Aug-13 18:02 (p 15 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:49

Analysis ID: 18-3354-6518 Endpoint: MaleMedianTubercleScore CETIS Version: CETISv1.8.7

Analysis: Parametric-Control vs Treatments Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical MSD P-Value Decision(α:5%)

Dunnett Multiple Comparison Test

DF P-Type

Negative Control 0.635 0.737 2.68 5.91 6 0.8042 CDF Non-Significant Effect

6.9 0.737 2.68 5.91 6 0.8042 CDF Non-Significant Effect

74.42 0.794 2.68 5.91 6 0.7730 CDF Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 23.3% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 30.3125 10.10417 3 1.04 0.4102 Non-Significant Effect

Error 116.625 9.71875 12

Total 146.9375 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 7.15 11.3 0.0673 Equal Variances

Distribution Shapiro-Wilk W Normality 0.92 0.841 0.1661 Normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

MaleMedianTubercleScore Summary

0 Negative Control 4 25.4 22 28.8 24.5 24 28.5 1.07 8.42% 0.0%

0.635 4 23.8 21.5 26 23.8 22 25.5 0.722 6.08% 6.4%

6.9 4 27 18.3 35.7 25.8 22 34.5 2.75 20.3% -6.4%

74.42 4 23.6 21.3 25.9 23.5 22 25.5 0.718 6.08% 6.9% Centered Untransformed

 Rankits

-1

-2

-3

-4

-5

0

1

2

3

4

5

6

7

8

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

MaleMedianTubercleScore

 C-μg ai/L

Reject Null

Reject Null

0

5

10

15

20

25

30

35

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 140 of 207
Report Date: 28 Aug-13 18:02 (p 16 of 16)

Test Code: 056502 49042102 | 03-9257-0391

CETIS Analytical Report

OPPTS 890.1350 EDSP Fish Short-Term Reproduction Assay (FSTRA) Wildlife International

Analyzed: 28 Aug-13 17:48

Analysis ID: 14-6379-8478 Endpoint: MaleVTG CETIS Version: CETISv1.8.7

Analysis: Nonparametric-Two Sample Official Results: Yes

Batch ID: 00-3404-4484

Start Date: 26 Sep-12

Ending Date: 17 Oct-12

Test Type: EDSP FSTRA Tier 1

Duration: 21d 0h

Protocol: OCSPP 890.1350 Tier I FSTRA Diluent: Well Water

Species: Pimephales promelas Brine: Not Applicable

Source: Osage Catfisheries, Osage Beach, MI

Analyst:

Age: 5.5m

Control vs C-μg ai/L Test Stat Critical Ties P-Value Decision(α:5%)

Mann-Whitney U Two-Sample Test

DF P-Type

Negative Control 0.635 10 NA 0 6 0.6857 Exact Non-Significant Effect

6.9 9 NA 0 6 0.8857 Exact Non-Significant Effect

74.42 10 NA 0 6 0.6857 Exact Non-Significant Effect

Data Transform Zeta Alt Hyp Trials Seed PMSD NOEL LOEL TOEL TU

Untransformed NA C <> T NA NA 342.0% 74.42 >74.42 NA

ANOVA Table

Source Sum Squares Mean Square DF F Stat P-Value Decision(α:5%)

Between 20256000 6752002 3 0.547 0.6598 Non-Significant Effect

Error 148244200 12353680 12

Total 168500200 15

Distributional Tests

Attribute Test Test Stat Critical P-Value Decision(α:1%)

Variances Bartlett Equality of Variance 10.8 11.3 0.0128 Equal Variances

Distribution Shapiro-Wilk W Normality 0.817 0.841 0.0046 Non-normal Distribution

C-μg ai/L Control Type Count Mean 95% LCL 95% UCL Median Min Max Std Err CV% %Effect

MaleVTG Summary

0 Negative Control 4 1.78E+3 -2.61E+3 6.17E+3 465 2.71E+2 5.92E+3 1.38E+3 155.0% 0.0%

0.635 4 1.83E+3 -1.70E+3 5.37E+3 918 3.78E+2 5.12E+3 1.11E+3 121.0% -3.07%

6.9 4 6.64E+2 -1.76E+2 1.51E+3 588 1.33E+2 1.35E+3 2.64E+2 79.5% 62.7%

74.42 4 3.79E+3 -5.83E+3 1.34E+4 1050 2.18E+2 1.28E+4 3.02E+3 160.0% -113.0% Centered Untransformed

 Rankits

-2000

-4000

0

2000

4000

6000

8000

10000

-2.0 0.0 0.5 1.0 1.5 2.0 -1.5 -1.0 -0.5

MaleVTG

 C-μg ai/L

0

2000

4000

6000

8000

10000

12000

14000

0 N 0.635 6.9 74.42

Graphics

000-516-187-1 CETISTM v1.8.7.10 Analyst:________ QA:________

Page 141 of 207
DATA EVALUATION RECORD

PCNB

Study Type: OCSPP 890.1400, In vivo Hershberger Assay

EPA Contract No. EP10H001452 

Task Assignment No. 3-26-2012 (MRID 48916702) 

Prepared for

Health Effects Division 

Office of Pesticide Programs

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by

CSS-Dynamac Corporation

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer Signature:

Rebecca L. Bryan, B.S. Date: 10/9/2012

Secondary Reviewer Signature: Michelle J. Sharpe-Kass, M.S. Date: 10/12/2012

Program Manager: Signature:

Jack D. Early, M.S. Date: 10/19/2012

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 10/19/2012

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 142 of 207
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 143 of 207
PCNB I 056502 

Primary Reviewer: N~a~c ..... v~M'-'"-""c ..... Carr.-.= ...... oll=-------

RAB VI, Health Effects Division 

Secondary Reviewer: Greg Akerman, Ph.D. 

Health Effects Division 

In vivo Hershberger Assay (2012)/ Page 1 of 13 

OCSPP 890.1400/ OECD 441 

Sign•~:::~ J~t;:{:.r.~s- Signature: ~ ,A: 

Date: Git> )1 c 

Template version 101201 l 

DATA EVALUATION RECORD 

STUDY TYPE: In Vivo Hershberger Assay (Rat); OCSPP 890.1400; OECD 441 

PC CODE: 056502 DP BARCODE: 0405372 

TXR#: 0056474 CAS#: 82-68-8 

TEST MATERIAL (PURITY): PCNB (95.6% a.i.; Lot# 107030L052) 

SYNONYMS: Pentachloronitrobenzene; Quintozene 

CITATION: Donington, S. (2012). PCNB Technical: Hershberger bioassay in the castrated 

rat (oral administration). Huntingdon Life Sciences, Cambridgeshire, England. 

Laboratory Project Study ID: BDG0121, June 19, 2012. MRID 48916702. 

Unpublished. 

SPONSOR: 

Donoghue, K (2012) PCNB Technical; Development and Validation of an 

Analytical Method and Liquid Formulation Preparation, Homogeneity and 

Stability. Huntingdon Life Sciences, Cambridgeshire, England. Laboratory 

Project Study ID BDG0122. April 27, 2012. MRID 48916703 Unpublished. 

AMY AC Chemical Corporation, 4100 E. Washington Blvd., Los Angeles, CA 

TEST ORDER #: EDSP-056502-105 

EXECUTIVE SUMMARY: In a Hershberger assay (MRID 48916702) screening for 

androgenic activity, PCNB (95.6% a.i., Lot# 107030L052) in aqueous sodium carboxymethyl 

cellulose (1 % SCMC) was administered daily via oral gavage to groups of 55-day old, castrated 

male Sprague Dawley (Crl:CD[SD]) rats (IO/group) at dose levels of 0 (vehicle), 300, or 1000 

mg/kg/day. The androgenic assay included a positive control group consisting of 10 castrated 

rats exposed to 0.4 mg/kg/day of testosterone propionate (TP) by subcutaneous (s.c.) injection. 

To screen for potential anti-androgenic activity, PCNB in 1 % SCMC was administered daily via 

oral gavage to 54-day old, castrated male Sprague Dawley rats (10/group) at dose levels of 100, 

300, or 1000 mg/kg/day in conjunction with a daily dose ofreference androgen TP at 0.4 

mg/kg/day by s.c. injection. The control group for the anti-androgenic assay consisted of ten 

castrated male rats dosed daily with TP (0.4 mg/kg/day) in com oil by s.c. injection, and the 

positive control group consisted of ten castrated male rats dosed orally with flutamide (FT) in 

com oil at 3 mg/kg/day in conjugation with a daily s.c. dose of TP (0.4 mg/kg/day). 

Page 144 of 207
In vivo Hershberger Assay (2012)/ Page 2 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

For both components of the assay, the animals were dosed for 10 consecutive days and 

necropsied approximately 24 hours after the final dose administration to determine weights of 

the five androgen-dependent tissues.

In the androgen agonist assay, body weights and body weight gains for the 300 and 1000 

mg/kg/day treatment groups were comparable to controls throughout the assay. Animals dosed 

with TP had increased (p≤0.05) body weights on Days 8-11 (↑5-8%) and overall body weight 

gains (↑48%) compared to controls. There were no treatment-related weight increases in any of 

the accessory sex organs of animals dosed with PCNB. At 1000 mg/kg/day, the adjusted liver 

weights were increased by 8% (p≤0.05) and the unadjusted liver weights were increased by 7% 

(not significant, NS). Animals in the TP group had increases (p≤0.01) in unadjusted accessory 

sex organ weights as follows: 750% in seminal vesicles, 1316% in ventral prostate, 179% in 

levator ani-bulbocavernosus (LABC), 518% in Cowper’s gland, and 50% in glans penis. The 

unadjusted liver weights in the TP group were increased by 15% (p≤0.01) and the adjusted liver 

weights were increased by 8% (p≤0.05). All %CV values were less than or equal to the 

maximum recommended values.

In the anti-androgen assay, body weights and body weight gains for the 100, 300, and 1000 

mg/kg/day dose groups were comparable to controls throughout the assay. No treatment-related 

decreases in weights of androgen sensitive tissues were observed in any PCNB dose group, 

although there was a 15% increase (p≤0.05) in Cowper’s gland weights at 1000 mg/kg/day. No 

treatment-related decreases were observed in any of the accessory sex organs of PCNB-dosed 

animals. The unadjusted liver weights were increased by 8% (NS) at 1000 mg/kg/day. Animals 

dosed with TP + FT (positive control) had decreases (p≤0.01) in unadjusted accessory sex organ 

weights as follows: 76% in seminal vesicles, 72% in ventral prostate, 53% in LABC, 58% in 

Cowper’s gland, and 27% in glans penis. The unadjusted liver weights in the TP + FT group 

were increased by 11% (p≤0.05) and the adjusted liver weights were increased by 10% (p≤0.01). 

All %CV values were less than or equal to the maximum recommended values.

The dosing levels selected for the study were acceptable as animals were dosed up to limit dose 

(1000 mg/kg/day) for the assay. 

Statistically significant changes were not seen in two or more of the five androgen sensitive 

tissue weights. PCNB was negative for androgenicity and anti-androgenicity in the Hershberger 

assay.

The assay satisfies the EDSP Tier 1 Test Order requirements for a Hershberger assay (OCSPP 

890.1400). 

COMPLIANCE: Signed and dated GLP Compliance and Quality Assurance statements were 

provided. 

Page 145 of 207
In vivo Hershberger Assay (2012)/ Page 3 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Huntingdon Life Sciences, Ltd.

Location: Cambridgeshire, England

Study Director: S. Donington

Other Personnel: Ballantine, A. (Team Leader), Clarke, R. (Senior Animal Technician), 

Rodgers, D. (Senior Pharmacology Assistant), and Viles, T. (Senior 

Technician)

Study Period: February 1, 2012 to June 19, 2012

2. Test Substance: PCNB

Description: Light brown powder

Source: AMVAC Chemical Corporation (Los Angeles, CA)

Lot/Batch #: 107030L052 (expires July 2016)

Purity: 95.6% a.i.

Stability: Stable in the vehicle for up to 15 days refrigerated and at room temperature 

(Huntingdon Life Sciences Study No. BDG0122).

CAS #: 82-68-8

Structure:

Cl

Cl

Cl

Cl

Cl

NO2

3. Reference Androgen: Testosterone propionate (TP)

Supplier: Sigma-Aldrich 

Batch #: 048K1328 (expires April 30, 2012)

Purity: Not provided

CAS # : 57-85-2

4. Reference Anti-androgen: Flutamide (FT)

Supplier: Sigma-Aldrich 

Lot #: 009K1112 (expires June 15, 2012)

Purity: Not provided

CAS # : 13311-84-7

5. Solvent/Vehicle Control 

(PCNB): Aqueous sodium carboxymethyl cellulose (1% SCMC)

Supplier: BDH

Lot/Batch #: 82122 (expires November 21, 2013)

Rationale (if other than water) : Test substance had very low water solubility.

Final concentration: 1% w/v

6. Solvent/Vehicle Control

(Testosterone propionate and Flutamide): Corn Oil 

Supplier: Sigma-Aldrich 

Lot/Batch #: MKBD2427 (expires September 27, 2012)

Rationale (if other than water) : Background data collected using this vehicle.

Final concentration: Not applicable

Page 146 of 207
In vivo Hershberger Assay (2012)/ Page 4 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

7. Test Animals:

Species: Rat

Strain: Sprague Dawley (Crl:CD[SD])

Age/weight at dose initiation: Phase I: Androgen Agonist Assay: Post-natal day (PND) 55; 228.6-312.5 g 

Phase II: Anti-Androgen Assay: PND 54; 227.8-280.5 g

Source: Charles River UK Ltd, Kent, UK

Housing: Rats were housed up to 3/cage in suspended plastic cages with solid floors 

and wood flake bedding (Lignocel® Grade 3⁄4 bedding).

Diet: Special Diet Services, UK standard certified laboratory rodent diet 

(RM1(E)SQC), ad libitum (phytoestrogen concentration results not 

reported).

Water: Tap water, ad libitum

Environmental conditions: Temperature:

Humidity:

Air changes:

Photoperiod:

21±2oC

55±15% 

Not reported

12 hrs light/12 hrs dark

Acclimation period: Prior to castration: 7 days

Post-castration: 9 days prior to initiation of dosing

B. STUDY DESIGN

1. In-life dates: Androgen Agonist Assay: Start: 3/5/2012 End: 3/15/2012 

 Anti-Androgen Assay: Start: 4/2/2012 End: 4/12/2012 

2. Study Design: This Hershberger Assay was conducted to screen for both potential 

androgenic and anti-androgenic activity. In the test for androgenic activity (Phase 1), PCNB

was administered daily via oral gavage to groups of castrated male rats. Positive androgenic 

activity is defined as a significant increase in two or more target organ weights compared to 

the vehicle control group. The positive control group for androgenic activity consisted of 

castrated male rats dosed by subcutaneous (s.c.) injection with TP at 0.4 mg/kg/day. In the 

test for anti-androgenic activity (Phase 2), PCNB was administered daily via oral gavage to 

groups of castrated male rats in conjunction with TP at 0.4 mg/kg/day by s.c. injection. 

Anti-androgenic activity is indicated by a statistically significant decrease in two or more 

target organ weights of the treated groups (test substance + TP) compared to the TP-only 

control group. The positive control group for anti-androgenic activity consisted of castrated 

male rats dosed by s.c. injection with TP (0.4 mg/kg/day) in conjunction with an oral dose 

of FT (3.0 mg/kg/day). For both assays, the animals were dosed for 10 consecutive days 

and necropsied approximately 24 hours after the final dose administration for measurement 

of target organ weights. 

3. Study Schedule: Following the initial 7-day acclimation period, sexually mature male rats 

were castrated on PND 43-44 according to standard procedures and allowed 9 days for 

recovery and regression of accessory sex organ weights prior to initiation of dosing. The 

dose administration period was from PND 54-55 through PND 64-65. Rats were euthanized 

on PND 65-66 approximately 24 hours after the last dose and necropsied for organ weight 

measurements.

Page 147 of 207
In vivo Hershberger Assay (2012)/ Page 5 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

4. Animal Assignment: Animals were randomly assigned, stratified by body weight, to the 

test groups noted in Table 1. Statistical analysis indicated that there were no significant 

differences in group means at study initiation. Furthermore, the body weight of each animal 

was within 20% of the overall mean. 

TABLE 1. Study design a

Test group Dose (mg/kg/day) # of Males

Androgen Agonist Assay

Vehicle control (negative control) 0 10

Low (PCNB) 300 10

High (PCNB) 1000 10

Testosterone propionate (TP) (s.c.), positive control 0.4 10

Anti-Androgen Assay

1% SCMC + TP (negative control) 0 10

Low (PCNB+TP) 100 10

Mid (PCNB+TP) 300 10

High (PCNB+TP) 1000 10

Flutamide (oral gavage) + TP (s.c.), positive control 3 10

a Data were obtained from pages 14 and 15 of the study report (MRID 48916702). 

5. Dose Selection Rationale: The limit dose (1000 mg/kg/day) was selected as the high dose 

for the androgen agonist and anti-androgen assays based on EPA guidelines. For the 

androgen agonist assay, one additional dose of 300 mg/kg/day was tested. For the antiandrogen assay, two additional doses of 100 and 300 mg/kg/day were tested. 

6. (a) Dose Preparation: Dose formulations were prepared once prior to initiation of 

treatment by mixing the appropriate amounts of test substance in 1% SCMC. Flutamide and 

TP prepared were daily prior to dosing by mixing in corn oil. Concentration analyses were 

performed prior to administration on all dose levels. Homogeneity and stability analyses on 

PCNB formulations (10 and 200 mg/mL) were performed prior to administration 

(Huntingdon Study No. BDG0122; MRID 48916703, see Appendix I). Stability of the 

dosing suspensions was validated for 15 days under ambient and refrigerated storage 

conditions. 

(b) Dose Analysis

Results

Homogeneity (%CV): 0.57-4.69%

Stability (% of nominal): 97-104% 

Concentration (% of nominal): 91-95% 

The analytical data indicated that the mixing procedure was adequate and that the variation 

between nominal and actual dosage to the animals was acceptable. 

Page 148 of 207
In vivo Hershberger Assay (2012)/ Page 6 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

7. Dosage administration: Test formulations of PCNB were administered to the animals 

daily via oral gavage (5 mL/kg bw) for 10 days. TP was given via s.c. injection at 

0.5 mL/kg bw, and FT was administered via oral gavage at 5 mL/kg bw. Dose volumes 

were adjusted daily based on the concurrent body weight measurement. 

8. Statistics: Body weights, body weight gains, liver weight and accessory sex organ weights 

were first analyzed by Bartlett’s test for homogeneity of variances. Treatment groups were 

compared to the control using Williams’ test. For the accessory sex organ weights, analysis 

of covariance (ANCOVA) was also performed with terminal body weight as the covariate. 

For the androgenic agonist test, the TP group was compared to the control using Student’s 

t test. For the anti-androgenic test, the flutamide and TP group was compared to the control 

using Student’s t test. Significance was denoted at p≤0.05. Statistical analyses were 

performed using StarTox (version 3.2.1) and Quasar (version 1.1). The statistical analyses 

were considered adequate.

C. METHODS

1. Clinical Examinations: Clinical observations were conducted immediately after dosing, 1-

2 hours after dosing, and at the end of the working day. 

2. Body Weight: Animals were weighed on the day of castration surgery, for 6 days postsurgery, daily throughout the dosing period, and on the day of necropsy. 

3. Food Consumption (Optional): Food consumption was not determined. 

4. Serum Hormone Measurements (Optional): Serum hormone measurements were not 

conducted. 

5. Dissection and Measurement of Tissue and Organ Weights: On PND 65-66 

(approximately 24 hours after the final administration of the test substance), all animals 

were euthanized by cervical dislocation and subjected to a gross necropsy. The five 

mandatory androgen-dependent organs (ventral prostate, seminal vesicles, LABC, Cowper’s 

gland, and glans penis) were excised, trimmed free of adhering tissue, and weighed fresh 

(unfixed) according to the standard operating procedures detailed in the U.S. EPA Guideline 

(OCSPP 890.1400). Additionally, the liver was collected and weighed. 

II. RESULTS

A. OBSERVATIONS

1. Mortality: All animals survived until scheduled termination. 

2. Clinical signs of toxicity: No treatment-related clinical signs of toxicity were observed in 

animals from any dose groups. 

Page 149 of 207
In vivo Hershberger Assay (2012)/ Page 7 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

B. BODY WEIGHT AND WEIGHT GAIN: Selected body weight and body weight gains 

for the androgen agonist assay are presented in Table 2. No effects on body weights or body 

weight gains were observed for any PCNB dose groups. Animals dosed with TP had 

increased (p≤0.05) body weights on Days 8-11 (↑5-8%) and an overall body weight gain of 

48% compared to controls. 

TABLE 2. Selected Group Mean (±SD) Body Weights and Cumulative Body Weight Gains (g) in the 

Androgen Agonist Assay with PCNB a

Study Day #

Dose (mg/kg/day)

Vehicle Control Positive Control

Vehicle + TP (0.4) PCNB (300) PCNB (1000) 

N Mean SD N Mean SD N Mean SD N Mean SD 

1 10 271.0 18.4 10 270.6 20.7 10 271.9 21.0 10 268.7 15.3

4 10 287.0 19.6 10 297.1 21.3 10 289.3 24.4 10 286.2 15.1

7 10 304.8 21.7 10 324.6 22.5 10 306.4 27.7 10 304.1 17.8

11

(Necropsy)

10 324.9 22.5 10 350.5*

(↑8)

21.3 10 324.9 30.2 10 322.7 17.9

BWG

(Days 1-11)

10 53.9 7.0 10 79.9*

(↑48)

6.8 10 53.0 11.0 10 54.1 8.8

a Data were obtained from Table 3 on page 32 of the study report (MRID 48916702). Percent differences from controls 

(calculated by the reviewers) are included in parentheses. 

N Number of animals in the group

SD Standard Deviation

* Significantly different from controls at p≤0.05

Selected body weight and body weight gain data for the anti-androgen assay are presented in 

Table 3. Body weights and body weight gains in all dose groups were comparable to 

controls throughout the duration of the assay. 

TABLE 3. Selected Group Mean (±SD) Body Weights and Cumulative Body Weight Gains (g) in the AntiAndrogen Assay with PCNBa

Study 

Day #

Dose (mg/kg/day)

Vehicle Control

+ TP (0.4) 

Positive Control

TP + FT 

(0.4 + 3.0)

PCNB+TP

(100 + 0.4)

PCNB +TP

(300 + 0.4)

PCNB +TP

(1000 + 0.4)

N Mean SD N Mean SD N Mean SD N Mean SD N Mean SD 

1 10 260.8 14.7 10 262.5 10.8 10 262.3 14.3 10 262.1 13.8 10 261.5 13.8

4 10 283.7 16.7 10 287.1 11.9 10 289.3 16.2 10 287.9 14.0 10 285.8 16.2

7 10 307.9 17.8 10 308.2 15.2 10 314.7 16.2 10 312.6 17.0 10 309.6 17.8

11 b 10 332.0 17.4 10 334.6 18.1 10 339.8 19.6 10 337.7 18.9 10 337.5 24.0

BWG

(days 1-11) 10 71.2 10.3 10 72.1 11.2 10 77.5 11.4 10 75.6 10.4 10 76.0 12.6

a Data were obtained from Table 3 on page 33 of the study report (MRID 48916702). 

 b Necropsy

N Number of animals in the group

SD Standard Deviation

C. FOOD CONSUMPTION (Optional): Food consumption was not determined. 

Page 150 of 207
In vivo Hershberger Assay (2012)/ Page 8 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

D. SERUM HORMONE CONCENTRATIONS (Optional): Serum hormone concentrations 

were not determined.

E. ORGAN WEIGHTS: Accessory sex organ weights for the androgen agonist assay are 

presented in Table 4. There were no treatment-related weight increases in any of the 

accessory sex organs of animals dosed with PCNB. At 1000 mg/kg/day, the adjusted liver 

weights were increased by 8% (p≤0.05) and the unadjusted liver weights were increased by 

7% (not significant). Animals in the TP group had increases (p≤0.01) in unadjusted 

accessory sex organ weights as follows: 750% in seminal vesicles, 1316% in ventral 

prostate, 179% in LABC, 518% in Cowper’s gland, and 50% in glans penis. The unadjusted 

liver weight in the TP group was increased by 15% (p≤0.01) and the adjusted liver weight 

was increased by 8% (p≤0.05). All %CV values were less than or equal to the maximum 

recommended values.

TABLE 4. Accessory Sex Organ Weights (mg) from Androgen Agonist Assay with PCNB in SpragueDawley Rats a

Organ

Dose (mg/kg/day)

Vehicle control PCNB (300) PCNB (1000) Positive Control

Vehicle + TP (0.4)

N Mean SD

CV

(%) N Mean SD

CV

(%) N Mean SD

CV

(%) N Mean SD

CV

(%)

Seminal 

vesicles

U 10 69.7 12.3 18 10 74.8 12.0 16 10 74.3 14.1 19 10 592.6**

(↑750)

108.7 18

A 10 69.3 NA NA 10 74.5 NA NA 10 73.7 NA NA 10 569.9**

(↑722)

NA NA

Ventral 

prostate

U 10 24.2 8.52 35 10 26.8 7.84 29 10 30.5 12.2 40 10 342.6**

(↑1316)

61.4 18

A 10 23.1 NA NA 10 25.9 NA NA 10 28.9 NA NA 10 337.6**

(↑1361)

NA NA

LABC

U 10 245.6 39.7 16 10 232.4 32.3 14 10 243.5 12.1 5 10 685.0**

(↑179)

70.1 10

A 10 244.8 NA NA 10 232.4 NA NA 10 246.0 NA NA 10 662.3**

(↑171)

NA NA

Cowper’s 

glands

U 10 7.2 1.27 18 10 8.2 2.67 33 10 8.6 2.72 32 10 44.5**

(↑518)

6.54 15

A 10 7.1 NA NA 10 7.8 NA NA 10 8.2 NA NA 10 44.6**

(↑528)

NA NA

Glans 

penis

U 10 61.0 8.80 14 10 58.1 8.97 15 10 57.7 8.03 14 10 91.2**

(↑50)

10.8 12

A 10 61.3 NA NA 10 58.4 NA NA 10 58.1 NA NA 10 90.3**

(↑47)

NA NA

Liver

U 10 11.7 1.15 10 10 12.3 1.62 13 10 12.5

(↑7)

1.06 8 10 13.5**

(↑15)

0.92 7

A 10 11.9 NA NA 10 12.5 NA NA 10 12.8*

(↑8)

NA NA 10 12.8*

(↑8)

NA NA

a Data were obtained from Tables 1 and 2 on pages 28 and 30 of the study report (MRID 48916702). Percent differences 

from controls were calculated by the reviewers and included in parentheses.

N Number of animals in the group

SD Standard Deviation

CV Coefficient of Variation

NA Not applicable

U Unadjusted for terminal body weight 

A Adjusted for terminal body weight 

* Significantly different from controls at p≤0.05

** Significantly different from controls at p≤0.01

Page 151 of 207
In vivo Hershberger Assay (2012)/ Page 9 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

Accessory sex organ weights for the anti-androgen assay are presented in Table 5. There were 

no treatment-related weight decreases in any of the accessory sex organs of animals dosed with 

PCNB. The Cowper’s gland weights were increased by 15% (p≤0.05) at 1000 mg/kg/day. The 

unadjusted liver weights were increased by 8% (not significant) at 1000 mg/kg/day. Animals 

dosed with TP + FT (positive control) had decreases (p≤0.01) in unadjusted accessory sex organ 

weights as follows: 76% in seminal vesicles, 72% in ventral prostate, 53% in LABC, 58% in 

Cowper’s gland, and 27% in glans penis. The unadjusted liver weights in the TP + FT group 

were increased by 11% (p≤0.05) and the adjusted liver weights were increased by 10% (p≤0.01). 

All %CV values were less than or equal to the maximum recommended values.

Page 152 of 207
In vivo Hershberger Assay (2012)/ Page 10 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

TABLE 5. Accessory Sex Organ Weights (g) from Anti-Androgen Agonist Assay with PCNB in Sprague-Dawley Rats a

Organ

Dose (mg/kg/day)

Water Vehicle Control

+ TP (0.4)

PCNB+TP

(100 + 0.4)

PCNB +TP

(300 + 0.4)

PCNB +TP

(1000 + 0.4)

TP + FT (0.4+3.0)

Positive Control

N Mean SD

CV

(%) N Mean SD

CV

(%) N Mean SD

CV

(%) N Mean SD

CV

(%) N Mean SD

CV

(%)

Seminal 

vesicles

U 10 558.8 47.4 8 10 541.4 44.6 8 10 597.8 106.3 18 10 580.6 72.6 13 10 133.8**

(↓76)

33.5 25

A 10 555.4 NA NA 10 542.5 NA NA 10 594.6 NA NA 10 579.2 NA NA 10 133.5**

(↓76)

NA NA

Ventral 

prostate

U 10 169.8 32.6 19 10 177.0 30.4 17 10 164.9 45.3 27 10 183.9 41.9 23 10 48.0**

(↓72)

9.64 20

A 10 166.6 NA NA 10 174.6 NA NA 10 159.3 NA NA 10 179.0 NA NA 10 47.2**

(↓72)

NA NA

LABC

U 10 624.9 76.7 12 10 604.9 55.2 9 10 635.4 65.3 10 10 633.4 60.5 10 10 296.5**

(↓53)

18.48 6

A 10 623.5 NA NA 10 600.5 NA NA 10 631.4 NA NA 10 630.0 NA NA 10 296.5**

(↓52)

NA NA

Cowper’s 

glands

U 10 35.7 4.28 12 10 37.7 5.34 14 10 37.9 6.20 16 10 41.0*

(↑15)

7.43 18 10 15.0**

(↓58)

2.76 18

A 10 35.7 NA NA 10 37.8 NA NA 10 37.9 NA NA 10 41.0*

(↑15)

NA NA 10 15.0**

(↓58)

NA NA

Glans penis U 10 93.6 8.91 10 10 92.6 12.0 13 10 92.2 10.9 12 10 99.3 10.8 11 10 68.2**

(↓27)

9.97 15

A 10 94.4 NA NA 10 92.0 NA NA 10 91.9 NA NA 10 99.1 NA NA 10 68.5**

(↓27)

NA NA

Liver U 10 12.5 1.35 11 10 13.4 1.54 11 10 13.3 1.06 8 10 13.5

(↑8)

1.32 10 10 13.9*

(↑11)

1.13 8

A 10 12.7 NA NA 10 13.2 NA NA 10 13.2 NA NA 10 13.4

(↑6)

NA NA 10 14.0**

(↑10)

NA NA

a Data were obtained from Tables 1 and 2 on pages 29 and 31 of the study report (MRID 48916702). Percent differences from controls were calculated by the reviewers and 

included in parentheses.

N Number of animals in the group

SD Standard Deviation

CV Coefficient of Variation

NA Not applicable; 

U Unadjusted for terminal body weight

A Adjusted for terminal body weight 

* Significantly different from controls at p≤0.05

** Significantly different from controls at p≤0.01

Page 153 of 207
In vivo Hershberger Assay (2012)/ Page 11 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATOR’S CONCLUSIONS: In the androgenic phase of the assay, dosing of 

castrated male rats with PCNB at doses of 300 and 1000 mg/kg/day for 10 consecutive days 

showed no significant increases in any of the five androgen-dependent tissues compared 

with vehicle-treated control animals. Systemic toxicity was limited to a slight but 

statistically significant increase in relative liver weight at the 1000 mg/kg/day dose, which is 

the limit dose for this assay. Based on these findings PCNB is considered to have no 

androgenic effects under the conditions of this assay. 

In the anti-androgenic phase of the assay, dosing of castrated male rats with PCNB at 100, 

300 and 1000 mg/kg/day for 10 consecutive days, in conjunction with s.c. dosing of TP (0.4 

mg/kg/day) showed no significant reductions in any of the five androgen-dependent tissues 

compared with the TP-treated control animals. No systemic toxicity was noted at any dose 

in this study phase, including the 1000 mg/kg/day limit dose. Based on these findings 

PCNB is considered to have no anti-androgenic effects under the conditions of this assay. 

Overall, PCNB showed no evidence of interaction with the androgen pathway by either an 

androgenic or anti-androgenic mechanism under the conditions of this assay. 

B. AGENCY COMMENTS: All animals survived until scheduled termination. There were 

no treatment-related clinical signs of toxicity.

 In the androgen agonist assay, body weights and body weight gains for the 300 and 1000 

mg/kg/day treatment groups were comparable to controls throughout the assay. Animals 

dosed with TP had increased (p≤0.05) body weights on Days 8-11 (↑5-8%) and an overall 

body weight gain of 48% compared to the control. There were no treatment-related weight 

increases in any of the accessory sex organs of animals dosed with PCNB. At 1000 

mg/kg/day, the adjusted liver weights were increased by 8% (p≤0.05) and the unadjusted 

liver weights were increased by 7% (NS). Animals in the positive TP-control group showed 

the expected increases (p≤0.05) in accessory sex organ weights.

In the anti-androgen assay, body weights and body weight gains for the 100, 300, and 1000 

mg/kg/day treatment groups were comparable to controls throughout the assay. There were 

no decreases in weights of accessory sex organs of PCNB-treated animals, but the Cowper’s 

gland weights were increased by 15% (p≤0.05) at 1000 mg/kg/day. The unadjusted liver 

weights were increased by 8% (NS) at 1000 mg/kg/day. Animals dosed with FT + TP 

(positive control) showed the expected decreases in accessory sex organ weights. 

All %CV values were less than or equal to the maximum recommended values in both 

phases of the assay. The dosing levels selected for the study were acceptable as animals 

were dosed up to limit dose (1000 mg/kg/day) for the assay. No statistically significant 

changes were seen in two or more of the five androgen sensitive tissue weights. PCNB was 

negative for androgenicity and anti-androgenicity in the Hershberger assay. 

C. STUDY DEFICIENCIES: None 

Page 154 of 207
In vivo Hershberger Assay (2012)/ Page 12 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

Appendix I: PCNB Technical: Development and Validation of an Analytical 

Method and Liquid Formulation Preparation, Homogeneity and Stability.

 

The analytical laboratory provided validation data (MRID 48916703) for the HPLC/UV method 

(FIA/M005/12) used to determine PCNB concentrations in the dosing suspensions. PCNB 

concentrations in the dosing suspensions were determined directly by HPLC analysis without 

extraction, using an Inertsil ODS-3 column with an isocratic mobile phase of acetonitrile:water 

(7:3, v/v). PCNB was detected and quantified using a UV detector (254 nm). The analytical 

laboratory also provided data demonstrating the homogeneity and stability of PCNB Technical in 

the 1% SCMC dosing suspensions. 

I. Method Validation. A standard solution of PCNB Technical (Batch # 107030L052, 95.6% 

a.i., expires July 2016) was prepared by dissolving in acetonitrile, for a concentration of 100 

μg/mL Solutions for calibration were prepared by appropriate dilution to generate nominal 

concentrations of 1, 4, 6, 8 ad 10 μg/mL. The analytical procedure was validated by 

determining the following parameters; The specificity of the chromatographic analysis in 

the control sample chromatograms, the Limit of detection, the linearity of detector response 

over the calibration standard range, the precision of injection of the lowest and highest 

concentration calibration standards, and the accuracy and precision of the method. 

Procedural recoveries were prepared by fortifying samples of control matrix (1% SCMC) 

with known amounts of PCNB Technical. 

The analytical procedure was successfully validated for PCNB technical in 1% SCMC. The 

specificity was demonstrated by the absence of a peak at the characteristic retention time 

for PCNB Technical, the Limit of detection was 72.3 ng/mL, Linearity was confirmed with 

a r2

 of >0.999, the precision of injection was <1%, and the method accuracy and precision 

(Table 1) were within acceptable values, the overall mean procedural recovery was 98.6%. 

Table A1: Method Validation for PCNB Technical in 1% SCMCa

Sample Nominal Fortification (mg/mL)

10 200

1 94.7 98.4

2 98.9 99.4

3 99.0 98.7

4 101.7 97.9

5 98.7 99.0

6 99.7 96.5

Mean (%) 98.8 98.3

%CV 2.31 1.04

n 6 6.

Overall mean (%) 98.6

%CV 1.73

n 12 a Data were obtained from page 22 of the report

Page 155 of 207
In vivo Hershberger Assay (2012)/ Page 13 of 13

PCNB / 056502 OCSPP 890.1400/ OECD 441

II. Homogeneity and stability. The homogeneity and stability of PCNB Technical in 1% 

SCMC Formulation was assessed at concentrations of 10 mg/mL and 200 mg/ml, under 

ambient and refrigerated (4°C) storage conditions. Samples were stored at ambient 

temperature, and samples from the top, middle and bottom of each concentration were 

analyzed after 24 hours and 15 days to assess storage stability. Samples that were 

refrigerated were sampled on days 1, 8 and 15 to assess refrigerated storage stability. 

The homogeneity and storage stability of PCNB in 1% SCMC were confirmed. 

Homogeneity (%CV) ranged from 0.57-4.69%, and stability of PCNB was 97-104% of the 

time zero concentration. 

TABLE A2. Homogeneity and stability of PCNB Technical in 1% SCMC a 

Concentration 

(mg/mL)

Storage Conditions Analyzed Concentration (mg/mL)

Temperature Time Top Middle Bottom Mean % Time 

Zero

CV(%)

10 Ambient 

(21°C)

0h 8.31 8.68 8.92 8.64 100 3.54

1h 8.74 8.63 8.87 8.75 101.3 1.38

2h 8.91 8.72 8.64 8.75 101.3 1.55

24h 8.77 8.89 9.27 8.98 103.9 2.88

15 days 8.65 8.6 9.24 8.83 102.2 4.01

Refrigerated

(4°C)

1 day 8.37 8.41 8.73 8.51 98.5 2.33

8 days 8.6 8.86 9.42 8.96 103.7 4.69

15 days 8.59 9.28 9.09 8.98 103.9 4

200 Ambient 

(21°C)

0h 194 196 191 194 100 1.16

1h 193 195 194 194 100 0.57

2h 190 194 193 193 99.5 1.02

24h 191 187 193 191 98.5 1.62

15 days 185 184 194 188 96.9 3.02

Refrigerated

(4°C)

1 day 193 191 186 190 97.9 1.7

8 days 190 195 200 195 100.5 2.7

15 days 187 194 188 190 97.9 1.95 s Data were obtained from page 23 of the report. 

Page 156 of 207
DATA EVALUATION RECORD

PCNB

Study Type: OCSPP 890.1450, Female Pubertal Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-45-2013 (MRID 49042103) 

Prepared for

Health Effects Division

Office of Pesticide Programs

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by

CSS-Dynamac Corporation

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Michael E. Viana, Ph.D., D.A.B.T. Date: 03/29/2013

Secondary Reviewer: Signature:

Scott Studenberg, Ph.D., D.A.B.T. Date: 04/01/2013

Program Manager: Signature:

Jack D. Early, M.S. Date: 04/11/2013

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 04/11/2013

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 157 of 207
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 158 of 207
PCNB I 056502 

Primary Reviewer: Nancy McCarroll 

RAB VI, Health Effects Division 

Secondary Reviewer: Elizabeth Mendez, Ph.D. 

Health Effects Division 

Female Pubertal Assay (2012) I Page 1of15 

OCSPP 890.1450/ OECD None 

Signature: /IOA\'1 fltcCw.JJ 

Date: M~ , Signature: ~ ~ Date: 

Tomplotom22 

DATA EVALUATION RECORD 

STUDY TYPE: Female Pubertal Assay; OCSPP 890.1450; OECD None. 

PC CODE: 056502 DP BARCODE: D409239 

TXR#: 0056474 CAS No: 82-68-8 

TEST MATERIAL (PURITY): PCNB Technical (95.6% a.i.) 

SYNONYMS: 1,2,3,4,5-pentacbloro-6-nitrobenzene; Quintozene 

CITATION: Baxter, G.E. (2012) PCNB: Assessment of Pubertal Development and 

Thyroid Function in Juvenile Male and Female Rats. Huntingdon Life 

Sciences, East Millstone, NJ. Laboratory Study No.: 12-4389, December 19, 

2012. MRID 49042103A. Unpublished. 

SPONSOR: AMV AC Chemical Corporation, 2110 Davie A venue, Commerce, CA 

TEST ORDER #: EDSP-056502-105 

EXECUTIVE SUMMARY: In a Female Pubertal Assay (MRID 49042103A), 15 Sprague 

Dawley [Crl:CD® (SD) IGS BR] rats/dose group were treated daily via oral gavage with PCNB 

(95.6% a.i.; Lot # 107030L052) in aqueous 1 % sodium carboxymethyl cellulose at doses of 

0 (vehicle), 500, or 1000 (limit dose) mg/kg/day from post-natal day (PND) 22 to 42. Animals 

were examined for vaginal opening (VO) daily beginning on PND 22, and age and weight at day 

of attainment were recorded. Following sacrifice on PND 42, blood was collected for clinical 

chemistry and hormone analyses. Total serum thyroxine (T4) was determined by radioimmunoassay, but the method used for determination of thyroid stimulating hormone (TSH) levels was 

not reported. Adrenal, liver, pituitary, thyroid, and urogenital organs were we ghed~ and 

microscopic examinations were performed on the ovaries, uterus, thyroid, liver, and kidneys. 

There were no effects of treatment on mortality, clinical signs of toxicity, final body weights or 

body weight gains, food consumption, or gross pathology. Compared to the control group, 

absolute, adjusted, and relative (to body) liver weights were increased (p<0.05) by 6-8% at 500 

mg/kg/day and by 6% at 1000 mg/kg/day, and absolute, adjusted and relative kidney weights 

were increased (p<0.01) by 6-8% at500 mg/kg/day and by 8% at 1000 mg/kg/day. The 

following dose-dependent changes in clinical chemistry parameters were observed at 500 and 

I 000 mg/kg/day, respectively: alkaline phosphatase (ALP) activity was increased (p<0.05) by 

20 and 26%; alanine aminotransferase (ALT) activity was decreased (p<0.001) by 42 and 51%; 

total bilirubin was increased (p<0.01) by 44 and 56%; and urea nitrogen was increased (p<0.05) 

Page 159 of 207
Female Pubertal Assay (2012) / Page 2 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

by 8 and 15%. Additionally at 1000 mg/kg/day, albumin was decreased (p<0.05) by 3% and 

total protein was decreased (p<0.01) by 4%. 

There were no effects of treatment on age and body weight at attainment of VO. All females 

achieved complete VO. There were no effects of treatment on mean age at first vaginal estrus, 

mean cycle length, % cycling or regularly cycling, or cycle status at necropsy. Antral and 

tertiary follicles, corpora lutea, and atretic follicles were present in the ovary of all individuals, 

and the numbers of primordial and primary follicles showed no biologically relevant differences 

across groups. The number of 1000 mg/kg/day females classified in metestrus by examination of 

the uterus (with cervix) was increased (6 treated vs. 1 control; p<0.05); however, the biological 

significance of this finding is unclear.

Serum T4 levels were decreased (p<0.001) by 70% at 500 mg/kg/day and by 72% at 1000 

mg/kg/day. Concomitantly, serum TSH levels were increased (p<0.001) by 53% at 500 

mg/kg/day and by 59% at 1000 mg/kg/day. No significant changes were observed in thyroid 

histology; however, there was a slight, dose-related trend toward decreased colloid area and 

increase follicular cell height.

The dose levels tested in assay are adequate since the high dose was the Limit Dose (1000 

mg/kg/day). 

The assay satisfies the EDSP Tier 1 Test Order requirements for a Female Pubertal Assay 

(OCSPP 890.1450). 

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided.

Page 160 of 207
Female Pubertal Assay (2012) / Page 3 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Huntingdon Life Sciences

Location: East Millstone, NJ

Study Director: G.E. Baxter

Other Personnel: C. Willard-Mack (Pathologist), Y. Wang (Dose Formulation analysis), L. Ramaih 

(Clinical Pathologist), S. Polivy (TSH Hormone analysis), G. Thomas (Statistics)

Study Period: March 30, 2012 to December 19, 2012

2. Test Substance: PCNB Technical

Description: Off-white to dark tan crystalline solid or powder

Source: AMVAC Chemical Corporation (Los Angeles, CA)

Lot #: 107030L052 (Expiration July 2016)

Purity: 95.6% a.i.

Stability: 15 days under refrigerated (2-8 ̊C) or room temperature conditions

CAS #: 82-68-8

Structure:

3. Vehicle: 1% Aqueous carboxymethyl cellulose (sodium)

4. Test Animals:

Species: Rat

Strain: Sprague Dawley [Crl:CD®(SD)IGS BR]

Age/Weight at Allocation: PND 21 / 47.3-55.4 g

Source: Charles River Laboratories (Portage, MI)

Housing: Dams were individually housed in plastic shoebox cages with aspen bedding through 

parturition and weaning. Selected pups were housed in the same type cage with up to 

3/pups/sex/cage.

Diet: Certified Global 18% Protein Rodent Diet, 2018C, in pellet form (Harlan Teklad, 

Madison, WI), ad libitum. It was stated that the genistein-equivalent content of the diet 

was ≤300 μg/g.

Water: Deionized water without chlorine supplementation (made on-site), ad libitum.

Environmental 

Conditions:

Temperature:

Humidity:

Air changes:

Photoperiod:

22.1-25.0°C

44-52%

Not provided

14 h light / 10 h dark

B. STUDY DESIGN

1. In-Life Dates: Start: May 1, 2012 End: May 21, 2012 

2. Mating: Time-mated pregnant dams were received from the supplier on gestation day 

(GD) 8. The day evidence of mating was observed was designated as GD 0. Litters with 

fewer than 9 pups were excluded from the study; litters with 10 pups but less than four of a 

sex were retained. Litters with more than 10 pups were standardized by culling on PND 4 to 

5 pups/sex/litter where possible; culling to 6 males and 4 females or 4 males and 6 females 

was also acceptable. 

NH2

Cl Cl

Cl Cl

Cl

Page 161 of 207
Female Pubertal Assay (2012) / Page 4 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

3. Animal Assignment: Offspring were weaned on PND 21, weighed, and ranked by body 

weight. The 5 heaviest and 5 lightest female pups were then eliminated from use. The 

remaining females were then assigned to the groups noted in Table 1 starting with the 

heaviest females by assigning to the groups sequentially (Groups 1, 2 and 3) until each 

group contained 15 females. It was not stated if placing littermates in the same group was 

avoided. 

TABLE 1. Study Designa

Test group Dose (mg/kg/day) # of Females

Control 0 15

Low 500 15

High 1000 15

a Data were obtained from Text Table 2.3-1 on page 17 of the study report (MRID 49042103). 

4. Dose Selection Rationale: It was stated that the dose levels used in the present study were 

selected based on the results of four previously performed studies. In a developmental 

toxicity study, pregnant females were dosed with PCNB (10 mL/kg) at 0, 250, 750, or 

1500 mg/kg/day during GD 6-15. No clinical signs were noted up to 1500 mg/kg/day; 

however decreased body weight gains and food consumption were noted during GD 6-9 at 

750 and 1500 mg/kg/day. Food consumption rebounded post-dosing (GD 15-20) at 

1500 mg/kg/day. In a 2-year rat oncogenicity study, males and females were dosed with 0, 

5, 50, 500, or 1000 mg/kg/day. Body weights were decreased in the 1000 mg/kg/day males 

and in the 500 and 1000 mg/kg/day females. In a 2-generation reproduction toxicity study, 

rats were dosed with 0, 10, 100, or 1000 mg/kg/day from 10 weeks prior to mating in the P 

generation through weaning of the F2 generation. No clinical effects were observed. 

Therefore, doses of 0, 500, and 1000 mg/kg/day were chosen for a non-GLP dose 

range-finding pubertal study that also assessed the tolerability of a lower dose volume 

(5 mL/kg) compared to what was previously used (10 mL/kg). The dose levels and dose 

volume were acceptably tolerated. 

5. Dose Preparation and Analysis: Dose formulations were prepared every 3-4 days, and 

were stored at room temperature protected from light. An appropriate amount of the test 

substance (not adjusted for purity) was ground with a mortar and pestle into a fine powder 

and mixed with a small volume of the vehicle to form a paste. The paste was brought up to 

final volume with additional vehicle, homogenized, and stirred to yield a uniform 

suspension. Stirring was continuous during sampling and aliquoting. Homogeneity (top, 

middle, and bottom) and stability analyses were performed prior to study initiation on 

samples of the same concentrations used in the present study. Stability was determined after

storage for up to 15 days at both ambient and refrigerated temperatures. Concentration 

analyses were performed on all dose levels from the first preparation (administered on Days 

1-4).

Results of Dose Analysis

Homogeneity (%CV): 0.57-4.01% 

Stability (% of time 0): 97.1-97.7% 

Page 162 of 207
Female Pubertal Assay (2012) / Page 5 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

Concentration (% of nominal): 88.1-99.5% 

The analytical data indicated that the mixing procedure was adequate and that the variation 

between nominal and actual dosage to the animals was acceptable. Concentration analysis 

for the Week 1 (Days 1-4) 500 mg/kg/day formulation was 88.1% of nominal, which is 

outside the protocol-specified acceptance criteria of ±10%. However, this slight deviation 

did not affect the study results. 

6. Dosage Administration: All doses were administered once daily by gavage, from PND 22 

through PND 42, in a dose volume of 5 mL/kg. Individual doses were based on the most 

recently recorded body weights. Dosing was performed between 0700 and 0900 hours 

daily.

7. Statistics: The following parameters were subjected to statistical analysis: body weights, 

body weight gains, food consumption, age and body weight at attainment of VO, clinical 

chemistry, hormone levels, organ weights, estrus stage, and histopathology. For continuous 

parameters, Bartlett's test for variance homogeneity was applied. If Bartlett's test was not 

significant at the 1% level, parametric methods were applied, using an F1 approximate test 

for monotonicity. If the F1 test was not significant at the 1% level, Williams' test for a 

monotonic trend was applied. If the F1 test was significant, suggesting that the doseresponse was not monotonic, Dunnett's test was performed instead. If Bartlett's test was 

significant at the 1% level, logarithmic and square root transformations were tried. If

Bartlett's test was still significant, non-parametric methods were applied to mean ranks, with

an H1 approximate test for monotonicity. If the H1 was not significant at the 1% level, 

Shirley's test for a monotonic trend was applied. If the H1 test was significant, Steel's test 

was performed instead. For discrete parameters involving more than two groups, the 

Jonckheere-Terpstra test was applied. If the Jonckheere-Terpstra test was significant at the

5% level, the direction of the trend was established and one-tailed step-down testing in this 

direction was performed. If the Jonckheere-Terpstra test was not significant at the 5% level, 

the Kruskal-Wallis test was applied. If the Kruskal-Wallis test was significant at the 5% 

level, the treated groups were compared to the control using exact Wilcoxon rank sum tests; 

otherwise, no further comparisons were made. For binary parameters involving more than 

two groups, the Cochran-Armitage test was applied. If the Cochran-Armitage test was 

significant at the 5% level, the direction of the trend was established and one-tailed stepdown testing in this direction was performed. If the Cochran- Armitage test was not 

significant at the 5% level, the χ2 test (Armitage et al 2002) was applied. If the χ2 test was 

significant at the 5% level, the test-article treated groups were compared to the control with

Fisher's Exact tests, otherwise, no further comparisons were made.

VO (day of VO and bodyweight) and organ weight data were also analyzed as follows. 

Bartlett's test was applied; if this test was not significant at the 1% level, parametric analysis 

was applied. The bodyweight at PND 21 was used as a covariate in the analyses and 

comparisons were performed on the adjusted means after the analysis of covariance. The F1 

approximate test was applied; if the F1 test was not significant at the 1% level, Williams' 

test for a monotonic trend was applied, otherwise Dunnett's test was performed instead. If 

Bartlett's test was significant at the 1% level, logarithmic and square root transformations 

were tried. If Bartlett's test was still significant, non-parametric tests were applied. The H1 

Page 163 of 207
Female Pubertal Assay (2012) / Page 6 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

approximate test was applied; if the H1 test was not significant at the 1% level, Shirley's test 

was applied, otherwise Steel's test was performed instead. 

For histopathology, test-article treated groups were compared to the control with Fisher's 

Exact tests. 

Statistical significance was declared at the 5%, 1% and 0.1% levels. The statistical analyses 

were considered appropriate.

C. METHODS

1. Mortality and Clinical Examinations: All animals were observed twice daily for 

mortality and moribundity beginning on PND 21 and continuing throughout the study. 

Individual clinical examinations were conducted daily prior to dosing through the day of 

euthanasia. 

2. Body Weight: Animals were weighed at randomization, daily prior to dosing, and on the 

day of euthanasia. Mean body weight gains were calculated for each weighing interval, and 

for PND 22-42. 

3. Food Consumption: Food consumption (g/rat/day) was measured by placing a weighed 

feeder in each cage, reweighing it after 2-4 days, and dividing by the number of rats/cage. 

Food consumption was reported for PND 22-25, 25-29, 29-32, 32-36, 36-39, and 39-42. 

4. Vaginal Opening (VO): Each female was observed daily after dosing for vaginal 

perforation beginning on PND 22. The age and body weight on the day at which the vaginal 

lumen was first observed to open was recorded for each animal.

5. Estrous Cyclicity: Beginning on the day of VO, up to and including the day of necropsy, 

daily vaginal smears were obtained. The vaginal smears were classified as proestrus, estrus, 

metestrus, or diestrus, and estrus stage at euthanasia was reported. The age at first vaginal 

estrus was recorded, and the average cycle length was calculated and reported for complete 

cycles. Additionally, the percentage of females cycling and regularly cycling was calculated 

and reported. 

6. Sacrifice and Pathology: All animals were euthanized by exsanguination on PND 42 at 

least two hours post-dosing. All terminal procedures were completed by 1300 hours. 

Unfasted animals were anesthetized with isoflurane and blood was collected from the aorta. 

The blood was allowed to clot for at least 30 minutes and centrifuged to obtain serum. 

Samples were stored at <−20°C (as required) for subsequent hormone and clinical chemistry

evaluations. 

a. Hormone Analysis: Serum T4 concentrations were determined with a radioimmunoassay. 

Serum TSH levels were determined by an external laboratory (AniLytics, Inc., Gathersburg, 

MD); the method used was not reported. 

b. Clinical Chemistry: The following CHECKED (X) parameters were examined.

Page 164 of 207
Female Pubertal Assay (2012) / Page 7 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

ELECTROLYTES OTHER

Calcium X Albumin

Chloride X Creatinine*

Magnesium X Urea nitrogen*

Phosphorus Total cholesterol

Potassium X Globulins

Sodium Glucose

ENZYMES X Total bilirubin

X Alkaline phosphatase (ALP) X Total protein

Cholinesterase (ChE) Triglycerides

Creatine phosphokinase X Albumin/globulin ratio

Lactic acid dehydrogenase (LDH)

X Alanine aminotransferase (ALT/also SGPT)

X Aspartate aminotransferase (AST/also SGOT)

Sorbitol dehydrogenase (SDH)

Gamma glutamyl transferase (GGT)

Glutamate dehydrogenase

* Recommended for the pubertal assay in female rats based on Guideline 890.1450.

c. Organ Weights and Histopathology: The following CHECKED (X) tissues were 

collected and weighed. The (XX) organs, in addition, were subjected to histological 

examination. 

UROGENITAL OTHER

XX Ovaries (paired, without oviducts)*+ XX Thyroid*+

XX Uterus*+ XX Liver*

XX Kidneys (paired)*+ X Adrenals (paired)*

X Pituitary*

* Weights required based on Guideline 890.1450

+ Histopathological examination required based on Guideline 890.1450

Complete macroscopic examinations were performed on all animals. All organs collected 

except the thyroid/trachea were weighed prior to fixation. Paired organs (kidneys, adrenals, 

and ovaries) were weighed together. The uterus and cervix were separated from the vagina 

and weighed. The uterus was weighed again following removal of the fluid in the lumen 

(blotted weight). 

Kidneys were fixed in 10% neutral buffered formalin for no more than 24 hours; the left 

kidney was retained in 10% neutral buffered formalin, the right kidney was rinsed and 

stored in 70% ethanol. All other tissues were fixed in 10% neutral buffered formalin for no 

more than 24 hours, then rinsed and stored in 70% ethanol. After fixation, the thyroid was

dissected from the trachea. The thyroid, kidneys, liver, ovaries, and uterus were routinely 

processed, sectioned, stained with hematoxylin and eosin, and examined microscopically. 

Thyroid/parathyroid glands were subjectively graded based on the ratio of follicular 

epithelial cell height to colloid area using a five point grading scale, with 1 = shortest 

epithelium with the most abundant colloid, and 5 = tallest epithelium with the least abundant 

colloid. A minimum of two sections of each of the two lobes of the thyroid/parathyroid 

were evaluated. Evaluation of the ovaries included a qualitative evaluation of follicular 

development. Five sections, taken at least 100 μm apart from the middle third of the ovary, 

Page 165 of 207
Female Pubertal Assay (2012) / Page 8 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

were evaluated. The ovarian sections were examined for presence or absence of

antral/tertiary follicles, presence or absence of corpora lutea, changes in corpus luteum 

development and a qualitative evaluation of numbers of atretic follicles. In addition, a count 

of primordial and primary follicles (follicles with intact oocytes surrounded by a single layer 

of granulosa cells) was performed. The uterus was evaluated for uterine hyper- or 

hypotrophy, as characterized by changes in uterine horn diameter, as well as myometrial, 

stroma, or endometrial gland development. The stage of the estrous cycle of the female at 

the time of necropsy was considered in the final pathology assessment due to the 

dependence of ovarian and uterine cellular changes on endocrine status. The left kidney was 

evaluated by means of standard histopathology. 

II. RESULTS

A. MORTALITY: There was no treatment-related mortality. One 1000 mg/kg/day rat was 

euthanized on PND 25 when it was discovered to be a male rather than a female. All data 

for this animal were removed from calculations and analyses. 

B. CLINICAL SIGNS OF TOXICITY: No treatment-related clinical signs of toxicity were 

observed during the daily examinations. The only finding noted was moderate general 

dermal alopecia of the torso in one 500 mg/kg/day female (#2588) on PND 36-39. 

C. GENERAL GROWTH, VAGINAL OPENING, AND FOOD CONSUMPTION: Body 

weights, body weight gains, and age and body weight at attainment of VO are presented in 

Table 2. There were no effects of treatment on body weights, body weight gains, or age and 

body weight at attainment of VO. All females achieved complete VO.

During PND 22-25, food consumption was decreased (NS) by 37% at 500 mg/kg/day and 

by 39% (p<0.05) at 1000 mg/kg/day. However, food consumption rebounded and was 

similar to controls for the remainder of the study.

The means and %CV for age and body weight at VO and final body weight in the control 

group were within the recommended range of the performance criteria provided in the 

Guideline (890.1450). 

Page 166 of 207
Female Pubertal Assay (2012) / Page 9 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

TABLE 2. General Growth and Vaginal Opening (VO)a

Parameter Evaluated

Vehicle Control 500 mg/kg/day 1000 mg/kg/day

N Mean SD

CV 

(%) N Mean SD

CV 

(%) N Mean SD

CV 

(%)

Initial body weight

(PND 22; g)

U 15 54.6 2.96 5.42 15 54.8 2.04 3.72 14 54.5 1.78 3.27

A NA NA NA

Body weight at vaginal 

opening (g)

U 15 116.4 13.3 11.43 15 119.6 11.6 9.70 14 120.0 9.6 8.00

A 116.6 119.5 119.9

Final body weight

(g)

U 15 164.0 8.97 5.47 15 167.6 8.82 5.26 14 164.4 7.61 4.63

A 164.2 167.5 164.3

Final body weight 

(% of control)

U NA 102.2 100.2

A NA NA NA

Body weight gain

(final – initial; g)

U 15 109.4 7.66 7.00 15 112.8 8.85 7.85 14 110.0 6.73 6.12

A NA NA NA

Age at vaginal opening 

(PND)

U 15 33.6 1.7 5.06 15 33.5 1.4 4.18 14 34.2 1.3 3.80

A 33.6 33.5 34.2

Proportion unopened (#/N) 0/15 0/15 0/14

a Data were obtained from Table 2 on pages 68-69, Table 3 on page 74, Table 5 on page 78, and Table 9 on page 91 of the 

study report (MRID 49042103). CV(%) values were calculated by the reviewers. 

U Unadjusted for body weight on PND 21

A Adjusted for body weight on PND 21

N Number of animals examined

SD Standard Deviation

CV Coefficient of Variation

NA Not applicable

D. ORGAN WEIGHTS: Organ weights at necropsy are presented in Table 3. Absolute, 

adjusted, and relative (to body) liver weights were increased (p<0.05) at 500 (↑6-8%) and 

1000 (↑6%) mg/kg/day, and absolute, adjusted and relative kidney weights were increased 

(p<0.01) at 500 (↑6-8%) and 1000 (↑8%) mg/kg/day. All other organ weights were similar 

to the controls. 

The means and %CV of unadjusted values for all organ weights in the control group were 

within the recommended range of the performance criteria provided in the Guideline 

(890.1450). 

Page 167 of 207
Female Pubertal Assay (2012) / Page 10 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

TABLE 3. Organ Weights at Necropsya

Organ

Vehicle Control 500 mg/kg/day 1000 mg/kg/day

N Mean SD

CV 

(%) N Mean SD

CV 

(%) N Mean SD

CV 

(%)

Liver

(g) U 15 7.12 0.456 6.40 15 7.71*(↑8) 0.759 9.84 14 7.58*(↑6) 0.618 8.15

A 7.13 7.71*

(↑8)

7.57*

(↑6)

R 15 4.343 0.180 4.14 15 4.595*

(↑6) 0.318 6.92 14 4.605**(↑6) 0.258 5.60

Kidneys

(g) U 15 1.36 0.092 6.76 15 1.47**(↑8) 0.122 8.30 14 1.48**(↑8) 0.103 6.96

A 1.36 1.47**

(↑8)

1.48**

(↑8)

R 15 0.830 0.039 5.53 15 0.876**

(↑6) 0.0559 6.35 14 0.898***(↑8) 0.0427 4.76

Pituitary

(mg)

U 15 8.3 1.30 15.66 15 8.5 1.27 14.94 14 7.7 1.46 18.96

A 8.4 8.5 7.7

R 15 0.0051 0.0008 15.69 15 0.0051 0.0008 15.69 14 0.0047 0.0008 17.02

Adrenals

(mg)

U 15 39.6 6.75 17.05 15 44.1 4.93 11.18 14 40.2 5.54 13.78

A 39.6 44.1 40.2

R 15 0.0243 0.0047 19.34 15 0.0263 0.0027 10.27 14 0.0244 0.0030 12.30

Ovaries

(mg)

U 15 59.6 9.17 15.39 15 63.8 8.76 13.73 14 63.7 7.36 11.55

A 59.7 63.8 63.7

Uterus, wet

(mg)

U 15 397.2 184.41 46.43 15 392.8 155.64 39.62 14 413.0 192.56 46.62

A 401.6 391.2 410.0

Uterus, blotted

(mg)

U 15 328.0 93.35 28.46 15 351.9 70.35 19.99 14 338.0 94.76 28.04

A 329.6 351.3 336.8

Thyroid, fixed

(mg)

U 15 16.3 2.69 16.50 15 15.1 2.10 13.91 14 15.4 1.09 7.08

A 16.2 15.0 15.4

a Data were obtained from Table 9 on page 91-93 of the study report (MRID 49042103). Percent differences from controls, 

calculated by the reviewers, are included in parentheses. CV(%) values were calculated by the reviewers. 

U Unadjusted for body weight on PND 21

A Adjusted for body weight on PND 21

N Number of animals examined

SD Standard Deviation

CV Coefficient of Variation

R Organ-to-body weight ratio (relative to body weight)

* Significantly different from control; p<0.05

** Significantly different from control; p<0.01

*** Significantly different from control; p<0.001

E. ESTROUS CYCLICITY: Estrous cycle data are provided in Table 4. There were no

effects of treatment on mean age at first vaginal estrus, mean cycle length, % cycling or 

regularly cycling, or cycle status at necropsy.

Page 168 of 207
Female Pubertal Assay (2012) / Page 11 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

TABLE 4. Estrous Cyclicitya

Treatment 

Groups N

Mean Age at 

First Vaginal 

Estrus (PND)

Mean Cycle 

Length 

(days)

Cycling 

(%)

Regularly 

Cycling 

(%)

Cycle Status at Necropsy (# Females)

Diestrus Proestrus Estrus Metestrus

Vehicle Control 15 34.5±1.73 4.0±0.79 100 60.0 6 7 1 1

500 mg/kg/day 15 34.8±1.57 4.3±0.61 100 73.3 4 2 3 6

1000 mg/kg/day 14 35.0±1.30 4.5±0.99 100 71.4 4 4 1 4

a Data were obtained from Table 6 on page 79 and Table 10 on page 101 of the study report (MRID 49042103). 

N Number of animals

NP Not provided

F. CLINICAL CHEMISTRY AND HORMONE LEVELS: Mean hormone and clinical 

chemistry levels are presented in Table 5. Serum T4 levels were decreased (p<0.001) by 

70% at 500 mg/kg/day and by 72% at 1000 mg/kg/day. Concomitantly, serum TSH levels 

were increased (p<0.001) by 53% at 500 mg/kg/day and by 59% at 1000 mg/kg/day. The 

following dose-dependent changes in clinical chemistry parameters were observed at 500 

and 1000 mg/kg/day, respectively: ALP activity was increased (p<0.05) by 20 and 26%; 

ALT activity was decreased (p<0.001) by 42 and 51%; total bilirubin was increased 

(p<0.01) by 44 and 56%; and urea nitrogen was increased (p<0.05) by 8 and 15%. 

Additionally at 1000 mg/kg/day, albumin was decreased (p<0.05) by 3% and total protein 

was decreased (p<0.01) by 4%. 

The mean and %CV for serum T4 in the control group were within the recommended range 

of the performance criteria provided in the Guideline (890.1450). 

Page 169 of 207
Female Pubertal Assay (2012) / Page 12 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

TABLE 5. Hormone Levels and Clinical Chemistrya

Parameter

Evaluated

Vehicle Control 500 mg/kg/day 1000 mg/kg/day

N Mean SD CV (%) N Mean SD CV (%) N Mean SD CV (%)

Hormones

Serum T4, Total

(μg/dL)

15 4.16 1.076 25.87 14b 1.25***

(↓70)

0.282 22.56 13 b 1.15***

(↓72)

0.280 24.35

Serum TSH

(ng/mL)

15 1.35 0.386 28.59 15 2.07***

(↑53)

0.355 17.15 14 2.15***

(↑59)

0.898 41.77

Clinical Chemistry

A/G Ratio 15 1.9 0.09 4.74 15 1.9 0.09 4.74 14 1.9 0.12 6.32

Albumin (g/dL) 15 3.6 0.08 2.22 15 3.6 0.09 2.50 14 3.5*

(↓3)

0.10 2.86

ALP (U/L) 15 249 74.0 29.72 15 300*

(↑20)

56.2 18.73 14 313**

(↑26)

31.3 10.00

ALT (U/L) 15 53 7.6 14.34 15 31***

(↓42)

5.4 17.42 14 26***

(↓51)

2.0 7.69

AST (U/L) 15 130 21.3 16.38 15 133 14.0 10.53 14 129 17.4 13.49

Creatinine (mg/dL) 15 0.1 0.04 40.00 15 0.1 0.05 50.00 14 0.1 0.05 50.00

Globulin (g/dL) 15 1.9 0.06 3.16 15 1.9 0.09 4.74 14 1.8 0.08 4.44

Total Bili (mg/dL) 15 0.09 0.033 36.67 15 0.13**

(↑44)

0.033 25.38 14 0.14***

(↑56)

0.020 14.29

Total Protein (g/dL) 15 5.5 0.10 1.82 15 5.4 0.14 2.59 14 5.3**

(↓4)

0.14 2.64

Urea Nitrogen (mg/dL) 15 13 0.9 6.92 15 14*

(↑8)

1.9 13.57 14 15**

(↑15)

1.2 8.00

a Data were obtained from Table 7 on page 82 and Table 8 on page 85 of the study report (MRID 49042103). Percent 

differences from controls, calculated by the reviewers, are included in parentheses. CV(%) values were calculated by the 

reviewers. 

b One animal each in the 500 and 1000 mg/kg/day groups had serum T4 levels below the method LOD (0.82 μg/dL); 

therefore, the T4 levels for these animals were not used in calculation of the mean or SD.

N Number of animals examined

SD Standard Deviation

CV Coefficient of Variation

* Significantly different from control; p<0.05

** Significantly different from control; p<0.01

*** Significantly different from control; p<0.001

G. MACROSCOPIC EXAMINATIONS: There were no gross findings reported at necropsy. 

H. HISTOPATHOLOGY: The incidences of histopathological findings of the thyroid gland 

are presented in Table 6. No significant differences were observed in the ratio of follicular 

cell height or colloid area between the controls and treatment groups. However, there was a 

slight, dose-related trend toward decreased colloid area and increase follicular cell height.

Page 170 of 207
Female Pubertal Assay (2012) / Page 13 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

TABLE 6. Incidence of Histopathological 

Lesions of the Thyroid Glanda

Treatment Groups

Parameter Evaluated

Follicular Cell Height to 

Colloidal Area Score

Gradeb Incidence

Vehicle Control

1 0

2 6

3 9

4 0

5 0

500 mg/kg/day

1 0

2 5

3 10

4 0

5 0

1000 mg/kg/day

1 0

2 3

3 11

4 0

5 0

a Data were obtained from Table 11 on page 102 of the study report

(MRID 49042103). 

b Thyroid histopathology is graded 1-5, with 1 = shortest epithelium 

with the most abundant colloid, and 5 = tallest epithelium with the 

least abundant colloid. 

The incidence of histopathological findings of the kidney, liver, and uterus are presented in 

Table 7. There were no treatment-related microscopic findings. Minimal basophilic 

tubules, cyst, and mononuclear inflammatory cell infiltrate were observed in the kidneys, 

but occurred in a non-dose-dependent fashion. Minimal increased inflammatory foci with or 

without single cell necrosis was noted in the liver in only 1-2 animals/dose group. Antral 

and tertiary follicles, corpora lutea, and atretic follicles were present in the ovary of all 

individuals, and the numbers of primordial and primary follicles showed no 

biologically-relevant differences across groups. The number of 1000 mg/kg/day females 

classified in metestrus by examination of the uterus (with cervix) was increased (6 treated 

vs. 1 control; p<0.05).

Page 171 of 207
Female Pubertal Assay (2012) / Page 14 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

TABLE 7. Incidence of Histopathological Lesions of the Ovaries, Uterus and Kidneya

Findings

Dose Level

Vehicle Control 500 mg/kg/day 1000 mg/kg/day

Number examined 15 15 14

Kidney (left)

Basophilic tubules Minimal 6 6 4

Cyst Minimal 1 0 0

Mononuclear inflammatory cell infiltrate Minimal 0 1 0

Liver

Increased inflammatory foci with/without Minimal

single cell necrosis 1 1 2 

Uterus (w/cervix)

Proestrus 6 1 2

Estrus 3 8 2

Metestrus 1 4 6*

Diestrus 5 2 4

a Data were obtained from Table 11 on pages 101-105 of the study report (MRID 49042103). 

* Significantly different from control; p<0.05

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATORS’ CONCLUSIONS: PCNB was tested in a female pubertal study at 

doses up to and including the limit dose (1000 mg/kg/day). There were no test articlerelated effects on clinical signs, body weights, or feed consumption. The most consistent 

organ weight changes were statistically-significant, marginal increases in absolute and 

relative liver weights in both sexes at 500 and 1000 mg/kg/day, with no correlative 

histopathology. The liver weight increases correlate with significantly decreased ALT

activity at >500 mg/kg/day, and represent systemic hepatic effects from PCNB exposure. 

The liver weight increases are considered to signify mixed-function oxidase induction as has 

been reported previously. Liver weight increases and decreased ALT have been reported in 

previous PCNB chronic toxicity studies. Additionally, decreased ALT activity has been 

reported in some cases to be associated with increased Cyp(p450) enzyme induction, which 

is a potential mechanism for the decreases in circulating T4 (through enhancing excretion) 

observed in the current study. Overall, these findings do appear exposure-related and 

suggest a possible indirect thyroid pathway interaction mediated by hepatic enzyme 

induction. 

B. AGENCY COMMENTS: There was no treatment-related mortality, and no treatmentrelated clinical signs of toxicity were observed during the daily examinations. There were 

no effects of treatment on body weights or body weight gains. There were no gross findings 

reported at necropsy. During PND 22-25, food consumption was decreased (NS) by 37% at 

500 mg/kg/day and by 39% (p<0.05) at 1000 mg/kg/day. However, food consumption 

rebounded and was similar to controls for the remainder of the study. 

Compared to the control group, absolute, adjusted, and relative (to body) liver weights were 

increased (p<0.05) by 6-8% and 6% at 500 and 1000 mg/kg/day, respectively, and absolute, 

adjusted and relative kidney weights were increased (p<0.01) by 6-8% and 8% at 500 and 

1000 mg/kg/day. The following dose-dependent changes in clinical chemistry parameters 

were observed at 500 and 1000 mg/kg/day, respectively: ALP activity was increased 

(p<0.05) by 20 and 26%; ALT activity was decreased (p<0.001) by 42 and 51%; total 

Page 172 of 207
Female Pubertal Assay (2012) / Page 15 of 15

PCNB / 056502 OCSPP 890.1450/ OECD None

bilirubin was increased (p<0.01) by 44 and 56%; and urea nitrogen was increased (p<0.05) 

by 8 and 15%. Additionally at 1000 mg/kg/day, albumin was decreased (p<0.05) by 3% and 

total protein was decreased (p<0.01) by 4%. 

The means and %CV of final body weight and unadjusted values for all organ weights in the 

control group were within the recommended range of the performance criteria provided in 

the Guideline (890.1450). 

There were no effects of treatment on age and body weight at attainment of VO. All 

females achieved complete VO. There were no effects of treatment on mean age at first 

vaginal estrus, mean cycle length, % cycling or regularly cycling, or cycle status at 

necropsy. Antral and tertiary follicles, corpora lutea, and atretic follicles were present in the 

ovary of all individuals, and the numbers of primordial and primary follicles showed no 

biologically relevant differences across groups. The number of 1000 mg/kg/day females 

classified in metestrus by examination of the uterus (with cervix) was increased (6 treated 

vs. 1 control; p<0.05); however, the biological significance of this finding is unclear.

The means and %CV for age and body weight at VO in the control group were within the 

recommended range of the performance criteria provided in the Guideline (890.1450). 

Serum T4 levels were decreased (p<0.001) by 70% at 500 mg/kg/day and by 72% at 1000 

mg/kg/day. Concomitantly, serum TSH levels were increased (p<0.001) by 53% at 500 

mg/kg/day and by 59% at 1000 mg/kg/day. However, no significant differences were 

observed in the ratio of follicular cell height to colloid area between the control and 

treatment groups. However, there was a slight, dose-related trend toward decreased colloid 

area and increase follicular cell height. The changes in serum T4 and TSH concentrations, 

combined with modest increases in liver weight and a trend in thyroid histopathology may 

be related to hepatic enzyme induction, but the data are not definitive for this effect.

The mean and %CV for serum T4 in the control group were within the recommended range 

of the performance criteria provided in the Guideline (890.1450). 

The high dose tested (1000 mg/kg/day) was the Limit Dose; effects observed included 

ncreased liver and kidney weights, changes in clinical chemistry parameters, and effects on 

serum T4 and TSH levels.

C. STUDY DEFICIENCIES: None 

Page 173 of 207
DATA EVALUATION RECORD

PCNB

Study Type: OCSPP 890.1500, Male Pubertal Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-45-2013 (MRID 49042103) 

Prepared for

Health Effects Division

Office of Pesticide Programs

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by

CSS-Dynamac Corporation

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Michael E. Viana, Ph.D., D.A.B.T. Date: 04/01/2013

Secondary Reviewer: Signature:

Scott Studenberg, Ph.D., D.A.B.T. Date: 04/4/2013

Program Manager: Signature:

Jack D. Early, M.S. Date: 04/10/2013

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 04/10/2013

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 174 of 207
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 175 of 207
PCNB I 056502 

Male Pubertal Assay (2012) I Page 1 of JS 

OCSPP 890.1500/ OECD None 

Primary Reviewer: ..... N ..... an==c,,,_y-=--=-c"""'C"'"'arr~o'"""'ll'--_ _ _ ____ Signature: -------+---..---.----

RAB VI, Health Effects Division Date: __,,~~~~r:;:;:;.~ 

Secondary Reviewer: John Liccione. Ph.D. Signature: _)~~::!::;::;e~=-

HeaJth Effects Division Date: --=-&ff-G-1-~~-

DATA EVALUATION RECORD 

STUDY TYPE: Male Pubertal Assay; OCSPP 890.1500; OECD None. 

PC CODE: 056502 DP BARCODE: D409239 

TXR#: 0056474 CAS No: 82-68-8 

TEST MATERIAL (PURITY): PCNB Technical (95.6% a.i.; Lot# 107030L052) 

SYNONYMS: 1,2,3,4,5-pentachloro-6-nitrobenzene; Quintozene 

CITATION: Baxter, G.E. (2012) PCNB: Assessment of Pubertal Development and 

Thyroid Function in Juvenile Male and Female Rats. Huntingdon Life 

Sciences, East Millstone, NJ. Laboratory Study No.: 12-4389, December 19, 

2012. MRID 49042103. Unpublished. 

SPONSOR: AMV AC Chemical Corporation, 211 0 Davie Avenue, Commerce, CA 

TEST ORDER#: EDSP-056502-105 

EXECUTIVE SUMMARY: In a Male Pubertal Assay (MRlD 49042103), 15 Sprague Dawley 

[Crl:CD® (SD) IGS BR] rats/dose group were treated daily via oral gavage with PCNB (95.6% 

a.i.; Lot # 107030L052) in aqueous 1% sodium carboxymethyl cellulose at doses ofO (vehicle), 

500, or 1000 (limit dose) mg/kg/day from post-natal day (PND) 23 to 53. Animals were 

examined for preputial separation (PPS) daily beginning on PND 30, and age and weight at day 

of attainment were recorded. Following sacrifice on PND 53, blood was collected for clinical 

chemistry and hormone analyses. Total thyroxine (T4) and testosterone serum levels were 

determined by radioimmunoassay, but the method used for determination of thyroid stimulating 

hormone (TSH) levels was not reported. Adrenal, liver, pituitary, thyroid, and urogenital organs 

were weighed, and microscopic examinations were performed on the epididymis, testis, thyroid, 

liver, and kidneys. 

There were no treatment-related effects on mortality, clinical signs of toxicity, body weights or 

body weight gains, food consumption, or gross pathology. Compared to the control, absolute, 

adjusted, and relative (to body) liver weights were increased (p<0.05) by 8-10% at 500 

mg/kg/day and by 10-11 % at 1000 mg/kg/day, and relative kidney weights were increased 

(p<0.05) by 8 and 6% at 500 and 1000 mg/kg/day, respectively. Alanine aminotransferase 

(ALT) was decreased (p<0.001) by 38% at 500 mg/kg/day and by 52% at 1000 mg/kg/day and 

total bilirubin was increased (p<0.001) by 100% at 500 and 1000 mg/kg/day. Additionally at 

1000 mg/kg/day, alkaline phosphatase (ALP) was increased (p<0.05) by 15%. Minimal 

Page 176 of 207
Male Pubertal Assay (2012) / Page 2 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

increased inflammatory foci with/without single cell necrosis was observed in livers of 5/15 

males at 1000 mg/kg/day (NS) compared to 2/15 controls. 

There were no effects of treatment on age and body weight at attainment of PPS. All males 

achieved complete PPS, and serum testosterone levels were unaffected by treatment. There were 

also no treatment-related changes in weights or microscopic findings for the male reproductive 

tissues.

Compared to the controls, serum T4 levels were decreased (p<0.001) by ≥78% at 500 and 1000 

mg/kg/day, with T4 levels being below the method limit of detection (<LOD, 0.82μg/dL) in 6/15 

males at 500 mg/kg/day and 12/15 males at 1000 mg/kg/day. Concomitantly, serum TSH levels 

were increased (not significant [NS]) by 39 and 25% at 500 and 1000 mg/kg/day, respectively. 

However, no treatment-related changes were noted in thyroid histology. 

The high dose (1000 mg/kg/day) was adequate based on increased liver and kidney weights, and 

changes in clinical chemistry parameters in the study, and considering that 1000 mg/kg/day is the 

limit dose for the assay. 

The assay satisfies the EDSP Tier 1 Test Order requirements for a Male Pubertal Assay (OCSPP 

890.1500).

COMPLIANCE: Signed and dated Data Confidentiality, GLP Compliance, and Quality 

Assurance statements were provided.

Page 177 of 207
Male Pubertal Assay (2012) / Page 3 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Huntingdon Life Sciences

Location: East Millstone, NJ

Study Director: G.E. Baxter

Other Personnel: C. Willard-Mack (Pathologist), Y. Wang (Dose Formulation analysis), L. Ramaih 

(Clinical Pathologist), S. Polivy (TSH Hormone analysis), G. Thomas (Statistics)

Study Period: March 30, 2012 to December 19, 2012

2. Test Substance: PCNB Technical

Description: Off-white to dark tan crystalline solid or powder

Source: AMVAC Chemical Corporation (Los Angeles, CA)

Lot #: 107030L052 (Expiration July 2016)

Purity: 95.6% a.i.

Stability: 15 days under refrigerated (2-8 ̊C) or room temperature conditions

CAS #: 82-68-8

Structure:

3. Vehicle: 1% Aqueous carboxymethyl cellulose (sodium)

4. Test Animals:

Species: Rat

Strain: Sprague Dawley [Crl:CD®(SD)IGS BR]

Age/Weight at Allocation: PND 21 / 48.7-57.4 g

Source: Charles River Laboratories (Portage, MI)

Housing: Adult males were individually housed in plastic shoebox cages with aspen bedding. 

Selected pups were housed in the same type cage with up to 3/pups/sex/cage.

Diet: Certified Global 18% Protein Rodent Diet, 2018C, in pellet form (Harlan Teklad, 

Madison, WI), ad libitum. It was stated that the genistein-equivalent content of the diet 

was ≤300 μg/g.

Water: Deionized water without chlorine supplementation (made on-site), ad libitum.

Environmental 

Conditions:

Temperature:

Humidity:

Air changes:

Photoperiod:

22.1-25.0°C

44-52%

Not provided

14 h light / 10 h dark

B. STUDY DESIGN

1. In-Life Dates: Start: May 2, 2012 End: June 1, 2012 

2. Mating: Time-mated pregnant dams were received from the supplier on gestation day 

(GD) 8. The day evidence of mating was observed was designated as GD 0. Litters with 

fewer than 10 pups were excluded from the study; litters with 10 pups but less than four of a 

sex were retained. Litters with more than 10 pups were standardized by culling on PND 4 to 

5 pups/sex/litter where possible; culling to 6 males and 4 females or 4 males and 6 females 

was also acceptable. 

NH2

Cl Cl

Cl Cl

Cl

Page 178 of 207
Male Pubertal Assay (2012) / Page 4 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

3. Animal Assignment: Offspring were weaned on PND 21, weighed, and ranked by body 

weight. The 5 heaviest and 5 lightest male pups were then eliminated from use. The 

remaining males were then assigned to the groups noted in Table 1 starting with the heaviest 

males by assigning to the groups sequentially (Groups 1, 2 and 3) until each group contained 

15 males. It was not stated if placing littermates in the same group was avoided. 

TABLE 1. Study Designa

Test group Dose (mg/kg/day) # of Males

Control 0 15

Low 500 15

High 1000 15

a Data were obtained from Text Table 2.3-1 on page 17 of the study report (MRID 49042103). 

4. Dose Selection Rationale: It was stated that the dose levels used in the present study were 

selected based on the results of four previously performed studies. In a developmental 

toxicity study, pregnant females were dosed with PCNB (10 mL/kg) at 0, 250, 750, or 

1500 mg/kg/day during GD 6-15. No clinical signs were noted up to 1500 mg/kg/day; 

however, decreased body weight gains and food consumption were noted during GD 6-9 at 

750 and 1500 mg/kg/day. Food consumption rebounded post-dosing (GD 15-20) at 

1500 mg/kg/day. In a 2-year rat oncogenicity study, males and females were dosed with 0, 

5, 50, 500, or 1000 mg/kg/day. Body weights were decreased in the 1000 mg/kg/day males 

and in the 500 and 1000 mg/kg/day females. In a 2-generation reproduction toxicity study, 

rats were dosed with 0, 10, 100, or 1000 mg/kg/day from 10 weeks prior to mating in the P 

generation through weaning of the F2 generation. No clinical effects were observed. 

Therefore, doses of 0, 500, and 1000 mg/kg/day were chosen for a non-GLP dose 

range-finding pubertal study that also assessed the tolerability of a lower dose volume 

(5 mL/kg) compared to what was previously used (10 mL/kg). The dose levels and dose 

volume were acceptably tolerated. The present GLP male pubertal study duplicated the 

conditions of the range-finding study. 

5. Dose Preparation and Analysis: Dose formulations were prepared every 3-4 days, and 

were stored at room temperature protected from light. An appropriate amount of the test 

substance (not adjusted for purity) was ground with a mortar and pestle into a fine powder 

and mixed with a small volume of the vehicle to form a paste. The paste was brought up to 

final volume with additional vehicle, homogenized, and stirred to yield a uniform 

suspension. Stirring was continuous during sampling and aliquoting. Homogeneity (top, 

middle, and bottom) and stability analyses were performed prior to study initiation on 

samples of the same concentrations used in the present study. Stability was determined after 

storage for up to 15 days at both ambient and refrigerated temperatures. Concentration 

analyses were performed on all dose levels from the first preparation (administered on Days 

1-4).

Results of Dose Analysis

Homogeneity (%CV): 0.57-4.01% 

Stability (% of time 0): 97.1-97.7% 

Page 179 of 207
Male Pubertal Assay (2012) / Page 5 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

Concentration (% of nominal): 88.1-95.5% 

The analytical data indicated that the mixing procedure was adequate and that the variation 

between nominal and actual dosage to the animals was acceptable. Concentration analysis 

for the Week 1 (Days 1-4) 500 mg/kg/day formulation was 88.1% of nominal, which is 

outside the protocol-specified acceptance criteria of ±10%. However, this slight deviation 

did not affect the study results. 

6. Dosage Administration: All doses were administered once daily by gavage, from PND 23 

through PND 53, in a dose volume of 5 mL/kg. Individual doses were based on the most 

recently recorded body weights. Dosing was performed between 0700 and 0900 hours 

daily.

7. Statistics: The following parameters were subjected to statistical analysis: body weights, 

body weight gains, food consumption, age and body weight at attainment of PPS, clinical 

chemistry, hormone levels, organ weights, and histopathology. For continuous parameters, 

Bartlett's test for variance homogeneity was applied. If Bartlett's test was not significant at 

the 1% level, parametric methods were applied, using an F1 approximate test for 

monotonicity. If the F1 test was not significant at the 1% level, Williams' test for a 

monotonic trend was applied. If the F1 test was significant, suggesting that the doseresponse was not monotonic, Dunnett's test was performed instead. If Bartlett's test was 

significant at the 1% level, logarithmic and square root transformations were tried. If

Bartlett's test was still significant, non-parametric methods were applied to mean ranks, with

an H1 approximate test for monotonicity. If the H1 was not significant at the 1% level, 

Shirley's test for a monotonic trend was applied. If the H1 test was significant, Steel's test 

was performed instead. For discrete parameters involving more than two groups, the 

Jonckheere-Terpstra test was applied. If the Jonckheere-Terpstra test was significant at the

5% level, the direction of the trend was established and one-tailed step-down testing in this 

direction was performed. If the Jonckheere-Terpstra test was not significant at the 5% level, 

the Kruskal-Wallis test was applied. If the Kruskal-Wallis test was significant at the 5% 

level, the treated groups were compared to the control using exact Wilcoxon rank sum tests; 

otherwise, no further comparisons were made. For binary parameters involving more than 

two groups, the Cochran-Armitage test was applied. If the Cochran-Armitage test was

significant at the 5% level, the direction of the trend was established and one-tailed stepdown testing in this direction was performed. If the Cochran-Armitage test was not 

significant at the 5% level, the χ2 test (Armitage et al 2002) was applied. If the χ2 test was 

significant at the 5% level, the test-article treated groups were compared to the control with 

Fisher's Exact tests, otherwise, no further comparisons were made.

PPS (day of PPS and bodyweight) and organ weight data were also analyzed as follows. 

Bartlett's test was applied; if this test was not significant at the 1% level, parametric analysis 

was applied. The bodyweight at PND 21 was used as a covariate in the analyses and 

comparisons were performed on the adjusted means after the analysis of covariance

(ANCOVA). The F1 approximate test was applied; if the F1 test was not significant at the 

1% level, Williams' test for a monotonic trend was applied, otherwise Dunnett's test was

performed instead. If Bartlett's test was significant at the 1% level, logarithmic and square 

root transformations were tried. If Bartlett's test was still significant, non-parametric tests 

Page 180 of 207
Male Pubertal Assay (2012) / Page 6 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

were applied. The H1 approximate test was applied; if the H1 test was not significant at the 

1% level, Shirley's test was applied; otherwise Steel's test was performed instead. 

For histopathology, test-article treated groups were compared to the control with Fisher's 

Exact tests. 

Statistical significance was declared at the 5%, 1% and 0.1% levels. The statistical analyses 

were considered appropriate.

C. METHODS

1. Mortality and Clinical Examinations: All animals were observed twice daily for 

mortality and moribundity beginning on PND 21 and continuing throughout the study. 

Individual clinical examinations were conducted daily prior to dosing through the day of 

euthanasia. 

2. Body Weight: Animals were weighed at randomization, daily prior to dosing, and on the 

day of euthanasia. Mean body weight gains were calculated for each weighing interval, and 

for PND 23-53. 

3. Food Consumption: Food consumption (g/rat/day) was measured by placing a weighed 

feeder in each cage, reweighing it after 2-4 days, and dividing by the number of rats/cage. 

Food consumption was reported for PND 23-26, 26-30, 30-33, 33-37, 37-40, 40-44, 44-47, 

47-51, and 51-53. 

4. Preputial Separation (PPS): Each male was observed daily prior to dosing for PPS 

beginning on PND 30. The age and body weight on the day at which PPS was completed 

was recorded for each animal.

5. Sacrifice and Pathology: All animals were euthanized by exsanguination on PND 53 at 

least two hours post-dosing. All terminal procedures were completed by 1300 hours. 

Unfasted animals were anesthetized with isoflurane and blood was collected from the aorta. 

The blood was allowed to clot for at least 30 minutes and centrifuged to obtain serum. 

Samples were stored at <−20°C (as required) for subsequent hormone and clinical chemistry

evaluations. 

a. Hormone Analysis: Serum T4 and testosterone concentrations were determined by 

radioimmunoassays; no other details about the radioimmunoassays were provided. Serum 

TSH levels were determined by an external laboratory (AniLytics, Inc., Gathersburg, MD); 

the method used was not reported. 

Page 181 of 207
Male Pubertal Assay (2012) / Page 7 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

b. Clinical Chemistry: The following CHECKED (X) parameters were examined.

ELECTROLYTES OTHER

Calcium X Albumin

Chloride X Creatinine*

Magnesium X Urea nitrogen*

Phosphorus Total cholesterol

Potassium X Globulins

Sodium Glucose

ENZYMES X Total bilirubin

X Alkaline phosphatase (ALP) X Total protein

Cholinesterase (ChE) Triglycerides

Creatine phosphokinase X Albumin/globulin ratio

Lactic acid dehydrogenase (LDH)

X Alanine aminotransferase (ALT/also SGPT)

X Aspartate aminotransferase (AST/also SGOT)

Sorbitol dehydrogenase (SDH)

Gamma glutamyl transferase (GGT)

Glutamate dehydrogenase

* Recommended for the pubertal assay in male rats based on Guideline 890.1500.

c. Organ Weights and Histopathology: The following CHECKED (X) tissues were 

collected and weighed. The (XX) organs, in addition, were subjected to histological 

examination. 

UROGENITAL OTHER

XX Testes (left and right separately)*+ XX Thyroid*+

XX Epididymides (left and right separately)*+ XX Liver*

X Seminal vesicle plus coagulating glands (with and without fluid)* X Adrenals (paired)*

X Ventral prostate* X Pituitary*

X Dorsolateral prostate*

X Levator ani-bulbocavernosus (LABC) muscle complex*

XX Kidneys (paired)*+

* Weights required based on Guideline 890.1500

+ Histopathological examination required based on Guideline 890.1500

Complete macroscopic examinations were performed on all animals. All organs collected 

except the thyroid/trachea were weighed prior to fixation. The kidneys, adrenals, and 

seminal vesicles were weighed together; the epididymides and testes were weighed 

separately. The seminal vesicles were weighed again following removal of the fluid in the 

lumen (blotted weight). 

The testes and epididymides were fixed in Bouin’s fixative for no more than 24 hours, then 

were rinsed and stored in 70% ethanol. Kidneys were fixed in 10% neutral buffered 

formalin for no more than 24 hours; the left kidney was retained in 10% neutral buffered 

formalin, the right kidney was rinsed and stored in 70% ethanol. All other tissues were 

fixed in 10% neutral buffered formalin for no more than 24 hours, then rinsed and stored in 

70% ethanol. After fixation, the thyroid was dissected from the trachea. The thyroid, left 

kidney, liver, left epididymis, and left testis were routinely processed, sectioned, stained 

with hematoxylin and eosin, and examined microscopically. 

Page 182 of 207
Male Pubertal Assay (2012) / Page 8 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

Thyroid/parathyroid glands were subjectively graded based on the ratio of follicular 

epithelial cell height to colloid area using a five point grading scale, with 1 = shortest 

epithelium with the most abundant colloid, and 5 = tallest epithelium with the least abundant 

colloid. A minimum of two sections of each of the two lobes of the thyroid/parathyroid 

were evaluated. Testes and epididymides were evaluated as required by US EPA Health 

Effects Test Guideline OPPTS 870.3800: Reproduction and Fertility Effects. In the testes, 

these evaluations were conducted in order to identify treatment-related effects such as 

retained spermatids, missing germ cell layers or types, multinucleated giant cells, or 

sloughing of spermatogenic cells into the lumen. Examination of the intact epididymis 

included the caput, corpus, and cauda, accomplished by evaluation of a longitudinal section, 

and was conducted in order to identify such lesions as sperm granulomas, leukocytic 

infiltration (inflammation), aberrant cell types within the lumen, or the absence of clear cells 

in the cauda epididymal epithelium. The left kidney was evaluated by means of standard 

histopathology. 

II. RESULTS

A. MORTALITY: There was no treatment-related mortality. 

B. CLINICAL SIGNS OF TOXICITY: No treatment-related clinical signs of toxicity were 

observed during the daily examinations. The only findings noted were general dermal 

alopecia of the head/neck in a control male (#1058) during PND 36-38, general dermal 

scabs in a control male (#1056) during PND 22-32 and in a 500 mg/kg/day male (#2034) 

during PND 37-53, and general dermal alopecia of the limbs in a 500 mg/kg/day male 

(#2035) during PND 48-53. 

C. GENERAL GROWTH, PREPUTIAL SEPARATION, AND FOOD CONSUMPTION: 

Body weights, body weight gains, and age and body weight at attainment of PPS are 

presented in Table 2. There were no effects of treatment on body weights, body weight 

gains, or age and body weight at attainment of PPS. All males achieved complete PPS. 

During PND 33-37 and 37-40, food consumption was increased (p<0.05) by 10 and 20%, 

respectively, at 1000 mg/kg/day. These transient increases were not considered to have 

resulted from treatment, and did not affect the outcomes of the study. 

The means and %CV for age and body weight at PPS and final body weight in the control 

group were within the recommended range of the performance criteria provided in the 

Guideline (890.1500) with one exception. The %CV for body weight at PPS was above the 

top of the recommended range (8.12% control vs. 7.57% top of range). 

Page 183 of 207
Male Pubertal Assay (2012) / Page 9 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

TABLE 2. General Growth and Preputial Separation (PPS)

a

Parameter Evaluated

Vehicle Control 500 mg/kg/day 1000 mg/kg/day

N Mean SD

CV 

(%) N Mean SD

CV 

(%) N Mean SD

CV 

(%)

Initial body weight

(PND 23; g)

U 15 60.5 2.41 3.98 15 61 2.34 3.84% 15 61.2 2.33 3.81%

A NA NA NA

Body weight at PPS (g) U 15 221.8 18.0 8.12 15 223.2 20.7 9.27 15 236.7 28.2 11.91

A 222 223.2 236.5

Final body weight

(g)

U 15 310.2 17.87 5.76 15 303.9 24.02 7.90 15 309.7 23.2 7.49

A 310.5 303.9 309.4

Final body weight 

(% of control)

U NA 98.0 99.8

A

Body weight gain

(final – initial; g)

U 15 249.7 17.89 7.16 15 242.8 22.75 9.37 15 248.5 22.49 9.05

A

Age at PPS

(PND)

U 15 43.2 1.6 3.70 15 44.2 2.8 6.33 15 44.5 2.0 4.49

A

Proportion unseparated 

(#/N) 0/15 0/15 0/15

a Data were obtained from Table 2 on pages 65-67, Table 3 on page 72, Table 5 on page 77, and Table 9 on page 87 of the 

study report (MRID 49042103). CV (%) values were calculated by the reviewers. 

U Unadjusted for body weight on PND 21

A Adjusted for body weight on PND 21

N Number of animals examined

SD Standard Deviation

CV Coefficient of Variation

NA Not applicable

D. ORGAN WEIGHTS: Organ weights at necropsy are presented in Table 3. Absolute, 

adjusted, and relative (to body) liver weights were increased (p<0.05) at 500 (↑8-10%) and 

1000 (↑10-11%) mg/kg/day, and relative kidney weights were increased (p<0.05) at 

500 (↑8%) and 1000 (↑6%) mg/kg/day. All other organ weights were similar to the controls.

The means and %CV of unadjusted values for all organ weights in the control group were 

within the recommended range of the performance criteria provided in the Guideline 

(890.1500) with the following exceptions: the mean weight of the kidney was below the 

recommended range (2.21 g vs. 2.242-3.050 g); the %CV for the seminal vesicle (without 

fluid) was above the top of the recommended range (22.55% vs. 21.06%); the left 

epididymis had a mean weight below the recommended range (235.5 mg vs. 364-528 mg) 

and a %CV above the top of the recommended range (27.89% vs. 16.39%); the mean weight 

of the right epididymis was below the recommended range (258.7 mg vs. 364-528 mg); and 

the %CV for the left testis was above the top of the recommended range (28.68% vs. 

17.62%). 

Page 184 of 207
Male Pubertal Assay (2012) / Page 10 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

TABLE 3. Organ Weights at Necropsya

Organ

Vehicle Control 500 mg/kg/day) 1000 mg/kg/day)

N Mean SD

CV 

(%) N Mean SD

CV 

(%) N Mean SD

CV 

(%)

Liver

(g) U 15 13.22 1.008 7.62 15 14.32*(↑8) 1.729 12.07 15 14.59**(↑10) 1.21 8.29

A 13.21 14.32*

(↑8)

14.60***

(↑11)

R 15 4.259 0.164 3.85 15 4.706***

(↑10) 0.328 6.97 15 4.720***(↑11) 0.327 6.93

Kidneys

(g)

U 15 2.21 0.106 4.80 15 2.34 0.256 10.94 15 2.33 0.169 7.25

A 2.21 2.33 2.32

R 15 0.715 0.051 7.13 15 0.770*

(↑8) 0.035 4.55 15 0.756*(↑6) 0.055 7.28

Pituitary

(mg)

U 15 10.2 1.39 13.63 15 9.7 1.53 15.77 15 9.3 0.95 10.22

A 10.2 9.7 9.3

R 15 0.0033 0.0005 15.15 15 0.0032 0.0005 15.63 15 0.0030 0.0003 10.00

Adrenals

(mg)

U 15 44.4 5.33 12.00 15 45 6.78 15.07 15 44.1 7.73 17.53

A 44.4 45 44.1

R 15 0.0143 0.0016 11.19 15 0.0148 0.0015 10.14 15 0.0142 0.0021 14.79

Seminal vesicle + 

coagulating gland, 

with fluid (mg)

U 15 830.1 178.78 21.54 15 807.9 158.93 19.67 15 856.2 127.56 14.90

A 830.2 807.9 856.1

Seminal vesicle + 

coagulating gland, 

without fluid (mg)

U 15 590.5 133.17 22.55 15 589.4 101.29 17.19 15 587.3 100.68 17.14

A 589.5 589.4 588.3

Ventral prostate

(mg)

U 15 250.0 44.01 17.60 15 233.5 57.12 24.46 15 243.2 53.83 22.13

A 251.0 233.6 242.1

Dorsolateral prostate

(mg)

U 15 104.1 32.07 30.81 15 97.7 43.35 44.37 15 105.5 38.48 36.47

A 104.3 97.7 105.4

LABC

(mg)

U 15 606.0 134.63 22.22 15 628.2 139.95 22.28 15 615.6 100.76 16.37

A 605.8 628.1 615.9

Epididymis, left

(mg)

U 15 235.5 65.67 27.89 15 239.3 25.93 10.84 15 237.0 31.54 13.31

A NC NC NC

Epididymis, right

(mg)

U 15 258.7 25.33 9.79 15 247 34.78 14.08 15 243.2 23.08 9.49

A 259.4 247 242.5

Testis, left

(mg)

U 15 1313.8 376.74 28.68 15 1435.7 93.54 6.52 15 1456.4 124.99 8.58

A NC NC NC

Testis, right

(mg)

U 15 1445.4 134.44 9.30 15 1468.4 95.91 6.53 15 1469.8 147.78 10.05

A 1450.1 1468.7 1464.8

Thyroid, fixed

(mg)

U 15 21.2 2.78 13.11 15 22.0 3.38 15.36 15 23.1 3.21 13.90

A 21.3 22.0 23.1

a Data were obtained from Table 9 on page 87-90 of the study report (MRID 49042103). Percent differences from controls, 

calculated by the reviewers, are included in parentheses. CV (%) values were calculated by the reviewers. 

U Unadjusted for body weight on PND 21

A Adjusted for body weight on PND 21

N Number of animals examined

SD Standard Deviation

CV Coefficient of Variation

R Organ-to-body weight ratio (relative to body weight)

NC Not calculated due to non-parametric tests

* Significantly different from control; p<0.05

** Significantly different from control; p<0.01

*** Significantly different from control; p<0.001

E. CLINICAL CHEMISTRY AND HORMONE LEVELS: Mean hormone and clinical 

chemistry levels are presented in Table 5. Serum T4 levels were decreased (p<0.001) by 

Page 185 of 207
Male Pubertal Assay (2012) / Page 11 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

>78% at 500 and 1000 mg/kg/day, with values below the method LOD (0.82 μg/dL) for 

6/15 males at 500 mg/kg/day and 12/15 males at 1000 mg/kg/day. Concomitantly, serum 

TSH levels were increased (NS) by 39% and 25% at 500 and 1000 mg/kg/day, respectively. 

Serum testosterone levels were unaffected by treatment. ALT activity was decreased 

(p<0.001) by 38% at 500 mg/kg/day and by 52% at 1000 mg/kg/day; total bilirubin was 

increased (p<0.001) by 100% at 500 and 1000 mg/kg/day. Additionally at 1000 mg/kg/day, 

ALP activity was increased (p<0.05) by 15%, with a trend towards an increase (NS) of 11% 

at 500 mg/kg/day. 

The mean and %CV for serum T4 and testosterone in the control group were within the 

recommended ranges of the performance criteria provided in the Guideline (890.1500). 

TABLE 5. Hormone Levels and Clinical Chemistrya

Parameter

Evaluated

Vehicle Control 500 mg/kg/day 1000 mg/kg/day

N Mean SD CV (%) N Mean SD CV (%) N Mean SD CV (%)

Hormones

Serum T4, Total

(μg/dL) 15 4.53 0.73 16.11 15b <0.97***(↓>78) 0.18 NC 15b <0.93***(↓>79) 0.23 NC

Serum TSH

(ng/mL) 15 2.81 1.241 44.16 15 3.91(↑39) 2.341 59.87 15 3.52(↑25) 1.738 49.38

Serum Testosterone

ng/mL 15 1.044 0.577 55.27 15 1.098 1.191 108.47 15 1.394 1.150 82.50

Clinical Chemistry

A/G Ratio 15 1.8 0.12 6.67 15 1.7 0.11 6.47 15 1.7 0.11 6.47

Albumin (g/dL) 15 3.5 0.08 2.29 15 3.5 0.10 2.86 15 3.5 0.14 4.00

ALP (U/L) 15 304 44.7 14.70 15 338

(↑11) 51.0 15.09 15 350*(↑15) 61.6 17.60

ALT (U/L) 15 56 6.6 11.79 15 35***

(↓38) 8.5 24.29 15 27***(↓52) 6.7 24.81

AST (U/L) 15 119 20 16.81 15 138 46 33.33 15 132 33.1 25.08

Creatinine (mg/dL) 15 0.2 0.03 15.00 15 0.2 0.03 15.00 15 0.2 0.00 0.00

Globulin (g/dL) 15 2.0 0.12 6.00 15 2.1 0.15 7.14 15 2.1 0.12 5.71

Total Bili (mg/dL) 15 0.06 0.030 50.00 15 0.12***

(↑100) 0.037 30.83 15 0.12***(↑100) 0.041 34.17

Total Protein (g/dL) 15 5.5 0.13 2.36 15 5.5 0.20 3.64 15 5.5 0.21 3.82

Urea Nitrogen (mg/dL) 15 14 1.7 12.14 15 15 2 13.33 15 15 1.8 12.00

a Data were obtained from Table 7 on page 81 and Table 8 on page 84 of the study report (MRID 49042103). Percent 

differences from controls, calculated by the reviewers, are included in parentheses. CV (%) values were calculated by the 

reviewers. 

b The mean and SD for T4 were recalculated by the reviewer using data from all 15 animals in the 500 and 1000 mg/kg/day 

groups. For animals with T4 values below the method LOD (<0.82 μg/dL), the LOD was used for calculation of the mean 

and SD. T4 values were <LOD for 6/16 males at 500 mg/kg/day and 12/15 males at 1000 mg/kg/day. %CVs were not 

calculated for these groups. 

N Number of animals examined

SD Standard Deviation

CV Coefficient of Variation

NC Not calculated

* Significantly different from control; p<0.05

** Significantly different from control; p<0.01

*** Significantly different from control; p<0.001

G. MACROSCOPIC EXAMINATIONS: There were no treatment-related gross findings 

reported at necropsy. 

Page 186 of 207
Male Pubertal Assay (2012) / Page 12 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

H. HISTOPATHOLOGY: The incidences of histopathological findings of the thyroid gland 

are presented in Table 6. No differences were observed in the ratio of follicular cell height 

to colloid area between the controls and treatment groups. 

TABLE 6. Incidence of Histopathological 

Lesions of the Thyroid Glanda

Treatment Groups

Parameter Evaluated

Follicular Cell Height to 

Colloidal Area Score

Gradeb Incidence

Vehicle Control

1 0

2 1

3 14

4 0

5 0

500 mg/kg/day

1 0

2 3

3 12

4 0

5 0

1000 mg/kg/day

1 0

2 2

3 13

4 0

5 0

a Data were obtained from Table 11 on page 100 of the study report

(MRID 49042103). 

b Thyroid histopathology is graded 1-5, with 1 = shortest epithelium 

with the most abundant colloid, and 5 = tallest epithelium with the 

least abundant colloid. 

The incidence of histopathological findings of the epididymis, kidney, liver, and testis are 

presented in Table 7. There were no treatment-related microscopic findings, with the 

exception of the liver. Minimal increased inflammatory foci with/without single cell 

necrosis was observed in 5/15 males at 1000 mg/kg/day (NS) compared to 2/15 controls. 

All other microscopic findings were noted in a single animal, were of minimal severity, 

and/or occurred in a manner unrelated to dose. 

Page 187 of 207
Male Pubertal Assay (2012) / Page 13 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

TABLE 7. Incidence of Histopathological Lesionsa

Findings

Dose Level

Vehicle Control 500 mg/kg/day 1000 mg/kg/day

Number examined 15 15 14

Epididymis (left)

Cauda: reduced/absent sperm Present 10 11 12

Epithelial vacuolation Minimal 0 0 1

Reduced sperm, sloughed degenerating Moderate

germinal cells and tubular contraction 0 1 0 

Epididymis (right)b

Hypospermia Minimal 1 0 0

Kidney (left)

Basophilic tubules Minimal 5 3 4

Mononuclear inflammatory cell infiltrate Minimal 1 0 1

Mineral deposits Minimal 0 1 0

Intratubular eosinophilic material Minimal 0 0 1

Kidney (right)b

Pelvic dilation Minimal 0 1 0

Liver

Increased inflammatory foci with or without Minimal

single cell necrosis 2 1 5 

Granuloma Minimal 0 0 1

Testis (left)

Tubular degeneration/atrophy Moderate 0 1 0

a Data were obtained from Table 11 on pages 98-100 of the study report (MRID 49042103). 

b Only one animal examined

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATORS’ CONCLUSIONS: PCNB was tested in a male pubertal study at 

doses up to and including the limit dose (1000 mg/kg/day). There were no test articlerelated effects on clinical signs, body weights, or feed consumption. 

The most consistent, statistically-significant organ weight changes were the marginal 

increases in absolute and relative liver weights at 500 and 1000 mg/kg/day. Microscopic 

findings in the liver consisted of minimal increased inflammatory foci with or without single 

cell necrosis, which was slightly greater in 1000 mg/kg/day animals compared to controls. 

Although these microscopic findings may be related to PCNB exposure, this change is a 

common background finding in rats and was not considered to be related to the increased 

organ weights as it was present in controls, and was of low incidence and minimal severity. 

The liver weight increases correlate with significantly decreased ALT activity at >500 

mg/kg/day, and may represent systemic hepatic effects from PCNB exposure. The liver 

weight increases are considered to signify mixed function oxidase induction as has been 

reported for PCNB previously. Liver weight increases and decreased ALT activity have 

been reported in previous PCNB chronic toxicity studies. Additionally, decreased ALT has 

been reported in some cases to be associated with increased Cyp(p450) enzyme induction 

which is a potential mechanism for the observed decreases in circulating T4 (via enhanced

excretion). Overall, the liver weight increases, decreased ALT activity and decreased T4

levels appear exposure-related and suggest a possible high dose indirect thyroid pathway 

interaction mediated by hepatic enzyme induction. However, the significant increases in 

relative kidney weights were not considered test article-related because they were small in 

Page 188 of 207
Male Pubertal Assay (2012) / Page 14 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

magnitude, consistent with normal biological variability, and there were no microscopic 

correlates. 

There were no effects on androgen-sensitive organ weights, testosterone levels or PPS data, 

and no exposure-related microscopic findings in reproductive organs. There is no evidence 

of potential interaction with either the androgen pathways or with the HPG axis. Adrenal 

and pituitary weights were not affected by PCNB exposures. Decreases in T4 levels were 

observed at >500 mg/kg/day and were correlated with marginal, but dose-related increases 

in TSH. However, these findings were not associated with any differences in 

thyroid/parathyroid organ weight or histopathology; therefore, the functional significance of 

these findings is not clear. As noted above, these findings may be associated with enhanced 

excretion of T4 mediated by hepatic enzyme induction. 

B. AGENCY COMMENTS: There was no treatment-related mortality, and no treatmentrelated clinical signs of toxicity were observed during the daily examinations. There were 

no effects of treatment on body weights, body weight gains, or gross findings reported at 

necropsy. During PND 33-37 and 37-40, food consumption was increased (p<0.05) by 10 

and 20%, respectively, at 1000 mg/kg/day. These transient increases were not considered to 

have resulted from treatment, and did not affect the outcomes of the study. 

Absolute, adjusted, and relative (to body) liver weights were increased (p<0.05) at by 8-10% 

at 500 mg/kg/day and by 10-11% at 1000 mg/kg/day, and relative kidney weights were 

increased (p<0.05) by 8 and 6% at 500 and 1000 mg/kg/day, respectively. ALT activity was 

decreased (p<0.001) by 38% at 500 mg/kg/day and by 52% at 1000 mg/kg/day and total 

bilirubin was increased (p<0.001) by 100% at 500 and 1000 mg/kg/day. Additionally at 

1000 mg/kg/day, ALP activity was increased (p<0.05) by 15%. There were no treatmentrelated microscopic findings, with the exception of the liver. Minimal increased 

inflammatory foci with/without single cell necrosis was observed in livers of 5/15 males at 

1000 mg/kg/day (NS) compared to 2/15 controls. 

The means and %CV of unadjusted values for all organ weights in the control group were 

within the recommended range of the performance criteria provided in the Guideline 

(890.1500) with the following exceptions: the mean weight of the kidney was below the 

recommended range (2.21 g vs. 2.242-3.050 g); the %CV for the seminal vesicle (without 

fluid) was above the top of the recommended range (22.55% vs. 21.06%); the left 

epididymis had a mean weight below the recommended range (235.5 mg vs. 364-528 mg) 

and a %CV above the top of the recommended range (27.89% vs. 16.39%); the mean weight 

of the right epididymis was below the recommended range (258.7 mg vs. 364-528 mg); and 

the %CV for the left testis was above the top of the recommended range (28.68% vs. 

17.62%). 

There were no effects of treatment on age and body weight at attainment of PPS. All males 

achieved complete PPS. Serum testosterone levels were unaffected by treatment. There 

were no treatment-related microscopic findings in the male reproductive tissues.

The means and %CV for age and body weight at PPS and final body weight in the control 

group were within the recommended range of the performance criteria provided in the 

Page 189 of 207
Male Pubertal Assay (2012) / Page 15 of 15

PCNB / 056502 OCSPP 890.1500/ OECD None

Guideline (890.1500) with one exception. The %CV for body weight at PPS was above the 

top of the recommended range (8.12% control vs. 7.57% top of range). 

Serum T4 levels were decreased (p<0.001) by at least 79% at 500 and 1000 mg/kg/day, with 

T4 levels being <LOD for 6/15 males at 500 mg/kg/day and 12/15 males at 1000 mg/kg/day. 

Concomitantly, serum TSH levels were increased (NS) by 39 and 25% at 500 and 1000 

mg/kg/day, respectively. However, no differences were observed in the ratio of follicular 

cell height to colloid area between the control and treatment groups. The decreased serum 

T4 and increased serum TSH concentrations are supportive of a treatment-related effect on 

the thyroid. This effect may be related to hepatic induction (liver weights were increased up 

to 11%), but no histopathological effect was observed in the thyroid. 

The mean and %CV for serum T4 in the control group were within the recommended range 

of the performance criteria provided in the Guideline (890.1500). 

The high dose (1000 mg/kg/day) was adequate based on increased liver and kidney weights, 

and changes in clinical chemistry parameters. 

C. STUDY DEFICIENCIES: The following deficiencies were noted that are not considered 

to have had an adverse impact on the results, interpretation or conclusions of this study: 

• The CV were not presented as a percent, and had to be recalculated by the reviewers. 

• Week 1 (Day 1-4) dose analysis for 500 mg/kg was 88.1% (< ±10%).

• Performance criteria data were not reported, but were determined by the reviewers.

• Testosterone data were reported in different units (ng/dL instead of ng/mL), but the 

conversion yielded acceptable results in the expected range.

Page 190 of 207
DATA EVALUATION RECORD

PCNB

Study Type: OCSPP 890.1550, Steroidogenesis Assay 

EPA Contract No. EP10H001452 

Task Assignment No. 3-26-2012 (MRID 48916704) 

Prepared for

Health Effects Division

Office of Pesticide Programs

U.S. Environmental Protection Agency 

2777 South Crystal Drive 

Arlington, VA 22202 

Prepared by

CSS-Dynamac Corporation

1910 Sedwick Road, 

Building 100, Suite B 

Durham, NC 27713 

Primary Reviewer: Signature:

Scott D. Studenberg, Ph.D., D.A.B.T. Date: 10/05/2012

Secondary Reviewer Signature:

Michelle Sharpe-Kass, M.S. Date: 10/10/2012

Program Manager: Signature:

Jack D. Early, M.S. Date: 10/18/2012

Quality Assurance: Signature:

Jack D. Early, M.S. Date: 10/18/2012

This Data Evaluation Record may have been altered by the Health Effects Division subsequent to 

signing by CSS-Dynamac Corporation personnel. 

Page 191 of 207
The US EPA Endocrine Disruptor Screening Program (EDSP) Tier 1 screening battery is 

comprised of eleven screening assays intended to identify a chemical’s likely endocrine 

bioactivity, i.e., its potential to interact with the estrogen, androgen, or thyroid (E, A, or T) 

pathways. The robustness of the Tier 1 battery is based on the strengths of each individual 

assay to identify potential endocrine bioactivity with complementary endpoints within the 

assay, where available, and redundancy across the battery. Thus, the results of each 

individual assay should not be considered in isolation but rather should be considered in 

the context of other assays in the battery as well as Other Scientifically Relevant 

Information (OSRI). In order to determine if a chemical has the potential to interact with 

the E, A or T pathways, a Weight of Evidence (WoE) evaluation of Tier 1 assay results, in 

combination with the findings in the OSRI, should be undertaken (refer to the WoE 

Document).

Page 192 of 207
PCN B I 056502 

Primary Reviewer: Stephen C. Dapson. Ph.D. 

Senior Pharmacologist, RAB6, BED (7509P) 

Secondary Reviewer: John Liccione. Ph.D. 

Health Effects Division 

Steroidogenesis Assay (201 l) I Pagel of 15 

OCSPP 890.1550/ OECD None 

Signature:}e~ JO,. ~e 

Signature:~ Date: ~ p r 

DatC -2 --1.> 

Template version 081201 l 

DATA EVALUATION RECORD 

STUDY TYPE: Steroidogenesis Assay (H295R Cells); OCSPP 890.1550 

PC CODE: 056502 DP BARCODE: 0405372 

TXR#: 0056474 CAS No.: 82-68-8 

TEST MATERIAL (PURITY): PCNB (95.6% a.i.) 

SYNONYMS: 

CITATION: 

SPONSOR: 

1,2,3,4,5-pentachloro-6-nitrobenzene; Quintozene 

Akhurst, L. C. (2012) PCNB Technical H295R Steroidogenesis Assay. 

Huntingdon Life Sciences Ltd., Cambridgeshire, England. Laboratory Study 

No. BDG0126, July 4, 2012. MRID 48916704. Unpublished. 

AMV AC Chemical Corporation, 4695 MacArthur Court, Suite 1200, 

Newport Beach, CA 

TEST ORDER#: EDSP-056502-105 

EXECUTIVE SUMMARY: In a steroidogenesis assay (MRID 48916704), H295R cells 

cultured in vitro in 24-well plates were incubated with PCNB (95.6% purity, Lot# 107030L052 

at log concentrations of 0.0001 to 100 μM for 48 hours in triplicate for three independent 

experiments. Dimethyl sulfoxide (DMSO) was used as the vehicle, at a final concentration of 

0.1%. 

Testosterone and estradiol levels were measured with specific EIA kits. A Quality Control (QC) 

plate was run concurrently with each independent run of a test chemical plate to demonstrate that 

the assay responded properly to positive control agents at two concentration levels. The positive 

controls included a known inhibitor (prochloraz) and a known inducer (forskolin) of estradiol 

and testosterone production. 

Precipitation and/or cell cytotoxicity was not observed at PCNB concentrations of :S 20 μM. 

However, cell viability was reduced to 78% at 30 μM in Run 2 and 31 % at 100 μMin Run 1, 

and precipitation was also noted at 100 μMin Run 1. Therefore, the highest PCNB 

concentrations evaluated were l 0 μMin Runs I and 2 and 20 μM in Run 3. 

Page 193 of 207
Steroidogenesis Assay (2011) / Page 2 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

For the test plates, the coefficients of variation (% CVs) ranged from 4.8–5.8% for absolute 

testosterone concentrations and 1.7–3.2% for absolute estradiol concentrations in the solvent 

control (SC) replicate wells within the test plates. The between-plate CVs for hormone 

concentrations in the SC wells were 13.6% for testosterone and 50.3% for estradiol. The withinplate CVs were low and met the performance criteria (≤30%), as did the between-plate CV for 

testosterone. Although the between plate CVs for estradiol exceeded the guideline performance 

criteria, the estradiol data is considered acceptable in light of the low within-plate CV values.

Basal hormone production in the SC wells was acceptable both in terms of the absolute 

concentrations and relative to the method’s lower limit of quantitation (LLQ). Compared to SC 

wells, 10 μM forskolin induced testosterone production on average by 2.26-fold, but induced 

estradiol by an unknown factor. For estradiol, the fold induction resulting from forskolin could 

not be confirmed to be above the guideline specified >7.5-fold for the first two assay runs 

because the estradiol levels were above the maximum limit of quantitation (MLQ); however, 

based on the MLQ, the minimum levels of induction for estradiol production were greater than 

5.12-, 3.12- and 7.70-fold in Runs 1, 2 and 3, respectively. Compared to the SC, 1 μM

prochloraz inhibited the synthesis of testosterone on average to 0.38-fold and estradiol to 0.09-

fold. The range of %CV for hormone concentrations for the SC replicates within the QC plates 

was 1.5–4.9% for testosterone and 2.5–5.2% for estradiol. The between plate CVs for the SC 

wells was 15.9% for testosterone and 45.0% for estradiol. Similar to the test plates, the withinplate CVs for hormone concentrations on the QC plates were low and met the performance 

criteria. The performance criteria (≤ 30%) for between-plate CVs for the QC plates was also met 

for testosterone, but exceeded for estradiol; as with the between-plate value for estradiol on the 

test plates, this value is considered acceptable in light of the within-plate CV values.

There were no significant differences in testosterone concentrations in the PCNB-treated cells 

relative to the SC, or in estradiol concentrations at PCNB levels ≤1 μM. PCNB caused small, 

but statistically significant (p ≤ 0.05), increases in estradiol concentrations in the culture medium 

at 10 μM in all three runs (1.09- to 1.21-fold) and at 20 μM in the third run (1.36-fold). 

However, all significant increases were <1.5-fold relative to the SC. 

Based on the hormone responses in each of three independent runs, PCNB treatment resulted in 

statistically significant and reproducible increases in estradiol production, but did not result in 

statistically significant and reproducible alterations in testosterone production.

The assay satisfies the EDSP Tier 1 Test Order requirements for a Steroidogenesis assay 

(OCSPP 890.1550). 

COMPLIANCE: Signed and dated Statements of Data Confidentiality Claims (no claim of 

confidentiality was made), Compliance with Good Laboratory Practice, Flagging, and Quality 

Assurance were provided. 

Page 194 of 207
Steroidogenesis Assay (2011) / Page 3 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

I. MATERIALS AND METHODS

A. MATERIALS

1. Test Facility: Huntingdon Life Sciences Ltd.

Location: Cambridgeshire, England

Study Director: L. C. Akhurst

Other Personnel: J. N. Carter, Head of In Vitro Technologies 

J. O. Hubbard, Study Manager

D. Speechley, Senior Study Manager

S. Bate, Senior Statistician

Study Period: February 2, 2012 through July 4, 2012

2. Test Substance: PCNB Technical

Description: Light brown powder

Lot # (expiration date): 107030L052 (July 2016)

Purity: 95.6%

Solubility: Soluble at tested concentrations in DMSO

Vapor pressure: Not provided

Stability: Not provided

Storage conditions: Room temperature in a sealed container protected from light

CAS #: 82-68-8

Molecular weight: 295.3

Structure:

Cl

Cl

Cl

Cl

Cl

NO2

3. Positive Control: Forskolin

Description (molecular weight): White powder (410.50)

Source: Sigma-Aldrich; Cat # F6886

Lot # (expiration date): 120M5054V (January 2016 retest)

Purity: 98%

Solubility (in solvent): Soluble at tested concentrations in DMSO

Storage conditions: Room temperature

CAS #: 66575-29-9

4. Negative Control: Prochloraz

Description (molecular weight): White powder (376.67)

Source: Sigma-Aldrich Fluka Analytical; Cat # 45631

Batch # (expiration date): 6220X (August 8, 2012 retest)

Purity: 99.1%

Solubility (in solvent): Soluble at tested concentrations in DMSO

Storage conditions: Room temperature

CAS #: 67747-09-5

Page 195 of 207
Steroidogenesis Assay (2011) / Page 4 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

5. Solvent/Vehicle Control: Dimethyl Sulfoxide (DMSO)

Description (molecular weight): Clear liquid (78.13)

Source: Sigma-Aldrich; Cat # 494429

Lot # (expiration date): 22896PMV (not provided)

Purity: 99.99%

Storage conditions: Not provided

CAS #: 67-68-5

Justification for choice of 

solvent:

Not provided. DMSO is a Guideline recommended solvent in which PCNB is 

reasonably soluble.

Final concentration in assay: 0.1% v/v

6. Stock Medium: Dulbecco’s modified Eagle’s medium/Ham’s F12 nutrient 

mixture, without phenol red

Source: Sigma-Aldrich (St. Louis, MO); Ref # D6434

Lot # (expiration date): RNBB8625 (November 2012)

Sodium bicarbonate: Component of stock medium

Nu-Serum: BD Biosciences; Ref # 355100; Lot # 11268; tested for background hormone 

concentrations by performing laboratory

ITS+premix: BD Biosciences; Ref # 354352; Lot # 18302 (expiry August 1, 2013), Lot # 

22771 (expiry October 14, 2013), and Lot # 09233 (expiry May 1, 2013)

7. Test Cells: H295R human adrenocortical carcinoma cells (ATCC CLR-2128; Batch # not 

provided) at passage 4.5 – 6.5 were incubated in the stock medium at the time of plating, 

dosing, and harvest. Incubation conditions were 5% CO2 and 37±2°C for approximately 24 

hours prior to exposure. 

The following performance criteria were met (indicated by an “x”): x Cell passage identifier. Cell Passage #: 4.5 – 6.5

x Cells frozen down at passage 5

x Frozen cells cultured for 4 additional passages

x Total number of passages does not exceed 10

B. METHODS

1. Pre-Test Information 

a. Hormone Assay Interference Test: The protocol for hormone analysis was validated, and 

the results are presented in a separate Methodology Validation report for study # HLS0809 

(data not provided). Hormone assay interference was also evaluated in this study. The fold 

difference compared to DMSO (SC) was 0.95-1.13 and 89-1.03 for estradiol and 

testosterone, respectively, indicating a lack of interference.

b. Hormone Extraction: Hormone extraction was not reported. The analytical method used 

for the measurement of testosterone and estradiol in supernatant was validated in study 

HLS0809 (data not provided). 

c. Laboratory Proficiency Test: Limited information was provided in Annex 2 of the study 

report. The author stated that the proficiency chemicals were tested in accordance with the 

Endocrine Disrupter Screening Program Test Guidelines OPPTS 890.1550: Steroidogenesis 

(Human Cell Line H295R) (EPA 640-C-09-003) of October 2009 and that there were no 

Page 196 of 207
Steroidogenesis Assay (2011) / Page 5 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

significant changes in personnel since the conduct of this test. All EC50 values were within 

the acceptance ranges, except in the first test with forskolin (Table 1). In that case, the 

EC50 value for estradiol was 0.28 μM, which fell just outside the range of 0.3 – 3.0 μM. 

However, the mean value for the three tests, 0.51 μM, was within the acceptable range. 

TABLE 1. Results of Laboratory Proficiency Test using Forskolin and Prochloraz.

a

Compound Concentrations 

tested (μM) Test EC50 (μM)b

Testosterone Estradiol

Forskolin 0.03, 0.1, 0.3, 1, 3 

and 10

1 1.34 0.28

2 0.35 0.43

3 0.38 0.81

Mean 0.69 0.51

Prochloraz 0.01, 0.03, 0.1, 

0.3, 1, and 3

1 0.05 0.08

2 0.03 0.07

3 0.04 0.07

Mean 0.04 0.07

a Data were obtained from page 75 of the study report. 

b The Guideline (890.1550) specified range for EC50s for forskolin are 0.2-2.0 μM for testosterone and 0.3-3.0 μM for 

estradiol, and the specified range for ED50s for prochloraz are 0.01-0.1 μM for testosterone and 0.03-0.3 μM for 

estradiol.

2. Test Solutions: PCNB was dissolved in DMSO to give a concentration of 100 mM. This 

solution was diluted in serial ten-fold dilutions in DMSO so that a total of seven 

concentrations were obtained. All solutions were prepared fresh immediately before 

treatment of the cells. Forskolin and prochloraz were dissolved in DMSO to make 10 mM 

solutions. Dilutions were conducted in DMSO to give a 1 mM solution for forskolin and 1 

mM and 0.1 mM solutions for prochloraz. When added to the cell culture plates, these 

dilutions yielded final concentrations of 1 μM and 10 μM for forskolin, 0.1 μM and 1 μM 

for prochloraz, and 100 μM, 10 μM, 1 μM, 100 nM, 10 nM, 1 nM, and 0.1 nM for PCNB. 

The final concentration of DMSO in the medium was held constant at 0.1% (v/v). No 

precipitation was visible.

3. Cell Plating and Preincubation: Cells were maintained in the Stock Medium described 

above. The hormone concentrations in undiluted Nu-Serum were 8.86 ng/mL for 

testosterone and 1.76 ng/mL for estradiol. H295R cells were grown for five passages, 

frozen in liquid nitrogen, then thawed and cultured for four to six additional passages prior 

to use in the assay. The cells were plated into wells of a 24-well cell culture plate at a 

density of approximately 300,000 cells in 1 mL. The cells were then placed into a 5% CO2

incubator at 37±2°C for approximately 24 hours prior to chemical exposure. Prior to 

dosing, the cells were checked microscopically for degree of confluence, attachment, and 

proper morphology. 

4. Exposure: The medium was removed from the cells and replaced with 1 mL of medium 

containing concentrations of PCNB (or solvent control) in triplicate, according to the 

schematic presented in Table 2. 

Page 197 of 207
Steroidogenesis Assay (2011) / Page 6 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

TABLE 2. Dosing Schematic for the Exposure of H295R Cells to Acephate (Final Concentrations in μM).a

1 2 3 4 5 6

A DMSO DMSO DMSO 0.1 0.1 0.1

B 100 100 100 0.01 0.01 0.01

C 10 10 10 0.001 0.001 0.001

D 1 1 1 0.0001 0.0001 0.0001

a Data were obtained from page 14 of the study report. 

A concurrent QC plate was included with each of the three independent runs of the test 

chemical plates to demonstrate the assay’s response to forskolin (an inducer of testosterone 

and estradiol production) and prochloraz (an inhibitor of testosterone and estradiol 

production). The QC plate was prepared and dosed in the same manner with either forskolin 

or prochloraz, according to the schematic presented in Table 3. 

TABLE 3. Dosing Schematic for the QC Plate for Positive Controls (Final Concentrations).a

1 2 3 4 5 6

A Blank b Blank Blank Blank + methanol Blank + methanol Blank + methanol

B DMSO DMSO DMSO DMSO + methanol DMSO + methanol DMSO + methanol

C Forskolin 

1 μM

Forskolin 

1 μM

Forskolin 

1 μM

Prochloraz 

0.1 μM

Prochloraz 

0.1 μM

Prochloraz 

0.1 μM

D Forskolin 

10 μM

Forskolin 

10 μM

Forskolin 

10 μM

Prochloraz 

1 μM

Prochloraz 

1 μM

Prochloraz 

1 μM

a Data were obtained from page 15 of the study report. 

b Blank wells received only medium. 

Following dosing, the plates were incubated for approximately 48 hours under the 

previously described conditions. After the incubation period, the plates were removed from 

the incubator and every well checked under the microscope for signs of cytotoxicity 

(attachment, morphology, etc.) and also as a qualitative assessment of cell density. Two 

aliquots of medium (490 μL) were collected and frozen at −70°C until further processing. 

5. Cell Viability/Cytotoxicity Assay: Cytotoxicity was determined by the MTT (3-(4,5-

dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) assay. Briefly, the medium was 

removed from the wells, and the wells were washed with DPBS. Methanol was added to 

wells A4-6 and B4-6 of the QC plate to provide controls for cytotoxicity. The QC plate was 

allowed to stand at room temperature for 30 minutes. After this time, the methanol was 

removed, and all wells were rinsed with DPBS. MTT (0.5 mg/mL culture media) was added 

in 1 mL per well immediately after removal of the DPBS, and the plates were incubated at 

37±2°C/5% CO2 for three hours. At the end of three hours, the MTT was removed from the 

wells, 1-mL portions of acidic isopropanol were added to each well, and the plates were 

shaken for 10 minutes. Portions (200 μL) were collected, and absorbance was read (along 

with acidic isopropanol blanks) at 540 nm with a plate reader. 

6. Hormone Measurement System: The concentration of each hormone (testosterone and 

estradiol) was evaluated in triplicate in the culture medium derived from each well with

specific EIA kits supplied by DRG for testosterone (catalog # EIA-1559) and estradiol 

(catalog # EIA-2693). The lower limits of quantification were 200 pg/mL for testosterone 

Page 198 of 207
Steroidogenesis Assay (2011) / Page 7 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

and 25 pg/mL for estradiol, which are above the guideline specified limits of 100 pg/mL for 

testosterone and 10 pg/mL for estradiol. 

 

The following performance criteria were met (indicated by an “x”):

NR Method detection limit (100 pg/mL testosterone; 10 pg/mL estradiol)

NR Spiked sample recovery acceptable for two concentrations of testosterone and estradiol (mean measured amount 

from triplicate samples within 30% of nominal concentration)

NR Hormone cross-reactivity (antibody-based assays only; ≤30% of basal production of the respective hormone)

X Solvent control within 75% range below maximum response on standard curve

X Test compound tested for interference with measurement system

C. DATA ANALYSIS: Mean values and standard deviations for testosterone and estradiol 

concentrations were calculated for each test concentration of PCNB, reference chemicals, 

the solvent controls, and blanks. The percent CVs were reported for within-plate and 

between-plate variation in hormone concentrations. Relative changes in testosterone and 

estradiol production were calculated by using the following equation: 

Relative Change = Hormone concentration in each well ÷ Hormone concentration of mean 

solvent control 

A response was considered to be statistically significant if the difference from the solvent 

control had a p≤0.05. Data were expected to follow a concentration-related profile.

A parametric analysis was performed if Bartlett's test for variance homogeneity was not 

significant at the 1% level. The F1 approximate test for monotonicity of means was applied. 

If the F1 approximate test for monotonicity of dose-response was not significant at the 1% 

level, Williams' test for a monotonic trend was applied. If the F1 approximate test was 

significant, suggesting that the dose response was not monotonic, Dunnett's test was 

performed instead. 

A non-parametric analysis was performed if Bartlett's test was still significant at the 

1% level after both logarithmic and square-root transformations. The H1 approximate test, 

the non-parametric equivalent of the Fl test described above, was applied. If the H1

approximate test for monotonicity of dose response was not significant at the 1% level, 

Shirley's test for a monotonic trend was applied. If the H1 approximate test was significant, 

suggesting that the dose-response was not monotonic, Steel's test was performed instead. 

The statistical analysis procedures were considered appropriate.

II. RESULTS

A. TEST COMPOUND: In the first run, PCNB was cytotoxic at the highest concentration 

(100 μM), with a viability of 31% relative to the SC. Additionally, a precipitate was 

observed at this concentration when the cells were examined by microscopy at 48 hours 

after treatment. Based on the viability results from the first run, the highest PCNB 

concentration tested in the second assay run was 30 μM. Although no precipitation was 

Page 199 of 207
Steroidogenesis Assay (2011) / Page 8 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

observed at 30 μM of PCNB, viability was 78% of the SC at this concentration. In the third 

assay run, the highest concentration of PCNB was further reduced to 20 μM, and this 

concentration was not cytotoxic or associated with precipitation. For the SC replicate wells 

within the test plate, the %CVs ranged from 4.8–5.8% for absolute testosterone 

concentrations and 1.7–3.2% for absolute estradiol concentrations. The between plate CVs

for the SC were 13.6% for testosterone and 50.3% for estradiol; the between plate CV for 

estradiol exceeded the Guideline criteria (≤30%). 

There were no significant differences on testosterone concentration in the PCNB-treated 

cells relative to the SC (Table 4; 0.91- to 1.05-fold change). However, in all three runs, 

PCNB caused small, but statistically significant, increases in the concentration of estradiol 

in the culture medium at the highest analyzable PCNB test concentrations. In all three runs, 

10 μM of PCNB resulted in a 1.09- to 1.21-fold increase (p<0.05) estradiol production, and 

in the third run, 20 μM of PCNB resulted in a 1.36-fold increase (p≤0.001) in estradiol 

production The effects of PCNB on testosterone and estradiol production are shown in 

Figures 1 and 2. 

TABLE 4. Mean (±SD) Hormone Concentrations Following Treatment with PCNB for 48 Hours.a

Nominal 

Concentration 

(μM)

Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 Mean ± SD Statistical 

Significance

Testosterone (pg/mL) Fold Difference

DMSO 2150 2000 1640 — — — — — —

20 — — 1560 — — 0.96 0.96 NA —

10 2230 2030 1690 1.04 1.01 1.03 1.03 0.02 —

1 2220 1990 1680 1.03 0.99 1.03 1.02 0.02 —

0.1 1980 1980 1640 0.92 0.99 1.00 0.97 0.04 —

0.01 2180 1870 1710 1.01 0.94 1.04 1.00 0.05 —

0.001 2270 1810 1650 1.05 0.91 1.01 0.99 0.07 —

0.0001 2200 1920 1620 1.02 0.96 0.99 0.99 0.03 —

Estradiol (pg/mL) Fold Difference

DMSO 327.7 618.2 238.1 — — — — — —

20 — — 322.6 — — 1.36 1.36 NA Run 3

10 396.4 675.6 266.6 1.21 1.09 1.12 1.14 0.06 Runs 1, 2 and 3

1 350.7 613.9 234.6 1.07 0.99 0.99 1.02 0.05 —

0.1 329.9 625.3 234.6 1.01 1.01 0.99 1.00 0.01 —

0.01 318.6 605.3 227.6 0.97 0.98 0.96 0.97 0.01 —

0.001 335.8 603.1 232.1 1.02 0.98 0.97 0.99 0.03 —

0.0001 343.8 644.5 233.2 1.05 1.04 0.98 1.02 0.04 —

a Data were obtained from pages 25 of the study report. The lower limit of quantification (LLQ) was 200 pg/mL for 

testosterone and 25 pg/mL for estradiol.

NA Not applicable; n=1

Page 200 of 207
Steroidogenesis Assay (2011) / Page 9 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

FIGURE 1. Change in Testosterone Production Relative to PCNB Concentration. 

Page 201 of 207
Steroidogenesis Assay (2011) / Page 10 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

FIGURE 2. Change in Estradiol Production Relative to PCNB Concentration. 

Page 202 of 207
Steroidogenesis Assay (2011) / Page 11 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

B. CYTOTOXICITY: PCNB was not cytotoxic to the H295R cells at concentrations ≤20 μM 

(Table 5). Relative to the SC, cell viability in each run ranged from 88-112% at ≤20 μM 

PCNB, but viability was 78% at 30 μM in Run 2 and 31% at 100 μM in Run 1. In the 

quality control plate, viability in each run ranged from 92-111%, except in the methanoltreated cells (6-15% viability). 

TABLE 5. Mean (±SD) MTT Cell Viability Results after Treatment with Forskolin, Prochloraz, or PCNB for 48 

Hours.a

Compound Concentration (μM) Cell Viability

Mean SD

Blank NA 99.0 5.29

Background NA 106 4.58

SC + Methanol NA 105 4.58

Forskolin 1 98.7 2.52

Forskolin 10 95.3 3.51

Prochloraz 0.1 10.3 4.51

Prochloraz 1 9.67 2.52

PCNB 100 31 NA

PCNB 30 78 NA

PCNB 20 88 NA

PCNB 10 100 5.57

PCNB 1 99 2.00

PCNB 0.1 103.7 4.73

PCNB 0.01 101.7 2.89

PCNB 0.001 102 9.17

PCNB 0.0001 101.3 4.04

a Values were calculated by the reviewers from data obtained from page 24 of the study report.

NA Not applicable; n=1 

C. QC PLATE: The hormone concentrations after exposure to OPP, SC, blank and 

background samples, as well as the fold-difference change relative to SC (individual and 

mean ± SD) for the three assay runs, are presented in Table 6. The minimum basal hormone 

production levels (500 pg/mL for testosterone, 40 pg/mL for estradiol) were met in both 

blank and SC wells, and basal hormone production in the SC wells was >9.9-fold LLQ for 

testosterone and >10.5-fold LLQ for estrogen. Compared to SC, 10 μM forskolin, on 

average, induced testosterone production by 2.26-fold and estradiol production by an 

unknown factor. For estradiol, the fold induction resulting from forskolin could not be 

confirmed to be above the guideline specified >7.5 for the first two assay runs because the 

estradiol levels were above the MLQ (2000 pg/mL) and the basal levels of estradiol 

production were relatively high in the SC wells for Runs 1 and 2. Based on estradiol levels 

being >MQL (>2000 pg/mL), the relative fold induction for 10μM forskolin was greater 

than 5.12-fold, 3.12-fold and 7.70-fold for Runs 1, 2 and 3, respectively. Compared to SC 

wells, 1 μM prochloraz on average inhibited the synthesis of testosterone to 0.38-fold and 

estradiol to 0.09-fold, which are below the guideline specified 0.5-fold reduction. 

The range for %CV for SC replicates within each plate was 1.5–4.9% for absolute 

testosterone concentrations and 2.5-5.2% for absolute estradiol concentrations. The 

between-plate CVs for hormone levels in the SC wells were 15.9% for testosterone and 

Page 203 of 207
Steroidogenesis Assay (2011) / Page 12 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

45.0% for estradiol, which is above the Guideline criteria of ≤30%. 

The Guideline requirements were generally met indicating that the assay was sensitive to 

induction and inhibition of testosterone and estradiol. Departures from the Guideline 

included: (i) testosterone was only induced by 1.89-fold rather than the Guideline specified 

of ≥2-fold in the second assay run (ii) induction of estradiol production by 10 μM forskolin 

did not definitively meet the >7.5-fold criterion in Runs 1 and 2, and (iii) inter-plate viability 

for estradiol concentrations in the SC wells were above the guideline specified 30% limit. 

TABLE 6. Mean (±SD) Hormone Concentrations Following Treatment with Forskolin or Prochloraz for 48 Hours.a

Concentration (μM)

Run 1 Run 2 Run 3 Run 1 Run 2 Run 3 Mean ± SD

Testosterone (pg/mL) Fold Difference (Relative to DMSO)

Blank 2590 2300 1990 1.11 1.10 1.18 1.13 0.04

DMSO 2330 2090 1690 — — — — —

1 μM Forskolin 4340 3400 3580 1.86 1.63 2.12 1.87 0.25

10 μM Forskolin 5610 3940 4180 2.40 1.89 2.48 2.26 0.32

0.1 μM Prochloraz 1240 1120 1080 0.53 0.54 0.64 0.57 0.06

1 μM Prochloraz 720 790 760 0.31 0.38 0.45 0.38 0.07

Estradiol (pg/mL) Fold Difference (Relative to DMSO)

Blank 406.9 686.1 264.7 1.05 1.07 1.02 1.05 0.03

DMSO 388.8 640.1 259.9 — — — — —

1 μM Forskolin MLQ MLQ MLQ >5.14 b >3.12 b >7.70 b NA NA

10 μM Forskolin MLQ MLQ MLQ >5.14 b >3.12 b >7.70 b NA NA

0.1 μM Prochloraz 242.1 314.6 154.1 0.62 0.49 0.59 0.57 0.07

1 μM Prochloraz 35.28 59.34 25.18 0.09 0.09 0.10 0.09 0.01

a Data were obtained from page 26 of the study report. The lower limit of quantification (LLQ) was 200 pg/mL for 

testosterone and 25 pg/mL for estradiol. ALQ indicates the concentration was above the maximum limit of quantification 

(MLQ, >2000 pg/mL).

b The minimum level of the fold induction for estradiol was calculated by dividing the MQL for estradiol by the estradiol 

concentration in the respectively SC wells.

NA Not applicable

III. DISCUSSION AND CONCLUSIONS

A. INVESTIGATORS’ CONCLUSIONS (from the study report): The results for the 

cytotoxicity of PCNB are shown in Table 1 [of the study report]. In the first test, PCNB was 

cytotoxic at the highest concentration of 100 μM; the viability was 31% of the solvent 

control. Additionally, a precipitate was observed when examining the cells using a 

microscope 48 hours after treatment at this PCNB concentration. As the viability was < 80% 

of the solvent control and the test substance was not fully soluble, data from the highest 

concentration were not used in the data analysis. In the second test, the highest 

concentration of PCNB was reduced to 30 μM; however, the viability was 78% of the 

solvent control at this concentration. No precipitate of the test substance was observed at 

this concentration. As the viability was < 80% of the solvent control, data from this highest 

concentration were not used in the data analysis. In the third test, the highest concentration 

of PCNB was reduced to 20 μM. This concentration was not cytotoxic or associated with 

precipitation.

Page 204 of 207
Steroidogenesis Assay (2011) / Page 13 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

The interference assay (Tables 13 and 15 of the Immunoassay phase report, Annex 1) [of the 

study report] demonstrated that PCNB did not interfere with the hormone measurement 

assay system. Concentrations determined for estradiol and testosterone were similar in the 

absence and presence of PCNB. The interference assay for testosterone was repeated as a 

spurious value was obtained for the blank DMSO (Table 14) [of the study report]. 

The concentrations of estradiol and testosterone observed in the three tests are summarized 

in Table 2 [of the study report]. In all three tests, PCNB caused small statistically significant 

increases in the concentration of estradiol in the culture medium at the highest analyzable 

PCNB test concentration (10 μM) in the first and second tests (P < 0.001 and P < 0.05, 

respectively) and at the highest two analyzable PCNB test concentrations (20 and 10 μM; P

< 0.001 and P < 0.01, respectively) in the third test. However, all statistically significant 

increases were < 1.5 fold when compared with the solvent control concentrations. The value 

of 1.5 fold was used as a cutoff for a positive response in the joint EPA/OECD validation 

program for the steroidogenesis assay (Hecker et al 2011).

In all three tests, PCNB caused no statistically significant changes in the concentration of

testosterone in the culture medium.

The concentrations of estradiol and testosterone are detailed in the Immunoassay phase 

report, Table 1 to Table 6 and Table 16 (Annex 1) [of the study report]. 

The LOEC for estradiol induction was considered to be 10 μM in all three tests, with a 

NOEC of 1 μM. The NOEC for testosterone inhibition was considered to be 100 μM for all 

three tests.

A QC plate was run on all three occasions. Forskolin at 10 μM caused an increase in the

concentrations of both estradiol and testosterone, whereas prochloraz at 1 μM caused a 

decrease in the concentrations of both hormones (see Table 7 to Table 12 and Table 17 of 

the Immunoassay phase report, Annex 1) [of the study report]. The highest measurable fold 

increases in estradiol and testosterone by 10 μM forskolin were > 7.5 and 2.48, respectively. 

The highest measurable fold decreases in estradiol and testosterone by 1 μM prochloraz 

were 0.09 and 0.31, respectively. 

The acceptance criteria for forskolin and prochloraz on the QC plate were met on all 

occasions with the following exception:

In the 1st and 2nd tests: 10 μM forskolin produced an increase in estradiol concentration 

which was above the limit of quantification of 2000 pg/mL and could not be confirmed as > 

7.5 times solvent control. This was due to a higher level of basal production of estradiol in 

the 1st and 2nd tests when compared to the 3rd test. In the 3rd test, although the increase in 

estradiol also lay above the limit of quantitation, it was confirmed as > 7.5 times solvent 

control. 

All other criteria for CV and basal hormone production were met (Tables 16 and 17 of the 

Immunoassay phase report, Annex 1) [of the study report] with the following exception:

Page 205 of 207
Steroidogenesis Assay (2011) / Page 14 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

The between plate CV for the solvent control values in the test plates was 50.3% for 

estradiol instead of < 30%. However, as the CV values for the solvent controls within the 

plates were all low (< 3.2%), and all fold changes were calculated relative to the solvent 

control on any one plate, the high CV observed between plates was not considered to affect 

the integrity of the study.

It was concluded that PCNB demonstrated an influence on the steroidogenesis pathway, 

acting as a very mild inducer of estradiol production. However, the level of induction was 

below the cutoff value used to determine a positive response in the EPA/OECD joint 

validation effort (Hecker et al., 2011). The LOEC for the overall study for estradiol 

induction was 10 μM, with a NOEC of 1 μM.

B. AGENCY COMMENTS: Guideline acceptability recommendations were generally met, 

including adequate production of testosterone and estradiol, acceptable within plate 

reproducibility (low % CV), and appropriate induction and inhibition with positive controls. 

Minor departures from the Guideline were observed (see Deficiencies Section below), but 

these minor departures did not adversely affect the results or conclusions of this study. 

Precipitation and/or cell cytotoxicity was not observed at PCNB concentrations of ≤ 20 μM. 

Relative to the SC, cell viability in each run ranged from 88-112% at ≤ 20 μM PCNB. Cell

viability was reduced to 78% at 30 μM in Run 2 and 31% at 100 μM in Run 1, and 

precipitation was also noted at 100 μM in Run 1. 

For the test plates, the % CVs ranged from 4.8–5.8% for absolute testosterone 

concentrations and 1.7–3.2% for absolute estradiol concentrations in the SC replicate wells 

within the test plates. The between-plate CVs for hormone concentrations in the SC wells 

were 13.6% for testosterone and 50.3% for estradiol. The within-plate CVs for both 

hormones were low and met the performance criteria, as did the between-plate CV for 

testosterone. The between plate CV for estradiol exceed the specified 30% maximum, but is 

considered acceptable in light of the within-plate CV values.

There were no significant differences in testosterone concentrations in the PCNB-treated 

cells relative to the SC, or in estradiol concentrations at PCNB concentration ≤ 1 μM. 

PCNB caused small statistically significant increases (p ≤ 0.05) in the estradiol 

concentrations in the culture medium at 10 μM in all three runs (1.09- to 1.21-fold) and at 

20 μM in the third run (1.36-fold). However, all significant increases were < 1.5-fold

relative to SC, which was the proposed cutoff for a positive response in the multi-laboratory 

validation report and the joint EPA/OECD validation program for the steroidogenesis assay. 

Basal hormone production in SC wells was acceptable both in terms of the absolute 

concentrations and relative to the method LLQ. Compared to the SC wells, 10 μM forskolin 

induced testosterone production by 2.26-fold and induced estradiol by an unknown factor. 

For estradiol, the fold induction resulting from forskolin could not be confirmed to be above 

the guideline specified >7.5 for the first two assay runs because the estradiol levels were 

above the MLQ; however, based on the MLQ, the minimum levels of induction for estradiol 

Page 206 of 207
Steroidogenesis Assay (2011) / Page 15 of 15

PCNB / 056502 OCSPP 890.1550/ OECD None

production were greater than 5.12-, 3.12- and 7.70-fold in Runs 1, 2 and 3, respectively. 

Compared to SC, 1 μM prochloraz on average inhibited the synthesis of testosterone to 

0.38-fold and estradiol to 0.09-fold. The ranges for % CV within-plate and between-plate 

SC replicates on the QC plates were of similar magnitude to those from the test plates. All 

% CV values for the SC well on the QC plates met the performance criteria (≤ 30%) except 

for the between-plate CVs for estradiol (45.0%).

Based on the results of this study, PCNB was not an inhibitor of steroidogenesis, but slightly 

induced estradiol production at PCNB concentrations of 10 – 20 μM.

C. STUDY DEFICIENCIES: The following deficiencies were noted that were considered 

not to have had an adverse impact on the results, interpretation and conclusions of this 

study: 

• Stability of PCNB in the test system was not reported.

• Departures from the Guideline included: (i) testosterone was only induced by 1.89-fold 

rather than the Guideline specified of ≥2-fold in Run 2 and (ii) induction of estradiol 

production by 10 μM forskolin did not definitively meet the >7.5-fold criterion in Runs 

1 and 2. 

• The between-plate CVs for estradiol concentrations in the SC wells exceeded the 

acceptable 30% limit for both the test and QC plates. 

Page 207 of 207